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Glycaemic dysregulation drives type II diabetes (T2D) pathogenesis, perpetuating 
multimorbidity that is thought to be linked to mood and cognitive decline. Glucagon-
like peptide-1 receptor agonists (GLP-1Ras) are an effective insulin sensitising and 
weight loss medication. Preclinical studies have shown them to have positive effects 
on cognition. Whether such effects are seen in humans is unknown. The aims of this 
PhD were to investigate potential disease mechanisms and assess current and novel 
biomarker panels, clinically, that relate to T2D, cognitive decline and GLP-1Ra 
response. qPCR arrays using 3 in-vivo models showed leptin and insulin related genes 
were differentially affected by treatment duration in brain, and these changes may 
be evident peripherally. Clinically, ECR records of 500 T2D patents indicated diabetes 
is poorly managed, and that cardiovascular disease (CVD) and hyperlipidaemia 
management appear to be prioritised. Current biochemical measures of diabetes 
(HbA1c, BMI and plasma lipid profile) did not correlate strongly with any aspect of 
T2D, while C-peptide, currently not routinely measured, may be a valuable addition 
to the clinic. Multiplex proteomics of 374 T2D participants and 20 controls, screened 
368 proteins across 12 variables; previously shown to be central in T2D. Unique 
protein panels were identified for each variable, and vascular endothelial 
dysfunction was a commonalty between all. Genetic supplementation of the 
proteomic markers was also achieved via SNP genotyping of 20 insulin and leptin-
related genes. One hundred and five SNPs differentiated T2D and controls and 25 
were indicative of GLP-1Ra response. GLP-1Ra non-responders were found to have 
the greatest level of comorbidity and highest scores on the Beck depression and 
anxiety inventories. This translated to lower cognitive domain scores in, memory and 
perception. These data have identified prescribing and comorbidity patterns in a 
Northern Irish T2D population, and demonstrated that current measures do not 
adequately correlate with disease progression or comorbidity onset. Novel markers 
identified may allow for higher predictive capability, and may reduce the impact of 
cognitive decline in T2D.  
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Diabetes mellitus is characterised by high blood glucose due to either the pancreas’ 
inability to produce enough insulin or the bodies inability to effectively use the 
insulin it produces (Chamberlain et al., 2017b, WHO, 1999). Early symptoms include, 
excessive thirst (polydipsia), increased passage of urine (polyuria), blurred vision, 
constant hunger and fatigue (Diabetes UK, 2017b).  
Type I diabetes (T1D) accounts for 5-10% of all cases. It is caused by the auto-
immune destruction of insulin producing pancreatic β-cells, resulting in significant 
insulin deficiency (Maahs et al., 2010). The disease is thought to have a short 
prodome with a rapid onset. It is widely thought that clinical symptoms do not 
manifest until 90% of β-cells are destroyed (Veijola et al., 2016). Onset of T1D is 
thought to be linked to acute stress and increased insulin resistance, which 
accentuate the effects of an underlying insulin deficiency (Wang et al., 2017). T1D 
predominantly occurs at a younger age and can be triggered by infection, illness or 
physiological changes related to insulin (Akirav et al., 2008). In 1993 another form of 
T1D was introduced, latent adult onset diabetes (LADA). Contrasting classic Type 1 
(Type Ia) characteristics, this disease presents in adult life with a slow onset and no 
initial dependence for insulin therapy (Thivolet, 2001).  
Type II diabetes (T2D) is the most common form, accounting for 90% of all 
cases (Maahs et al., 2010). It is directly linked to obesity, with 80% of individuals with 
T2D being classed as overweight (WHO, 1999). The WHO classifies obesity as having 
a total body fat percentage (TBF) of >35% in women and >25% in men and advise 
that obese individuals are 80 times more likely to develop T2D (WHO, 1999).  
Studies have shown that abdominal fat initiates an inflammatory response 
causing the body to become less responsive to insulin (Patel and Abate, 2013). There 
is also a significant dysregulation of glucose dynamics in the liver. Obesity and 
diabetes impair insulin-induced suppression of gluconeogenesis and glycogenolysis 
and impairments have been shown to correlate with plasma free fatty acid 
concentrations (Basu et al., 2005).   
It is well established that age, lifestyle, diet and obesity have a substantial 
impact on the development of T2D but it is still not fully understood why some 
people develop pre-diabetes and then T2D and others do not (Tuomilehto and 
Bahijri, 2016). Genetic risk factors are now thought to be increasingly important. 
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There are a number of genetic variants implicated in the pathogenesis of the disease 
in genes associated with insulin secretion, insulin sensitivity and obesity. These 
include ABCC8 and TCF7L2 which both negatively affect insulin secretion (Jäger et al., 
2017).  It has also recently been shown that hyperglycaemia, due to reduced insulin 
secretion, seems in part to be genetically determined (Park, 2011), with a 4 fold 
increased risk of developing the condition if it is present within the immediate family 
(Meigs et al., 2000).  
  
1.1 Demographics of diabetes 
 
Recent figures estimate the diagnosed global prevalence of diabetes to be 422 
million (World Health Organisation, 2016), and 46% of individuals with diabetes are 
thought to be undiagnosed. Prevalence has been projected to rise to 642 million by 
2040 (World Health Organisation, 2016). In the United Kingdom (UK) 3.5 million 
people have been diagnosed with diabetes with an estimated 550,000 individuals 
undiagnosed, representing 6% of the UK population. This number is projected to rise 
to 5 million by 2025 (Diabetes UK, 2016).  
Diabetes is already having a profound impact on the National Health Service 
(NHS). It was estimated in 2012 that diabetes and its complications cost the NHS £14 
billion; the treatment of complications represents the majority of that spend, with a 
reported £9 billion (66%) spent on inpatient care and £3.2 billion (22%) on 
pharmacological treatment (Hex et al., 2012).  
 
1.2 Diagnosis of diabetes 
 
Glycated haemoglobin (HbA1c) is the current preferred diagnostic measure for 
diabetes (Edge et al., 2010). It is formed when haemoglobin in red blood cells (RBCs)  
binds to glucose and provides an average blood sugar level over the lifespan of  
RBCs, which is approximately 8-12 weeks in humans (Argento et al., 2014).    
Currently a diabetes diagnosis is established if a patient presents with an 
HbA1c of >48 mmol/mol (6.5%) on two occasions. Pre-diabetes is diagnosed when 
HbA1c is between 42 (6%) - 47 (6.4%) mmol/mol., while a normal HbA1c level is below 
42 mmol/mol (6%) (Kowall and Rathmann, 2013). Diagnostically, HbA1c has several 
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limitations (Lippi and Targher, 2010). Readings can be affected by genetic variants, 
chemically altered by-products of haemoglobin (Soranzo, 2011) and various 
conditions that affect RBCs and RBC survival such as pregnancy and anaemia (English 
et al., 2015). Other diagnostic measures include; Fasting Plasma Glucose (FPG) and 
oral glucose tolerance tests (OGTT), however both require a minimum of 8 h fasting 
and are therefore not as convenient as HbA1c. A glucose reading of 43 mmol/mol 
(6.1%) or above is indicative of diabetes in the FPG test (Yun et al., 2010), while a 
glucose concentration of 48 mmol/mol (6.5%) 2 hours after consumption of 75g of 
glucose in the OGTT warrants a diabetes diagnosis (Hutchinson et al., 2012).  
 
1.3.1 Non-pharmacological treatment  
 
T2D may be prevented or treated by lifestyle changes alone. Upon diagnosis it is 
recommended that patients receive education and ongoing nutritional and dietary 
support to provide them with the knowledge and skills to effectively manage their 
disease outside of primary and secondary care (National Institute for Health and 
Care Excellence, 2017). The major environmental risk factors for T2D are an 
unbalanced diet and a sedentary lifestyle (Cai et al., 2017).  Both factors are more 
prevalent in urbanised areas but are now equally relevant across both hemispheres 
(Bhupathiraju and Hu, 2016). Dietary advice can have a profound impact on the 
management of diabetes (NICE, 2017). Simple carbohydrates rapidly increase blood 
glucose levels requiring a large, rapid insulin response (Marsh et al., 2011). It is 
recommended that those with T2D avoid simple carbohydrates and focus on 
complex carbohydrates which result in a slow sustained release of glucose providing 
lasting energy and fullness (NICE, 2017). Physical activity reduces the risk of T2D by 
up to 50%; just 30 minutes of moderate exercise a day significantly reduces the risk 
of CVD by improving hepatic insulin resistance, reducing dyslipidaemia and 
ultimately reducing body weight (Cai et al., 2017). The American Diabetes 
Association (ADA) states that exercise induced improvements in glucose 
management, blood fats and body weight will result in patients experiencing more 




1.3.2 Pharmacological treatment   
 
Pharmacological management of blood glucose and achieving a healthy HbA1c is 
directly related to a reduced risk of heart disease, kidney damage and other 
microvascular complications. Diabetes is not simply a disease about glucose control 
but a close interaction between glucose, lipids and blood pressure (BP) (Skrha et al., 
2016). The Action to Control Cardiovascular Risk in Diabetes (ACCORD) (Ismail-Beigi 
et al., 2010), Action in Diabetes and Vascular Disease (ADVANCE) (Group et al., 2008) 
and Veterans Affairs Diabetes (VADT) (Duckworth et al., 2009) randomised clinical 
trials indicated that aggressive glycaemic control significantly reduced cardiovascular 
complications. Other trials such as the UK Prospective Diabetes Study (UKPDS) 
(Scheen et al., 2008) and Diabetes Control and Complications Trial (DCCT) (American 
Association of Diabetes, 2002) suggested that such intensive treatment creates a 
“legacy effect” and benefits to the patient are not apparent until years later. 
Consideration of the benefit of insulin over oral therapy must be assessed carefully 
as the more aggressive the glycaemic control the greater the risk of weight gain, 
hypoglycaemia and drug interactions (Gale, 2008).   
     
1.3.3 Non-insulin Diabetes treatments 
 
There are currently seven classes of non-insulin antidiabetic drugs available; 
biguanides, sulphonylureas, meglitinides, thiazolidinediones, sodium-glucose 
Cotransporter-2 inhibitors (SGLT2i), dipeptidyl peptidase IV inhibitors (DDP-IVi), and 
glucagon-like peptide-1 receptor agonists (GLP-1Ra). Each class has a specific mode 
of action and adverse event profile, and all, except GLP-1Ra, are oral medications 
and have a more favourable risk profile than insulin (NICE, 2017). NICE (National 
Institute for Health and Care Excellence) have published guidance for clinicians and 
recommend prescription strategies for each class of anti-diabetic drugs which aims 
to minimise adverse events, drug reactions and cost, while achieving adequate 
control (NICE, 2017). The definition of “adequate control” varies depending on the 
severity of diabetes. If diabetes can be managed by monotherapy the target HbA1c is 
48 mmol/mol (6.5%), if HbA1c rises above 58 mmol/mol (7.5%) it is recommended 
that drug treatment is intensified and a new target of 53 mmol/mol (7.0%) set. 
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Diabetes treatment regimens are intensified until a 4th line treatment is prescribed, 
with insulin introduced as a last resort if adequate control cannot be achieved   




Metformin is the preferred first line therapy. It reduces hepatic glucose output and 
improves insulin sensitivity (DeFronzo and Goodman, 1995). Doses are titrated from 
500-2000 mg over several weeks, as necessary, provided gastrointestinal side effects 
are not limiting (NICE, 2017). The major risk associated with metformin is lactic 
acidosis (Salpeter et al., 2010), which results in a low blood pH, sickness, and in 
severe cases death (Connelly et al., 2017). Biguanides are cleared via the kidneys 
therefore not suitable in patients suffering from chronic kidney disease (CKD).  
 
1.3.3.2 Dual Therapy 
 
If 2000 mg/day of metformin does not initiate a satisfactory HbA1c response, NICE 
guidelines recommend intensification of treatment. This involves the addition of 
either sulphonylurea, thiazolidinedione, SGLT2i or a DDP-IVi (NICE, 2017). 
Sulphonylureas (SU) regulate glycaemia by increasing insulin release from β-
cells. They block potassium (K+) channels, inhibiting the influx of K+ thus opening 
calcium (Ca2+) channels triggering insulin release (Linden and Brooker, 1978). They 
also sensitise β-cells to glucose, limit glucose production in the liver and decrease 
lipolysis (Kuhn, 1988). Adverse events include hypoglycaemia and weight gain. 
Meglitinides, also induce insulin secretion, differing only in their affinity and faster 
dissociation from the sulphonylurea receptor (SUR1) (Guardado-Mendoza et al., 
2013). Functioning β-cells are required by both SU and meglitinides, therefore it is 
advised that patients with low C-peptide are not initiated on either therapy (Linden 
and Brooker, 1978).  
Thiazolidinediones (TZDs) reduce the bodies resistance to insulin by targeting lipid 
metabolism. These drugs activate the peroxisome proliferator-activated receptor 
gamma receptor (PPARy), which is found abundantly on adipocytes (Flemmer and 
Scott, 2001). Treatment results in lower plasma fatty acid levels due to increased 
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storage of free fatty acids (FFA) by adipocytes (Flemmer and Scott, 2001). This causes 
cells to oxidise blood glucose for cellular processes thereby reducing plasma glucose 
(Sengupta et al., 2012). TZDs also lower BP, increase high-density lipoproteins (HDL), 
lower LDL and have shown promise in the treatment of CVD (Griffis et al., 2004). 
TZDs today (pioglitazone) are generally well tolerated but are associated with weight 
gain and oedema of the lower extremities. This is thought to occur in 5% of patients 
and the exact cause is not known (Sengupta et al., 2012).  
SGLT2 inhibitors prevent reabsorption of glucose in the kidney and increase 
glucose excretion in the urine (Steen and Goldenberg, 2017). This has been shown to 
increase insulin sensitivity, reduce gluconeogenesis and improve first phase insulin 
release (Reed, 2016). The mode of action is independent of β-cell function and 
insulin resistance (Kawasoe et al., 2017).  There is no loss of potency as β-cell 
function declines, and no interference with native glucose transport or insulin 
release which results in increased glycaemic efficacy, reduced body weight and a 
positive effect on blood pressure (BP) (Kadokura et al., 2014). Due to the high output 
of glucose in urine some patients, particularly women, are at risk of urinary tract 
infection. Diabetic ketoacidosis is also reported as a risk (NICE, 2017). Patients 
suffering with CKD are not suitable for this medication (Farahani, 2017).  
Dipeptidyl peptidase IV inhibitors (DDP-IVi)  block the action of the DDP-IV 
enzyme which metabolises the incretin hormones glucagon-like peptide-1 (GLP-1) 
and glucose-dependent insulinotropic polypeptide (GIP) (Kazafeos, 2011). GLP-1 has 
been implicated in having a number of positive effects on glycaemia including; 
increasing insulin secretion (only during hyperglycaemia), delaying gastric emptying 
and suppressing glucagon secretion (Astrup et al., 2012). DDP-IVi have been shown 
to significantly increase GLP-1 levels and have a mild adverse event profile, with 
most incidences being gastrointestinal (Brunton, 2014). DDP-IVi are metabolised via 
renal and hepatic systems and have been assessed in patients with various degrees 
of renal impairment (Ramirez et al., 2013). NICE advise that they are safe to be 
prescribed with advanced CKD, although dosing is to be modified according to CKD 





1.3.3.3 Triple and Quad therapy  
 
Triple therapy is recommended if HbA1c targets have not been achieved after 6 
months dual therapy. NICE guidelines recommend third line therapies consist of 
metformin and sulphonylurea plus either, DDP-IVi, SGLT2i, or a thiazolidinedione. 
The patient must be trialled on a triple medication for 6 months with regular renal 
assessments and HbA1c and weight recordings upon completion. Only upon 
inadequate response can 4th line therapy or initiation of GLP-1R agonists be 
considered (NICE, 2017).   
GLP-1R agonists are an injectable therapy and are modified versions of the 
native hormone GLP-1. GLP-1 potentiates the release of insulin after feeding, 
however the native peptide has a very short half-life due to degradation by DDP-IV 
(Kazafeos, 2011). GLP-1Ra are resistant to DDP-IV degradation and therefore have a 
sustained effect on insulin release, glucagon activity and gastric emptying, with no 
chance of hypoglycaemia unless used in combination (Kazafeos, 2011). Liraglutide 
has been shown to have a positive impact on weight loss and has been licensed as an 
obesity treatment in the USA (Nuffer and Trujillo, 2015). Side effects are common 
but tend to be mild gastrointestinal effects (Buse et al., 2011).  
NICE have stipulated specific guidelines for the prescription of GLP-1Ras. The 
patient must have a body mass index (BMI) of 35 kg/m2 and another medical 
problem associated with obesity. The only time it is recommended to prescribe this 
drug to an individual with a BMI less than 35 kg/m2 is if insulin therapy would have a 
significant occupational implication or if weight loss would benefit other co-
morbidities (NICE, 2017). As with other therapies patients are trialled on a GLP-1Ra 
for 6 months. Response is defined as a reduction in HbA1c of 11 mmol/mol (1%) and 
a 3% reduction in body weight, if these criteria are not met, the therapy must be 
discontinued and it is recommended that insulin should be introduced to achieve 
target HbA1c (NICE, 2015). 
 
1.3.4 Insulin therapy 
 
Insulins are classed as rapid, intermediate, long or ultralong based on initiation 
phase, maximum peak duration and total duration (Figure 1). All can be injected 
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subcutaneously or intravenously, and have various delivery mechanisms including 
needle and syringe and cartridge systems. On initial prescription dose is calculated 
dependent on weight, height and sensitivity (Kakou, 2002). The initiation of insulin 
therapy is accompanied with significant risks and side effects, the most common of 
which are hypoglycaemia and hypertrophy of the injection site (Honegger and 
Spinas, 1997).  
 
Table 1.1 – Current clinically available types of insulin for the treatment of type II 
diabetes. Rapid acting insulins (Humalog, Eli Lilly) active ingredient is insulin lipro 
and typically initiates response after 10 min. It most commonly prescribed in T1D but 
is used to treat T2D (Home, 2012). Intermediate insulin (Neutral proatamine 
Hagedorn, NPH) is commonly prescribed with short acting insulin but risks of night 
time hypoglycaemia are reported, and it has a 1 hour activation lag. Long insulin 
(Lantus, Sanofi-Aventis) and ultralong insulins (Tresiba, Novo Nordisk) are often 
favoured by the NHS as they have a long initiation period of 8 h and no peak action, 
therefore a lower risk of hypoglycaemia (Lepore et al., 2000).      
 
1.3.5 Metabolic surgery for T2D 
 
Pharmaceutical approaches aimed at restoring glucose homeostasis in diabetes are 
effective and can reduce long term complications and mortality but adherence is a 
significant confounding factor (Ionova et al., 2015). There is emerging evidence that 
gastrointestinal operations such as vertical sleeve gastrectomy, roux-en-Y gastric 
bypass, biliopancreatic diversion and laparoscopic adjustable gastric banding can 
provide significant weight loss, reduce obesity-related complications and reverse 
insulin resistance, dramatically improving glucose control (Osland et al., 2017). 
Metabolic surgery causes rapid transport of nutrients to the lower intestine which 
has been shown to result in increased incretin secretion (Osland et al., 2017). The 








Rapid acting (Humalog®) 10 min 1 hour 2 h 
Intermediate (Neutral proatamine) 1 hour 5 h 18 h 
Long acting (Lantus®) 8 h No peak 24 h 
Ultra-Long acting (Tresiba®) 8 h No peak 48 h 
10 
 
by affecting peptide YY (PPY) and ghrelin (Cummings et al., 2007). These unique 
circumstances enable a sustained incretin effect, which impacts on food intake, 
weight loss and insulin sensitivity (Alamuddin et al., 2017).   
  The cost of this type of surgery is £9000 - £15000 (Villamizar and Pryor, 
2011). This may be more cost effective than years of pharmacological treatment, and 
has led to organisations such as the International Diabetes Federation (IDF) taskforce 
to suggest T2D patients with a BMI >40 kg/m2 and patients with a BMI between 35 - 
39.9 kg/m2 undergo surgery if HbA1c is inadequately controlled by medical therapy 
(IDF, 2012).  
 
1.4 Complications associated with T2D 
 
1.4.1 Microvascular complications 
 
T2D patients usually suffer from multiple chronic conditions that arise directly or 
indirectly from hyperglycaemia (Bhupathiraju and Hu, 2016). The UKPDS and DCCT 
trials (American Association of Diabetes, 2002) defined a clear link between 
microvascular disease and glucose control (American Association of Diabetes, 2002). 
Microvascular disease occurs predominantly in the retina, kidney and vascular 
endothelium (McElduff, 2016), where glucose uptake is independent of insulin 
(Duckworth et al., 2009). High levels of glucose directly damage the endothelium, 
causing oxidative stress (OS), and advanced glycation end-products (AGEs) which 
alter blood flow and cause significant organ dysfunction (Ettelaie et al., 2008).  
Diabetic retinopathy is the most common form of visual loss in the western 
world (Gale, 2008). It occurs due to microvascular damage in the retina and is 
associated with basement membrane thickening, increased capillary permeability 
and micro-aneurysms (Chronopoulos et al., 2011). These changes cause retinal 
ischaemia which drives the production of neo-vascularisation, poor lymphatic 
drainage and ultimately macular oedema (Yun and Adelman, 2015). Retinopathy is 
directly related to duration of diabetes and tends to be more prevalent in long term 
patients (Mathur et al., 2017).  
Nephropathy is caused by elevated blood glucose in combination with 
hypertensive driven glomerular damage (Tan et al., 2013). Oxidative stress reduces 
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dilation of blood vessels in the kidney causing endothelial dysfunction and the 
release of cytokines, exacerbated by atherosclerosis, leading to significant kidney 
damage (Cade, 2008). This is thought to happen in 40% of T2D patients within 25 
years (Tan et al., 2013). Aggressive BP reduction is recommended for the treatment 
of nephropathy. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin 
receptor blockers (ARB) are recommended by NICE as a first line treatment. If 
adequate control cannot be achieved pharmacologically then renal replacement 
therapy is a last resort (NICE, 2017).  
Diabetic neuropathy refers to a range of nerve disorders caused by diabetes. 
The condition is usually persistent and most commonly a distal, symmetrical 
sensorimotor neuropathy which affects both feet (Greig et al., 2014). Symptoms 
include tingling, numbness, weakness and pain (Malik, 2014). The risk of developing 
neuropathy is proportional to the magnitude and duration of hyperglycaemia (Greig 
et al., 2014). Initial management is achieved through good glycaemic control but 
once neuropathy is established glucose medications have little effect on the pain and 
analgesics and opiates are prescribed, dependent on severity (NICE, 2017). Tricyclic 
antidepressants such as amitriptyline have also shown promise, particularly in the 
early stages (Max et al., 1992).  
Complications associated with neuropathy including ulceration, infection and 
charcot arthropathy, and are the main driving forces behind most foot amputations 
(Mascarenhas and Jude, 2014).  
 
1.4.2 Macrovascular complications 
 
Macrovascular complications of T2D are coronary artery disease, peripheral arterial 
disease and stroke (Fowler, 2008). Pathologically the macrovasculature is at greatest 
risk from atherosclerotic processes, which lead to the narrowing and eventual 
blocking of arteries leading to heart attacks or stroke (Bhupathiraju and Hu, 2016). It 
is thought that atherosclerosis is the result of chronic inflammation and oxidative 
stress that damages peripheral arterial walls (Dinh et al., 2017). Dyslipidaemia 
greatly increases the risk of macrovascular conditions and is common in T2D. 
Dyslipidaemia is characterised with abnormally high levels of LDL (Shishino et al., 
2007). These particles penetrate and form strong attachments to arterial walls 
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before being oxidised. Once oxidised the immune system recognises LDL as “foreign” 
and results in a cascade resulting in the formation of atherosclerotic plaque (Chiesa 
et al., 1998).  This causes a number of serious complications; angina is one of the 
most common and occurs if the heart is not receiving enough blood, resulting in pain 
and discomfort (Yao et al., 2017). Myocardial infarction and cerebral infarction 
occurs as a result of a blood clot that completely cuts off blood supply to the heart or 
the brain, both of which are life threatening (Xia et al., 2017). As many as 80% of T2D 
patients die from cardiovascular related complications (Grimaldi and Heurtier, 1999).   
Lipids and blood pressure (BP) are aggressively treated in T2D to reduce CVD 
risk (NICE, 2016a). Statins are often first line therapy to reduce hyperlipidaemia due 
to their clinical effectiveness and low cost. A blood pressure target of 140/90 mmHg 
is set for any individual under 80 years of age (NICE, 2016a). First line therapy for BP 
control are ACE inhibitors or angiotensin receptor blockers. (NICE, 2016a). 
 
1.4.3 Other associated complications 
 
1.4.3.1 Gastrointestinal complications 
 
Diabetes commonly causes problems with digestion, and results in a condition called 
gastroparesis. In healthy stomach the vagus nerve stimulates (Homko et al., 2016) 
contractions that drive food out via the pyloric sphincter and into the small intestine. 
Prolonged hyperglycaemia damages the vagus nerve and disrupts gastric emptying 
resulting in symptoms including abdominal pain, nausea, vomiting, heartburn and an 
over secretion of enzymes and acids (Koch et al., 2016). Gastroparesis can also result 
in bacterial infections from undigested food (Homko et al., 2016).  
Proton pump inhibitors (PPI’s) are a group of medications that cause a long 
lasting and pronounced reduction in gastric acid production. NICE recommend their 
use for a number of conditions including; dyspepsia, peptic ulcer, gastroesophageal 
reflux disease and gastritis (NICE, 2014a). These drugs address a number of 
symptoms related to gastroparesis but do not treat the underlying damage to the 
vagus nerve or the delay in gastric emptying (Seol, 2006).  It is recommended that 
strict dieting and lowering HbA1c has the best clinical outcomes over the long term 




1.4.3.2 Respiratory complications 
 
Diabetes has been directly linked to a decline in lung function and numerous 
respiratory conditions (Bazdyrev et al., 2015). It is thought that those with diabetes 
are 8% more likely to get asthma, 22% more likely to get chronic obstructive 
pulmonary disease (COPD), 54% more likely to get pulmonary fibrosis and twice as 
likely to get pneumonia than the general population (Diabetes UK, 2014). 
Hyperglycaemic conditions cause systematic inflammation and oxidative stress 
impairing the immune system (Craig et al., 2009). A low oxygen environment and 
poor immune response allow for easy colonisation of bacteria such as streptococcus 
pneumonia (Rao, 2016). High blood glucose has also been shown to be a direct cause 
of pulmonary fibrosis, which negatively effects gaseous exchange causing shortness 
of breath and chest pain (Ehrlich et al., 2010). 
 
1.4.3.3 Musculoskeletal disorders 
 
T2D increases the risk of bone and joint disorders due to diabetic neuropathy, 
vascular disease and obesity. Osteoporotic fractures are most common, and higher 
in females than males (Xia et al., 2012), attributable to the effect of the menopause 
on bone mineral density and bone size (Sotornik, 2016). Insulin resistance, obesity, 
inflammation and the formation AGEs are associated with changes in bone structure 
and fracture risk in T2D (Xia et al., 2012).  
Osteoarthritis (OA) is a chronic joint disease common at older age and can 
affect the knees, hands and hips (Thijssen et al., 2015). It is caused by the 
degradation of articular cartilage (Roach, 2008). The high incidence in T2D is likely 
due to obesity (Thijssen et al., 2015). Obese patients have increased loads on the 
joints, which breaks down collagen and proteoglycans disrupting cartilage integrity 
(Dong et al., 2017). Chondrocytes then undergo apoptosis reducing joint space and 
increasing friction between the bones, causing stiffness, swelling and pain (Thijssen 
et al., 2015). Diabetes tends to make arthritis worse; the inflammatory state induced 
by hyperglycaemia has been shown to increase pro-inflammatory cytokines Tumor 
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necrosis factor alpha (TNFα) and Interleukin 6 (IL-6) in the synovial fluid, increasing 
cartilage degradation and disease progression (Mobasheri et al., 2002).  
Gout is another form of arthritis which most commonly affects men. Gout is 
associated with an increased risk of T2D (Rho et al., 2016).  Gout is diagnosed when 
urate crystals saturate the serum (6 mg/dl) and is worsened if the patient is suffering 
from obesity (Vargas-Santos and Neogi, 2017). Uric acid crystallises in the joints 
causing inflammation and severe pain.  
 
1.4.4 Psychological factors and Diabetes Mellitus 
 
One third of individuals with diabetes are thought to have psychological and/or 
social problems which impact their ability to manage their condition (Garrett and 
Doherty, 2014). This is thought to be due to significant changes being required in 
how they live their lives which impacts relationships, work and finances (Penckofer 
et al., 2007). The most significant changes are the requirement for multiple 
medications throughout the day, and regular clinic or hospital visits to monitor 
response. This is known to have a negative effect on mental health, leaving 
individuals vulnerable to anxiety disorders, mild and severe depressive disorders and 
other emotional conditions (Rasmussen et al., 2013). Studies have shown that 
depression is prevalent in T2D, with patients more likely to suffer a depressive 
episode than the general population (Nouwen et al., 2010). Depression is a known 
risk factor for non-compliance in terms of diabetic regimes (Hasan et al., 2015) and 
many studies highlight links between depression and increased mortality in diabetes 
(Hofmann et al., 2013).          
Treating and managing depression can be difficult. Surveys have indicated 
only 34% of patients with chronic or recurrent depression believe they receive 
adequate treatment (Bostwick, 2010).  NICE do not offer any prescription guidance 
in relation to depression subtypes but instead focus on the effect certain types of 
anti-depressants have on other physical disorders (NICE, 2016b). There are 9 classes, 
with similar efficacy, but the severity of side effects can be quite different depending 
on the individual and their underlying conditions (NICE, 2016b). There is growing 
evidence that supports depression being a significant risk factor for the onset of 
Alzheimer’s disease (AD) (Tsuno and Homma, 2009). Previous history of depression, 
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up to 10 years prior to AD diagnosis, doubles the risk (Ownby et al., 2006). 
Neuropathologically patients with a history of depression have been found to have 
substantially more hippocampal beta amyloid plaque and neurofibrillary tangle 
formation when compared to patients without a history of depression; pathology 
characteristic of AD (Rapp et al., 2006). This damage is thought to be due to 
sustained elevations in cortisol associated with a depressive state (Swaab et al., 
2005). Some suggest that depression represents a pre-dementia syndrome as many 
patients with late onset depression (LOD) go on to develop AD within a couple of 
years (Chertkow et al., 2013).  
 
1.4.4.1 Increased risk of Alzheimer’s disease in T2D 
 
Alzheimer’s disease (AD) is the most common type of Dementia (Dening and 
Sandilyan, 2015) and T2D is a risk factor for development of AD (Biessels et al., 2006) 
with patients having a 60% increased risk of developing the condition if they are 
suffering from hyperglycaemia (Peila et al., 2002). Clinically most cases (60%) of AD 
are classified as late onset (LOAD) and characterised by a progressive memory loss 
and gradual cognitive decline (Luchsinger, 2010). AD is a progressive 
neurodegenerative disease, recognised by various neuropathologies including; 
neurofibrillary tangles (NFT), senile plaques and significant neuron and synapse loss 
in the cerebral cortex and other subcortical regions (Haroutunian et al., 2008). 
Substantial epidemiological evidence links T2D to AD (Ramirez et al., 2015). Both are 
characterised by various signalling mechanisms that are involved in insulin 
resistance, inflammation and oxidative stress (Malkki, 2015).  
A model for cognitive decline in obesity is illustrated in Diagram 1. T2D and 
obesity are associated with poor cognitive function (Nameni et al., 2017). High BMI 
has been found to positively correlate with cognitive deficits and is consistent 
irrespective of age (Benito-Leon et al., 2013). HbA1c is a significant risk factor for 
cognitive decline; elevations have been shown to correlate with increased incidence 
of all cause dementia and AD (Ramirez et al., 2015). Poor glycaemic control 
decreases brain integrity and is linked to reduced hippocampal volume (Ho et al., 
2010). This is thought to be due to adverse brain changes caused by glucolipotoxity 
(Pugazhenthi et al., 2017). High glucose and FFA reduce cerebral perfusion and alter 
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hemodynamics (Alosco et al., 2013). This is known to affect brain regions essential 
for reasoning, attention, processing speed and verbal memory (Alosco et al., 2012). 
Macrovascular complications are also linked to cognitive decline (Ezzati et al., 2017). 
Hypertension, atherosclerosis and hyperlipidaemia have been shown to increase 
circulating inflammatory markers (Kasashima et al., 2017). Advanced glycation end 
products (AGE) are associated with elevated glucose and are implicated in cognitive 
decline associated with T2D, obesity and AD (Du Yan et al., 1996, Münch et al., 
1998). Impaired insulin action and chronic hyperglycaemia increases the rate of 
cognitive decline (Jakobsen et al., 1990) and are associated with reduced amyloid 
beta (Aβ) degradation (Ravona-Springer et al., 2012). Diabetes patients have brain 
changes analogous to those in AD, such as reduced total brain volume, white matter 
hypertensities (WMH) and altered brain structure (Schmidt et al., 2004). This is 
thought to be due to tau and amyloid beta (Aβ) protein abundance (Luchsinger, 
2012), high levels of Reactive Oxygen Species (ROS) and pro-inflammatory cytokines; 
key markers of insulin resistance in obesity, T2D and of deteriorating cognitive 
function (Block and Hong, 2005). A number of hormones and neuropeptides 
including leptin and ghrelin are also disrupted in T2D and obesity (Akieda-Asai et al., 
2014), and leptin, in particular, has been shown to be neuroprotective, and 














Diagram 1.1 – Model for cognitive decline in obesity. Obesity has a number of associated comorbidities, clinical features and novel risk factors (Weng et al., 
2017). Insulin resistance and chronic hyperglycaemia are key pathologies in the development of adverse brain changes (Naderali et al., 2009) and have been 
implicated in the development of AD even in the absence of diabetes (Talbot et al., 2012a). Reduced insulin signalling and hyperinsulinemia results in 
hyperphosphorylation of GSK3β and tau, decreasing GSK3 enzymatic activity and increasing NFT formation respectively (Wick et al., 2003). Reduced PI3K/AKT 
signalling reduces IDE, ultimately increasing Aβ neuronal protein levels (Vekrellis et al., 2000). Chronic hyperglycaemia affects AD development via multiple 
mechanisms. High LDL and glucose increase the production of Advanced Glycation End products (AGE) that mediate RAGE (the receptor for advanced glycation 
end products) induced neuronal inflammation and oxidative stress (Slowik et al., 2012). Weight loss and eating a diet  low in saturated fats has been found to 
have positive effects on cognition (Hardman et al., 2016) 
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In brain, insulin and insulin growth factors (IGFs) control synaptic maintenance and 
have neuroprotective qualities (Freude et al., 2009).  The insulin receptor and IGF 
receptor type-1 (IGF-1R) are functionally and structurally similar allowing insulin and 
IGF-1 to activate both receptors (Laviola et al., 2007), to trigger auto 
phosphorylation of the insulin receptor substrate (IRS) (Gasparini and Xu, 2003). IRS 
is essential for the activation of various insulin signalling cascades including Protein 
kinase B (AKT), the mammalian target of rapamycin (mTOR) and glycogen synthase 
kinase 3 (GSK3). Disruption of this substrate has been shown to result in severe 
insulin resistance (Wick et al., 2003).   
Inflammation is a characteristic of T2D, obesity and cognitive decline and 
perpetuates insulin resistance (Ndumele et al., 2006).  Mitochondrial injury induced 
by hyperglycemia can trigger the formation of proinflammatory protein complexes 
called inflammasomes, which cause the activation of Caspase 1 (CASP1) and 
neuronal secretion of IL-18 and IL-1β (Singhal et al., 2014). Another inflammatory 
pathway triggered by hyperglycaemia is the Mitogen-Activated Protein Kinase 
(MAPK) pathway, which contributes to cognitive decline (Chen et al., 2017) by 
regulating neuronal apoptosis and phosphorylating APP and tau (Blurton-Jones and 
LaFerla, 2006).  
 
1.5 Implications for treatment of cognitive decline with current T2D 
medications 
 
1.5.1 Metformin and Thiazolidinediones 
 
 It is well established that improved insulin action in neurons improves cognitive 
function (Yu et al., 2015). Metformin increases insulin sensitivity and reduces 
gluconeogenesis in liver (Tokubuchi et al., 2017). Preclinical data has indicated 
metformin can cross the BBB (Moreira, 2014). Hyperinsulinemic neuronal cells lines, 
when treated with metformin, can re-establish normal insulin signalling (El-Mir et al., 
2008). Hippocampal neurons treated with metformin are protected against MAPK 
induced apoptosis and beta amyloid (Aβ) induced cytotoxicity (Chen et al., 2016). 
These protective effects are supported in-vivo in tau transgenic mice (Kickstein et al., 
2010). Clinical studies have raised questions regarding the safety of metformin in AD. 
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One study assessed long term usage of SUs, TZDs, insulin and metformin on AD 
progression and indicated metformin was associated with a decline in cognitive 
function via an increase in beta secretase-1 (BACE1) (Imfeld et al., 2012).  
TZDs regulate plasma FFAs via the PPARy receptor (Kelly et al., 1999), which 
was  thought to have a significant impact on cognition after it was found to be highly 
expressed in the temporal cortex of AD patients (Sato et al., 2011).  Pre-clinical work 
demonstrates PPARy agonists reduce pro-inflammatory genes and decrease Aβ 
plaques (Cramer et al., 2012), however clinical trial outcomes have been variable 
(Risner et al., 2006). There is currently a large phase III clinical trial underway 
assessing the effect of 24 months treatment with pioglitazone on mild cognitive 
impairment (MCI) in individuals with different apolipoprotein (APOE) status 
(Tomorrow trial, NCT1931566).  
 
1.5.2 Glucagon-like peptide-1 receptor agonists (GLP-1Ra)  
 
In brain GLP-1R activation has neuroprotective effects (Dunphy et al., 1998). In vitro 
GLP-1 has been shown to reduce apoptotic cell death and induce outgrowth of 
neuronal processes (Kimura et al., 2009).  Studies with Val(8)GLP-1 (Gengler et al., 
2012) and liraglutide in the APP(swe)/PS1(ΔE9) (APP/PS1) mouse model (McClean 
and Holscher, 2014) of AD have demonstrated significant improvements in learning 
and memory and reductions in AD pathologies. A clinical trial in early Alzheimer’s 
disease is ongoing, Evaluating Liraglutide in Alzheimer’s disease (ELAD, 
NCT01843075). 
 
1.5.2.1 GLP-1 analogues currently licenced for the treatment of T2D 
 
GLP-1Ras are designed to mimic the effects of native hormone GLP-1. This peptide is 
synthesised in intestinal endocrine cells and is one of two incretin hormones GLP-1 
and glucose-dependent insulinotropic polypeptide (GIP) (Drucker, 2001). GLP-1’s 
main effect is known as the incretin effect, characterised by increased insulin 
secretion due to an oral glucose load, when compared to the same load 
administered intravenously (Nauck et al., 1986). This effect is thought to account for 
60% of insulin secreted after a meal and has be shown to be impaired in T2D (Nauck 














Diagram 1.2 –T2D therapeutics for the treatment of cognitive decline and AD. Inflammation, insulin resistance and insulin deficiency are characteristics of T2D 
and AD. TZDs such as pioglitazone have been shown to reduce fatty acid mediated inflammation and as a secondary effect improve insulin resistance (Kelly et 
al., 1999). Metformin has also been shown to improve insulin resistance. It is thought it achieve this by increasing insulin receptor activity, enhancing glycogen 
synthesis and augmenting GLUT4 translocation, all of which are compromised in AD (El-Mir et al., 2008). Stimulation of the incretin effect is a third mechanism 
by which cognitive deficits and AD may be targeted with T2D drugs. DPP-IVi and GLP-1a have been shown to increase insulin secretion and sensitivity as well as 
having a significant effect on appetite and weight loss (Nuffer and Trujillo, 2015). GLP-1Ras are capable of crossing the BBB and activating neuronal GLP-1Rs 
(Astrup et al., 2012). GLP-1R activation has various effects on insulin sensitivity, and insulin secretion via the activation of the cAMP signaling cascade, and 
leptin pathways (Kazafeos, 2011).    
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emptying, inhibiting glucagon secretion and regulating food intake (Astrup et al., 
2012). Native GLP-1 is rapidly degraded within 2 min by DDP-IV (Kazafeos, 2011). 
Various enzyme resistant analogues have been developed to prolong its half-Life 
(Kalra, 2013). There are currently five GLP-1 analogues in use, albiglutide 
(Tanzeum©), dulaglutide (Trulicity©), Exenatide (Byetta© + Bydureon©), 
lixisenatide (Lyxumia©) and liraglutide (Victoza©), each with different 
pharmacokinetics and pharmacodynamics (Table 2) and adverse event profiles 
(Table 3).  
Albiglutide is a recombinant peptide made up of two 30 amino acid 
sequences of altered human GLP-1 which is fused to human albumin (Bronden et al., 
2017). It is administered once weekly and in clinical trials has been shown to lower 
HbA1c by 11 mmol/mol (1%) (Rendell, 2017). It is considered less effective than 
liraglutide (1.8 mg) when used as add on therapy and does not have an effect on 
weight loss (Nauck et al., 2016). Injection site reactions are common but nausea is 
significantly less frequent than with other GLP-1R agonists (Rendell, 2017). 
Dulaglutide is also a once weekly analogue, it is covalently bonded to an Fc section of 
human immunoglobulin G4 (IgG4) and has been shown to reduce HbA1c by 11 
mmol/mol (Pozzilli et al., 2017). Interestingly, it is the only other GLP-1Ra that has 
not been shown to be inferior to liraglutide with respect to glycaemic control and 
weight loss (Morey-Vargas and Shah, 2014).  The main reason it is not as widely used 
as liraglutide is its adverse advent profile. Along with the classical gastrointestinal 
side-effects it is also associated with various digestive system problems including 
gastrointestinal reflux disease, anaphylaxis, and pancreatitis (Dungan et al., 2016). 
Exenatide (Byetta©) was the first GLP-1Ra approved. It is a synthetic version of 
exendin-4, a hormone first isolated from Gila monster venom, and has 50% amino 
acid homology with native GLP-1 (Bhavsar et al., 2013). It is suitable for twice daily 
(Byetta©) and once weekly injections (Bydureon©). Byetta has the most severe 
adverse event profile out of all GLP-1 analogues. The most common are the classic 
incretin effects (nausea, vomiting and diarrhoea) but it also poses a significant risk of 
hypoglycaemia when used in combination with a SU (Simo et al., 2015). Injection site 
reactions, headaches, dizziness, anaphylaxis and pancreatitis have been reported 


















Table 1.2 – Pharmacokinetic and pharmacodynamic profile of currently available GLP-1Ras. Clinical trial results have indicated that each GLP-1a analogue has 
different tissue specific effects (Kalra, 2013). The pharmacokinetic profile of each drug is different. Injection frequency varies from twice daily to weekly. 
Dependent on the frequency of injection the time at peak plasma concentration (PPC) is variable (Bronden et al., 2017). Bioavailability tends to be 
approximately 50%, with the exception of Exenatide. Cmax is the maximum serum concentration the drug can achieve and Tmax is the amount of time is takes to 
reach Cmax. The volume of distribution (V.O.D) is the amount of liquid the drug needs to be distributed into be equal concentration to that of plasma. The 
excretion rate is how quickly the drug is removed from the body and excretion method describes the mechanism that may involve filtration by the kidneys or 
ubiquitous protease degradation (Geiser et al., 2016). Each analogue induces insulin secretion, reduces glucagon secretion, improves β-cell function and 
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Table 1.3 – Adverse events associated with currently available GLP-1Ras from phase III clinical trials. Studies have indicated that GLP-1 analogues are 
commonly associated with gastrointestinal adverse events and some pose a risk of hypoglycaemia if used as a combination therapy (Danne et al., 2017). Each 
analogue has a different adverse event profile and affects individuals in different ways. Discontinuation of therapy can often be because of adverse events and 
not because patients have not responded to the medication. Exenatide is considered as having the most severe adverse event profile (Shi et al., 2012) while 
liraglutide has the mildest (Danne et al., 2017). It is important to recognise the different risk factors with each drug and take into account comorbidity when 
prescribing. Albiglutide, for example, is less associated with nausea when compared to liraglutide but is thought to pose a risk to CVD patients (Bronden et al., 
2015). 
Drug 
Adverse Events (Phase III clinical trials) 
Common Uncommon Rare 
Albiglutide 30 mg (Tanzeum©) 
(Nauck et al., 2016) 
Injection site reactions, diarrhoea, nausea, 
hypoglycaemia when used in combination 
with insulin, pneumonia 
Atrial fibrillation, hypoglycaemia when used in 
combination with metformin, gastro reflux 
Pancreatitis, hypersensitivity reaction 
Dulaglutide 1.5 mg (Trulicity©)  
(Pozzilli et al., 2017) 
Nausea, vomiting, diarrhoea, hypoglycaemia 
when used in combination with insulin or SU 
Fatigue, various digestion problems, injection 
site reaction 
Anaphylactic reaction, acute 
pancreatitis 
Exenatide 2 mg (Byetta©) 
(Shi et al., 2012) 
Nausea, vomiting, diarrhoea, hypoglycaemia 
when used in combination with SU 
Various injection site reactions, headache, 
dizziness, various digestion problems 
Anaphylactic reaction, acute 
pancreatitis, ocular disorders 
Lixisenatide 10 mcg (Lyxumia©) 
(Meier et al., 2015) 
Nausea, vomiting, diarrhoea, hypoglycaemia  
when used in combination with SU  
Hypoglycaemia when used in combination 
with metformin, dizziness, dyspepsia, 
injection site pruritus 
Anaphylactic reaction 
Liraglutide 1.8 mg (Victoza©) 
(Russell-Jones, 2009) 
Nausea, Vomiting, Diarrhoea 
Gastritis, abdominal pain, gastro reflux, 





Lixisenatide and liraglutide are more commonly prescribed in the clinic (Werner et 
al., 2010). Both drugs have been shown to have a similar pharmacodynamic profile 
but liraglutide has consistently demonstrated superior efficacy in head to head 
clinical trials (Meier et al., 2015).  This is likely due to the formulation and structure 
of the peptides. Lixisenatide is a 44 amino acid peptide, derived from the first 39 
amino acids of Exenatide (Werner et al., 2010). Liraglutide is 97% homologous to the 
native GLP-1 with one lysine to arginine substitution at position 34 and the addition 
of a C16 acyl group to lysine 26 (Neumiller, 2009). It tends to have a more sustained 
impact on HbA1c and a greater propensity to induce weight loss (Davies et al., 2015). 
Real world evidence in the form of electronic care records (ECR) is now emerging and 
supporting the findings of clinical trials highlighting liraglutide as being the most 
effective GLP-1Ra available in the clinic today (Nyeland et al., 2015). Liraglutide also 
has the most favourable adverse event profile of the GLP-1Ras (Kaku et al., 2011).      
 
1.5.3 Identification of potential genes and proteins that may be 
important in response to GLP-1 therapy derived from mechanism of 
action 
 
1.5.3.1 Glucagon-like peptide-1 receptor signalling in the pancreas 
 
The GLP-1R is a seven transmembrane domain protein and a member of the 
glucagon receptor family (Yang et al., 2016). It is wildly expressed in pancreatic islets, 
brain, gastrointestinal tract, heart and kidney (Dunphy et al., 1998). In the pancreas 
GLP-1 increases insulin gene transcription (Buteau et al., 1999) and replenishes β-cell 
stores (Xu et al., 1999). GLP-1R activation causes PDX1 protein levels to increase 
causing it to translocate to the nucleus and increase insulin gene promoter activity 
(Wang et al., 2005a). This activity results in phosphorylation of AKT and Forkhead 
box protein O1 (FOXO1). Upon activation FOXO1 is excluded from the nucleus which 
results in further disinhibition of PDX1 activity (Elghazi et al., 2006). GLP-1R 
activation also increases cAMP response element-binding protein (CREB). This 
transcription factor binds to cAMP response elements (CRE) on the insulin promoter 
gene increasing its transcription (Jhala et al., 2003).  
GLP-1 is an effective stimulator of glucose-induced insulin secretion. 
Adenylate cyclase (AC) is positively coupled to its receptor (Bos, 2006). When 
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activated this catalyses the conversion of adenosine triphosphate (ATP) to cyclic 
adenosine monophosphate (cAMP) leading to the activation protein kinase A (PKA) 
and exchange protein directly activated by cAMP 2 (EPAC2) (Shigeto et al., 2017). 
Calcium entry carries Inositol trisphosphate receptors (IP3R) and ryanodine (RYR) 
inside the cell which are activated by PKA and EPAC2, respectively. PKA then 
phosphorylates the KATP channel facilitating its closure ultimately regulating the 
docking and fusion of insulin granules to the plasma membrane (Seino and Shibasaki, 
2005). It has been shown in vivo that Gs alpha subunit (Gsa) and the PI3K/AKT 
complex are the key proteins involved in GLP-1’s β-cell protective effects. In a Gsa 
deficient mouse model β-cell proliferation is severely compromised resulting in 
reduced insulin secretion and β-cell mass (Xie et al., 2007). 
 A relatively new anti-apoptotic target of GLP-1 is the enzyme protein 
arginine methyltransferase-1 (PRMT-1) (Hashimoto et al., 2016). Studies in the 
diabetic kidney found that GLP-1R activation resulted in significant reductions in 
AGE-induced RAGE expression and reduced the generation of ROS (Ojima et al., 
2013). GLP-1R activation was found to directly increase mRNA levels of PRMT-1 
which negatively regulates asymmetric dimethylarginine (ADMA) which is essential 
in AGE induced ROS generation, and is elevated by oxidised LDL (Böger et al., 1998). 
Interestingly ADMA is also increased in AD (Selley, 2003) and is associated with 
vascular pathology and increased inflammation (Zhu et al., 2007). In kidney, in 
addition to its anti-inflammatory properties, PRMT1 has been shown to methylate 
FOXO1, critically blocking AKTs phosphorylation, allowing FOXO1 to translocate into 
the nucleus (Yamagata et al., 2008). It is well established that this process increases 
genes involved in cell death (Yamagata et al., 2008). Recent studies have identified 
PRMT1 as being widely expressed in the CNS and essential for healthy brain function. 
PRMT1 KO mice have significant brain abnormalities and die within two weeks of 
birth, due to substantial loss of oligodendrocytes (Hashimoto et al., 2016). 
Accordingly the effects of GLP-1 analogues on this enzyme are of interest. 
 
1.5.3.2 Glucagon-like peptide-1 receptor signalling in the brain 
 
The effect that insulin has in the brain is well documented (Vilsbøll et al., 2008). 
Acute action in the central nervous system, affects whole body metabolic function 
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(Obici et al., 2002b, Obici et al., 2002a), and emerging data has implicated it in 
memory and cognition (Benedict et al., 2007). GLP-1R activation is also known to 
regulate appetite and induce weight loss via an interaction with leptin (Goldstone et 
al., 1997b).  Insulin and leptin are closely linked and both capable of crossing the 
blood brain barrier (BBB) and acting as adiposity feedback signals (Baskin et al., 
1999). In obesity and T2D this mechanism is severely impaired, resulting in excessive 
weight gain (Kahn et al., 2006).     
The relationship between the following factors is illustrated in Diagram 3. 
After Leptin binds to its receptor (LEP-R) it forms a complex with Janus kinase 2 
(JAK2) (Agrawal et al., 2011). Under ‘normal’ conditions this causes the 
phosphorylation of signal transducer and activator of transcriptome 3 (STAT3), which 
results in its translocation into the nucleus and appetite reduction via Pro-
opiomelanocortin (POMC) expression and neuropeptide Y (NPY) inhibition (Bates et 
al., 2003). The LEP-R / JAK2 complex is now thought to provide a link between 
appetite regulatory mechanisms and insulin signalling pathways (Morris et al., 2010). 
Src homology 2B 1 (SH2B1) protein has been found to enhance leptin’s anti-obesity 
action by recruiting to the LEP-R/JAK2 complex and amplifying STAT3 activity; this 
recruitment has now also been shown to also allow for the binding and activation of 
IRS1 (Ren et al., 2007). 
When IRS1 is activated via the IR it phosphorylates PI3K at its p85 subunit but 
when it is recruited to the LEP-R/JAK2/SH2B1 complex it activates PI3K at its second 
subunit (p110) (Duan et al., 2004). This indirect action allows for dual 
phosphorylation of PI3K and increased activity of its downstream target AKT 
(Cantley, 2002). This process increases glucose translocation, and FOXO1 
phosphorylation allowing for increased CREB (insulin gene transcription) and POMC 
expression (appetite reduction) (Morris et al., 2010). The expression of SH2B1 is 
thought to be critical in the maintenance of leptin and insulin signalling; studies have 
found SH2B1 deficiency or various single nucleotide polymorphisms (SNPs) of the 
gene to result in severe leptin resistance, energy imbalance, obesity, and T2D 
(Jamshidi et al., 2007).  
Tight regulation of STAT3 is essential for appetite regulation. High nucleic 















Diagram 1.3 – Mechanism by which liraglutide treatment in brain affects insulin and leptin signalling improving glucose sensitivity, appetite and 
inflammation. GLP-1 regulates appetite via the activation of the leptin signalling pathway. The binding of leptin to the LEP-R results in auto-phosphorylation of 
JAK2 and the recruitment of SH2B1. This triple complex has profound effects on both insulin and leptin signalling. It allows for increased phosphorylation and 
translocation of STAT3 into the nucleus to regulate POMC expression and appetite (Bates et al., 2003), but also permits IRS1 binding. IRS bound to the LEP-
R/JAK2/SH2B1 complex can phosphorylate PI3K at its P110 subunit rather than its P85 subunit which has a positive effect on downstream AKT, inhibiting 
FOXO1 nuclear localisation, thereby increasing CREB activity and increasing glucose transport across the plasma membrane via GLUT4 (Ren et al., 2007). From 
an anti-inflammatory perspective treatment is thought to increase energy expenditure and movement, increasing adiponectin and decreasing lipolysis. This has 
been shown to result in reductions in IL-1β and TNFα and an increase IL-4. This expression pattern negatively regulates NFKB reducing its inhibitory effect on 
IRS1 signalling (Bjørbæk et al., 2000).  
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signalling 3 (SOCS3) (Bjørbæk et al., 2000) (Diagram 3). SOCS3 negatively regulates 
key aspects of both leptin and insulin signaling via suppression of STAT3 and IRS1 
(Yang et al., 2012).  
 
1.5.4 GLP-1’s effect on leptin signalling  
 
Both GLP-1 analogues and leptin therapies have been shown to have weight loss, 
neuroprotective and insulin sensitising effects (Ronveaux et al., 2015b). Recently 
attention has been drawn to potential combination therapies. Pre-clinical work in 
rats has shown that hypothalamic and hindbrain neurons are critical for GLP-1R and 
LEP-R interaction and that combined activation of the receptors in brain results in a 
more pronounced effect on weight loss than either receptor alone (Scott et al., 
2011b). A follow up study showed that leptin increased pSTAT3, and this effect was 
increased when co-administrated with liraglutide (Kanoski et al., 2015). Tyrosine-
protein phosphatase non-receptor type 1 (PTP1B) is a well-established negative 
regulator of JAK2, causing it to de-phosphorylate which inhibits STAT3 activation 
(Zabolotny et al., 2002b).  GLP-1R activation has been shown to directly reduce 
PTP1B at the protein level, directly augmenting leptin activity (Kanoski et al., 2015).  
In obese mice (ob/ob) leptin signalling is severely compromised and they are 
characterised by hyperleptinaemia (Münzberg et al., 2004). This effect is also 
documented in obese humans and is a result of leptin resistance (LR) (Caprio et al., 
1996), whereby the body is resistant to circulating leptin, resulting in hyperphagia 
and increased bodyweight (Raposinho et al., 2001). 
Recent clinical evidence no longer supports the notion that leptin is an 
appetite reducing hormone” but that it is an “anti-fasting” signal (Nuttall et al., 
2016). This signal is activated as adiposity reduces, which in turn lowers circulating 
leptin, resulting in increased food seeking behaviour (Nuttall et al., 2016). Clinical 
evidence shows that liraglutide treatment over short and long term trials results in 
reductions in appetite and weight loss and reduced plasma leptin (Iepsen et al., 
2015a). It has also been shown to have a significant impact on the leptin receptor 
(LEP-R) (Iepsen et al., 2015a), of which there are three classes; long (Ob-Rb), short 
(Ob-Ra) and soluble (Ob-Re) (Tartaglia, 1997). The long and soluble receptors have 
the greatest impact in the brain; the long form is the anchored receptor and 
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represents the primary signalling form in the brain and intestine (Tartaglia, 1997). 
Soluble leptin receptors are produced by proteolytic cleavage of anchored receptors 
and are the main binding protein in blood. Soluble receptors modulate leptin 
bioavailability (Gorska et al., 2010). Studies have shown a down regulation of 
anchored receptors and upregulation of soluble receptors during weight loss (Schaab 
et al., 2012). This expression pattern has been linked to decreased plasma glucose, 
insulin and PYY, and increased ghrelin supporting the anti-fasting signal hypothesis 
(Faraj et al., 2003). 
Leptin therapy induces weight loss in lean and obese subjects (Heymsfield et 
al., 1999), and results in significant improvements in insulin resistance and ingestion 
behaviours (Petersen et al., 2002). Evidence from transgenic animal studies have 
shown leptin to have a similar effect to insulin on AD pathology (Greco et al., 2011). 
Human studies have shown that AD patients have particularly low leptin levels 
(Merlo et al., 2010) and elderly patients with high leptin levels are at a much reduced 
risk of developing AD compared to those with low levels (Lieb et al., 2009).  
 
1.6 Biomarkers associated with glycaemic control and response to 
therapy 
 
1.6.1 Biomarkers  
 
Biomarkers can be any piece of information that functions as an indicator of 
physiological, pharmacological or pathological processes. In modern medicine they 
are essential for the development of personalised medicine (Falco et al., 2016). Over 
the past 20 years there has been an influx of new biomarkers published but very few 
have been accepted into routine healthcare. New markers tend to fail to meet 
clinical demands (Cramer et al., 2011). They either do not significantly impact patient 
care (Cramer et al., 2011) or do not affect clinical decision making. As such, T2D is 
still diagnosed clinically by HbA1c (identified 1975) (Tattersall et al., 1975), FPG 
(identified 1946)  (Hurwitz and Jensen, 1946) and OGTT (identified 1923) (CrawfordT, 
1938). Within the Western Health and Social Care Trust (WHSCT) C-peptide is 
measured at the point of diagnosis, but is not measured routinely at diabetes clinics. 
This means that currently T2D management relies solely on HbA1c measurement at 
6-monthly appointments to assess if current therapies are adequately managing 
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glycaemia in T2D, leaving patients vulnerable to adverse reactions and development 
of secondary complications if they do not respond to the drugs they have been 
prescribed. There is much room for improvement. 
Identification of blood based biomarkers (of glycaemic control and response 
to therapy in this case) is particularly clinically relevant due to minimal invasiveness, 
accessibility and low cost (Thambisetty and Lovestone, 2010). Blood based 
biomarker discovery is difficult, particularly in T2D and AD were the connection 
between peripheral expression levels and tissue specific levels are poorly 
understood (Glatt et al., 2005). Many of the current developments focus on how 
small alterations in a genes nucleic sequence can directly affect its function. These 
alterations are called Single Nucleotide Polymorphisms (SNPs) and can have 
profound effects on disease progression, drug response and metabolism (Jablonski 
et al., 2010). Studies have shown mRNA structure and gene expression alterations 
that occur as a result of SNPs, result in abnormal proteins that influence disease 
susceptibility (Harold et al., 2009).  
 
1.6.2 Current pathogenic variants that may influence response to GLP-1 
analogue therapy  
 
Low cost genome wide arrays have facilitated large scale screening for SNPs (Akpinar 
et al., 2017). Classification of pathogenic SNPs is a high priority in medical science 
(Florez, 2017) and Genome-Wide Association Studies (GWAS) have had success in 
identifying variants associated with traits of disease (Chung et al., 2015). More 
recently studies have shifted focus to defining genetic variation indicative of drug 
response, but have had little success (Pollastro et al., 2015). 
Targeted and whole genome sequencing has identified a number of leptin 
and insulin regulatory genes and polymorphisms that are associated with T2D (Table 
4) (Ternouth et al., 2011). The GLP-1R gene has multiple variants but only one 
(rs10305492) has been associated with any significant clinical outcome (Scott et al., 
2016). A large genome wide association study identified a non-synonymous variant 















Table 1.4 – Pathogenic variants that effect insulin and leptin signalling identified in the type II diabetes knowledge portal. The GLP-1R has been found to 
have one protective variant, thought to affect glucose and lipid metabolism (Wessel et al., 2015). The POMC gene has two pathogenic SNPs that negatively 
affect body weight and food intake (Ternouth et al., 2011). They have also been verified across multiple studies in various ethnicities (Lombard et al., 2012). 
There are three pathogenic SNPs linked to the SH2B1 gene all negatively affecting BMI, also verified in large clinical studies (Jamshidi et al., 2007). To date 
other SNPs present on these genes have not been associated with T2D traits or response to therapy (T2D-GENES Consortium, 2017).       
Gene Evidence  Chromosome position 
HG 
build 
db SNP ID Frequency % Effect 
GLP-1R Strong 6 39046794 19 RS10305492 
European (2.81%), 
Hispanic (0.66%),  
Lowers fasting 
glucose, protects 
against CVD African American (0.22%) 









ratio nutrient intake 
 African American 
(37.8%), 
East Asian (41.2%) 












 African American 
(22.4%) 





glucose, reduced T2D risk and improved insulin secretion (Wessel et al., 2015), which 
was validated in another study (Scott et al., 2016).  
Variants associated with the POMC gene have been shown to affect weight gain and 
eating behaviour; the two most prevalent and clinically significant are rs6713532 
(Ternouth et al., 2011) and rs7565427 (Lombard et al., 2012). 
The gene that codes for SH2B1 has become an interesting candidate for 
targeted genetic studies because of its relationship between insulin and leptin 
pathways. Many pathogenic variants are linked with this gene, particularly in 
Europeans (T2D-GENES Consortium, 2017). A Belgian study comparing  obese and 
healthy lean individuals showed a 26% increased risk of obesity if rs7498665 was 
present (Beckers et al., 2011). Another study  identified that this variant altered 
serum leptin and cholesterol levels (Jamshidi et al., 2007).  
 
1.6.3 Cognitive screening in T2D 
 
Early detection of cognitive dysfunction in T2D is critical for the management and 
treatment of the disease and its complications, however cognitive screening is not 
currently part of the care pathway.  
 The mini mental state exam (MMSE) is generally used in general practice on 
presentation of memory complaints. The Standardized Mini-Mental State 
Examination (SMMSE) is a second generation of the MMSE with specific guidelines 
on scoring, time allowed and administration to reduce intra test variability (-86%, 
P<0.003) (Molloy et al., 1991). It measures 2 domains of cognitive function; 
orientation and cognition over 12 questions taking approximately 10 minutes and is 
scored out of 30. Assessment cut off points have been developed to allow for 
maximum sensitivity and specificity and there is clear guidance on how scores should 
be adjusted for differing levels of education, disability and any language or cultural 
differences (Molloy and Standish, 1997). Generally any score above 26 is normal, 20-
25 indicative of MCI, 10-19 moderate cognitive impairment and 0-9 indicative of 
severe impairment or AD.  
The Quick mild cognitive impairment screen (qMCI) was designed to identify 
MCI. It is a short examination with high sensitivity and specificity for early alterations 
in cognition (O'Caoimh et al., 2013). It has been validated against many tests around 
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the world including the ABCS 135 in Canada (O’Caoimh et al., 2016), the SMMSE in 
Holland (Bunt et al., 2015) and the six item cognitive impairment test in Ireland 
(O’Caoimh, 2014). It is scored out of 100 and has been shown to take approximately 
5 minutes to administer and score. From a design perspective there are 6 domains; 
orientation, registration, clock drawing, verbal memory (VM), verbal fluency (VF) and 
logical memory (LM). The greatest weight of marks are associated with VM, VF and 
LM and when this has been compared to other CSIs allowed for a  more sensitive 
differentiation between MCI and normal cognition (O'Caoimh et al., 2013). It has 
been shown to improve sensitivity by measuring an individual’s capacity to retell a 
story; ability has been shown to be unaffected by education or age. Cut off points for 
MCI and dementia are <62 and <36 respectively (O'Caoimh et al., 2012). Each 
instrument will be used to assess cognition in T2D with and without GLP-1 analogue 
therapy. 
 
1.7 Electronic care records (ECR) 
 
The progression of medicine has increased the need for advanced data management 
facilities capable of streamlining data capture, data storage and searchability (Adler-
Milstein and Bates, 2010). Routinely recorded data on electronic care records (ECRs) 
include biochemical (HbA1c, Lipids, BP), prescription, co-morbidity and patient 
contact details. This is recorded longitudinally and often displayed graphically 
(Menachemi and Collum, 2011). It can provide important insights into local 
populations and provide opportunities to characterise disease progression, drug 
efficiency and the effects of various interventions (Herrett et al., 2015). They can also 
act as “real world” verification of clinical trial outcomes in different sub populations, 
verifying findings and directly informing on best practice to improve patient care 
(Herland et al., 2005).  
Current biomarkers, if used in conjunction with ECR data, may be capable of 
predicting future risk and even preventing disease.  Research into CVD developed a 
new measure of cardiometabolic health by using routinely collected biomarkers in 
ECRs and generating a new measure that is directly proportional to chronic biological 
stresses, or the ‘allosteric load’ in CVD (McEwen and Stellar, 1993). This was 
validated in three cohorts of patients (diabetes, CVD, healthy), demonstrating that 
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the newly developed measure was just as capable of predicting biological stress 
levels as the standard, expensive cytokine measures (Nobel et al., 2017). A key 
feature of ECRs is the ability to collect longitudinal medical information. A recent 
study analysed 10 years’ worth of data, focusing on BP variability in T2D patients and 
the risk of peripheral arterial disease (Yeh et al., 2016); high risk patients had high 
systolic and diastolic inter visit variability compared to low risk individuals.  
The use of ECRs is becoming increasingly prevalent in clinical research. The 
main limitation with ECR data sets is that they are reliant on health care staff to 
input all information deemed relevant (Carrington and Effken, 2011). A study in the 
USA assessed the accuracy of the International Statistical Classification of Diseases 
and Related Health Problems (ICD-9) coding system in ECR databases (Chiu et al., 
2017); results indicated that major discrepancies exist between actual and recorded 
comorbidities and that common T2D conditions such as obesity were severely under 
reported.    
 
1.7.1 Future direction of ECR research   
 
As ECR technology develops the incorporation of more data sources will occur 
(Purvis, 2015).  The most significant and beneficial development for clinical research 
will be the addition of data from connected devices, including wearable technology. 
There have been huge developments in real-time 24/7 glucose monitors, heart 
sensors and “smart” inhalers (Coda et al., 2017). These devices can provide live 
biomarker readings to ECRs that can relay important healthcare advice back to the 
patient via platforms such as mobile phone apps (Westerik et al., 2016).   
The ultimate goal is to develop fully integrated ECRs that include all standard 
clinical information from primary and secondary care and from real time connected 
devices (Ventola, 2014).  This vision is supported across Europe through the 
Connected care consortium (CONNECARE) project; this work is planning to release 
an adaptive integrated ECR for chronic care management (Ferrer et al., 2016). The 
group hopes to support and nurture adaptive management and personalised care, 
empowering the patient by providing them accurate recommendations on how to 
manage their disease. We propose using ECRs, held locally, to characterise T2D 
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patients recruited in clinical studies to gain a comprehensive overview of 






























Aims of the Thesis  
 
The aim of the work described in this thesis was to define peripheral proteomic and 
genetic biomarker panels, suggestive of chronic central processes relating to 
glycaemic control, multimorbidity, cognitive decline, and response to GLP-1Ra 
therapy in T2D. The hypothesis of this thesis states that current clinical diabetes 
measures insufficiently stratify patients, ultimately potentiating poor anti-diabetes 
pharmacological response, high levels of comorbidity and increased cognitive 
decline. The identification of novel peripheral biomarkers indicative of T2D and 
response to GLP-1 analogue therapy, and assessment of the impact of GLP-1 
analogues on cognition in T2D may be used to stratify GLP-1 therapy towards 
responders, and provide rationale for the use of GLP-1 analogues earlier in the T2D 
disease course 
Five results chapters; one preclinical, four clinical, describe results relating to 
biomarker identification and clinical analyses. Preclinical findings were attained 
utilising GLP-1 RKO, APP/PS1 and C57BL/6 mouse models. Clinical data was acquired 
after the recruitment of participants to two clinical studies, DiaStrat (n=500), and 
GLP-1 response study (n=69).  
 
To investigate the main hypothesis the following aims were addressed:   
I. To explore the molecular mechanisms downstream of GLP-1R activation in brain 
and whole blood in animal models to identify potential markers of GLP-1 
response. 
II. To assess the clinical profile of the DiaStrat cohort, including prescribing 
patterns, comorbidities and pharmacological adverse reactions and evaluate 
characteristics in those receiving GLP-1Ra treatment compared to other drug 
classes. 
III. To identify proteins associated with glycaemic control, anti-diabetes drug 
response and comorbidity in T2D. 
IV. To identify SNPs in genes related to insulin and leptin signalling associated with 
T2D and response to GLP-1Ra treatment. 
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V. To assess the effect of GLP-1Ra therapy on depression, anxiety, and cognitive 
function in T2D and to correlate observed performance with Body Mass Index 




















































2.1.1 APPswe/PS1ΔE9 mouse model of Alzheimer’s disease 
 
The APPswe/PS1ΔE9 mouse model of AD (APP/PS1) were originally acquired from 
Jackson laboratories (USA). These transgenic mice were created by coinjection of 
mouse/human chimeric amyloid precursor protein (Mo/HuAPP695swe) and the 
exon-9-deleted variant of human presinilin one (PS1-dE9), controlled by the mouse 
prion protein promoters in order to direct expression primarily to the CNS. Each 
mutation has a different pathogenic affect, the APP mutation increases the affinity of 
APP for β-secretase resulting in increased Aβ production. The PS1 mutation causes a 
significantly greater Aβ42- Aβ40 ratio ensuring increased plaque deposition (Maia et 
al., 2013). APP/PS1 positive males were bred with C57BL/6 females from a colony 
maintained within the Biomedical and Behavioural Research Unit (BBRU) at Ulster 
University. 
All male mice used were genotyped, using ear snips obtained at 
approximately 3 weeks of age, upon weaning. Animals were anaesthised briefly, 
using isofluorane (Abbott, Berkshire, UK), and surgical scissors were used to remove 
a small portion of tissue from the mouse ear, which was placed into a labelled 0.2 ml 
PCR tube (VWR International, Radnor, PA, USA, Cat. No. 732-0548) and kept on ice 
until needed. Scissors, forceps and worktops were cleaned with 70% ethanol 
between sampling in order to avoid cross-contamination. DNA was extracted using 
alkaline lysis buffer (75 μl; 25 mM NaOH, 0.2 mM Na2EDTA; pH12) which was added 
to each tube and heated to 95oC for 30 min using a TC-5000 gradient thermal cycler 
(Techne TC-5000, Davidson & Hardy Ltd UK). Samples were then cooled to 4°C and 
75μl of neutralising buffer (40 mM Tris-HCL; pH5) was added to each tube and mixed 
thoroughly using pipette.  
Polymerase chain reaction (PCR) was conducted using a Taq PCR master mix 
kit (Qiagen, West Sussex; Cat.No. 210443) using APP primers to detect the presence 
of the transgene (forward “GAATTCCGACATGACTCAGG”, reverse 
“GTTCTGCTGCATCTTGGACA”) and mPrP primers as a negative control (forward 
“CAGCAC CGCTGAAATCTAAT”, reverse “TTGCTGCCAATACTGAGACA.”  
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DNA (1 μl) from each animal was added to a prelabelled PCR tube with 12.5 μl taq 
PCR mastermix, 100 pmol of each of the primers above (0.5 μl of each) and 9.5 μl 
RNAse free H2O Negative controls with RNAse free water (1 μl), and positive controls 
with DNA from a previously confirmed APP/PS1 positive mouse (1 μl) were also run. 
Samples were then placed in a PCR thermocycler for 5 min at 95°C, followed by 35 
cycles of 45 sec at 95°C, 45 sec at 58°C and 45 sec at 72°C. Samples were then held at 
72°C for 5 min, before the cycler was cooled to 4°C and samples removed.  
 Gel electrophoresis was then conducted using 1% agarose gels prepared in 
TAE buffer (40 mM Tris Base (pH 7.6), 20 mM acetic acid and 1 mM Na2EDTA). 
Agarose was dissolved by microwave heating, and, on cooling, 5 l per 100 ml 
ethidium bromide (Sigma-Aldrich, St Louis, Mo, USA; Cat. No. E1510) was added and 
the solution poured into casting trays (Embi Tec, San Diego; Cat No.EP1001) and left 
to cool.  
 The RunOne Electrophoresis System (Embi Tec, San Diego; Cat No.EP2000) 
was then filled with 1x TAE buffer and gels inserted. Samples and controls (12 μl) 
were mixed with 3 μl Orange G (20 mg Orange G in 10 ml of 30% glycerol) and 
carefully loaded. The gel was run at 100 V for 40 min. Gels were then visualised on a 
UV Transilluminator (Biorad, Richmond, CA, USA) and photographed using a digital 
camera (Kodak 1DTM). 
Positive males and wild-type controls were used for all experiments and kept 
individually in standard cages in a temperature (T: 21.5 ± 1°C) and light (12 h 
light/dark) controlled environment. Food and water access was ad libitum. For 
subsequent experiments mice were separated into two aged defined groups. The 
first group (n=5) was aged for 8 weeks before sacrifice and used to assess how the 
APP/PS1 genotype affected our genes of interest before any significant Aβ42 burden 
was apparent compared to age-matched wild-type (WT) controls (n=5). The second 
group was aged for 10 months (n=9) and separated into two subgroups treated (n=6) 
and untreated (n=3). These were used to assess the effect 7 days 25 nmol/kg body 
weight liraglutide treatment on our panel of genes after significant AD pathology 





2.1.2. GLP-1 RKO model   
 
Brain tissue, and plasma, previously collected from GLP-1 RKO mice was used (n=4) 
in preclinical studies. Mice were bred in house at the Ulster University (UU), 
Coleraine, but the original generation is described elsewhere (Lamont et al., 2012). 
Phenotypically these mice are known to exhibit normal satiety, fasting 
hyperglycemia, normal peripheral glucose utilisation and increased insulin sensitivity 
(Ayala et al., 2010). Male mice were used for all experiments. Animals were housed 
individually and fed ad libitum in an air conditioned (T:21.5±1°C), light (12h 
light/dark) controlled room. Whole brains and plasma were obtained at 18 months 
and used to assess how our panel of appetite and insulin regulatory genes are 
affected in the absence of the GLP-1R.  
 
2.1.3 C57BL/6 Wild type controls 
 
C57BL/6 were used for further experiments due to them being used as the 
background strain for our transgenic models, and also because they are a well-
established and commonly used WT model in the literature. They are easily bred, 
long lived, have a low tumor risk and high susceptibility to diet induced obesity and 
diabetes, making them a good model to assess anti-diabetic treatments (Mogil et al., 
1999).  
At 8 weeks of age mice were separated into two groups, one received 7-days 
saline treatment (n=12) and the other 7 days liraglutide treatment (n=12), Blood 
samples were obtained from the tail vein at baseline and on days 1-7. At the end of 7 
days treatment whole brains and 2 aliquots of whole blood (1x 50 µl for gene 
analysis 1x 100 µl for plasma) were removed for genetic, proteomic and cytokine 
analysis.  
Brain tissue from a previous experiment from 11 week old C57BL/6 mice who 
had received 21-day saline or liraglutide treatment from 8-11 weeks was also 
assessed (n=6 per group).  
The purpose of these experiments was to determine mRNA alterations in brain in 
response to 7 and 21 days liraglutide treatment and to assess if brain changes may 




All animal experiments were conducted in accordance with the UK Home Office 
Animals (Scientific Procedures) Act 1986 and approved by the UU animal ethics 
committee. All precautions were taken to ameliorate any possible suffering. Animals 
were handled daily for 2 weeks prior to experiments, and sacrificed using inhaled 
anaesthetic isoflurane followed by cervical dislocation. All excised tissues were snap 
frozen in liquid nitrogen and then stored at -80°C until required. 
 
2.2. Glucose Tolerance Test 
 
A glucose tolerance was conducted to determine the acute effect of liraglutide. After 
an 8 hour fast, body weight was taken and liraglutide or saline was administered by 
intraperitoneal (i.p) injection in both C57BL/6 and APP/PS1 mice. Glucose was 
administered 30 min later (18 mmol/kg of body weight) in 0.9% NaCl. Blood was 
taken from the tail vein to measure basal glucose, then after glucose injection blood 
glucose reads were taken at 15, 30, 60 min, using the Ascencia Contour blood 
glucose meter (Bayer Health Care, UK). 
 
2.3. Peptide  
 
Liraglutide (MW 3751.202 g/mol) was obtained from EZ biolabs (Indiana, USA). 
Purity was analysed previously and determined to be > 99%. Aliquots were stored in 
polypropylene tubes at a concentration of 1 mg/ml diluted in ultrapure® water and 
kept at -80° C to permit fresh preparation, as required.   
 
2.4. Quantitative polymerase chain reaction (qPCR) 
 
This technique was used to measure the relative expression of 13 genes of interest. 
In relative qPCR all CT values must be normalised to a reference gene that is stable 
between genotypes and treatments. Common references are βACT, GAPDH, RNS16-
18. These are then inputted into a mathematical model, known as the ∆∆Ct method, 
which makes the assumption that the normalised CT value of the target gene is 




2.4.1 RNA extraction 
 
2.4.1.1 Brain tissue 
 
RNA was obtained from whole brain tissue using the RNeasy lipid tissue mini kit 
(Qiagen Ltd, Manchester, UK; Cat. No. 78404). Each brain was thawed on ice before 
being homogenized using the Fisher Scientific™ disposable pestle system (Fisher 
Scientific, Loughborough, UK; Cat. 03-392-103) in 1 ml of QIAzol lysis reagent (Qiagen 
Ltd, Manchester, UK; Cat. No. 79306). Homogenisation continued until the sample 
was uniformly dispersed in lysis buffer and then left for 5 min at room temperature 
(20°C) to promote the dissociation of nucleoprotein. Chloroform (CHCl3, 200 µl) was 
then added and the sample vortexed for 15 sec to ensure maximum phase 
separation. The homogenate was incubated for a further 3 min at room temperature 
before a 15 min centrifugation at 12,000g (4°C). Post centrifugation three distinct 
phases, organic phase (protein), interphase (DNA) and aqueous phase (RNA) were 
visible. The aqueous phase (approximately 500 µl) was removed without any DNA 
contamination and transferred to a new polypropylene tube. One volume of 70% 
ethanol was added and mixed by vortexing for 15 sec. The sample was transferred to 
an RNeasy mini spin column and placed in a 2 ml collection tube. It was then 
centrifuged for 15 sec at 8000g (20°C) and the flow through discarded. RNA captured 
on the RNeasy mini spin column membrane was then washed using 700 µl RW1 
buffer (flow through discarded) and 500 µl RPE buffer (flow through discarded), each 
was spun through the column at 8,000 g (20°C) for 15 sec. The sample was then 
washed for a final time with 500 µl RPE buffer and centrifuged for 2 min at 8,000g 
(20°C). The RNeasy mini column was then transferred to a fresh polypropylene tube 
and total RNA eluted (8000 g, 20°C, 1 min) in 50 µl RNase free water. All samples 






2.4.1.2 Whole Blood 
 
RNA from 50 µl whole blood was obtained using the QIAamp RNA blood mini kit 
(Qiagen Ltd, Manchester, UK; Cat. No. 52304). Blood samples were thawed on ice 
then transferred to a fresh polypropylene tube and 250 µl of buffer EL (Qiagen Ltd, 
Manchester, UK; Cat. No. 79217) was added. All samples were then incubated for 30 
min on ice, to allow for maximum red blood cells (RBC) lysis, before being 
centrifuged at 400 g (4oC) for 10 min. This lysis step was repeated to ensure minimal 
RBC contamination. After discarding the supernatant the pellet was re-suspended in 
1ml buffer RLT (Qiagen Ltd, Manchester, UK; Cat. No. 79216) plus 10 µl 98% 2-
Mercaptoethanol (Sigma-Aldrich, Irvine, UK, Cat. No M3701) and vortexed at high 
speed to mix. The solution was then transferred to a QIAshredder spin column and 
placed in a 2 ml collection tube before being spun at 20,000 g for 2 min at 4oC. The 
homogenized lysate was kept and 600 µl of 70% ethanol added. This was then 
transferred to a new QIAmp spin column and placed in another 2 ml collection tube 
and spun for 15 sec at 8000 g. RNA captured on the QIAmp spin column membrane 
was then washed using 700 µl RW1 buffer (flow through discarded) and 500 µl RPE 
buffer (flow through discarded), each was spun through the column at 8,000 g (20°C) 
for 15 sec. The sample was then washed for a final time with 500 µl RPE buffer and 
centrifuged for 3 min at 20,000g (20°C).  The QIAmp spin column was then 
transferred to a fresh polypropylene tube and total RNA eluted (8000g, 20°C, 1 min) 
in 20 µl RNase free water. Samples were then stored at -80°C until required.      
RNA quantity and quality was determined using a nanodrop (purity criteria 
was set at 260/280, >1.8, <2.2, and 260/230 >2.0, <2.2, Nanodrop 2000c, 
ThermoFisher Scientific, Wilmington, DE). Once quantified complementary DNA 
(cDNA) Synthesis was carried out immediately.   
 
2.4.2 Complementary DNA (cDNA) Synthesis   
   
For complementary DNA (cDNA) synthesis a Transcriptor First Strand cDNA synthesis 
kit was used (Roche Diagnostics Ltd., West Sussex, UK; Cat. No. 04379012001). A 
“master mix” was then prepared in a 1.5 ml polypropylene tube containing 
(‘individual volumes described’ x ‘number of samples’); 4 µl Transcriptor RT reaction 
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buffer 5x concentrated (final concentration 8 mM MgCl2), 0.5 µl Transcriptor reverse 
transcriptase (RT) 20 U/µl (final concentration 10 U; Roche Diagnostics Ltd., West 
Sussex, UK; Cat. No. 03531317001), 0.5 μl Protector RNase inhibitor 20 U/µl (final 
concentration 20 U; Roche Diagnostics Ltd., West Sussex, UK; Cat. No. 
03335399001), 2μl Deoxynucleotide Mix, 10 mM each (final concentration 2 mM 
each; Roche Diagnostics Ltd., West Sussex, UK; Cat. No. 11969064001), 2 µl random 
hexamer primer 600 pmol / µl (final concentration 60 µM; Roche Diagnostics Ltd., 
West Sussex, UK; Cat. No. 11034731001).  
Total RNA (500 ng from brain, 100ng from whole blood) was added to a 200 
µl PCR tube, with  9 µl of the “master mix” above and the final reaction volume 
brought to 20 μl in RNase-free water (Roche Diagnostics Ltd., West Sussex, UK; Cat. 
No. 03315932001). The reaction was conducted on a Techne prime thermo cycler 
(Applied Biosystems, USA) with cycling conditions of 10 min at 25°C, followed by 1 




All qPCR reactions consisted of template cDNA (25 ng/µl for brain and 5 ng/µl for 
whole blood) and 9 µl of master mix. Master mix was composed of; 5 µl LightCycler® 
480 Probes Master (Roche Diagnostics Ltd., West Sussex, UK; Cat. No. 04710436001), 
1μl (10 pM/l) gene-specific probes and 3μl of RNase free water (Roche Diagnostics 
Ltd., West Sussex, UK; Cat. No. 03315932001). Real-time ready Custom Single Assays 
were used for all experiments (Roche Diagnostics Ltd., West Sussex, UK) and 
consisted of; GLP-1 receptor (Glp1r M. musculus, Assay ID 314784, transcript length 
1480bps, amplicon length 71 bps), GIP receptor (Gip M. musculus, Assay ID 316856, 
transcript length 1792 bps, amplicon length 92 bps), LEP-R (LEP-R M. musculus, Assay 
ID 310938, transcript length 4127, amplicon length 69 bps), STAT3 (Stat3 M. 
musculus, Assay ID 316898, transcript length 4516, amplicon length 93 bps), POMC 
(Pomc M. musculus, Assay ID 316887, transcript length 1031 bps, amplicon length 
64bps), GHSR (Ghsr M. musculus, Assay ID 317858, transcript length 4433, amplicon 
length 89 bps), CREB1 (Creb1 M. musculus, Assay ID 300049, transcript length 8420 
bps, amplicon length 76 bps), PRMT1 (Prmt1 M. musculus, Assay ID 317397, 
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transcript length 1360 bps, amplicon length 89 bps), IRS-1 (Irs1 M. musculus, Assay 
ID 301044, transcript length 9144 bps, amplicon length 93 bps), JAK2 (Jak2 M. 
musculus, Assay ID 300439, transcript length 5030, amplicon length 68 bps), SH2B1 
(Sh2b1 M. musculus, Assay ID 318310, transcript length 3317 bps, amplicon length 
72 bps), SOCS3 (Socs3 M. musculus, Assay ID 300387, transcript length 2552 bps, 
amplicon length 126 bps), AKT (Akt1 M. musculus, Assay ID 317539, transcript length 
2690 bps, amplicon length 122 bps), RNS18 (Rn18s M. musculus, Assay ID 307906, 
transcript length 1870 bps , amplicon length 106 bps).  
All qPCR reactions were pipetted onto a white, 96-well LightCycler® 480 
Multi-well Plate (Roche Diagnostics Ltd., West Sussex, UK; Cat. No. 04729692001). 
The plate was then sealed with an adhesive plate cover and centrifuged at 1500 RPM 
for 2 min. The plate was then placed in Roche LightCycler 480® (Roche Diagnostics 
Ltd., Switzerland) and exposed to 95oC for 10 min followed by 55 cycles of 95°C for 
10 sec, 60°C for 30 sec and 1 second at 72°C. CT values were recorded on the 
accompanying software package (Roche, LightCycler 480 software, v1.5). 
Quantification was conducted by comparing mean CT values of target gene to 
housekeeping gene using the 2ΔΔCT method.   
 
2.5. Western blot  
  
2.5.1 Total protein extraction  
 
Whole hemibrains were used for all protein extractions. Brains were defrosted on ice 
and homogenised using the Fisher ScientificTM disposable pestle system (Fisher 
Scientific, Loughborough, UK; Cat. 03-392-103) in a polypropylene tube containing 
500 µl RIPA buffer (25 mM TrisHCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS; Thermo scientific, UK; Cat. No. 89900) and Pierce Protease 
Inhibitor (Thermo scientific, UK; Cat. No. A32965). Samples were kept on ice and 
vortexed at 5 min intervals for 20 min. Homogenates were centrifuged at 20,000 g 




2.5.2 Determination of protein concentration  
Protein concentration was determined using a Pierce™ BCA Protein Assay Kit 
(Thermo scientific, UK; Cat. No. 223227). Each protein sample was diluted 1:10 and 
1:20 in phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
2 mM KH2PO4; pH 7.4) and run in duplicate. Protein standards were prepared from 
Bovine Serum Albumin (BSA) over 9 concentrations; A- 2000 µg/ml, B- 1500 µg/ml, 
C- 1000 µg/ml, D- 750 µg/ml, E-500 µg/ml, F-250 µg/ml, G-125 µg/ml, H-25 µg/ml, I- 
blank. All samples and standards (10 µl) were added to individual wells on a 96 well 
plate and 15 µl of PBS added before the addition of 200 µl BCA working reagent 
(WR). The total WR volume was determined using (# standards + # unknowns × # 
replicates × 200 µl) and was prepared by mixing 50 parts BCA reagent A (sodium 
carbonate, sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1 M 
sodium hydroxide) and 1 part BCA reagent B (4% cupric sulphate; Thermo scientific, 
UK; Cat. No. 23227). Samples were then incubated at 30oC for 30 min, before being 
allowed to cool for 2 min. Absorbance was then read on a BioTek Epoch Microplate 
Spectrophotometer (BioTek, UK, Cat. No. 15306176) at 562 nm. The absorbance 
values for the standards were used to plot a standard curve, from which unknown 
protein concentrations were determined. 
 
2.5.3 Sample preparation 
 
All samples (50 µg) were prepared in polypropylene tubes, to which 5 µl of NuPAGE™ 
LDS Sample Buffer (4X; Thermo scientific, UK; Cat. No. NP0008) and 2 µl NuPAGE™ 
Sample Reducing Agent (10X; Thermo scientific, UK; Cat. No. NP0004) was added. 
Samples were then made up to a final volume of 20 µl with deionised water, and 
heated at 70oC for 10 min immediately prior to electrophoresis.       
2.5.4 Western blot (SDS-page) 
 
All gels were run in an XCell SureLock™ Mini-Cell Electrophoresis System (Thermo 
scientific, UK; Cat. No. EI0002), submerged in 1 litre of NuPAGE™ MOPS SDS Running 
Buffer (1X) (Thermo scientific, UK; Cat. No. NP0001) and 100 µl of NuPAGE™ 
Antioxidant (Thermo scientific, UK; Cat. No. NP0005). Samples were loaded into 10-
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well NuPAGE™ 4-12% Bis-Tris, gradient protein gels (Thermo scientific, UK; Cat. No. 
NP0335BOX). Novex™ Sharp Pre-stained Protein Standard (7 µl; Thermo scientific, 
UK; Cat. No. LC5800) was loaded as a molecular weight control. Gels were then run 
for 20 min at 90 volts and a further 1 hour at 150 volts. They were then transferred 
on to a methanol (99.9%) soaked Polyvinylidene difluoride (PVDF) membrane 
(Thermo scientific, UK; Cat. No. LC2005) using the XCell II™ Blot Module (Thermo 
scientific, UK; Cat. No. EI0002). This was carried out in 1 litre of NuPAGE™ Transfer 
Buffer (1X + 10% methanol; Thermo scientific, UK; Cat. No. NP0006) at 30 volts for 1 
hour. All membranes were blocked in 5% milk / 0.05% PBS-Tween (PBS-T) for 1 hour 
before overnight incubation at 4oC with primary antibody. All overnight incubations 
were left on an analogue tube roller (Stuart, UK. Cat. No SRT6). 
Antibodies were; β-actin (Cell Signalling, Cat. No 4970, Rabbit, MW45, 
dilution 1:1000); Total IRS-1 (Abcam, Cat. No ab52167, Rabbit, MW180, dilution 
1:500); phospho IRS-1 S616 (Abcam, Cat. No ab4776, Rabbit, MW165, dilution 
1:100); Total STAT3 (Cell Signalling, Cat. No 9132, Rabbit, MW79/82, dilution 
1:1000); phospho STAT3 T705 (Cell Signalling, Cat. No 9145, Rabbit, MW79/86, 
dilution 1:1000); AKT (Cell Signalling, Cat. No 4685, Rabbit, MW60, dilution 1:1000); 
phospho FOXO1 (Cell Signalling, Cat. No 9461, Rabbit, MW82, dilution 1:1000); 
POMC (Cell Signalling, Cat. No 23499, Rabbit, MW10/28/32, dilution 1:1000); SOCS3 
(Cell Signalling, Cat. No 2923, Rabbit, MW26, dilution 1:1000); GLP-1R (BIOSS, Cat. 
No bs1559R, Rabbit, MW53, dilution 1:100); GIP-R (BIOSS, Cat. No bs13292R, Rabbit, 
MW53, dilution 1:100).  
After overnight incubation in primary antibody membranes were washed 
three times for 5 min with 0.05% PBS-T and then incubated at 20oC for 1 hour in 
Anti-rabbit IgG, HRP-linked secondary antibody (Cell signalling, Cat. No 7074, Rabbit, 
dilution 1:1000). Blots were then washed another three times with 5% PBS-T before 
being incubated in SuperSignal Chemiluminescent Substrate (Thermo scientific, UK; 
Cat. No. 34080). Working Solution was generated by mixing equal parts of the Stable 
Peroxide Solution and the Luminol/Enhancer Solution. Blots were then imaged using 
the UVP Chemidock Imaging System (Analytik Jena, Germany, model It2 515, Cat. No 
97-0685-04). Membranes were exposed for 10 min and densitometry carried out on 
ImageJ-1x (Schneider et al., 2012) open source software.      
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2.6. Meso Scale Discovery Proinflammatory panel 1 analysis 
 
Plasma Cytokines IFN, IL1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, TNF- and 
chemokine KC/GRO (CXCL1) were measured using the Meso Scale Discovery (MSD®) 
Multi-spot Assay Pro-inflammatory panel 1 (mouse) kit (Meso Scale Discovery, 
Rockville, MD, USA, Cat. No. K15048D), according to the manufacturer’s instructions. 
Plasma (20 µl) was transferred onto a 10-spot Multi-spot® 96-well plate, which was 
pre-coated with capture antibodies on individual, well-defined assay spots. The plate 
was sealed with an adhesive plate cover and incubated at 4°C overnight to allow for 
maximum antibody binding. Excess sample was then decanted off and the plate 
washed three times using 150 l 0.05% PBS-T per well. The 10 specific detection 
antibodies where then prepared with Diluent 45 in a master mix at 1:50 dilution. 
These were added (25 µl) to each well and the plate resealed with a fresh adhesive 
plate cover before shaking for 2 h at room temperature. The final step involved 
washing each well a further three times with PBS-T and adding the Read Buffer T 
(150 µl) at a working concentration of 2x. The plate was then read on the MSD 
instrument. 
The MSD® is a desktop device that allows for highly sensitive (dynamic range; 
LLOD 2.7 pg/ml – UPOD 150-1500 pg/ml), rapid (90 sec read time), cost effective, 
multiplex cytokine analysis. MSDs electrochemiluminescence detection technology 
uses SULFO-TAGTM labels. These emit light after electrochemical stimulation, 
initiated at the electrode surface. Accurate, reproducible multiplex is achievable via 





Diagram 2.1 - MSD 10-spot® assay.  Each spot is coated with a specific antibody. After 
applying the sample and exciting with electricity a chemical reaction occurs involving Tris 
(bipyridine) ruthenium (Ru (bpy) and terephthalic acid (TPA), which ultimately generates 
light, emitted at 620 nm. There is very low background as stimulation mechanism is 





2.7 Participant Recruitment 
 
2.7.1 DiaStrat recruitment  
 
Participants were identified by clinicians at the Altnagelvin Hospital, diabetes clinic, 
in Northern Ireland.  Eligibility was determined by inclusion and exclusion criteria. 
Participants had to be clinically diagnosed with type 2 diabetes and be between the 
ages 18—80. If type 1, secondary or gestational diabetes was present individuals 
were excluded. Eligible participants were provided a Participant information sheet 
which included the aims and ethical considerations of the research. After a 48 hour 
cooldown period, participants were contacted regarding their willingness to 
participate. Those who agreed to participate were invited back to the clinic, to 
permit completion of the informed consent process and sample collection. 
 
2.7.2 GLP-1 response study recruitment   
 
Participants were identified by their clinician at the Altnagelvin Hospital, diabetes 
clinic, NI.  Eligibility was determined by strict inclusion and exclusion criteria. 
Participants had to be clinically diagnosed with; 1. Non-Diabetes (n=19), 2. T2D + 
GLP-1Ra naïve (n=13), 3. T2D + GLP-1Ra responder (n=22), 4. T2D + GLP-1Ra non-
responders (n=15), and be between the ages 18—100. GLP-1Ra response was 
determined by either a recent 1% reduction in HbA1c, 3% reduction in body weight or 
both. If type I, secondary or gestational diabetes was present individuals were 
excluded. Eligible participants were provided a participant information sheet which 
included the aims and ethical considerations of the research. After a 48 hour cool 
down period, participants were then contacted regarding their willingness to 
participate. Those who agreed were invited back to the clinic, to permit completion 
of the informed consent process, questionnaires and screening instruments and 
blood sample collection. Non-diabetes controls were identified and sampled at the 
University of the Third Age (U3a), Derry, NI. This centre aims to stimulate and 








2.8.1.1 Buccal Swab sampling  
 
Samples were taken in a clinical room after informed consent had been obtained. A 
single buccal swab was acquired using a MasterAmpTM buccal brush (Epicentre, 
Madison, WI USA; Cat no. 4459). Each cheek of the participant was lightly brushed, 
and the swab was then placed in a 15 ml conical polypropylene tube for DNA 
extraction. 
 
2.8.1.2 Blood sampling   
Blood samples were obtained using 21G Vacuette® safety needles (Greiner Bio-One, 
Stonehouse, UK; Cat no. 450091), coupled with a Vacuette® Leur adapter (Greiner 
Bio-One, Stonehouse, UK; Cat no. 450070) and BD vacutainer®  (BD, Oxford, UK; Cat 
no. 364815). Approximately 26 ml of blood was collected into 2 x 9ml EDTA (K3E 
K3EDTA) coated Vacuette® tubes (Greiner Bio-One, Stonehouse, UK; Cat no. 455036) 
and 1 x 8ml Serum (Z Serum Sep Clot Activator) tube (Greiner Bio-One, Stonehouse, 
UK; Cat no. 455071). Samples were stored and transported in a cooled (approx. 4oC) 
medical blood transportation bag (Versapak, Kent, UK; Cat no. BLD1_RDS). Blood 
samples were processed immediately after collection.  
 
2.8.1.3 Blood processing 
 
Prior to sample processing, 10 polypropylene tubes (per sample) were prelabelled 
using Item Tracker© software (ItemTracker Software Ltd, Suffolk, UK), ensuring 
compliance with the Human Tissue Act 2004 regulations. One 9 ml EDTA blood 
sample was also labelled as whole blood and immediately frozen at -80oC for future 
DNA extractions. The remaining 9 ml EDTA and 8 ml Serum blood samples were 
centrifuged at 4000 rpm (4oC) for 15 min. The resulting EDTA sample separated into 
three distinct layers, the upper layer was designated plasma, middle layer, white 
blood cells (WBC) and the bottom layer, RBC. The plasma was aliquoted into four 
1.5ml prelabelled Eppendorfs (Plasma A-D). WBCs were then carefully removed and 
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placed in a polypropylene tube, washed once with PBST (1 ml) and split between two 
prelabelled tubes (Protein, RNA) before being washed again with PBST (1 ml). WBCs 
in the protein tube were stored in 1 ml Mammalian Protein Extraction Reagent M-
PER™ (Thermo Scientific, UK; Cat no. 78501) and WBCs in the RNA tube in 1ml 
RNAlater (Thermo Scientific, UK; Cat no. AM7020). The supernatant from the 8ml 
serum tube was designated serum, and aliquoted into four 1.5 ml Eppendorf tubes 
(Serum A-D). All samples were then frozen at -80oC and were separated between 
primary and secondary freezers. Sample maps were updated after each day of 
recruitment to ensure sample traceability and compliance with HTA. 
 
2.8.2 GLP-1 response Study 
 
2.8.2.1 Blood sampling   
All blood samples were obtained using 21G Vacuette® safety needles (Greiner Bio-
One, Stonehouse, UK; Cat no. 450091), coupled with a Vacuette® Leur adapter 
(Greiner Bio-One, Stonehouse, UK; Cat no. 450070) and BD vacutainer®  (BD, Oxford, 
UK; Cat no. 364815). Approximately 50ml of blood were extracted into 2x 9 ml EDTA 
(K3E K3EDTA) coated Vacuette® tubes (Greiner Bio-One, Stonehouse, UK; Cat no. 
455036), 2x 4 ml EDTA (K3E K3EDTA) coated Vacuette® tubes (Greiner Bio-One, 
Stonehouse, UK; Cat no. 455021) and 1x 8 ml Serum (Z Serum Sep Clot Activator) 
tube (Greiner Bio-One, Stonehouse, UK; Cat no. 455071). Any human tissue was 
stored and transported in a cooled (approx. 4oC) medical blood transportation bag 
(Versapak, Kent, UK; Cat no. BLD1_RDS). All blood samples were processed 
immediately after collection.  
 
2.8.2.2 Blood processing 
 
Prior to sample processing, 10 polypropylene tubes (per sample) were prelabelled 
using Item Tracker© software (ItemTracker Software Ltd, Suffolk, UK), ensuring 
compliance with the Human Tissue Act 2004 regulations. One 9 ml EDTA blood 
sample was also labelled as whole blood and immediately frozen at -80oC for future 
DNA extractions. The remaining 9 ml EDTA and 8 ml Serum blood samples were 
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centrifuged at 4000 rpm (4oC) for 15 min. The resulting EDTA sample separated into 
three distinct layers, the upper layer was designated plasma, middle layer, white 
blood cells (WBC) and the bottom layer, red blood cells (RBC). The plasma was 
aliquoted into corresponding prelabelled tubes (Plasma A-D). WBCs were then 
carefully removed and placed in a polypropylene tube, washed once with PBST and 
split between two prelabelled tubes (Protein, RNA) before being washed again with 
PBST. WBCs in the protein tube were stored in 1 ml Mammalian Protein Extraction 
Reagent M-PER™ (Thermo Scientific, UK; Cat no. 78501) and WBCs in the RNA tube 
in 1 ml RNAlater (Thermo Scientific, UK; Cat no. AM7020). The supernatant from the 
8ml serum tube was designated serum, and aliquoted between corresponding tubes 
(Serum A-D). All samples were then frozen at -80oC and were separated between 
primary and secondary freezers. Sample maps were updated after each day of 
recruitment to ensure sample traceability and compliance with HTA.  
The two 4 ml EDTA (K3E K3EDTA) coated Vacuette® tubes (Greiner Bio-One, 
Stonehouse, UK; Cat no. 455021) were transported to Altnagelvin hospital labs for 
HbA1c and full blood count analysis. 
 
2.9 DNA extraction 
2.9.1 Buccal Swab DNA extraction 
 
DNA was extracted from MasterAmpTM buccal brushes (epicentre, Madison, WI USA; 
Cat no. 4459) using the QIAamp DNA blood mini kit (Qiagen, Manchester, UK; Cat no. 
51106). Each brush was incubated at 56oC for 10 min in; 600 µl PBS, 400 µl buffer AL 
(Qiagen, Manchester, UK; Cat no. 19075) and 20 µl protease stock solution (Qiagen, 
Manchester, UK; Cat no. 1021055). Throughout the incubation samples were 
intermittently vortexed on high power for 5 sec. Ethanol (400 µl, >96-100%) was 
added to each sample and tubes vortexed to precipitate the DNA. The mixture was 
then transferred to a QIAamp mini spin column in a 2 ml collection tube and 
centrifuged at 6000 g for 1 min at room temperature (20oC). DNA was captured on 
the QIAamp mini spin column membrane and any flow through was discarded. The 
DNA was then washed using 500 µl of buffer AW1 (Qiagen, Manchester, UK; Cat no. 
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19081), spun through the column at 6000 g for 1 min (20oC). Each sample was then 
washed a final time using buffer AW2 (Qiagen, Manchester, UK; Cat no. 19072), 
centrifuged at 20,000 g for 3 min (20oC). The QIAamp mini spin column was then 
inserted into a clean polypropylene tube and total DNA was eluted (6000 g, 1 min, 
20oC) in 50 µl buffer AE (Qiagen, Manchester, UK; Cat no. 19077). Samples were 
stored at -80oC until required.    
 
2.9.2 Whole blood DNA extraction        
 
DNA was extracted from EDTA whole blood samples using the Gentra Puregene 
blood kit (Qiagen, Manchester, UK; Cat no. 158445). Samples were thawed at room 
temperature (20oC) immediately before the procedure. Once defrosted, 900 µl of 
RBC Lysis solution (Qiagen, Manchester, UK; Cat no. 158904) was dispensed into a 
1.5 ml polypropylene tube, to which 300 µl of whole blood was added and mixed by 
inversion 10 times. Samples were then incubated in solution for 5 min (20oC) to 
maximize lysis. After incubation samples were centrifuged for 20 sec at 13,000 g to 
pellet remaining cells. The supernatant was carefully discarded, leaving 
approximately 10 µl of residual liquid. The cell pellet was then resuspended by 
vortexing before the addition of 300 µl Cell Lysis Solution (Qiagen, Manchester, UK; 
Cat no. 158906). To ensure homogeneity and removal of any cell clumps, samples 
were incubated at 37oC for 15 min. RNase A solution (1.5 µl) (Qiagen, Manchester, 
UK; Cat no. 19101) was then added and mixed by inversion (25x). Samples were then 
incubated for a further 15 min at 37oC and then quickly cooled for 1 minute on ice. 
Protein precipitate solution (Qiagen, Manchester, UK; Cat no. 158910) was then 
added (100 µl) to each sample and mixed by vortexing for 10 sec, prior to a 1 min 
centrifugation at 13,000g (20oC). In a clean 1.5 ml polypropylene tube, 300 µl >99.9% 
isopropanol (Sigma-Aldrich, UK; Cat no. 437522) was added. The supernatant from 
the centrifugation step was then carefully poured into the isopropanol and mixed by 
inverting 50 times, before being centrifuged at 13,000 g for 1 min (20oC). The DNA 
was then visible as a white pellet. The supernatant was removed and 300 µl 70% 
ethanol added to wash the DNA pellet. A final centrifugation was conducted at room 
temperature for 1 min at 13,000 g and ethanol removed. The DNA pellet was 
allowed to air dry for 5 min before 100 µl DNA hydration solution (Qiagen, 
55 
  
Manchester, UK; Cat no. 158914) was added. Samples were then incubated at 65oC 
for 5 min to dissolve the DNA and left at room temperature overnight, before being 
stored at -80oC for future use.    
 
2.9.3 DNA quantification  
 
DNA was quantified using a Qubit®Fluorometer (ThermoFisher Scientific, UK; Cat no. 
Q33216) and QubitTM dsDNA HS Assay kit (ThermoFisher Scientific, UK; Cat no. 
Q32854). DNA extracted from whole blood samples was thawed at room 
temperature before use. Qubit® assay tubes (ThermoFisher Scientific, UK; Cat no. 
Q32856) were labelled prior to working reagent preparation. The working reagent 
consisted of a 1:200 dilution of Qubit® dsHS reagent (200 x concentrate in Dimethyl 
sulfoxide, DMSO, (CH3)2SO) in Qubit® dsDNA HS buffer. Qubit® DNA standards and 
samples were then prepared, in individual Qubit® assay tubes, 10 µl of each standard 
(standard 1, 0 ng/µL in TE; standard 2, 10 ng/µL in TE buffer), followed by 2 µl of 
each sample. Once all DNA was aliquoted into individual tubes, Qubit® working 
reagent was added to each; 190 µl to standards and 198 µl to unknown samples. The 
final volume for all reactions was 200 µl. Tubes were then incubated at room 
temperature (20oC) for 2 min before being read on the Qubit®Fluorometer. 
 
2.10 Enzyme-Linked Immunosorbent Assays (ELISA)   
 
2.10.1 Insulin sandwich ELISA     
 
Plasma insulin was quantified using human Mercodia insulin ELISA kit (Mercodia, 
Uppsala, SE; Cat no. 10-1113-10). All plates (96 well) were precoated with mouse 
monoclonal anti-insulin antibody. Calibrators 0-5 and unknown samples (human 
plasma) were then thawed at room temperature (20oC), briefly vortexed and 25 µl 
pipetted in duplicate onto the plate. A 1X enzyme conjugate solution was prepared 
by diluting 11X Enzyme conjugate in Enzyme Conjugate buffer, 100 µl was then 
added to each well and left to incubate on a microtitre plate shaker (Stuart, UK., Cat. 
No SSM1) for 1 h at 700 rpm (20oC). Each plate was then manually washed 6 x with 
200 µl, 1X wash buffer, prepared from a 21X stock in ultra-distilled water (ELGA, 
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Wycombe, UK; Cat no. PF2XXXXM1). Once complete 200 µl 3,3', 5,5;-
tetramethylbenzidine (TMB) solution was added to each well and left to incubate at 
room temperature (20oC) for 15 min. This reaction was light and time sensitive so 
precise timings were ensured with each plate. Stop solution (0.5 M, H2SO4, 50 µl) 
was then added to each well. All plates were briefly incubated on microtitre plate 
shaker (Stuart, UK., Cat. No SSM1) to ensure mixing, then absorbance was read on a 
BioTek Epoch Microplate Spectrophotometer (BioTek, UK, Cat. No. 15306176) at 450 
nm. Insulin concentration for all samples was determined by extrapolating 
corresponding absorbance readings from the calibrator standard curve (0-5) on a 
log/log scale.  
 
2.10.2 C-peptide sandwich ELISA 
Plasma C-peptide was measured using human Alpco C-peptide ELISA kit (Alpco, 
Salum, US; Cat no. 80-CPTHU-E01.1, E10). Plates were first equilibrated to room 
temperature (20oC) before 25 µl of each standard (Blank-0, A-20, B-100, C-300, D-
1000, E-3000 pM) and diabetes controls supplied control 1 & 2 were pipetted into 
designated wells. Unknown  samples were then thawed at room temperature (20oC) 
and briefly vortexed, before 25 µl was pipetted, in duplicate, into designated wells. 
Assay buffer (50 µl) was then added to each well before plates were sealed (Roche, 
UK; Cat. No 04729757001) and left to incubate for one hour on a microtitre plate 
shaker at 700 rpm (Stuart, UK., Cat. No SSM1). Wells were washed 6 times with 1X 
wash buffer (200 µl per well), prepared from a 21 x concentrate in ultra-distilled 
water (ELGA, Wycombe, UK; Cat no. PF2XXXXM1). A 1 x enzyme conjugate solution 
was prepared by diluting 11 x Enzyme conjugate in Enzyme Conjugate buffer, 100 µl 
of which was then added to each well and left to incubate on a microtitre plate 
shaker (Stuart, UK., Cat. No SSM1) for 1 h at 700 rpm (20oC). Plates were washed 
another 6 times with 1X wash buffer (200 µl), before the addition of 100 µl TMB. The 
plate was then sealed and incubated for 15 min at 20oC.  Stop solution (100 µl) was 
added to each well and absorbance read on a BioTek Epoch Microplate 
Spectrophotometer (BioTek, UK, Cat. No. 15306176) at 450 nm. C-peptide plasma 
concentration for all samples was determined by extrapolating corresponding 
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absorbance readings from the assay standard curve using a 5 parameter logistic (pl) 
model.  
 




Relevant clinical information for all participants, who provided consent, was 
obtained from Western Health and Social Care Trusts, Hicom Diamond.NET diabetes 
management system (Hitcom, Surrey, UK) and Orion Health technologies, Northern 
Ireland Electronic Care Record (NIECR) (Orion health, Hammersmith, UK). Both 
computer systems allowed collation of longitudinal data from primary and secondary 
care. Data collected included; Sex, DOB, age at diagnosis, first diabetes appointment, 
current high and low HbA1c, weight, BP systolic/diastolic, HDL, LDL, total cholesterol 
and BMI, alcohol units per day and comorbidities and the related ICD-10 codes. In 
addition we collected all current diabetes drugs including dose, date started, time on 
(days) and all other prescribed medication including dose, date started, time on 
(days). Unscheduled care records including, reason for attendance and date, drug 
reaction and allergies were also noted. All data was inputted into Microsoft excel for 
future analysis.    
2.11.2 GLP-1 response Study 
 
Relevant clinical information for all participants was obtained from Western Health 
and Social Care Trusts, Hicom Diamond.NET diabetes management system (Hitcom, 
Surrey, UK) and Orion Health technologies, Northern Ireland Electronic Care Record 
(NIECR) (Orion health, Hammersmith, UK). Data collected was: Sex, DOB, 
unscheduled care records including clinic attended, date and reason, current 
diabetes and non-diabetes prescriptions, cognitive and mood screening 
questionnaire data (Chapter 2, section 2.14), education, personal and family health 
information, HbA1c, full blood count (Chapter 2, Section 2.8.2.1), weight (Kg), height 
(cm) and BMI (Kg/m2). Data was collated into a Microsoft excel spreadsheet for 
future analysis.    
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2.12. Multiplex proteomics   
 
Protein analysis on 374 type 2 diabetes samples and 20 controls was out-sourced to 
OLink proteomics (OLink, Uppsala, SW). Four panels were assessed including 
Cardiovascular II, Cardiovascular III, Inflammation and Immune response, each with 
92 proteins. OLink utilises unique Proximity Extension Assay (PEA) technology that 
enables 92plex biomarker research. All wells are treated with 96 pairs of unique 
oligonucleotide labelled antibodies. Specific probes bind to target proteins in the 
sample via a homogeneous assay and when pairs are in close proximity create a 
unique DNA reporter sequence (OLink, 2017). These DNA polymerization events are 
detected and quantified using qPCR and remove any risk of cross reactivity seen on 
other 10plex technologies.         
EDTA plasma samples were thawed at room temperature (20oC), before 50 µl 
of each pipetted into 96-well, clear PCR plates. Row 12 of each plate (n=5) was left 
blank for OLink control plasma. All plates were sealed using adhesive cover slips and 
shipped on dry ice (CO2, -78oC).  
OLink conducted a two-step internal quality control (QC) that evaluated each 
sample against the standard deviation of the internal controls and the degree of 
deviance from the median of the internal controls. Only samples above 0.2 
Normalised Protein Expression (NPX) and samples that deviate less than 0.3 NPX 
passed QC. All data is presented as NPX values, OLink Proteomics’ arbitrary unit on a 
log2 scale.  Analyses on raw data returned from OLink was conducted in excel, SPSS, 
and Prism to assess proteins that were significantly altered in T2D, T2D patients 
prescribed specific anti-diabetes drugs, related comorbidities and associated 










2.13. SNP genotyping using the Affymetrix UK Biobank array 
 
2.13.1 Sample Preparation  
 
Whole blood samples were obtained (Section 2.8.2.1) and DNA was extracted 
(Section 2.9.2). All samples were quantified using the Qubit®Fluorometer 
(ThermoFisher Scientific, UK; Cat no. Q33216) and QubitTM dsDNA HS Assay kit 
(ThermoFisher Scientific, UK; Cat no. Q32854) (Section 9.3). A total of 266 T2D, and 
19 non-diabetes control DNA samples were added to ABgene 96 Square Well Storage 
plates (ThermoFisher Scientific, UK), and cap mats were used to seal the plates. Final 
concentration was 5 ng/µl and total mass per well was 100 ng. All samples were 
diluted in EDTA TE buffer (10 mM Tris-HCL pH8.0, 0.1 mM EDTA).  
 
2.13.2 Data generation  
 
Sample plates were shipped to Cambridge Genomic Services (CGS, UK) on dry ice 
(CO2). The Affymetrix UK Biobank SNP array was run onsite at CGS, and the final data 
output was returned for analysis.   
 
2.13.3 Variant Calling 
 
Raw data was returned in .CEL files and SNPs were identified using Axiom’s 
Genotype Console software, version 4.2 (Affymetrix, UK). Samples with a SNP call 
rate of less than 97.2% or a QC value of <0.82 were considered to have failed QC and 
were excluded from subsequent analyses. SNP lists were generated for 20 genes of 
interest (GLP-1R, GIPR, INSR, IRS-1, IGFBP2, AKT, MAPK1, MTOR, LEP-R, STAT3, 
SH2B1, POMC, IL6, IL10, IL18, IL1RN, HGF, HAVCR1, SORT1, CASP3). Comparisons 
were made between non-diabetes controls and T2D patients and also between GLP-
1Ra responders (patients with good glycaemic control (<53 mmol/mol HbA1c)) and 






2.14. Mood and cognition screening  
 
2.14.1 Beck Anxiety Inventory  
 
Participants self-scored 21 symptoms, according to how much each one had 
bothered them the previous week. There were 4 possible answers; Not at All; Mildly 
(It did not bother me much); Moderately (It was very unpleasant, but I could stand 
it), and; Severely (I could barely stand it). Values are assigned to each response: Not 
at All = 0; Mildly = 1; Moderately = 2, and; Severely = 3. The total sum of the answers 
indicates the level of anxiety experienced. A total score of 0 - 7 is indicative of 
"Minimal" anxiety; 8 - 15 as "Mild"; 16 - 25 as "Moderate", and 26 - 63 as "Severe". 
Full inventory can be found in Appendices; Supplementary Screen 1.  
 
2.14.2 Beck Depression inventory  
 
Participants self-scored 21 questions ranking severity from 0-3. The minimum score 
is 0 and maximum score is 63. Higher scores are indicative of greater symptom 
severity. Standardised cut offs are; 1-10 normal ups and downs, 11-16 mild mood 
disturbance, 17-20 borderline clinical depression, 21-30 moderate depression, 31-40 
severe depression, over 40 extreme depression. Full inventory can be found in 
Appendices; Supplementary Screen 2.   
 
If participants indicated symptoms of either anxiety or depression, a notification was 
sent to their General Practitioner (GP).      
 
2.14.3 Standardized Mini-Mental State Examination (SMMSE) 
 
Before conducting the SMMSE, all props were prepared (pen, paper, visual cues) and 
hearing and vision checks were made with the participant. The examination was 
conducted with Dr Molloy’s proposed script (Molloy and Standish, 1997). The test 
consisted of 12 questions, was scored out of 30 and took approximately 10 min. It 
measures 2 domains of cognitive function; orientation and cognition. Strict cut off 
points have been developed to allow for the maximum sensitivity and specificity. 
Generally any score above 26 is seen as normal, 20-25 is indicative of MCI, 10-19 
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moderate cognitive impairment and 0-9 severe impairment or developed AD. Full 
test can be found in Appendices; Supplementary Screen 3.   
 
2.14.4 Quick mild cognitive impairment screen (qMCI)  
 
The questionnaire consists of 6 questions and is designed to address 6 domains of 
cognition; orientation, registration, clock drawing, verbal memory (VM), verbal 
fluency (VF) and logical memory (LM). The greatest weight of marks is associated 
with VM, VF and LM. The examination is scored out of 100; scores <62 are indicative 
of MCI, and scores <36 indicative of dementia. The screen takes approximately 5 min 
to administer and score, and is easy to learn and use. The qMCI can be used in an 
informal setting, reducing patient stresses and testing time in the clinic. It also 
compares favourably to other established cognitive screens (O'Caoimh et al., 2012). 
Full test can be found in Appendices; Supplementary Screen 4.   
    
2.15. Statistics  
 
All statistical analysis was conducted using Graphpad Prism software (Graphpad 
Software Inc., La Jolla, CA, USA; v6.0h), and graphs represent mean values ± standard 
deviation of the mean.  
Initial gene expression data (Chapter 3) was analysed using Student’s t tests, 
enabling comparisons to be made between two experimental groups. Ordinary one-
way ANOVA was later used to detect differences in gene expression between 3-7 
groups. Tukey’s post-hoc test was utilised to determine differences between groups. 
A P value less than 0.05 was deemed significant. Cytokine profiling and western blot 
experiments in Chapter 3, also had 3 and 4 groups respectively. Ordinary one-way 
ANOVA with Tukey’s post-hoc analysis was used here.  
For comparing patient group demographics in Chapters 4 (males vs. females) 
and 5 (Diabetes vs. non-diabetes controls), Student’s t tests were used to determine 
differences in age, HbA1c and BMI. Student’s t tests were also used to determine 
changes in a number of variables in specific comorbidities in patients positive for 
that comorbidity compared to those without the condition (Chapter 4).    
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Correlation analysis was conducted in Chapter 4 to determine any 
relationships between currently measured biomarkers. Two tailed, nonparametric 
Spearman’s correlation analysis (95% CI), was conducted as normal distribution 
could not be guaranteed. Linear regression was used in Chapter 5, to assess the 
relationship between protein expression and disease duration, LDL, total cholesterol, 
C-peptide, number of comorbidities and diabetes medications. A line of best fit was 
generated, origin was automated and confidence interval set at 95%. Non-linear 
regression with normal (Gaussian) distribution was used to correlate protein levels 
to HDL. Least squares ordinary fit was used as recommended by the software. 
  Receiver Operating Characteristics (ROC) graphs (logistic regression) were 
used in Chapter 5 to assess the specificity and sensitivity of proteins associated with 
diabetes vs non-diabetes controls; an area under the curve (AUC) value of 0.7 was 
deemed a fair distinction in line with recommendations. All protein comparisons 
made between 3+ groups in Chapter 5 were made using Ordinary one-way ANOVA 
with Tukey’s post-hoc test, and dual comparisons were made using Student’s t tests.  
In chapter 6 genotyping experiments significant SNPs were identified using 
the Z score test for two proportions. This analysis was used to compare SNP 
genotype proportions for T2D vs. non-diabetes controls, and T2D GLP-1Ra 
responders vs. non-responders for all SNPs across 20 genes of interest. The Z-test 
was also used in Chapter 4 to assess proportion differences in comorbidities, adverse 
reactions and unscheduled care in those receiving GLP-1Ra therapy vs. those 
receiving other diabetes drugs,   
Analysis of cognitive screening examination (SMMSE, qMCI) scores in chapter 
7 was conducted using repeated measures two-way ANOVA; this enabled variation 
between 4 groups and multiple questions to be identified. Holm-Šídák’s multiple 
comparisons post-hoc test was applied.  All correlations between Beck depression 
and anxiety inventories, SMMSE and qMCI with BMI a HbA1C and Neutrophils were 
conducted using Two tailed, nonparametric Spearman correlation analysis (95% CI). 
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Type II diabetes (T2D) and AD share several pathophysiologies and brain insulin 
resistance is characteristic of both diseases. GLP-1Ras are known to increase insulin 
sensitivity, are used in the treatment of T2D and show promise in AD. This study was 
designed to explore the molecular mechanisms downstream of GLP-1R activation in 
brain. We identified potential insulin and leptin signalling-associated genetic and 
proteomic markers of GLP-1 response. GLP-1 RKO and APP/PS1 mouse models were 
used to assess the importance of GLP-1 signalling and the impact of brain insulin 
resistance on gene expression. In brain, GLP-1R, LEP-R, GHSR, CREB1, STAT3, POMC, 
PRMT1 and GIP were affected in both genotypes (P<0.05 - P<0.0001). AD progression 
had a profound effect on all genes; 8 week old APP/PS1 mice displayed increases 
(P<0.05-P<0.0001), and 10 month APP/PS1 mice had global reductions (P<0.05-
P<0.0001).  
The effect of liraglutide treatment on genes of interest was analysed in 
C57BL/6 mice. In brain, genes of interest were upregulated after 7 days (P<0.05 - 
P<0.001), and downregulated after 21 days (P<0.0001). A daily peripheral expression 
pattern for all genes of interest was detected over 7 day’s liraglutide treatment in 
C57BL/6 mice. Peripheral and central expression patterns differed, but early changes 
in periphery were predictive of gene expression patterns observed in brain after 3 
weeks liraglutide administration.  
In APP/PS1 and WT mice differences in baseline peripheral expression of GLP-
1R and LEP-R were detected and liraglutide treatment normalised this.  IL-10 and IL-4 
were increased in APP/PS1 liraglutide treated mice, suggestive of anti-inflammatory 
effects. Protein levels of GLP-1R, IRS-1, AKT, STAT3α, POMC, SOCS3 and GIPR were 
consistent in C57BL/6, APP/PS1, GLP-1RKO, and APP/PS1 after 7 days liraglutide 
treatment. Post-translational modifications differed significantly between genotypes 
in IRS1 s616 and FOXO1 s256 (P<0.05 - P<0.001). These results indicate that leptin 
signalling is important in response to liraglutide and that gene expression changes in 







Type 2 diabetes (T2D) and Alzheimer’s disease (AD) are linked by mechanisms that 
are not fully understood (Ramirez et al., 2015). It is estimated that 4.5 million people 
suffer from T2D in the United Kingdom (Diabetes UK, 2016) and that these patients 
are at a 3 fold increased risk of developing AD (Arvanitakis et al., 2004). The 
incidence and prevalence of both diseases increases with age and both share several 
pathophysiological abnormalities including insulin resistance, oxidative stress, 
dyslipidaemia, advanced glycation end products and changes to hormonal signalling 
(Malkki, 2015).  
Insulin is essential for the maintenance of physiological and biochemical 
processes in the brain and periphery (Robertson et al., 2004). It can alter feeding 
behaviour and numerous aspects of metabolism (Khodabandehloo et al., 2016). 
Insulin binds to its receptor, the IR, causing the tyrosine phosphorylation of IRS-1 
(Waters and Pessin, 1996). In the central nervous system (CNS) this interaction 
affects body weight, cell growth, and glucose homeostasis by activating a number of 
signalling cascades including Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), 
MAPK (Sugano et al., 2006) and a number of other transcription factors involved in 
apoptosis and cell differentiation (Burgos-Ramos et al., 2012). Much of insulin’s 
activity is mediated by AKT (Spolcova et al., 2014). It is involved in glucose transport 
to the plasma membrane via GLUT4 (Chang et al., 2004), but it is also involved in a 
number of anti-inflammatory pathways (Orellana et al., 2015). AKT inhibits the 
phosphorylation of GSK3 and phosphorylates FOXO1 at serine 256; activity which 
alters a number of transcription factors including nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-KB) and B-cell lymphoma 2 (BcL2) which are 
involved in gene expression, cell viability and apoptosis (Niyomchan et al., 2015).  
In T2D insulin transport across the BBB, irrespective of blood concentration, 
is negatively affected (Banks et al., 1997). This lowers the level of brain insulin and 
has been shown to impact insulin signalling affecting central and peripheral 
metabolism, exacerbating metabolic disorders and insulin resistance (Kaiyala et al., 
2000). Much of this T2D pathogenesis has also been shown in the brains of 
Alzheimer’s mouse models (Malkki, 2015). In human clinical trials reduced insulin 
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sensitivity has been shown to be a characteristic of AD and prolonged insulin 
resistance is significantly linked to late stage AD (Chen and Zhong, 2013). Molecularly 
both disease have a destabilized IR/IRS-1/PI3K pathway and a link is no longer in 
doubt (Talbot et al., 2012a).   
In neuron-specific IR knockout mice (NIRKO), increased levels of insulin, 
leptin, lipids and moderate insulin resistance is common and has been shown to 
result in peripheral insulin resistance and impaired suppression of gluconeogenesis, 
which leads to hyperglycaemia (Obici et al., 2002c). In the brain of NIRKO mice 
impaired IR/IRS-1/P1-3K signalling leads to the phosphorylation of tau protein which 
is a central mechanism linking T2D to AD (Koch et al., 2010).  
Insulin signalling may be augmented by increasing insulin concentrations, 
reducing insulin resistance or activating parallel signalling mechanisms (Kahn et al., 
2006). Injectable insulin is not effective in this case due to the limitations in 
transport across the BBB, and significant risk of hypoglycaemia (Banks et al., 1997). 
There are now other pharmaceutical options that have been shown to increase brain 
insulin signalling (Salcedo et al., 2012). One that has gained particular interest, due 
to its mode of action and particularly mild adverse event profile, is Glucagon-like 
peptide-1 receptor agonist (GLP-1Ra), liraglutide. This drug is a synthetic incretin 
hormone, and in clinical trials has been shown to increase insulin secretion, insulin 
sensitivity and affect appetite and weight loss (Ard et al., 2016). GLP-1Ra have 
central and peripheral effects, acting as neurotransmitters and growth factors 
(Hayes, 2012). Liraglutide has been shown to induce significant insulin secretion in 
response to nutrient ingestion via c-AMP (Iepsen et al., 2015b) and it can penetrate 
the BBB to interact with the insulin and leptin signalling cascades (Blonde and 
Russell-Jones, 2009). The main mechanism by which it achieves this is by inhibiting 
PTP1B (Tiganis, 2013). PTP1B is insulin’s main negative regulator, but is also linked to 
leptin pathways (Zabolotny et al., 2002a). Leptin has recently been shown to be 
capable of activating PI3K and affecting insulin resistance (Ren et al., 2007) but is 
also critical in the regulation of energy intake and metabolism. Classically leptin 
activates its receptor (LEP-R) inducing activation of Janus kinase 2 (JAK2) and STAT3 
but recently it has been shown that the binding of SH2B1 to JAK2 allows for leptin 
mediated IRS-1 phosphorylation and downstream PI3K activation (Duan et al., 2004). 
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The LEP-R/JAK/SH2B1 complex can stimulate genes that code for IR and IRS proteins, 
and inhibition of SH2B1 increases insulin resistance (Chua, 2010). This has been 
shown to be an important process; alterations in SH2B1 result in abnormal 
metabolism, insulin resistance and obesity (Doche et al., 2012). Leptin signaling has 
also been implicated in neuronal damage. Alterations lead to impaired synaptic 
plasticity and insulin sensitivity in the hypothalamus (Perez-Gonzalez et al., 2014). 
Therefore GLP-1Ra stimulation of leptin signalling may be one mechanism by which 
liraglutide mediates its reported neuroprotective effects, reducing synapse loss and 
restoring neuronal function (McClean and Holscher, 2014). 
Anti-inflammatory effects, of GLP-1 analogues may also mediate some of the 
reported neuroprotective properties. It has been shown that liraglutide reduces 
microglia and pro-inflammatory cytokines in an x-ray inflammation model 
(Parthsarathy and Hölscher, 2013). Liraglutide-induced reductions in inflammation 
have been shown in APP/PS1 mice to be directly linked to learning and memory 
(McClean et al., 2015). Anti-inflammatory effects have also been observed in a 
mouse model of intracerebral haemorrhage (ICH) (Hou et al., 2012) and a rat model 
of traumatic brain injury (TBI) (Hakon et al., 2015). Interestingly in the rat it was 
shown to improve integrity of the BBB (Hakon et al., 2015).  
GLP-1R are widely expressed in the brain and on the BBB and stimulation by 
GLP-1 has been shown to have significant effects on insulin sensitivity, neurogenesis 
and energy metabolism (Kanoski et al., 2011). Due to the close link between insulin 
and leptin neuronal signalling and GLP-1’s ability to interact with both systems 
(Akieda-Asai et al., 2014), it is now considered a good pharmaceutical candidate to 
stimulate both pathways (Adamska et al., 2014).  The present study was designed to 
explore the relationship between incretin receptor expression and leptin signalling in 
the absence of the GLP-1 receptor, using GLP-1 RKO mice and in a model of brain 
insulin resistance, the APPswe/PS1ΔE9 mouse model of AD. Subsequently we 
assessed response to acute (7 days) or chronic (21 days) liraglutide treatment on the 
same panel of genes in brain in a C57BL/6 mouse model. Finally we investigated 
whether gene expression profiles observed in brain may be detected, or predicted, 







APP/PS1 mice were aged and treated with liraglutide as described in Chapter 2; 
Section 2.1.1. GLP-1 RKO mice are described in Chapter 2; Section 2.1.2. C56BL/6 
mice are described in Chapter 2; Section 2.1.3. All experiments were conducted in 
accordance with the UK home office Animals (Scientific Procedures) Act.  
 
3.2.2 Total RNA extraction for gene expression analysis 
  
3.2.2.1 Brain tissue 
 
The RNeasy lipid tissue mini kit (Qiagen Ltd, Manchester, UK; Cat. No. 78404) was 
used to extract total RNA from whole hemibrain, as described in Chapter 2; Section 
2.4.1.1 
 
3.2.2.2 Whole blood 
 
Whole blood was obtained from the tail vein and RNA was extracted from a 50 µl 
aliquot using the QIAamp RNA blood mini kit (Qiagen Ltd, Manchester, UK; Cat. No. 
52304), as described in Chapter 2; Section 2.4.1.2  
 
RNA quality and quantity was determined immediately before cDNA synthesis using 
a nanodrop (Nanodrop 2000c, ThermoFisher Scientific, Wilmington, DE).  
  
3.2.3 Complementary DNA (cDNA) Synthesis      
   
Reverse transcription was conducted using a Transcriptor First Strand cDNA 
synthesis kit (Roche Diagnostics Ltd., West Sussex, UK; Cat. No. 04379012001). Total 
RNA was dependant on sample type (Brain (25 ng) and blood (5 ng) per reaction), as 






3.2.4 Quantitative Polymerase Chain Reaction (qPCR) 
 
All qPCR experiments were normalised to a stable housekeeping gene (RNS18 M. 
musculus, Assay ID 307906, transcript length 1870 bps, amplicon length 106 bps) in 
whole blood and brain and under various treatment conditions, using the 2ΔΔCT 
method. Full real-time ready probe list, reagents and method are available in 
Chapter 2; Section 2.4.3.   
 
3.2.5 Total protein extraction and sample preparation for proteomic 
analysis 
  
Protein was extracted from one hemisphere of mouse brain using RIPA lysis buffer 
(Chapter 2; Section 2.5.1). Concentration was determined using a Pierce™ BCA 
Protein Assay Kit (Thermo scientific, UK; Cat. No. 223227) and BioTek Epoch 
Microplate Spectrophotometer (BioTek, UK, Cat. No. 15306176), according to 
manufacturer’s instructions. Full protocol outlined in Chapter 2; Section 2.5.2. 
 
3.2.6 Western blot SDS-page 
  
Protein samples were run on a 10-well NuPAGE™ 4-12% Bis-Tris, gradient protein Gel 
(Thermo scientific, UK; Cat. No. NP0335BOX) and transferred on to Polyvinylidene 
difluoride (PVDF) membranes (Thermo scientific, UK; Cat. No. LC2005) before being 
blocked (5% milk/ 0.05 %TBS-T) and incubated in primary antibody overnight. 
Proteins were developed using Anti-rabbit IgG, HRP-linked secondary antibody (Cell 
signalling, Cat. No 7074, Rabbit, dilution 1:1000) and SuperSignal Chemiluminescent 
Substrates (Thermo scientific, UK; Cat. No. 34080). Full protocol and reagent 
inventory outlined in Chapter 2; Section 2.5.4.  
 
3.2.7 Meso Scale Discovery proinflammatory array 
 
Cytokine and chemokine analysis was conducted using the Meso Scale Discovery 
(MSD®) Multi-spot Assay Pro-inflammatory panel 1 (mouse) kit (Meso Scale 
Discovery, Rockville, MD, USA, Cat. No. K15048D) according to the manufacturer’s 
instructions, as described in in Chapter 2; Section 2.6. 
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3.2.7 Statistical analysis 
 
All statistical analysis was conducted using Graphpad Prism software (Graphpad 
Software Inc., La Jolla, CA, USA; v6.0h). Student t tests and one way ANOVA with 
































3.3.1 Leptin and Insulin regulatory genes are upregulated in the brain of 
GLP-1R KO and young APP/PS1 mice. 
 
3.3.1.1 Incretin receptor compensation in GLP-1RKO and APP/PS1 mice 
 
Both GLP-1R and GIP-R expression levels were significantly altered in GLP-1R 
knockout (KO) mice. GLP-1R mRNA levels were reduced by 70 ± 3% compared to wild 
type (P<0.05; Fig. 3.1A). Although not completely ‘knocked out’, GLP-1R knockdown 
had an effect on GIP-R levels which were increased by 64 ± 13% (P<0.01; Fig. 3.1H).  
In 8 week old APP/PS1 mice GLP-1R expression was significantly increased by 152 ± 
30% compared to WT (P<0.001; (Fig. 3.1A), however GIP-R expression was not 
significantly different compared to WT (88 ± 19%; Fig. 3.1H). GIPR expression was 
significantly increased in GLP-1 RKO mice compared to APP/PS1 mice (P<0.01).   
 
3.3.1.2 GLP-1R –LEP-R crosstalk 
  
In GLP-1 RKO mice GHSR was increased by 261 ± 16%, (P<0.0001; Fig. 3.1C) and LEP-
R increased 153% ± 41 %, (P<0.005; Fig. 3.1B), compared to WT mice. In the APP/PS1 
model we recorded a similar significant increase in GHSR (224 ± 34%; P<0.0001), 
however LEP-R expression was comparable to controls.  
As expected, increased LEP-R expression in the GLP-1 RKO model had a 
significant impact on downstream components STAT3 (+158 ± 46%; P<0.005; Fig. 
3.1E), and POMC (+84 ± 3%; P<0.05; Fig. 3.1F).  In the APP/PS1 model STAT3 mRNA 
levels were comparable to WT and significantly reduced compared to GLP-1 RKO 
mice (-102 ± 16%, P<0.05; Fig. 3.1D). POMC expression was increased in the APP/PS1 
model compared to control (+101 ± 34%, P<0.01; Fig 3.1E).  
 
3.3.1.3 Neuroprotective effect  
      
GLP-1 RKO mice exhibited a 144 ± 24% increase in CREB1 (P<0.0001; Fig. 3.1D). 
CREB1 was also significantly increased in the APP/PS1 model (173 ± 13%; P<0.001). 
Interestingly the major regulator of CREB1 transcription in pancreas, PRMT1 (Fig. 
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3.1G), was also significantly upregulated in both GLP-1R KD and APP/PS1 mice by 178 
± 41% (P<0.001) and 67 ± 9% (P<0.05), respectively.  
 
3.3.2 Downstream cell regulators maintained at normal levels in GLP-1 
RKD and APP/PS1 mice  
 
In the brain of GLP-1 RKD mice, IRS-1 (103 ± 5%; Fig. 3.2A) and AKT (115 ± 14.35%; 
Fig. 3.2E) expression was not significantly different from WT mice. Similarly, key 
genes involved in Leptin signalling; JAK2 (95 ± 7%, Fig. 3.2B), SH2B1 (98 ± 12%, Fig. 
3.2C) and SOCS3 (106 ± 12%, Fig. 3.2D) were unaffected in this genotype. 
The 8 week old APP/PS1 mice exhibited a similar expression profile to GLP-1R 
KD mice, showing normal leptin gene expression levels and therefore IRS-1 (93 ± 
11%, Fig. 3.2A), AKT (133 ± 28%, Fig. 3.2E), JAK2 (84 ± 20.11%, Fig. 3.2B), SH2B1 (97 ± 
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Figure 3.1 – Insulin and appetite regulatory genes are upregulated in the brain of GLP-1RKO and APP/PS1 mouse models. GLP-1R (A), LEP-R (B), GHSR 
(C), CREB1 (D), STAT3 (E), POMC (F), PRMT1 (G) and GIPR (H) gene expression was determined by quantitative real-time PCR and normalised to internal 
housekeeping control RNS18. GLP-1R ‘knockout’ resulted in increased LEP-R and GIPR which corresponded with increased related and downstream 
genes GHSR, CREB1 ,STAT3, POMC PRMT1 (p<0.05-p<0.001). APP/PS1 mice had increased GLP-1R and unchanged LEP-R and GIPR but experienced the 
same significant downstream increases in GHSR, CREB1, POMC, PRMT1 (p<0.05-p<0.001), highlighting a regulatory relationship between GLP-1R and 
LEP-R. Wild Type (WT, n=6), GLP-1R KO (n=4) and APP/PS1 (n=5). Statistical significance determined using one-way ANOVA and Tukey’s multiple 
comparisons test.  *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 vs WT control. Δ P<0.05, ΔΔ P<0.01, ΔΔΔ P<0.001 and ΔΔΔΔ P<0.0001 vs. APP/PS1.    






G L P -1 R























   






L E P R





























S T A T 3





























P O M C


















































Figure 3.2 – Expression levels of cell regulators that link leptin and insulin signalling are 
unaltered in GLP-1RKO and APP/PS1 mouse models. IRS1 (A), JAK2 (B), SH2B1 (C), SOCS3 
(D) and AKT (E) gene expression was determined by quantitative real-time PCR and 
normalised to internal housekeeping control RNS18. No significant change was observed in 
any of the cell regulators in either genotype compared to WT controls. WTS, GLP1-RKO and 
APP/PS1, n=3 per group. Expression changes compared to WT control.  
 
 
3.3.3 Alzheimer’s disease progression has a negative effect on key 
regulatory genes involved in Leptin and insulin signalling 
 
In young APP/PS1 mice (8 week) the mRNA levels of major regulators of Leptin and 
insulin signalling were maintained, likely a result of the significant upregulation of 
the related upstream genes observed. To further characterise the effect of the 
APP/PS1 genotype on genes of interest we measured mRNA levels of the key 
regulators in 10 month APP/PS1 mice that phenotypically have a higher levels of Aβ 
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3.3.3.1 Incretin signalling disruption  
 
In early AD (8 week, APP/PS1) GLP-1R expression (Fig. 3.1A) was increased however 
in aged APP/PS1 mice at 10 months both GLP-1R (Fig. 3.3F) and GIP-R (Fig. 3.3G) 
were significantly downregulated, 66 ± 18% (P<0.01) and 54 ± 15% (P<0.05), 
respectively, characteristic of impaired incretin action in brain.   
 
3.3.3.2 Major disruption of downstream cell regulators in 10 month 
APP/PS1 mice  
 
Expression of the major leptin regulating genes in 10 month APP/PS1 mice contrasts 
the expression pattern observed in younger mice. The LEP-R binding protein JAK2 
(Fig. 3.3B) was reduced 66 ± 17% (P<0.05) and SH2B1 61% ± 15% (P<0.05, Fig. 3.3C). 
IRS-1 was reduced 74 ± 5%, (P<0.0001, Fig. 3.3A) and it downstream target AKT 
reduced by 62% ± 5%, (P<0.005, Fig. 3.3E), indicative of substantial alterations in 
insulin signalling (Cong et al., 1997). SOCS3 was not significantly affected (45% ± 
21.5%; P< 0.10) in aged APP/PS1 mice. 
 
3.3.4 Liraglutide differentially affects leptin and insulin signalling genes 
dependent on treatment duration 
 
3.3.4.1 Liraglutide affects GLP-1R but not GIP-R transcription.  
 
To further explore potential insulin sensitising mechanisms in brain we treated 
C57BL/6 mice with liraglutide for 7 and 21 days. GLP-1R mRNA (Fig. 3.4A) was 
unaffected by liraglutide treatment after 7 days (23 ± 15%, P< 0.15) however a 
significant decrease was apparent after 21 days (82 ± 16%, P<0.0001). GIP-R 
expression was unchanged in response to 7 day and 21 day liraglutide treatment 
(Fig. 3.4H).  
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Figure 3.3 – Expression levels of cell regulators that link leptin and insulin signalling in brain from APP/PS1 mice with significant Aβ deposition 
(10month). IRS-1(A), JAK2 (B), SH2B1 (C), SOCS3 (D), AKT (E), GLP-1R (F), GIP-R (G) gene expression was determined by quantitative real-time PCR and 
normalised to internal housekeeping control RNS18. Contrasting what was observed in young APP/PS1 mice, before beta amyloid deposits develop, IRS-
1, SH2B1, AKT, GLP-1R and GIPR were all significantly downregulated (p<0.05-p<0.001), suggestive of severely dysregulated leptin and insulin signalling.  




3.3.4.2 Liraglutide increases brain mRNA of Leptin and insulin signalling 
genes after 7 days treatment  
 
After 7 days liraglutide treatment, LEP-R expression (Fig. 3.4B) was upregulated by 
36 ± 6% (P<0.05) which resulted in a significant increase in its downstream target 
STAT3 (P<0.05; Fig. 3.4E) by 15 ± 7%. The neuronal peptide POMC (Fig. 3.4F) was also 
significantly affected (P<0.05) with mRNA levels reduced by 48 ± 11% compared to 
untreated controls.  GHSR (Fig. 3.4C) mRNA levels were comparable between 7-day 
and untreated controls. CREB1 (Fig. 3.4D) was upregulated by 22 ± 6% (P<0.05), as 
was the neuroprotective enzyme PRMT1 (+48 ± 10%, P<0.0001). 
 
3.3.4.3 Global down regulation of Leptin and insulin signalling genes in 
brain after 21 days Liraglutide treatment  
 
All genes of interest were down regulated after 21 days liraglutide treatment. LEP-R 
expression was significantly reduced by 78 ± 18% (P<0.0005, Fig. 3.4B), followed by 
an 81 ± 4% decrease in STAT3 expression (Fig. 3.4C, P<0.0001) and an 84 ± 4% 
decrease in POMC (P<0.0001; Fig. 3.4F) mRNA. Unexpectedly the GHSR was also 
significantly reduced by 86 ± 5% compared to UT controls, indicative of maintained 
appetite suppression (P<0.001; Fig. 3.4C). CREB1 (Fig. 3.4D) and PRMT1 (Fig. 3.4G) 
were both significantly reduced (P<0.0001) by 77 ± 5% and 75 ± 4%, respectively, 
after 21 days liraglutide treatment. 
 
3.3.5 Downstream cell regulators exhibit contrasting expression profiles 
in brain after 7 and 21 days treatment  
 
Neuronal cell regulator mRNA was maintained at a normal levels after 7 days 
liraglutide treatment. We found that JAK2 (93 ± 5%; Fig. 3.5B), SH2B1 (100 ± 9%; Fig. 
3.5C), SOCS3 (121 ± 9%; Fig. 3.5D) were not affected by treatment. As a result 
neither IRS-1 (92 ± 6%; Fig. 3.5A) nor AKT expression levels (102 ± 14%; Fig. 3.5E), 













Figure 3.4 – Leptin and insulin genes are differentially expressed in brain of WT mice treated with liraglutide (25 nmol/Kg) after 7 and 21 days. GLP-1R 
(A), LEP-R (B), GHSR (C), CREB1 (D), STAT3 (E), POMC (F), PRMT1 (G) and GIP-R (H) gene expression was determined by quantitative real-time PCR and 
normalised to internal control gene RNS18. A significant upregulation in LEP-R, CREB1, STAT3 and PRMT1 (P<0.05-P<0.001), and a significant down 
regulation in POMC (P<0.01) was observed after 7 days treatment. In contrast after 21 days a significant down regulation in GLP-1R (P<0.001), LEP-R 
(P<0.0001), GHSR (P<0.01) CREB1 (P<0.0001), STAT3 (P<0.0001), POMC (P<0.0001) and PRMT1 was observed (P<0.0001). Untreated (UT), 7 day treated, 
and 21 day treated, n=6 per group. Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparisons test *P<0.05, 
**P<0.01, ***P<0.001 and ****P<0.0001 vs. untreated control.   ΔΔ P<0.01, ΔΔΔ P<0.001 and ΔΔΔΔ P<0.0001 vs. 7-day treated group 
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Similar to what we observed with upstream components, treating the mice for 21 
days caused a completely different expression profile. IRS-1 (14 ± 5%; Fig. 3.5A) and 
AKT (25 ± 9%; Fig. 3.5E) were both significantly downregulated, P<0.0001 and 
P<0.001 respectively. Leptin signalling components JAK2 (74 ± 11%; P<0.001; Fig. 
3.5B), SH2B1 (86 ± 5%; P<0.0001; Fig. 3.5C) and SOCS3 (72 ± 8%; P<0.0001; Fig. 3.5D) 





















Figure 3.5 – Expression levels of key cell regulators linking leptin and insulin signalling are 
down regulated after 21 days liraglutide treatment. IRS1 (A), JAK2 (B), SH2B1 (C), SOCS3 (D) 
and AKT (E) gene expression was determined by quantitative real-time PCR and normalised 
to internal housekeeping control RNS18. No significant change was observed after 7 days 
but expression of all genes was significantly reduced (P<0.001-P<0.0001) after 21 days 
treatment when compared to UT WT controls. UT, 7 and 21 day n=3 per group. Statistical 
significance was determined one-way ANOVA with tukey’s post-hoc test. ***P<0.001, 
****P<0.0001 vs. untreated control. ΔΔΔ P<0.001 and ΔΔΔΔ P<0.0001 vs. 7-day treated 














3.3.6 Peripheral detection and assessment of Leptin and insulin signalling 
genes after 7 days liraglutide treatment 
 
3.3.6.1 Detection of Leptin and insulin signalling genes is possible in 
whole blood  
 
Peripheral gene expression is rapidly affected by liraglutide treatment. Expression of 
genes of interest was significantly altered after 24 h and a peak effect occurred after 
48 h. After 30 min GLP-1R expression was reduced and LEP-R expression increased 
however significant variability in response (GLP-1R, Fig. 3.6A) had a SEM of ± 69% 
and the LEP-R (Fig. 3.6B) of ± 83% negated significance. After 24 h mRNA levels of 
GLP-1R, 74 ± 26% (P<0.01), and the LEP-R, 14.9% ± 1.9%, were downregulated. GLP-
1R mRNA levels declined further over time with the lowest level being recorded at 
72 h (5 ± 5%, P<0.0001) before being undetectable on the 7th day. Expression of LEP-
R remained constant after 24 h, until the 7th day, when mRNA could no longer be 
detected. GHSR (Fig. 3.6C) could not be detected in whole blood.  
 
3.3.6.2 Peripheral Leptin and insulin gene expression exhibits a specific 
expression profile over 7 days Liraglutide treatment  
 
Many studies have shown the fast pharmacodynamic profile of Liraglutide 2 h 
initiation, 18 h duration) (Astrup et al., 2012). Only GLP-1R and LEP-R were not 
rapidly affected 30 min after a first liraglutide injection. Leptin receptor and GLP-1 
receptor expression was affected after 24 h and peripheral mRNA for both could not 
be detected after 168 h (section 3.3.6.1). STAT3 (Fig. 3.6E) mRNA was significantly 
reduced (P<0.01) by 45 ± 11% after 30 min this declined a further  
49 ± 2% (P<0.01) after 24 h before a maximum reduction of 98 ± 0.3% (P<0.0001) 
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Figure 3.6 – mRNA expression profile of leptin and insulin regulatory genes in whole blood from WT liraglutide treated mice over 7 days. GLP-1R (A), 
LEP-R (B), GHSR (C), CREB1 (D), STAT3 (E), POMC (F) and PRMT1 (G) gene expression in whole blood 30 min, 24 h, 48 h, 72 h, 96 h and 168 h after first 
administration of liraglutide was determined by quantitative real-time PCR and normalised internal control RNS18. Animals received a once daily 
injection of liraglutide at 15.00. Liraglutide exerted a maximum effect on gene expression 24-48hrs after initiation of treatment. At 24 h significant down 
regulation was observed in GLP-1R (P<0.01), LEP-R (P<0.0001), CREB1 (P<0.0001), STAT3 (P<0.0001) and PRMT1 (P<0.0001), while POMC was 
significantly upregulated (P<0.0001). This, excluding the acute effect on POMC, shows a contradictory peripheral expression profile compared to what 
was observed in brain after 7 day treatment with liraglutide, but mirrors gene expression in brain after 21 day. GHSR was undetectable in peripheral 
blood. N=5, Statistical significance was determined using one-way ANOVA and Tukey’s multiple comparisons test *P<0.05, **P<0.01,***P<0.001 and 
****P<0.0001 vs. UT control. ΔP<0.05 and ΔΔP<0.01 vs. indicative time point.  
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This expression pattern directly contrasted neuronal peptide POMC (Fig. 3.6F), which 
was unchanged at 30 min but significantly increased (P<0.0001) by 658 ± 82% after 
24 h and 1055 ± 115% (P<0.0001) after 48 h. This relationship is seen throughout the 
duration of treatment; at 72 h when STAT3 mRNA begins to increase, POMC 
expression significantly decreases (P<0.01) 291 ± 100%.   
The same 24 / 48 h transcription profile was also evident with CREB1 (Fig. 
3.6D). CREB1 was significantly decreased 58% ± 11% after 30 min (P<0.001) and 
continued to reduce after 24 h reaching a maximum reduction after 2 days (97 ± 
0.9%, P<0.0001) when compared to time point 0. The same trend was recorded for 
PRMT1, which was decreased (50 ± 15%, P<0.005) after 30 min and most 
significantly reduced after 24 h by 97 ± 1% (P<0.0001). 
 
3.3.7 Liraglutide differentially affects peripheral gene expression in WT 
and APP/PS1 mice 
 
3.3.7.1 Baseline GLP-1R and LEP-R expression is different in WT and 
APP/PS1 mice 
 
Initial peripheral gene expression profile (day 0) of WT and APP/PS1 mice was not 
significantly different for most genes of interest (GHSR Fig. 3.7C, CREB1 Fig. 3.7D, 
STAT3 Fig. 3.7E, POMC Fig. 3.7F, PRMT1 Fig. 3.7G). GLP-1R expression was 
significantly reduced in APP/PS1 (Fig. 3.7A; -6 ± 2;, P<0.0001), compared to WT mice.  
LEP-R expression was significantly increased (4 ± 1; P<0.05; Fig. 3.7B). GHSR was 
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Figure 3.7 - Peripheral GLP-1R and LEP-R expression is different in WT and APP/PS1 mice at 
8 weeks of age. Whole blood (WB) (A) GLP-1R, day 0, (B) WB LEP-R, day 0, (C) WB GHSR, day 
0. (D) WB CREB1, day 0, (E) WB STAT3, day 0, (F) WB POMC, day 0. (G) WB PRMT1, day 0. 
Gene expression in WB was determined by quantitative real-time PCR and normalised 
internal control RNS18. Expression at day 0 (T=0) for APP/PS1 is shown as a percentage of 
WT control. WT and APP/Ps1 baseline expression level was opposite for GLP-1R, LEP-R. 
There was no difference in any of the other genes. GHSR was undetectable in peripheral 
blood. Statistical significance was determined using students T-test *P<0.05, ****P<0.0001 
vs. WT saline control.  
 
3.3.7.2 Peripheral gene expression after 7 days liraglutide treatment in 
WT and APP/PS1 mice 
 
After 7 days liraglutide treatment GLP-1R (-1 ± 0, P<0.0001, Fig. 3.8A) and CREB1 (0.7 
± 0.4, P<0.0001, Fig. 3.8C) were downregulated, POMC was upregulated (Fig. 3.8F, 
P<0.01) and STAT3 (Fig. 3.8E) and PRMT1 (Fig. 3.8J) were unchanged in WT mice. The 
expression of LEP-R opposed that of the GLP-1R, and was significantly upregulated in 
WT treated mice (3 ± 0.02; P<0.0001; Fig. 3.7B). It is worth noting that this data 
corresponds with the expression trends seen in our previous peripheral gene 
experiments using WT mice (Fig. 3.6).  
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Interestingly APP/PS1 mice had an opposing expression profile of GLP-1R and LEP-R 
after 7 days liraglutide treatment.  GLP-1R (Fig. 3.8A) was significantly upregulated in 
the blood of APP/PS1 mice (1 ± 0.01; P<0.0001) and LEP-R (Fig. 3.8B) was 
significantly downregulated in blood of APP/PS1 mice (0.86 ± 0.02, P<0.0001). All 
other genes in APP/PS1 mice exhibited the same expression profile as WT treated 
mice after 7 days liraglutide treatment.   
 
3.3.7.3 Comparison of blood/brain gene expression profiles after 7 days 
liraglutide treatment in WT and APP/PS1 mice 
 
Figure 3.4 demonstrated that genes of interest increased in brain after 7 days 
liraglutide treatment in WT mice. The present data (Fig. 3.8) supports this and the 
central (brain) gene expression profile that was identified in APP/PS1 mice at 8 
weeks, illustrated in Figure 3.1. We expand on this data by showing the relationship 
between brain and peripheral (blood) gene expression; generally and in response to 
liraglutide treatment. Expression of all genes of interest significantly increased in 
brain after 7 days treatment in all groups when compared to 7-day treated blood 
from the same group. GLP-1R expression (P<0.0001, Fig. 3.8A) and LEP-R (P<0.0001, 
Fig. 3.8B) were increased most. No significant difference was detected between 
APP/PS1 treated mice and WT saline treated mice for any genes of interest in brain. 
GHSR was detected in brain, but not blood (Fig. 3.7F).  
 
3.3.8 Liraglutide treatment in the APP/PS1 model induces a greater anti-
inflammatory response than in WT mice 
 
Expression of 10 cytokines in plasma from WT saline, WT liraglutide and APP/PS1 
liraglutide-treated mice is illustrated in Fig. 3.9. No significant differences were 
observed between genotype or in response to liraglutide in IL-12P70 (F) IL-2 (G), IL-6 
(H), IL-5 (I) OR KC/GRO (J).  As illustrated in Fig. 3.9A, IL-10 was significantly increased 
from day 0 to day 7 in all groups, WT saline group  (P<0.0001), WT liraglutide group 
(P<0.0001) and APP/PS1 liraglutide group (P<0.00001). IL-10 was also significantly 
increased in the APP/PS1 liraglutide-treated group on day 7 compared to the wild-
type saline-treated group on day 7 (P<0.01).  
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Figure 3.8 - Peripheral receptor expression is different in APP/PS1 mice and is modulated 
by liraglutide treatment. (A) GLP-1R, day 7, (B) LEP-R, day 7, (C) GHSR, day 7. (D) CREB1, day 
7, (E) STAT3, day 7, (F) POMC, day 7. (G) PRMT1, day 7. Gene expression in whole blood and 
whole hemibrain was determined by quantitative real-time PCR and normalised internal 
control RNS18. After 7 days treatment (T=7) WT expression was determined by comparing 
WT T=7 to WT T=0 and APP/PS1 T=7 to APP/PS1 T=0. In T=7 brain expression is presented as 
a percentage change of the treatment groups peripheral T=7 expression. Animals were aged 
for 8 weeks then received a once daily injection of liraglutide at 15.00 for 7days. GHSR was 
undetectable in peripheral blood. Statistical significance was determined using one-way 
ANOVA and Tukey’s multiple comparisons test *P<0.05, **P<0.01, ****P<0.0001 vs. T=0 
peripheral genotype specific control. ΔP<0.05 and ΔΔΔP<0.001, ΔΔΔΔP<0.0001  vs. 7th day 
peripheral genotype specific expression. 
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Figure 3.9 – Plasma cytokine profile of WT saline, WT liraglutide and APP/PS1 liraglutide treated mice.  IL-10 (A), IL-4 (B), TNFα (C), IL-1β (D), IFN-Y (E), 
IL-12-P70 (F), IL-1(G), IL-4 (H), IL-5 (I) and KC/GRO (H) plasma concentrations were measured, using the Meso Scale Discovery (MSD®) Multi-spot Assay 
Pro-inflammatory panel 1, in WT mice treated with saline (n=3) or liraglutide (n=5) and APP mice treated with liraglutide (n=6). Animals received a once 
daily injection of liraglutide, or saline at 15.00 for 7 days. Statistical significance was determined using one-way ANOVA and Tukey’s multiple 
comparisons test. *P<0.05  ***P<0.001, ****P<0.0001 vs. day 0 control.  
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IL-4 was significantly increased from day 0 to day 7 upon liraglutide administration in 
WT (P<0.05) and APP/PS1 mice (P<0.0001; Fig. 3.9B), while levels were unaltered by 
7 days saline administration. No significant difference was observed between WT 
saline and WT Liraglutide groups after 7 days, however the APP/PS1 saline-treated 
group had increased IL-4 compared to both WT saline (P<0.0001) and WT liraglutide-
treated mice (P<0.001).  
 
3.3.9 Liraglutide affects leptin and insulin associated proteins in the brain 
of APP/PS1 mice 
 
 
3.3.9.1 Liraglutide reduces phosphorylation of IRS-1 s616 in APP/Ps1 
mouse brain 
 
There was no difference in the total protein level of GLP-1R (Fig. 3.10.1. A), IRS-1 
(Fig. 3.10.1. C) or GIPR (Fig. 3.10.1. B) in APP/PS1 mice treated with liraglutide (7 
days), GLP-1 RKO mice, untreated APP mice or WT saline treated (7 days) mice. 
Levels of phosphorylated IRS-1 s616, a putative marker for insulin resistance, varied 
between genotypes. The levels in the WT saline mice were very low, and had a 
densitometric value of 0.029 ± 0.006. Levels were significantly increased in the 
APP/PS1 genotype (0.231 ± 0.054, P<0.05), highly significantly increased in the GLP-
1RKO model (0.568 ± 0.064, P<0.001) compared to WT saline-treated mice. Seven 
days treatment with liraglutide abolished serine phosphorylation of IRS-1 as s616 













3.3.9.2 Liraglutide increases total STAT3β in APP/PS1 mouse brain 
 
We measured both STAT3 isoforms (α, β) and STAT3 activation (t705). STAT3α was 
unchanged across groups (Fig. 3.10.2. A), however STAT3β (Fig. 3.10.2. B) was 
comparable between WT and GLP-1 RKO mice but undetectable in untreated 
APP/PS1 mice (P<0.001). Seven-day liraglutide treatment in APP/PS1 mice had a 
profound effect; STAT3β levels were significantly increased (P<0.001) compared to 
WT saline-treated mice. Many studies have found STAT3β to be directly linked to 
reduced inflammation (Maritano et al., 2004).  
 
3.3.9.3 Liraglutide increases pFOXO1 in APP/PS1 mouse brain 
 
POMC (Fig. 3.10.3. C) and SOCS3 (Fig. 3.10.3. D) protein levels were not significantly 
different in APP/PS1 mice or the GLP-1R KD model compared to controls. Liraglutide 
treatment also had no effect on these proteins in the present experiment (Fig. 
3.10.3. A, B).    
AKT was not significantly affected by genotype or treatment (Fig. 3.10.3. A) 
but downstream pFOXO1 was (Fig. 3.10.3. B). In the APP/PS1 mice treated with 
liraglutide pFOXO1 protein levels were significantly increased compared to WT 
saline-treated mice, indicative of cytoplasmic retention and increased CREB activity 
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Figure 3.10.1 – Incretin receptor and IRS1 protein levels in C57BL/6, APP/PS1 and GLP-
1RKO mice and after liraglutide-treatment in the APP/PS1 model. Total protein levels of 
GLP-1R (A), GIPR (B), total IRS1 (C), phospho IRS1 s616 (D) were measured via western blot. 
C57 (WT), APP/PS1 (APP) and APP/PS1 treated with liraglutide (APPL) mice were 12 weeks of 
age, GLP-1RKO (KO) mice were 18 months old. Treated animals received a once daily 
injection of liraglutide at 15.00 for 7 days. Densitometry was conducted using imagej 
software. N=4 per group and replicated n=2. Statistical significance was determined using 
one-way ANOVA and Tukey’s multiple comparisons test. *P<0.05, ****P<0.0001 vs. WT 
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Figure 3.10.2 – Total and phosphorylated STAT3 protein levels in C57BL/6, APP/PS1 and 
GLP-1RKO mice and after liraglutide-treatment in the APP/PS1 model Total protein levels 
of STAT3α (A), STAT3β (B), phospho STAT3 t705 (C) were measured via western blot. C57 
and APP/PS1 mice were 12 weeks of age. GLP-1RKO mice were 18 months old. C57 (WT), 
APP/PS1 (APP) and APP/PS1 treated with liraglutide (APPL) mice were 12 weeks of age, GLP-
1RKO (KO) mice were 18 months old. Treated animals received a once daily injection of 
liraglutide at 15.00 for 7 days. Densitometry was conducted using imagej software. N=4 per 
group and replicated n=2. Statistical significance was determined using one-way ANOVA and 
Tukey’s multiple comparisons test. ***P<0.001, ****P<0.0001 vs. WT saline control. 
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Figure 3.10.3 – Phosphorylation levels of FOXO1 are elevated in APP/PS1 mice treated with 
liraglutide.  Total protein levels of AKT (A) phosphoFOXO1 (B), POMC (C) and SOCS3 (D) were 
measured via western blot. C57 and APP/PS1 mice were 12 weeks of age. GLP-1RKO mice 
were 18 months old. Treated animals received a once daily injection of liraglutide at 15.00 
for 7 days. Densitometry was conducted using imagej software. N=4 per group and 
replicated n=2. Statistical significance was determined using one-way ANOVA and Tukey’s 












This data demonstrates that leptin and insulin gene expression profiles are affected 
in the brain in the absence of the GLP-1 receptor and during the progression of AD. It 
also illustrates that the same panel of genes are altered in response GLP-1Ra 
(liraglutide) treatment, with different effects dependent on treatment duration. The 
relationship between brain and peripheral gene expression was also identified, and 
indicates tighter control of transcriptional alterations in brain than in blood, 
presumably as a protective mechanism. 
This, to our knowledge, is the first study to explore the effect of liraglutide 
treatment on a wide array of genetic and protein biomarkers in WT and APP/PS1 
mice in the brain and periphery. Previous work within our laboratory has highlighted 
liraglutide’s ability to improve aspects of learning and memory and to reduce classic 
AD pathology (McClean et al., 2015), however mechanistic insights behind these 
effects are poorly described.   
Others have indicated a close relationship between leptin and GLP-1 (Akieda-
Asai et al., 2014) demonstrating that each peptide can modulate the other to 
elucidate tissue specific responses in C57BL/6 intestine (Anini and Brubaker, 2003) 
and obese (ob/ob) mouse brain (Ronveaux et al., 2015b). The present study assessed 
this concept in the brain of GLP-1 RKO mice and found that reducing GLP-1R resulted 
in significantly increased LEP-R expression and that this translated to its downstream 
targets. We also observed GIP-R expression was increased in the GLP-1R KO model, 
and published data supports this finding (Preitner et al., 2004, Pederson et al., 1998).     
 The GLP-1R was not completely ‘knocked out’ in the GLP-1RKO model but 
the significant reduction had a major impact on LEP-R expression and appetite 
related signalling, increasing downstream genes STAT3 and POMC (Ernst et al., 
2009). This is interesting as a number of in vivo studies have shown co-stimulation of 
LEP-R and GLP-1R control food intake in an addictive manor and blocking GLP-1R 
reduces the LEP-R inhibitory effect (Reidelberger et al., 2012). Other in vitro studies 
have shown that knockout of the GLP-1R and subsequent stimulation with a GLP-1Ra 
increases LEP-R signalling by directly affecting leptin’s negative regulator PTP1B 
(Kanoski et al., 2015). The present study  supports initial characterisations of GLP-1 
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RKO mice that showed them to have elevated GIP (Preitner et al., 2004) and normal 
satiety (Lamont et al., 2012), but further adds to this knowledge by defining the close 
relationship between incretin and leptin signalling.   
This transcriptional relationship between GLP-1R and LEP-R signalling 
pathways, and a desire to understand changes in incretin signalling in a model of 
Alzheimer’s disease, with known brain insulin resistance, provided the rationale to 
characterise the same panel of genes in an APP/PS1 model and assess the effect of 
disease progression on expression. Interestingly, in 8 week old APP/PS1 mice, GLP-1R 
expression was significantly increased and LEP-R expression comparable to control. 
The elevated expression of GLP-1R in APP/PS1 mice may represent a response to 
inflammation. Studies have shown that GLP-1 is secreted in response to 
inflammatory stimuli (Kahles et al., 2014), and at 8 weeks these mice have activated 
microglia, low level Aβ and high levels of pro-inflammatory cytokines such as TNFα 
(Malkki, 2015). It is possible that these conditions induce secretion of GLP-1 from 
both intestinal L cells (Ronveaux et al., 2015a) and microglia in the brain to reduce 
inflammation (Kappe et al., 2012). As a secondary effect high levels of GLP-1 have 
been shown to cause hyperactivation of the LEP-R (Zhao et al., 2012), increasing 
leptins downstream components (Akieda-Asai et al., 2014). Hyperactivation has been 
linked to internalisation, which can occur as a regulatory mechanism (Kuna et al., 
2013). Such internalisation has also been demonstrated with the GLP-1R under 
chronic GLP-1R agonist treatment (Thompson and Kanamarlapudi, 2015). 
Internalisation of the Leptin receptor could explain why downstream components of 
leptin signaling are upregulated, yet the receptor is not. Receptor internalisation is 
likely an essential process for maintaining the steady state of expression of key 
genes relating to insulin sensitivity, in both the GLP-1 RKO and APP/PS1 models. 
The same panel of genes were measured in 10-month-old APP/PS1 mice to 
assess the effect of disease progression. At this age these mice phenotypically have 
significant plaque formation, synaptic loss and cognitive impairment (Malkki, 2015). 
All genes were down regulated indicative of significant insulin desensitisation. Other 
research has detailed IRS1/PI3K and AKT signalling disruption in the APP/PS1 model 
(Talbot et al., 2012a), however, to our knowledge there are no reports of 
dysregulation of leptin signalling in this model.   
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To further characterise the GLP-1/leptin relationship focus was shifted to the 
effect of GLP-1 analogue treatment (liraglutide) on the same panel of genes in 
C57BL/6 mice after 7 and 21 days.  Differential expression was observed dependent 
on treatment duration; genes involved in leptin and insulin signalling were 
significantly upregulated after 7 days and significantly downregulated after 21 days 
treatment. The expression profile after 7 days is consistent with what has been 
described in other work, with raised LEP-R/STAT3 expression indicative of appetite 
suppression (Kanoski et al., 2015) as well as increased mRNA levels of genes involved 
in neurogenesis and insulin gene transcription (Bao et al., 2015). It has been 
reported that GLP-1R agonists reduce the cleavage of membrane bound LEP-R 
(Iepsen et al., 2015a). This effect results in decreased soluble receptors and 
increased free leptin, which would maintain weight loss and prevent the normal 
appetite increase and energy expenditure decrease associated with decreased 
weight or fat mass (Rosenbaum et al., 2008).  
After 21 days liraglutide treatment, GLP-1R mRNA was significantly reduced 
in brain. Other in vitro work has shown liraglutide increases GLP-1R expression in a 
dose and time dependent manner although in much shorter time frames (h) (Zhao et 
al., 2015). In vivo studies have shown GLP-1 analogues increase GLP-1R expression in 
tissues including the heart, pancreas and kidneys, although most experiments were 
short (1 week) (Noyan-Ashraf et al., 2009). There is in vivo evidence that prolonged 
treatments (6 weeks), reduces GLP-1R activity, possibly indicative of reduced 
expression (Bock et al., 2003). It is possible that chronic GLP-1Ra therapy, such as the 
3 weeks treatment reported here may cause receptor internalisation. A number of 
pre-clinical studies have shown G protein-coupled receptors (GPCRs) internalise 
upon activation (Baggio et al., 2004). This reduces cell surface expression, and is a 
way of reducing biological response, to re-sensitise the receptor (Marchese et al., 
2003). This recycling could have a significant downstream effect for all related 
pathways, including LEP-R/JAK2. Circulating peptide levels (GLP-1, Leptin, insulin) 
were not measured, however bodyweight was not significantly different between 
groups. The present data suggest that liraglutide has a profound effect on Leptin and 
incretin receptor gene expression in brain and lends support to other studies that 
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have indicated GLP-1 mediates weight loss and affects insulin sensitivity via the LEP-
R (Iepsen et al., 2015a). 
Mechanistic insights are important, however detecting central changes in the 
periphery increases clinical relevance of such findings considerably (Thambisetty and 
Lovestone, 2010). As such we assessed the relationship between gene expression in 
the brain and in peripheral whole blood to determine differences between genotype 
(APP/PS1 vs. WT) and in response to liraglutide administration. This analysis 
indicated that peripheral expression is not perfectly correlated with gene expression 
in the brain for the genes of interest. Findings supported work that proposed some 
genes are appropriate and some are not for peripheral analysis (Glatt et al., 2005) as 
GHSR could not be detected peripherally. Results indicated an inverse relationship 
between central and peripheral gene expression after 7 days treatment for GLP-1R, 
CREB1, STAT3 and POMC in both WT and APP/PS1 treated mice, while blood was 
more predictive of chronic changes observed in brain at 3 weeks. Identification of 
genes capable of being detected with any surrogate relationship with the brain is 
thought to be difficult (Tsuang et al., 2005). The complexity of the brain and BBB is 
well established (Kadakkuzha and Puthanveettil, 2013) but whole blood is also a 
complex multi cell tissue, with cells that vary in function, morphology and lineage 
(Watkins et al., 2009). There is growing evidence that brain gene expression affects 
peripheral tissues via the CNS and circulatory system (Luykx et al., 2016). This work 
suggests that blood mRNA changes in genes of interest may be predictive of those 
observed in brain in response to chronic liraglutide administration, however more 
work is required to support this hypothesis.  
 The effect of liraglutide on brain and peripheral whole blood gene expression 
in WT and APP/PS1 was assessed. The APP/PS1 transgenes had a profound effect on 
peripheral gene expression at baseline. Expression of GLP-1R was reduced and LEP-R 
increased compared to WT controls. This further supports a relationship between 
GLP-1R and LEP-R (Akieda-Asai et al., 2014) and also highlights that pathology 
associated with the APP/PS1 transgenes in brain (Maia et al., 2013) affects whole 
blood gene expression. Liraglutide treatment differentially affected the peripheral 
expression of GLP-1R and LEP-R after 7 days in the APP/PS1 model. GLP-1R was 
increased and LEP-R decreased. This peripheral expression change resulted in 
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significantly more brain GLP-1R and LEP-R which ultimately resulted in increased 
expression of all downstream genes of interest, with the exception of POMC. There 
was no difference in brain gene expression between APP/PS1 and WT saline treated 
mice. This could indicate that liraglutide impacts peripheral leptin and insulin 
receptor expression to normalise central gene expression. This would not be 
unusual; cells maintain homeostasis by regulating surface expression of genes and 
synthesis of their products (Rue and Martinez Arias, 2015).  
Cytokines have been shown to be key mediators of T2D and AD. 
Quantification of 10 plasma cytokines in response to liraglutide treatment in wild-
type and APP/PS1 mice identified differences between the genotypes with respect to 
response to liraglutide treatment. We observed increased plasma TNFα over the 
course of treatment in all groups however no differences were observed between 
genotypes. APP/PS1 mice have been reported to have high levels of TNFα 
(Montgomery and Bowers, 2012), however such differences were not observed here. 
Interleukin 1 beta (IL-1β) was significantly increased in 7-day saline-treated WT mice, 
but not WT or APP/PS1 liraglutide-treated animals, indicative of an anti-
inflammatory effect (Schmidt et al., 2008). APP/PS1 mice treated with liraglutide had 
significantly higher plasma Interleukin 10 (IL-10) and Interleukin 4 (IL-4) than WT 
mice treated with saline or liraglutide, indicating that the APP/PS1 model is more 
susceptible to liraglutide mediated increases of IL-10 and IL-4, both of which have 
been linked to insulin signalling and inflammation (Ropelle et al., 2010). IL-10 is an 
anti-inflammatory cytokine; in T2D it is reported to function as a pro-inflammatory 
inhibitor (Dagdeviren et al., 2017), and can act as an activator of the LEP-R, 
mediating downstream insulin related affects (Niemand et al., 2003). IL-10 is also 
involved in the adaptive immune response and can induce the differentiation of 
CD4+ T cells to T helper cells (Mitchell et al., 2017). Both of these characteristics are 
beneficial in T2D and AD, and could be a mechanism by which GLP-1Ras mediated 
anti-inflammatory and neuroprotective effects previously observed (McClean and 
Holscher, 2014). The increase in IL-4 is supported by other research that has shown 
liraglutide to increase IL-4 and Signal transducer and activator of transcription 6 
(STAT6) activity (Kaplan et al., 1996). These proteins can reduce ROS and NF-Kb 
signalling in diabetes (Clarke et al., 1998). This protective effect is also seen in 
97 
  
APP/PS1 mice with increased IL-4 being directly linked to reduced Aβ peptide and 
deposition and improved neurogenesis (Kiyota et al., 2010). IL-4 has also been linked 
to improved learning and memory (Derecki et al., 2010).  
The present study indicates liraglutide has anti-inflammatory effects in wild-
type and APP/PS1 mice, with more significant increases in IL-10 and 1L-4 in the 
transgenic model, which is worthy of additional study. An obvious limitation of the 
present study is the absence of an APP/PS1 saline-treated group. Future studies will 
assess the cytokine profile in a saline-treated APP/PS1 control group. The increased 
levels in the majority of cytokines after 7 days saline-treatment in wild-type mice 
was surprising, and may represent a stress response at the time of sample 
(Mormède et al., 2002). Despite this differences between groups are considered 
valid as all mice experienced the same procedure. 
A number of proteins related to our pathways of interest were quantified in 
the present study. Surprisingly total protein levels for all genes of interest were not 
affected by genotype (C57BL/6, APP/PS1, GLP-1RKO) or by treatment in the case of 
the APP/PS1 model. This highlights a possible disconnect between transcription and 
translation with respect to the leptin and insulin genes of interest. There is a body of 
work that has shown a large number of mRNAs are not equal in terms of protein 
translation (Schwanhausser et al., 2011). These genes tend to be related to key 
cellular processes involved in metabolism and homeostasis; genes that have a high 
gene-protein correlation tend to be stable housekeeping such as β-actin. Many 
studies have shown mRNA to be variable but protein to be constant. A steady state is 
thought to be mechanistically homeostatic and for many proteins represents 
‘healthy’ (Vogel and Marcotte, 2012). Interestingly, it is thought to be post-
transcriptional and translational modifications that compensate for changing mRNA 
and bring mRNA levels back to ‘normal’ (Shebl et al., 2010). The results from this 
study support post-translational modification of proteins of interest. Protein levels of 
phosphorylated FOXO1 s256 and IRS-1 s6161 are different between genotypes and 
in liraglutide-treated mice. Phosphorylation of FOXO1 at s256 was only significantly 
increased in the APP/PS1 mice treated with liraglutide. Pre-clinical work has shown 
this protein to be a key mediator of insulin gene transcription via CREB activity 
(Yamagata et al., 2008). The opposite effect was observed for IRS-1 activation; 
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treating APP/PS1 mice with liraglutide abrogated s616 phosphorylation. IRS1 pS616 
has been associated with brain insulin resistance (Talbot et al., 2012a), reduced AKT 
signalling (O' Neill, 2013) and progression of AD pathology (Talbot et al., 2012a). 
Others have reported liraglutide-induced reductions in IRS1 pS616 in older APP/PS1 
mice treated with liraglutide for 2 months (Long-Smith et al., 2013). The present data 
suggests IRS1pS616 may be detected early in the AD disease process and is altered 
after short treatment duration.   
Interestingly, IRS-1 pS616 was expressed at its highest level in the GLP-1R KO 
mice; studies have shown that these mice usually have increased peripheral insulin 
sensitivity (Moffett et al., 2014) but phosphorylation of IRS-1 at this residue is a 
widely accepted marker of insulin resistance (Talbot et al., 2012b). It may be that 
brain insulin resistance is a feature of the GLP-1RKO model. Indeed, GLP-1R KO mice 
are more susceptible to neuronal injury (Belsham et al., 2009) and studies have 
shown these mice to have impaired synaptic plasticity and memory (Abbas et al., 
2009), features which may be attributable to high pIRS-1 s616 in brain. Future work 
will assess IRS-1 phosphorylation in each of the models in more detail. 
The leptin signalling pathway is important for liraglutide’s insulin sensitising 
and anti-inflammatory effects in both T2D and AD. A direct relationship exists 
between the GLP-1R and LEP-R in brain, which is dysregulated by knockout of the 
GLP-1 receptor and in APP/PS1 mice with brain insulin resistance. Modulation of 
associated genes is observed in response to liraglutide treatment which affected 
central and peripheral gene expression. Gene expression changes observed in blood 
in response to liraglutide treatment after 24 h were not predictive of brain changes 
within 1 week, but reflective of changes observed after 3 weeks treatment for most 
genes of interest. Further studies will identify their efficacy as potential markers of 
response to therapy. 
 
 










Glycaemic control, comorbidity and 
the effect of GLP-1 analogue therapy in 












In type II diabetes (T2D), chronic hyperglycaemia causes short and long-term 
complications, and mortality is often a result of multimorbidity. This study aimed to 
assess the clinical profile of T2D patients in Northern Ireland (NI) and evaluate the 
effect of GLP-1Ra treatment on common diabetes measures (HbA1c, BMI and lipids). 
Prescribing patterns, comorbidity and pharmacological adverse reactions were also 
analysed. Five hundred T2D patients were enrolled; clinical data was obtained from 
ECR systems, and primary data analysis of insulin and C-peptide levels. 
 Glycaemia was poorly managed in the DiaStrat cohort who had an average 
HbA1c of 65.08 mmol/mol (8.4%). Ninety three percent of patients were overweight 
and 40% were on insulin therapy. Majority (~70%) were on 2 + anti-diabetes 
medications, and there was major deviation from NICE stepwise guidance. Over 60% 
of the cohort had more than 4 comorbidities and 69% had a rare combination 
affecting <3 patients. Cardiovascular comorbidity was common accounting for 25% 
of recorded comorbidity. Surprisingly, recent blood lipid tests showed that LDL and 
total cholesterol were higher (P<0.0001) in patients without a CVD diagnosis. Anti-
hypertensive and lipid regulating medications made up 47% of all non-diabetes 
prescriptions, indicative of aggressive cardiovascular risk management, both were 
overprescribed when compared to recorded diagnosis (P<0.0001). There was a high 
incidence of noted adverse events for these medications.  
Patients receiving GLP-1Ra were younger and heavier (P<0.01) while HbA1c 
was no different from the rest of the cohort. There were fewer (P<0.05) GLP-1Ra 
patients with no comorbidity and significantly more with CVD (P<0.05); GLP-1Ra 
patients were prescribed more antihypertensive and lipid regulating drugs (P<0.01). 
This data shows that T2D patients in NI are treated with complex polypharmacy for a 
wide range of comorbidities. Treatment does not follow NICE guidance or correlate 
strongly with biochemical measures. C-Peptide correlated with diabetes regime 
intensification and the assessed comorbidities, and would be a beneficial measure in 







Type II diabetes (T2D) affects 3.2 million ‘diagnosed’ individuals in the UK (Diabetes 
UK, 2016), at a cost to the economy £14 billion per year (Hex et al., 2012). Obesity is 
the greatest risk factor for T2D, with 80% of patients being overweight or obese 
(BMI>30 kg/m2) (NICE, 2017). T2D and obesity alone are associated with the 
development of comorbidities and complications (Choby, 2017), but patients 
suffering from both have a greatly increased risk of developing heart disease, 
hyperlipidaemia, hypertension and other microvascular complications (Alexopoulos 
et al., 2016).   
T2D is characterised by chronic hyperglycaemia (Gajos and Mostowik, 2016) 
and has been shown to worsen with weight gain and improve with weight loss 
(Sattar et al., 2016). Significant weight loss, such as that linked to gastric bypass 
surgery, has been shown to lead to partial or total remission of T2D and associated 
conditions (Schauer et al., 2016). Comorbidities linked to diabetes and obesity affect 
systems all around the body, and have been traditionally categorised as 
macrovascular and microvascular (Lu et al., 2009). Such characterisation can 
overshadow other complications such as endocrine, digestive, musculoskeletal and 
those associated with cognitive function and mental health (Pentakota et al., 2012). 
It is thought that in the UK most diabetes patients have at least one comorbidity and 
40% are thought to have at least three (Khan, 2017). It has been suggested that 
treatment of comorbidities may shift priority away from diabetes (Piette and Kerr, 
2006). This is supported by large retrospective studies (n=42,826), focusing on 
patients with new onset diabetes which indicate that those with comorbidities 
sharing a similar pathogenesis or management plan to diabetes received increased 
diabetes care testing (LDL, HbA1C,) than those with discordant conditions such as 
musculoskeletal disorders (Pentakota et al., 2012). 
The treatment options available to T2D patients have increased in recent 
years evident by the expanding guidance by the NICE (NICE, 2015), American 
Diabetes Association (ADA) (ADA, 2016) and European Association for the Study of 
Diabetes (EASD) (European Association for the Study of Diabetes, 2015). 
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NICE recommend a uniform stepwise intensification of therapy to achieve adequate 
HbA1c control (NICE, 2017), while the EASD are now recommending a personalised 
approach (European Association for the Study of Diabetes, 2015). This is thought to 
be due to failings in diabetes control despite comprehensive guidance and numerous 
therapeutic options (Iglay et al., 2016). Studies in the US have indicated ~55% of T2D 
patients have an HbA1C greater than 53 mmol/mol (7%) (Menon and Ahluwalia, 
2015), while in the UK ~51.3% of patients are thought to exceed the 53 mmol/mol 
(7%) threshold (Mauricio et al., 2017).  
A personalised approach to treatment of multiple chronic diseases can be 
difficult. Clinicians are often required to treat a constellation of diseases with 
different management approaches and pharmacological options (Pentakota et al., 
2012). NICE have guidelines for the prescription of glycaemic medications and non-
glycaemic medications which takes into account drug safety and tolerability profiles 
(NICE, 2015). 
Electronic Care Records (ECR) are a dependable source of clinical information 
that encompass a wealth of patient data related to treatment strategies, 
comorbidity and a range of biochemical readings (Franzen et al., 2016). Individuals 
with three comorbidities are prescribed on average 9 medications (Patel et al., 
2017), see multiple clinicians and receive 15 home visits a year (Hing et al., 2008). 
ECR systems promote coordination between primary and secondary health care 
providers enabling clinicians to exchange and update clinical information. This 
reduces duplicate hospital tests and data storage, and improves patient support and 
clinical decision making (Sulmasy et al., 2017).   
As a secondary use, ECR systems facilitate clinical research (Cowie et al., 
2017). Many systems are being used to conduct epidemiologic and observational 
research (Bower et al., 2017). ECR systems can be used as standalone data sets or 
used to link up with primary research data, proving integrated datasets with 
information spanning the patient’s life (Häyrinen et al., 2008). Such studies enable 
longitudinal analysis of disease progression and drug efficacy. Some countries have 
linked ECRs at the patient level, to secondary population data sets including; disease 
registries, education, social care and criminal justice systems (Casey et al., 2016). 
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Such comprehensive data linkage allows for greater understanding of factors such as 
socioeconomic status on disease.  
Safety and surveillance research is an emerging application for ECR systems 
(Cederholm et al., 2015). ECR can provide real world information (outside of clinical 
trial reports) on adverse events or reactions (Trifiro et al., 2009). The European 
Exploring and Reporting Adverse Reactions by Integrative Mining of Clinical Records 
and Biomedical Knowledge (EU-ADR) project encompasses 8 databases for the 
analysis of choice target adverse reaction numbers (Trifiro et al., 2009). This project 
works closely with the European Medicines Agency (EMA) to inform the European 
Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) on 
post marketing drug risk (Eichler et al., 2008). In the United States the Food and Drug 
Administration (FDA) also uses ECR to similar ends (Ball et al., 2016).  
Clinical research utilises ECR in a number of ways, the most common is the 
facilitation of patient recruitment, enabling efficient generation of patient lists that 
meet specific inclusion and exclusion criteria (Köpcke et al., 2013). These systems 
can also be used to collect and reuse information used in routine clinical care such as 
demographic, prescription and comorbidity data. As such data is inputted at point of 
care by a health professional it is thought to have a reduced risk of transcriptional 
error (Thadani et al., 2009). In a clinical trial setting, ECR systems have been shown 
to reduce timelines by removing manual data entry and enable remote data 
observation (Fordyce et al., 2015). Initiatives and online tools such as the Innovative 
Medicine Initiative (IMI) Electronic Health Records for Clinical Research project are 
examples of systems that simplify the reuse of clinical data for research (De Moor et 
al., 2015).  
Challenges and limitations exist when utilising ECR data. Data quality and 
validation issues have been reported by clinical studies, predominantly related to 
inaccurate information and coding errors (Hersh et al., 2013). As data entry is reliant 
on various medical personnel, across multiple centres, input parameters and 
methodologies vary. This can cause errors and lead to incomplete data capture. 
Current screening measures for multimorbidity require numerous patient-
clinic visits for effective management. This requirement exceeds currently available 
clinic hours in the UK (Baxter et al., 2016), and results in many conditions that would 
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usually be treated in an inpatient setting being treated on an outpatient basis 
(O'Connor et al., 2016). Optimisation of care strategies to deal with and support to 
multimorbid patients is critical (Khan, 2017). Defining the effect Multiple 
Comorbidity Clusters (MCC) have on mortality, therapy and choice of therapy is of 
significant importance (Li et al., 2013). 
 Diabetes glycaemic control, prescription trends, comorbidity and associated 
prescribing patterns have not been assessed in Northern Ireland, nor has the effect 
of glucagon-like peptide-1 receptor analogue (GLP-1Ra) therapy on such measures. 
The present study was designed to assess currently available ECR recorded data on 
glycaemic control, lipid profile, BMI and recorded comorbidity, prescription data, 
unscheduled care and noted adverse reactions in 500 type 2 diabetes participants. 
Additionally insulin and C-peptide, which are not routinely measured in clinical 
practice, were measured to identify their utility as a measure of disease progression 
or management. GLP-1R analogue prescribed patients were also characterised, to 
better inform clinical practice on best stratification policies of this phenotypically 



















4.2.1 Participant recruitment  
 
All participants were identified by diabetes clinicians at the Altnagelvin Hospital, in 
Northern Ireland, after ORECNI ethical approval and Western Trust governance 
approvals were in place, as described in Chapter 2, Section 2.7.  All participants were 
given a 48 hour cool down period prior to sample collection. 
 
4.2.2 Sample collection 
 
4.2.2.1 Buccal Swab 
 
A single buccal swab was obtained using a MasterAmpTM buccal brush (epicentre, 
Madison, WI USA; Cat no. 4459), as described in Chapter 2, Section 2.8.1.1. 
 
4.2.2.2 Blood sampling 
 
Blood samples were obtained using 21 G Vacuette® safety needle (Greiner Bio-One, 
Stonehouse, UK; Cat no. 450091), as described in Chapter 2, Section 2.8.1.2 
Approximately 26 ml of blood was extracted in total into 2 x 9 ml EDTA (K3E K3EDTA) 
coated Vacuette® tubes (Greiner Bio-One, Stonehouse, UK; Cat no. 455036) and 1 x 
8ml Serum (Z Serum Sep Clot Activator) tube (Greiner Bio-One, Stonehouse, UK; Cat 
no. 455071). All blood samples were processed immediately.  
 
4.2.3 Blood processing 
 
Polypropylene tubes were labelled using Item Tracker© software (ItemTracker 
Software Ltd, Suffolk, UK), prior to processing for serum, plasma, protein, RNA and 
whole blood, as described in Chapter 2, Section 2.8.1.3. Samples were stored at -






4.2.4 DNA extraction  
 
4.2.4.1 Buccal Swabs 
 
DNA was extracted from MasterAmpTM buccal brushes (epicentre, Madison, WI USA; 
Cat no. 4459) using the QIAamp DNA blood mini kit (Qiagen, Manchester, UK; Cat no. 
51106), as described in Chapter 2, Section 2.9.1.  
 
4.2.4.2 Whole blood  
 
EDTA whole blood samples were thawed at room temperature (20oC) and DNA 
extracted using the Gentra Puregene blood kit (Qiagen, Manchester, UK; Cat no. 
158445), as described in Chapter 2, Section 2.9.2. 
 
4.2.4.3 DNA quantification  
 
DNA was quantified using a Qubit®Fluorometer (ThermoFisher Scientific, UK; Cat no. 
Q33216) and QubitTM dsDNA HS Assay kit (ThermoFisher Scientific, UK; Cat no. 
Q32854), as described in Chapter 2, Section 2.9.3.  
 
4.2.5 Enzyme-Linked Immunosorbent Assays (ELISA)  
  
4.2.5.1 Insulin sandwich ELISA  
 
Plasma insulin (25 µl) was quantified using human Mercodia insulin ELISA kit 
(Mercodia, Uppsala, SE; Cat no. 10-1113-10), as described in Chapter 2, Section 
2.10.1. 
4.2.5.2 C-peptide sandwich ELISA 
 
Plasma C-peptide (25 µl) was measured using human Alpco C-peptide ELISA kit 
(Alpco, Salum, US; Cat no. 80-CPTHU-E01.1, E10), as described in Chapter 2, Section 
2.10.2. 
4.2.6 Clinical database construction 
  
Relevant clinical information for all participants (n=500) was obtained from Western 
Health and Social Care Trusts, Hicom Diamond.NET diabetes management system 
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(Hitcom, Surrey, UK) and Orion Health technologies, Northern Ireland Electronic Care 
Record (NIECR) (Orion health, Hammersmith, UK). All data was used in compliance 
with research ethics and Data Protection Act 1998. Full details on database 
construction are described in Chapter 2, Section 2.11.1.  
 
4.2.7 Statistical analysis 
 
 All statistical analysis was conducted using Graphpad Prism software (Graphpad 
Software Inc., La Jolla, CA, USA; v6.0h). Student’s t tests and one way ANOVA with 
Tukey’s post-hoc test, and Z-test proportions were used as described in Chapter 2; 

























The descriptive characteristics of the Diastrat Cohort are presented in Table 4.1. Data 
are presented for the total cohort, and also separated by gender. The cohort was 
predominantly male; of the 494 eligible participants 310 were male and 184 female. 
Obese females had a significantly higher BMI than obese males (39.3 ± 10 vs. 35.8 ± 
5 kg/m2; P<0.001). Females also started insulin therapy at a significantly younger age 
than males (53.97 ± 3, vs 57.45 ± 11; p><0.05). There were no sex differences in 
measures related to glycaemic control, blood pressure (BP) and lipids. Subsequent 
analyses were therefore conducted on the cohort as a whole. The mean age was 62 
± 11 years, 86% of participants were classified as being above HbA1c target (>48.9 
mmol/mol, 6.6%) and 93% were overweight (BMI >25 Kg/m2). Blood pressure (BP) 
was generally well managed. Mean systolic BP was 132 ± 14 mmHg and diastolic of 
76 ± 9 mmHg. Two hundred and nine participants had a clinically diagnosed lipid 
abnormality. Mean HDL was 1.13 mmol/l; LDL 1.93 mmol/l and total cholesterol 3.91 
mmol/l indicative of good management of hyperlipidaemia within the cohort. Overall 




















Table 4.1 – Demographics and clinical features of Type 2 Diabetes patients in Northern 
Ireland. Data is presented as Complete Cohort, Males and Females. Each column describes 
total number of participants, mean ± SD and % of total for each measure. All participants 
were aged 18-80 years. Targets used for HbA1C, BMI and BP classification were obtained 












Number of Participants 
 
494     310     184     
Age (Years) 
 
491 62.75 (11) 99.4 308 63.1 (11) 99.4 183 62.12 (12) 99.5 
Duration of Diabetes 
 
395 12.43 (8) 80.0 251 12.48 (8) 81.0 144 12.36 (9) 78.3 
 
      
  
        
HbA1c 
 
454 65.08 (17) 91.9 282  63.91 (17) 91.0 172 65.21(19)  93.5 
Below target <47.9 mmol/mol 
 
56 42.38 (4) 12.3 31 42.91 (3) 11.0 25 41.72 (5) 14.5 
Target 48 mmol/mol 
 
9 48 (0) 2.0 4 48 (0) 1.4 5 48 (0) 2.9 
above target >48.9 mmol/mol 
 
389 68.75 (15) 85.7 247 68.02 (14) 87.6 142 70.01 (17) 82.6 
 
            
   
BMI 
 
360 33.93 (8) 72.9 224 33.71(6)  72.3 136 34.69(10)  73.9 
Underweight <18.4 
 
0 0 (0) 0.0 0 0 (0) 0.0 0 0 (0) 0.0 
Healthy 18.5-24.9 
 
26 23.30 (1) 7.2 15 23.82 (1) 6.7 11 23.82 (1) 8.1 
Overweight 25-29.9 
 
84 27.87 (1) 23.3 50 27.94 (1) 22.3 34 27.77 (1) 25.0 
Obese >30 
 
250 37.07 (7) 69.4 159 35.8 (5) 71.0 91 39.39 (9)*** 66.9 
 
            
   
BP 
 
323   65.4 204   65.8 119   64.7 
Systolic 
 
323 132 (14)   204 131.6 (14)   119 132.8 (11)   
Diastolic 
 
323 76 (9)   204 76.3 (9)   119 76.4 (9)   
Target <130/80 mmHg 
 
68 120/71 21.1 41 121/71 20.1 27 119/71 22.7 
                    
Diagnosed Lipid abnormality 
 
209   41.8 124   40.0 85   46.2 
HDL 
 
447 1.13(1) 100.0 281 1.05(1) 90.6 166 1.26(1) 87.4 
LDL 
 
444 1.93(1) 100.0 278 1.83(1) 89.7 166 2.08(1) 87.4 
Total Cholesterol 
 
447 3.91(2) 100.0 281 3.77(2) 90.6 166 4.11(2) 87.4 
                    
Number on Insulin 
 
190   38.5 118   38.1 72   39.1 
Time on Insulin (Years) 
 
190 7.06 (5)   118 6.76 (5)   72 7.54 (5)   
Age at Insulin introduction 
 
188 56.13 (12) 98.9 117 57.45 (11) 99.2 71 53.97 (13)* 98.6 
Delay from diagnosis to insulin 
introduction 
184 9 (7) 96.8 115 9.44 (7) 97.5 69 8.27 (8) 95.8 
110 
 
4.3.1 Diabetes treatment regimes 
           
Illustrated in Figure 4.1 are the number of anti-diabetes medications per participant 
(A) and number of participants on each class of anti-diabetes therapy (B). Most 
participants were prescribed 3 (140) or 2 (129) anti-diabetes medications (Fig. 4.1A). 
Eight individuals were on 5 anti-diabetes drugs and 57 were not taking any anti-
diabetes medication (Fig. 4.1A).  Biguanides were the most prescribed drug class 
(365), followed by SU (166), short acting insulin (133), and DDP IV inhibitors (95). 
NICE advised 4th line therapy, GLP-1Ra, were prescribed to 81 participants (Fig. 4.1B).  
 
N u m b e r  o f a n ti D ia b e te s
m e d ic a t io n s  p e r  p a r t ic ip a n t  (n = 5 0 0 )
5 7       0  T re a tm e n ts
9 9       1  T re a tm e n t
1 2 9     2  T re a tm e n ts
1 4 0     3  T re a tm e n ts
6 7      4  T re a tm e n ts
8        5  T re a tm e n ts
T o ta l= 1 0 8 5
A P e r c e n ta g e  o f  P a r tc ip ita n ts  o n  e a c h
c la s s  o f a n ti-d ia b e te s  m e d ic a t io n s  (n = 4 4 3 )
T o ta l= 1 0 8 5
B
3 3 .6 4 %   B ig u a n id e s
1 5 .3 0 %   S u lfo n y lu re a
1 2 .2 6 %   S h o rt In s u lin
8 .7 6 %   D D P 4  in h ib ito r
8 .6 6 %   S G L T 2  In h ib ito r
7 .9 3 %   L o n g  In s u lin
7 .4 7 %   G L P -1  a n a lo g u e
2 .9 5 %   In te rm e d ia te  In s u lin
1 .5 7 %   T h ia z o ld id in e d io n e
0 .7 4 %   In s u lin  / G L P -1  a n a lo g u e
0 .1 8 %   b ig u a n id e s  / D D P 4  in h ib ito r
0 .1 8 %   M e g lit in id e s
0 .1 8 %   T h ia z o ld id in e d io n e  / b ig u a n id e s
0 .1 8 %   U ltra lo n g  In s u lin
 
 
Figure 4.1 – Number of anti-diabetes drug treatments and frequency of prescription of 
anti-diabetes drug classes in the DiaStrat cohort. (A) Total number of participants on 0-5 
anti-diabetes drugs (n=500). (B) Total number of prescribed drugs per diabetes drug class 
(n=443 participants, n=1085 recorded medications). All drugs were classified according to 





Across the cohort 443 participants were prescribed at least 1 anti-diabetes 
medication; 362 were on a regime that included metformin (+) and 81 were on a 
metformin negative (-) regime (Table 4.2). Participants were sub-grouped into 4 
classifications dependant on treatment intensification stage specified by NICE 
(monotherapy, dual therapy, triple therapy or quad plus therapy). Metformin 
monotherapy was prescribed to 71 individuals (19.6% of the total cohort), while 
insulin therapy (short, intermediate, long) was the most frequently prescribed 
treatment (18, 64.3%) if metformin was not tolerated. The most common additions 
for dual therapy in metformin positive regimes were; short acting insulin (28, 29.8%), 
sulphonylurea (SU) (22, 23.4%) and DDP IV inhibitors (17, 18.1%). In the metformin 
negative (-) group the most common dual therapy combinations were; long + short 
acting insulin (16, 45.7%) and DDP IV inhibitor + sulphonylurea (6, 17.1%).   
Majority of the cohort were on a triple therapy metformin positive (+) regime 
(124). Within this classification most were prescribed metformin plus; DDP IV 
inhibitor + SU (23, 18.5%), long + short acting insulin (18, 14.5%) or GLP-1Ra + SU (17, 
13.7%). Within the metformin negative (-) group the most frequently prescribed 
regime was a long + short acting insulin + a SGLT2 inhibitor (4, 25%). There were 75 
individuals prescribed four or more anti-diabetes medications in metformin positive 
(+) regimes. The most commonly prescribed were metformin plus: GLP-1Ra + SGLT2 
inhibitor + SU (12, 16.4%), DDP IV inhibitor + SGLT2 inhibitor + SU (8, 11%), long + 
short acting insulin + SGLT2 inhibitor (8, 11%). There were no quad therapy regimes 


















DiaStrat Cohort  n=500 Total on Metformin (+) 362 82% 











Metformin  (+) Metformin  (-) 
  Total %   Total % 
Metformin 71 100.0 Short acting insulin 11 39.3 
   
Intermediate Insulin 4 14.3 
   
DDP IV inhibitor 4 14.3 
   
Long acting insulin 3 10.7 
   
Sulphonylurea 4 14.3 
   
SGLT2 inhibitor 1 3.6 
   
GLP-1R agonist 1 3.6 










Short acting insulin 28 29.8 Long + Short acting insulin 16 45.7 
Sulphonylurea 22 23.4 DDP IV inhibitor + Sulphonylurea 6 17.1 
DDP IV inhibitor 17 18.1 
   
GLP-1R agonist 11 11.7 
   
Intermediate insulin 8 8.5 
   
SGLT2 inhibitor 3 3.2 
   
Thiazolidinediones 2 2.1 
   
Insulin + GLP-1 mix 2 2.1 
   
Long acting insulin 1 1.1 Other combinations (≤2) 13 37.1 










DDP IV inhibitor + Sulphonylurea 23 18.5 
Long +Short acting insulin 
+SGLT2 inhibitor 
4 25.0 
Long + Short acting insulin 18 14.5 
DDP IV inhibitor + SGLT2 
inhibitor + Sulphonylurea 
2 12.5 
GLP-1R agonist + Sulphonylurea 17 13.7 
   
SGLT2 inhibitor + Sulphonylurea 10 8.1 
   
GLP-1R agonist +  SGLT2 inhibitor 8 6.5 
   
GLP-1R agonist + Short acting insulin 5 4.0 
   
DDP IV inhibitor + Short acting 
insulin 
5 4.0 
   
DDP IV inhibitor + SGLT2 inhibitor 5 4.0 
   
SGLT2 inhibitor +Short acting insulin 5 4.0 
   
Short acting insulin + Sulphonylurea 4 3.2 
   
Long acting insulin +  Sulphonylurea 4 3.2 
   
Other combinations (≤3) 21 16.9 Other combinations (1) 10 62.5 












GLP-1R agonist + SGLT2 inhibitor + 
Sulphonylurea 
12 16.4 
   
DDP IV inhibitor + SGLT2 inhibitor + 
Sulphonylurea 
8 11.0 
   
Long + Short acting insulin + SGLT2 
inhibitor 
8 11.0 
   
Long acting insulin + SGLT2 inhibitor 
+ Sulphonylurea 
6 8.2 
   
GLP-1Ra + Long + Short acting 
insulin 
4 5.5 
   
SGLT2 inhibitor + Short acting 
insulin + Sulphonylurea 
3 4.1 
   
Other combinations (1) 32 43.8 Other combinations (1) 2 100.0 
Total 73 20.2 Total 2 2.5 
 
Table 4.2 – Prescription trends for anti-diabetes medications in the DiaStrat cohort.  Data is 
presented as a Metformin positive or Metformin negative and split into four groups as 
stipulated (Mono, Dual, Triple, Quad therapy) by NICE. Total is equal to the total count of 
participants in that drug/ combination, percentage is equal to total count / total number in 
treatment group.  
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4.3.1.1 Relationship between number of anti-diabetes medications and 
clinical measures of diabetes severity  
 
The number of anti-diabetes medications prescribed was positively correlated with 
HbA1c (R=0.40, P<0.0001; Fig. 4.2A). The mean HbA1c of individuals on 0 anti-diabetes 
drugs was 50.5 ± 8.4 mmol/mol; if prescribed 5 medications HbA1c was significantly 
higher at 78.0 ± 13.3 mmol/mol (P<0.0001). HbA1c was significantly higher in patients 
prescribed two or more anti-diabetes medications when compared to those on none 
(P<0.0001).  
C-peptide was negatively correlated with the number of diabetes 
medications (R= -0.23, P<0.0001; Fig. 4.2B). The average plasma C-peptide value for 
participants not receiving anti-diabetes drugs was 7.6 ± 7.4 ng/ml. A decline in C-
peptide concentration was recorded as the number of prescribed anti-diabetes 
medications increased; 3 medications (4.9 ± 5.1 ng/ml), 5 medications (3.6 ± 1.7 
ng/ml). C-peptide levels were significantly reduced in individuals prescribed 4 anti-
diabetes medications compared to those on none (P<0.01).   
BMI was positively correlated with the number of anti-diabetes medications 
(R=0.22, P<0.0001; Fig. 4.2C). Those on no medication had a BMI 31 ± 5 and those on 
4 medications had a BMI of 36 ± 7 (P<0.05). Interestingly, irrespective of the number 
of anti-diabetes medications all groups had a mean BMI >30.    
LDL was negatively correlated with the number of anti-diabetes medications 
(R=-0.2, P<0.0001), while HDL and total cholesterol were not (Fig. 4.2D). Participants 
on 3 and 4 anti-diabetes medications had significantly lower LDL cholesterol and 
total cholesterol compared to those on no anti-diabetes medications. (LDL values 0 
medications 2.1 ± 0.7 pg/ml, 3 medications 1.7 ± 0.7 pg/ml and 4 medications 1.5 ± 
0.6 pg/ml). Total cholesterol (0 = 4.1 ± 0.7 pg/ml, 3 = 3.6 ± 0.9 pg/ml, 4 = 3.5 ± 0.7 



















Figure 4.2 – Relationship between number of anti-diabetes medications and clinical 
measures of diabetes severity.  (A) HbA1c n= 454; (B) C-peptide n=368; (C) BMI n=360; (D) 
Lipid profile (HDL, LDL, Cholesterol) n=447. Participants were grouped dependant on the 
number of anti-diabetes medications prescribed and the mean value and standard deviation 
of HbA1c, C-peptide, BMI, LDL, HDL and total cholesterol plotted. Two tailed Spearman’s 
correlation analysis between number of diabetes mediations and each measure were 
calculated. Analysis of grouped data was conducted using one-way ANOVA and Tukey’s 
multiple comparisons test. *P<0.05, ****P<0.0001 vs. 0 medications. ΔP<0.05 and 
ΔΔP<0.01, ΔΔΔΔP<0.0001 vs 1 medication. 
 
4.3.1.2 The inter-relationship of C-peptide with HbA1c, BMI and insulin 
levels   
 
Plasma C-peptide levels negatively correlated with HbA1c (R= -0.12, P<0.05, Fig. 4.3A) 
and were not correlated with BMI (R=0.02, P<0.66, Fig. 4.3B). Plasma C-peptide and 
insulin were positively correlated in participants receiving exogenous insulin 
injections (R= 0.68, P<0.0001, Fig. 4.3C). C-peptide levels were 2.4 ng/ml when 
insulin was between 0.1 ng/ml and significantly increased to 6.3 ng/ml when insulin 
was 4+ ng/ml (P<0.0001). C-peptide levels were higher in participants not receiving 
exogenous insulin therapy, and also positively correlated with plasma insulin levels 
(R= 0.48, P<0.0001, Fig. 4.3D). C-peptide levels were 4.7 ng/ml when insulin was 
between 0-1 ng/ml and significantly increased (P<0.05) to 10.73 ng/ml when insulin 
was 4+ ng/ml  
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Figure 4.3 – The inter relationship of C-peptide with HbA1c, BMI and insulin levels (A) HbA1c; 
C-peptide, n= 333 (B) BMI; C-peptide, n=241 (C) C-peptide; Insulin (+exogenous); n= 112 (D) 
C-peptide; Insulin (-exogenous), n=260. Participants were grouped dependant on plasma 
levels of either C-peptide or insulin, the mean value for each group and standard deviation 
was plotted. Two tailed Spearman’s correlation analysis between; plasma C-peptide, HbA1c, 
BMI and insulin was conducted. Statistical significance was determined using one-way 
ANOVA and Tukey’s multiple comparisons test. ***P<0.001 vs. 0-1 ng/ml insulin. ΔP<0.05 
and ΔΔP<0.01 vs 1-2 ng/ml insulin. 
 
 
4.3.1.3 Effect of GLP-1R agonist therapy on markers of diabetes control 
 
Participants treated with a GLP-1Ra (4th line treatment) were compared to those 
who were not. There was no significant difference in duration of diabetes or HbA1c 
levels (Fig. 4.4A, C), however GLP-1Ra positive patients were significantly younger 
(59.4 ± 11.2 years, P<0.01, Fig. 4.4B) and BMI was significantly higher (P<0.05) than 
participants treated with other anti-diabetes medications. GLP-1Ra (+) participants 
had a mean BMI of 35.72 ± 7.1 compared to GLP-1Ra (-) participants who had a BMI 
of 33.45 ± 7.8.  Plasma insulin and C-peptide levels were not affected regardless of 
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Figure 4.4 – GLP-1Ra patient characteristics; Duration, age, HbA1c and BMI. (A) Duration: 
GLP-1Ra (+) n=80, GLP-1Ra (-) n=315. (B) Age: GLP-1Ra (+) n=88, GLP-1Ra (-) n=412 (C) HbA1c: 
GLP-1Ra (+) n=85, GLP-1Ra (-) n=371. (D) BMI: GLP-1Ra (+) n=77, GLP-1Ra (-) n=283.  
Participants were clustered dependant on the presence, or absence, of a GLP-1Ra in their 
anti-diabetes treatment regime. The mean duration, age, HbA1c and BMI values were plotted 
including standard deviation. Participants most recent HbA1c and BMI was used for analysis. 




















     
 
 


































































































Figure 4.5 – Effect GLP-1R agonist therapy on plasma insulin and C-peptide plus or minus 
exogenous insulin administration. (A) Plasma Insulin: GLP-1Ra (+) n=57, GLP-1Ra (-) n=311. 
(B) Plasma Insulin – exogenous insulin: GLP-1Ra (+) n=57, GLP-1Ra (-) n=311. (C) Plasma C-
peptide GLP-1Ra (+) n=57, GLP-1Ra (-) n=311. (D) Plasma C-peptide minus exogenous insulin: 
GLP-1Ra (+) n=57, GLP-1Ra (-) n=311. Participants were clustered dependant on the 
presence of a GLP-1Ra in their anti-diabetes treatment regime. The mean plasma insulin or 
C-peptide was plotted including standard deviation. Insulin and C-peptide values were 
obtained from a blood sample taken from non-fasted participants on the day of recruitment, 
Statistical significance was determined Student’s t-test. **P<0.01 vs. GLP-1Ra (-).    
  
 
4.3.2 Comorbidity in the DiaStrat cohort 
 
ICD-10 recorded comorbidities in the DiaStrat cohort were identified from the 
Northern Ireland Electronic Care Record. The most frequent number of 
comorbidities per participant was between 4-6 (133). Eighty four participants had no 
recorded comorbidity and thirteen participants had between 16-18 recorded 
comorbidities (Fig. 4.6A). The most common type of comorbidity was disease of the 
circulatory system, accounting for 24% of all comorbidity. This was followed by 
endocrine, nutritional and metabolic diseases (16%), diseases of the digestive system 
(11%) and diseases of the musculoskeletal system (7%) (Fig. 4.6B).  
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Microvascular complications retinopathy, nephropathy and neuropathy are 
associated with diseases of the eye and adnexa (4.1%), diseases of the genitourinary 
system (5.3%), and diseases of the nervous system (2.2%), respectively.  Each had a 
relatively low incidence compared to macrovascular complications and other 
comorbidity, however diseases of the genitourinary system were most common in 
this cohort indicting nephropathy may represent the most common microvascular 

















Figure 4.6 – Incidence of comorbidity per participant and most common types of 
comorbidity in a Northern Irish T2D population. (A) Total number of participants with 0, 1-
3, 4-6, 7-9, 10-12, 13-15, 16-18 (n=500). (B) Percentage of comorbidity per ICD-10 coded 
biological system (n=416 participants, n=2680 recorded comorbidities). All health related 
information was obtained from Northern Ireland Electronic Care Record (NIECR). All 
comorbidities were classified using the 10th version of International Statistical Classification 
of Diseases and Related Health Problems (ICD). Other refers to any system that attributed to 







Detailed analysis of the six most prevalent comorbidities are illustrated in Fig. 4.7. 
With respect to diseases of the circulatory system, hypertensive diseases were most 
common accounting for 48% (654, Fig. 4.7A), followed by ischemic heart disease 
(26%). Diseases of the endocrine system were the second most frequent comorbidity 
(417, Fig. 4.7B); hyperlipidaemia (50%) and obesity (17%) accounted for the majority.  
There were 303 incidences of digestive system disorders (Fig. 4.7C); 24% were 
associated with oesophagus, stomach and duodenum (including gastritis, acid reflux) 
and 24% were linked to intestinal disease. Ocular (111, Fig. 4.7D) and genitourinary 
(142, Fig. 4.7E) comorbidity are linked to microvascular complications. The most 
common ocular comorbidities were disorders of the lens, accounting for 44%, and 
disorders of the choroid and retina, 39%. Disorders of the retina most likely 
represent retinopathy and translate to 43 participants. Musculoskeletal disorders 
were the 4th most common type of comorbidity (184, Fig. 4.7F). Osteoarthritis was 
the most prevalent disorder constituting 35.9% of the total, followed by spinal disc 
abnormalities (15.8%), rheumatoid arthritis (10.9%) and bone density problems, such 
as osteoporosis (9.2%).     
 
4.3.2.1 Relationship between currently available clinical data and 
cardiovascular comorbidity 
 
Participants with cardiovascular disease (CVD), on average, have had diabetes for 5.6 
years longer (P<0.0001) than those without CVD (Fig. 4.8A), and are 6.25 years older 
(P<0.0001, Fig. 4.8B). The mean BMI was 34.6 in CVD (+) patients compared to 32.4 
in CVD (-) (P<0.05, Fig. 4.8C). C-peptide levels were significantly lower (1.4 ng/ml, 
P<0.05) in CVD (+) patients (Fig. 4.8D) compared to non-CVD patients (6.8 ± 6.1 
ng/ml) . HbA1c was significantly higher in CVD (+) (66 ± 12 mmol/mol, P<0.05) 
compared to CVD (-) (63 ± 15 mmol/mol, Fig. 4.8E). Interestingly, LDL and total 
cholesterol were significantly lower (P<0.0001) in CVD (+) participant; 1.7 ± 0.7 
mmol/l (CVD(+) vs. 2.0 ± 0.8 mmol/l (CVD (-); 3.7 ± 0.9 mmol/l (CVD (+) vs. 4.1 ± 0.9 
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Figure 4.7 – Detailed total incidence of six most prevalent comorbidities. (A) Percentage of 
total number of recorded cardiovascular comorbidities (654 records, 316 participants). (B) 
Percentage of total number of recorded Endocrine comorbidities (417 records, 271 
participants). (C) Percentage of total number of recorded Digestive system comorbidities 
(303 records, 162 participants). (D) Percentage of Ocular disorders (111 records, 83 
participants). (E) Percentage of Genitourinary disorders (142 records, 107 participants). (F) 
Percentage of musculoskeletal disorders (184 records, 125 participants). All comorbidities 
were classified using the 10th version of International Statistical Classification of Diseases and 
Related Health Problems (ICD) and descriptors of level 2 coding system. Other represents 
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Figure 4.8 – Relationship between currently available clinical data and cardiovascular 
comorbidity. Participants were grouped dependant on presence or absence of CVD. (A) 
Duration of Diabetes (years): CVD absent n=120, CVD present n=273. (B) Age (years): CVD 
absent n=174, CVD present n=316. (C) BMI: CVD absent n=107, CVD present n=253. (D) C-
peptide: CVD absent n=154, CVD present n=217. (E) HbA1c,: CVD absent n=154, CVD present 
n=299. (F) Lipid profile (HDL, LDL, Total Cholesterol): CVD absent n=152, CVD present n=294. 
Data presented as mean ± SD. Statistical significance was determined Student’s t-test. 
*P<0.05, ****P<0.0001 vs. cardiovascular disease absent.     
 
4.3.2.2 Relationship between currently available clinical data and diseases 
of the endocrine system 
 
Diseases of the endocrine system were associated with a significantly longer 
duration of diabetes (P<0.0001, Fig. 4.9A), and older age (P<0.05, Fig. 4.9B). HbA1c 
was significantly higher in those with endocrine disorders (68 ± 17 mmol/mol vs. 62 
± 18, P<0.001). C-peptide was significantly lower in patients with diseases of the 
endocrine system than in those without (4.8 ng/ml vs 7.2 ng/ml, P<0.001, Fig. 4.9D). 
LDL and total cholesterol were significantly lower in participants with endocrine 
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disorders, 1.7 ± 0.7 mmol/l vs 2.0 +0.8 mmol/l and 3.7 ± 0.9 mmol/l vs 3.9 ± 0.9 
mmol/l respectively (Fig. 4.9E, F). There was no difference between in BMI (Fig. 4.9C) 























Figure 4.9 – Relationship between currently available clinical data and diseases of the 
endocrine system. Participants were grouped dependant on clinically recorded presence of 
Endocrine disease. (A) Duration of Diabetes (years): Endocrine disease absent n=142, 
Endocrine disease present n=251. (B) Age (years): Endocrine disease absent n=219, 
Endocrine disease present n=271. (C) BMI: Endocrine disease absent n=118, Endocrine 
disease present n=242. (D) C-peptide: Endocrine disease absent n=196, Endocrine disease 
present n=175. (E) HbA1c: Endocrine disease absent n=307, Endocrine disease present n=147. 
(F) Lipid profile: Endocrine disease absent n=302, Endocrine disease present n=144.  Data 
presented as mean ± SD. Statistical significance was determined Student’s t-test. *P<0.05, 
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4.3.2.3 Relationship between currently available clinical data and diseases 
of the digestive system 
 
As illustrated in Fig. 4.10, patients with digestive system disorders were not 
distinguished by diabetes duration (A), age (B), BMI (C), HbA1c (E), LDL, HDL or total 
cholesterol (F). However, C-peptide was significantly lower (4.4 ng/ml vs. 6.9 ng/ml, 



















Figure 4.10 – Relationship between currently available clinical data and diseases of the 
digestive system. Participants were grouped dependant on clinically recorded presence or 
absence of digestive system disorders. (A) Duration of Diabetes (years): digestive disorders 
absent n=253, digestive disorders present n=141. (B) Age (years): digestive disorders absent 
n=328, digestive disorders present n=162. (C) BMI: digestive disorders absent n=230, 
digestive disorders present n=130. (D) C-peptide: digestive disorders absent n=255, digestive 
disorders present n=166. (E) HbA1c: digestive disorders absent n=307, digestive disorders 
present n=147. (F) Lipid profile: digestive disorders absent n=302, digestive disorders 
present n=144. Data presented as mean ± SD. Statistical significance was determined 
Student’s t-test. *P<0.05, ***P<0.001, ****P<0.0001 vs. digestive disorders absent     
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4.3.2.4 Relationship between currently available clinical data and disease 
of the musculoskeletal system  
 
As illustrated in Fig. 4.11 diabetes duration (A), age (B), BMI (C), C-peptide (D), HbA1c 
(E), HDL, LDL and total cholesterol (F) measurements were comparable in  





















Figure 4.11 – Relationship between currently available clinical data and diseases of the 
musculoskeletal system. Participants were grouped dependant on clinically recorded 
presence or absence of musculoskeletal disease. (A) Duration of Diabetes (years): 
musculoskeletal disease absent n=288, musculoskeletal disease present n=106. (B) Age 
(years): musculoskeletal disease absent n=365, musculoskeletal disease present n=125. (C) 
BMI: musculoskeletal disease absent n=265, musculoskeletal disease present n=95. (D) C-
peptide: musculoskeletal disease absent n=275, musculoskeletal disease present n=96. (E) 
HbA1c: musculoskeletal disease absent n=336, musculoskeletal disease present n=118. (F) 
Lipid profile: musculoskeletal disease absent n=332, musculoskeletal disease present n=114. 
Data presented as mean ± SD.  
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4.3.2.5 Relationship between currently available clinical data and disease 
of the eye  
 
Participants with disorders of the eye had significantly longer diabetes duration, 7.9 
yrs, (P<0.0001, Fig. 4.12A) and were significantly older (P<0.0001, Fig. 4.12B) than 
individuals without eye disease. C-peptide was significantly reduced (6.01 ng/ml vs 
4.02, P<0.05, Fig. 4.12D) in participants with eye disease. BMI (Fig. 4.12C), HbA1c, 
HDL, LDL and total cholesterol (Fig. 4.12F) were not different between participants 


















Figure 4.12 – Relationship between currently available clinical data and diseases of the 
eye. Participants were grouped dependant on clinically recorded eye disorders. (A) Duration 
of Diabetes (years): eye disorder absent n=319, eye disorder present n=74. (B) Age (years): 
eye disorder absent n=407, eye disorder present n=83. (C) BMI: eye disorder absent n=286, 
eye disorder present n=74. (D) C-peptide: eye disorder absent n=323, eye disorder present 
n=48. (E) HbA1c: eye disorder absent n=374, eye disorder present n=80. (F) Lipid profile: eye 
disorder absent n=367, eye disorder present n=79. Data presented as mean ± SD. Statistical 
significance was determined using a Student’s t-test. *P<0.05, ***P<0.001, ****P<0.0001 vs. 
eye disorder absent     
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4.3.2.6 Relationship between currently available clinical data and 
genitourinary disorders  
 
Longer diabetes duration is a characteristic of genitourinary disease (Fig. 4.13A), with 
sufferers having diabetes for 3.1 yrs longer than those without (P<0.001). HDL was 
also significantly lower in the presence of genitourinary disease (1.0 ± 0.2 mmol/l vs. 
1.2 ± 0.3 mmol/l, P<0.05, Fig. 4.13F). Age, BMI, C-peptide and HbA1c were not 



















Figure 4.13 – Relationship between currently available clinical data and genitourinary 
disorders. Participants were grouped dependant on presence or absence of recorded 
genitourinary disorders. (A) Duration of Diabetes (years): genitourinary disorder absent 
n=299, genitourinary disorder present n=94. (B) Age (years): genitourinary disorder absent 
n=383, genitourinary disorder present n=107. (C) BMI: genitourinary disorder absent n=272, 
genitourinary disorder present n=88. (D) C-peptide: genitourinary disorder absent n=302, 
genitourinary disorder present n=69. (E) HbA1c: genitourinary disorder absent n=354, 
genitourinary disorder present n=100. (F) Lipid profile: genitourinary disorder absent n=347, 
genitourinary disorder present n=99. Data presented as mean ± SD. Statistical significance 
was determined using a Student’s t-test. *P<0.05, ***P<0.001, vs. genitourinary disease 
absent. 
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4.3.2.7 Relationship between currently available clinical data and clinically 
diagnosed depression  
 
As illustrated in Fig 4.14, participants with clinically diagnosed depression, were 
indistinguishable from those without with respect to diabetes duration (A), age (B), 




















Figure 4.14 – Relationship between currently available clinical data and clinically 
diagnosed depression. Participants were grouped dependant on recorded presence or 
absence of clinically diagnosed depression. (A) Duration of Diabetes (years): depression 
absent n=346, depression present n=48. (B) Age (years): depression absent n=434, 
depression present n=55. (C) BMI: depression absent n=318, depression present n=43. (D) C-
peptide: depression absent n=330, depression present n=42. (E) HbA1c: depression absent 
n=399, depression present n=42. (F) Lipid profile: depression absent n=391, depression 
present n=55. Data presented as mean ± SD.  
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4.3.2.8 Relationship between currently available clinical data and 
participants prescribed an anti-depressant  
 
From analysis of prescription medications we identified that there were significantly 
more participants prescribed antidepressant medications than with clinically 
diagnosed depression, therefore we investigated whether there were differences in 
currently available clinical data in those prescribed antidepressants compared with 
those not prescribed antidepressant medications. As illustrated in Fig. 4.15 
participants prescribed an antidepressant were indistinguishable from those not in; 



















Figure 4.15 – Relationship between currently available clinical data and participants 
prescribed an antidepressant. Participants were grouped dependant on clinically recorded 
presence or absence of a prescribed antidepressant. (A) Duration of Diabetes (years): 
antidepressant absent n=208, antidepressant present n=187. (B) Age (years): antidepressant 
absent n=266 anti-depressant present n=224. (C) BMI: antidepressant absent n=191, 
antidepressant present n=169. (D) C-peptide: antidepressant absent n=203, antidepressant 
present n=168. (E) HbA1c: antidepressant absent n=241, antidepressant present n=213. (F) 
Lipid profile: antidepressant absent n=236, antidepressant present n=210. Data presented as 
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4.3.2.9 Most common comorbidity combinations in the DiaStrat cohort. 
 
Given the alarming rate of comorbidity in the DiaStrat cohort we were interested in 
the combinations of comorbid disorders diagnosed. Interestingly there were no 





















Figure 4.16 – Most commonly co-diagnosed comorbidities in the DiaStrat cohort. All data 
was obtained from Northern Ireland Electronic Care Record (NIECR), and coded using the 
ICD-10 classification system. Common comorbidities were clustered and sorted in Microsoft 
excel. Other combinations ≤3 includes all other combinations that had 3 or fewer patients in 






The overwhelming majority, 342 participants, had a comorbidity profile affecting 
fewer than 3 individuals. Eighty four participants had no recorded comorbidity. The 
most prevalent combination was disease of the circulatory and endocrine systems, 
present in 21 participants. Disease of the circulatory (9), digestive (8) and endocrine 
(6) systems alone were the next most frequent comorbidities reported (Fig. 4.16). 
This highlights the complexity of comorbidity in clinical medical practice.  
 
4.3.2.10 Effect GLP-1R agonist therapy on number of recorded 
comorbidities  
 
The number of comorbidities present in GLP-1R agonist positive vs. GLP-1R agonist 
negative participants was assessed, and is illustrated in Fig. 4.17. This analysis is 
suggestive of a more severe clinical comorbidity profile in GLP-1Ra (+) participants 
than in GLP-1Ra (-) participants in line with GLP-1R agonists being a fourth line 
therapy, and normally prescribed in late stage T2D.  GLP-1Ra (+) participants had 
45% fewer individuals with 0 comorbidity (Z= 2.08, P<0.05) and 30% more individuals 
with 7-9 comorbidities than GLP-1Ra (-) participants. The remaining comorbidity 
groups were well matched. Evidence of a more severe phenotype in GLP-1Ra 
participants is further supported in Table 4.3, demonstrating that GLP-1Ra (+) 
participants are 19% more likely to have cardiovascular disease (p=0.012) and 26% 
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Figure 4.17 – Effect of GLP-1R agonist therapy on number of recorded comorbidities. 
Participants were divided into two groups dependant on the presence or absence of a GLP-
1Ra in their anti-diabetes medication regime. GLP-1Ra (+) n=88, GLP-1Ra (-) n= 412. Data is 
























Total % Total % Total % Total % Total % Total % 
GLP-1Ra (+) 
(n=88) 
66 75* 61** 69 30 34 24 27 17 19 14 16 
GLP-1Ra (-) 
(n=412) 
250 61 210 51 132 32 101 25 90 22 69 17 
 
 
Table 4.3 – Major comorbidity in patients treated with and without  GLP-1R agonists. Data 
is presented as a percentage of total number of participants per group. A Z-test for the 
difference between two proportions demonstrated cardiovascular disease and diseases of 
the endocrine system were more common in participants receiving GLP-1 agonist therapy. 








4.3.3 Non-diabetes prescriptions in the DiaStrat cohort   
 
Subsequent to analysis of comorbidity data from the Northern Ireland Electronic 
Care Record, prescribed non-diabetes medications were investigated. As illustrated 
in Fig. 4.18A most participants were prescribed 5-8 non-diabetes drugs (229) or 1-4 
medications (130); 94% of the cohort were prescribed at least 1-4 non-diabetes 



















Figure 4.18 – Number and class of non-diabetes drugs prescribed to the DiaStrat cohort. 
(A) Total number of participants prescribed 0, 1-4, 5-8, 9-12, 13-16, 17-20, 20+ non-diabetes 
medications (n=500) (B) Total number of prescribed drugs per non-diabetes drug class 
(n=472 participants, n=3074 recorded medications). All drugs were classified according to 
the British National Formulary (BNF).  
 
Antihypertensives were the most frequently prescribed class of non-diabetes 
medication, accounting for 987 prescriptions out of the 3074 total. This was followed 
by lipid regulating drugs, including statins (463), and drugs used to treat digestive 
disorders (304), such as proton pump inhibitors. Surprisingly anti-depressants were 
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the 4th most commonly prescribed drug class, accounting for 295 prescriptions (Fig. 
4.18B), highlighting either an under reporting of depression within the ECR, or 
significant off-label prescribing of antidepressant medication (as only 55 participants 
had a diagnosis of depression ICD10 coded within their ECR) (Fig. 4.14).     
 
Analysis of the number of drug classes prescribed to the DiaStrat cohort (Fig. 4.19) 
revealed that most participants were prescribed medications from 4 drug classes 
(19.2%, 96) followed closely by 3 drug classes (16.2%, 81). There were 5.4% (27) of 
the cohort on 0 non-diabetes medications, while 75.4% (377) are prescribed drugs 













Figure 4.19 - Number of non-diabetes drug classes prescribed per participant of the 
DiaStrat cohort (n=500).  
 
4.3.3.1 Disconnect between recorded comorbidity and prescribed 
medications 
 
Following discovery of a disconnect between clinically recorded depression and 
antidepressive prescription we assessed other comorbidities and compared against 
prescribed medication. Results indicated that such a disconnect was not unique (Fig. 
4.20A). Lipid abnormalities were clinically noted in 209 participants, however 428 
were prescribed lipid regulating drugs (Z= -14.1, P= 0). A similar trend was observed 
with hypertension; 265 were clinically diagnosed while 392 were prescribed an anti-
hypertensive therapy, suggestive of aggressive management (Z= -8.46, P= 0). Eye 
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disorders and cancer were clinically noted (83 and 73 respectively) but very few 
participants were on any form of medication (1, eye disorders (Z= 9.98, P= 0); 5, 
cancer (Z= 8.02, P= 1.1-15)).  
Clinically noted incidence of common comorbidity was then compared to the 
participant’s most recent bodyweight or biochemical read (Fig. 4.20B). Obesity was 
clinically noted in 72 individuals however 251 had a BMI > 30kg/m2 (Z=-12.11, P=0). 
Interestingly hypertension was significantly over reported (265 diagnosed; 224 BP in 
NICE range (Z= 2.59, P= 0.009) while hyperlipidaemia diagnosis and laboratory 
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Figure 4.20 – Difference in clinically diagnosed (noted) and treated conditions. (A) Total 
number of participants that have a clinically diagnosed (ECR recorded) comorbidity versus 
total number of participants receiving treatment for the same comorbidity (n=500). (B) Total 
number of participants that have a clinically diagnosed comorbidity compared to total 
number of participants that are over normal guidelines as stipulated by NICE. Obesity BMI 
>30; Hypertension, either systolic >130 or diastolic >80; Hyperlipidaemia, either, LDL 





4.3.3.2 Relationship between number of non-diabetes medications and 
common measures of diabetes management  
 
Duration of diabetes was positively correlated with the number of non-diabetes 
medications (P<0.05, Fig. 4.21A). Participants on 0 non-diabetes medications had an 
average diabetes duration of 9 ± 6 yrs, while participants on more than 13 non-
diabetes medications had a duration of 15 ± 10 yrs.  
BMI was negatively correlated with the number of non-diabetes medications 
prescribed (Fig. 4.21B). Participants on 0 non-diabetes medications had a mean BMI 
of 36.1 ± 9 while participants on more than 13 non-diabetes medications had a mean 
BMI of 35.5 ± 7.  
HbA1c was not correlated with the number of non-diabetes medications (Fig. 
4.21C). Average HbA1c in participants on no non-diabetes medications was 59.5 ± 
17.5 mmol/mol, which increased to 65.0 ± 15.3 mmol/mol in the 1-4 medication 
group and remained constant with increasing number of additional prescribed drugs.  
LDL and total cholesterol were negatively correlated with the number of non-
diabetes medications (Fig. 4.21D), P<0.001 and P<0.05 respectively. There was no 
correlation between HDL and number of medications. The mean LDL value for 
participants on no non diabetes medications was 2.3 ± 0.7 mmol/l, while in 
participants on 9-12 medications this value was significantly reduced to 1.7 ± 0.7 
mmol/l (P<0.05) and further reduced after 13 + medications to 1.5 ± 0.7 mmol/l 
(P<0.01). Total cholesterol exhibited a similar trend. Average total cholesterol in 
participants on zero non-diabetes medications was 4.4 ± 0.7 mmol/l and was 
significantly reduced to 3.5 ± 0.7 mmol/l (P<0.05) in participants 13 + medications.  
Plasma C-peptide levels were not correlated with the number of non-
diabetes medications prescribed (Fig. 4.21E), nor was the number of diabetes 
medications (Fig. 4.21F). However post-hoc analysis revealed differences between 
the groups. Patients prescribed at least one non-diabetes medication were treated 

























Figure 4.21 – Relationship between number of non-diabetes medications and common 
measures of diabetes management.  (A) Duration of diabetes vs. number of non-diabetes 
medications, n= 395 (B) BMI vs. number of non-diabetes medications, n=360 (C) HbA1c vs. 
number of non-diabetes medications, n=454 (D) Lipid profile vs. number of non-diabetes 
medications, n=443 (E) C-peptide vs. number of non-diabetes medications, n=371 (F) 
Number of Diabetes medications vs. number of non-diabetes medications, n=443. 
Participants were grouped dependant on number of non-diabetes medications prescribed, 0, 
1-4, 5-8, 9-12 or 13+. Data presented as mean ± SD. Two tailed Spearman’s correlation 
analysis between, number of non-diabetes medications and diabetes duration, BMI, HbA1c, 
Lipids, C-peptide and number of diabetes medication was carried out using ungrouped data 
values. Statistical significance was determined using one-way ANOVA and Tukey’s multiple 
comparisons test. *P<0.05, **P<0.01 vs. 0 non diabetes medications.  
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4.3.3.3 Most frequently prescribed lipid regulating, hypertensive, 
circulatory system, digestive system, respiratory system and anti-
depressant medications. 
 
Detailed analysis of the six most commonly prescribed non-diabetes medications 
(Fig. 4.22), highlighted commonality in each class. Statins were the most common 
type of lipid regulating drug accounting for over 95% of all prescriptions in this drug 
class (Fig. 4.22A). Antihypertensive medications were the most commonly prescribed 
class of drugs overall. Angiotensin Receptor Blockers (ARBs) and Angiotensin-
converting enzyme (ACE) inhibitors the most frequently prescribed type (320 
prescriptions), followed by anti-coagulant (252) and Diuretics (126) (Fig. 4.22B). 
There were 153 prescriptions related to treating disorders of the circulatory system; 
51 were for anti-aggregants, 53 for anti-anginal, and 43 for anti-arrhythmia 
medications (Fig. 4.22C). There were 304 digestive system related medications 
prescribed to the DiaStrat cohort. The vast majority of these were proton pump 
inhibitors (216; Fig. 4.22D). There were 147 medications prescribed for the 
treatment of respiratory disorders (Fig. 4.22E), with beta-adrenoceptor agonists 
representing the vast majority of prescriptions. Anti-depressants were the 4th most 
frequently prescribed medication, accounting for 295 prescriptions. Amitriptyline 
accounted for the majority of prescriptions (154) (Fig. 4.22F),  
The top ten prescribed non-diabetes drugs are listed in Table 4.4. 
Atorvastatin (lipid regulating drug) is the most commonly prescribed non-diabetes 
drug; 64% of participants on lipid regulating drugs are prescribed Atorvastatin. 
Aspirin is prescribed to 57% of participants on anti-hypertensive medications. 
Omeprazole and amitriptyline account for the largest percentage of prescriptions for 
digestive disorders and depression/nerve pain at 70% and 69% respectively. As a 
drug class, anti-hypertensive medications are the most commonly prescribed, 






























Figure 4.22 – Sub classification of the most frequently prescribed lipid regulating, 
hypertensive, circulatory system, digestive system, respiratory system and anti-depressant 
medications prescribed in the DiaStrat cohort. (A) Total number of Lipid regulating 
medications prescribed (n=463 records). (B) Total number of Hypertensive medications 
prescribed (987 records). (C) Total number of circulatory system medications prescribed 
(153 records). (D) Total number of digestive system medications prescribed (304 records). 
(E) Total number of respiratory medications prescribed (147 records). (F) Total number of 
anti-depressant medications (n=295). A-E classified by drug class, F classified by drug name. 
‘Other’ accounts for single prescriptions.   
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Table 4.4 – Most frequently prescribed non-diabetes drugs.  Data is presented as drug name, type and purpose as denoted in the BNF. Quantity prescribed is 
the total number of individual prescriptions. The percentage of cohort is the percentage of patients currently on the medication compared to non-diabetes 
medication class total, lipid regulating = 428, anti-hypertensive = 392, Digestive disorders = 240, anti-depressant = 224. 
 











Atorvastatin Statin Lipid regulating 272 428 64 





disorders / Acid 
reflux 




154 224 69 





Hypertension 112 392 29 
Bisoprolol Beta blocker Hypertension 99 392 25 









Hypertension 80 392 20 
 
 
4.3.3.4 Prescription profile of participants receiving GLP-1R agonists 
compared to the remainder of the cohort 
 
Participants not prescribed a GLP-1Ra were more frequently prescribed no non-
diabetes medications (6.6% vs 1%) than GLP-1Ra-treated patients. The GLP-1Ra (+) 
group also had more individuals on more than 13 non-diabetes medications (8.0% vs. 
5.3%) (Fig. 4.23).   
 
 
Figure 4.23 – Comorbidity profile of participants prescribed GLP-1R agonists compared to 
the remainder of the cohort.  Participants were divided into two groups dependant on the 
presence or absence of a GLP-1Ra in their anti-diabetes medication regime. GLP-1Ra (+) 
(positive) n=88, GLP-1Ra (-)(negative) n=412. Data is presented as a percentage of each 
group.  *P<0.05 vs. GLP-1 Ra (-) group. 
 
Lipid regulating (94%, P=0.011) and anti-hypertensive (89%, P=0.009)) medications 
were more frequently prescribed to participants receiving GLP-1R agonist therapy, 
while no significant difference was determined in anti-depressant, digestive or 
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GLP-1Ra (+) (n=88) GLP-1Ra (-) (n=412) 
% % 
Lipid regulating drugs 94* 84 
Antihypertensive 89** 76 
Antidepressant 52 43 
Digestive disorders 42 50 
Vascular disorders 18 23 
 
 
Table 4.5 – Prevalence of prescription of major drug classes in participants receiving GLP-
1R agonists compared to those receiving other diabetes medications. Participants were 
divided into two groups dependant on the presence or absence of a GLP-1Ra in their anti-
diabetes medication regime. GLP-1Ra (+) n=88, GLP-1Ra (-) n=412. Data was analysed using a 
Z-test for 2 proportions. *P=0.0114 and **P=0.0017 vs. GLP-1Ra *(-) group. 
 
 
4.3.4 Unscheduled care in the DiaStrat cohort and comparison of 
unscheduled care in GLP-1Ra treated participants compared with those 
treated with other diabetes drugs 
 
Unscheduled care in the DiaStrat cohort was assessed using the Northern Ireland 
Electronic Care Record (NIECR). Attendance at the Accident and Emergency 
department (328) was the most frequent unscheduled care event and injuries such 
as fractures were the most common reason (27%), followed by abnormal clinical and 
laboratory findings (24%). Day care visits accounted for 221 incidences and in 
unscheduled inpatient admittances were recorded in 167 participants. Interestingly 
there were only 7 recorded out of hours visits, indicating unscheduled care in the 













Unscheduled Hospital attendance  Total 
Day care (DC) 221 
In patient (IP) 167 
Out Of Hours (OOH) 7 
Accident and Emergency (A&E) 328 
      
Reason for A&E attendance Total % 
Injury, poisoning and certain other consequences of external causes 88 27 
Symptoms, signs and abnormal clinical and laboratory findings 80 24 
Diseases of the musculoskeletal system and connective tissue 37 11 
Diseases of the circulatory system 28 9 
Diseases of the digestive system 19 6 
Diseases of the respiratory system 19 6 
Diseases of the skin and subcutaneous tissue  15 5 
Factors influencing health status and contact with health services 12 4 
Diseases of the eye and adnexa 7 2 
Certain infectious and parasitic diseases 6 2 
Diseases of the genitourinary system 6 2 
Endocrine, nutritional and metabolic diseases  6 2 
Mental, Behavioural and Neurodevelopmental disorders 4 1 
External causes of morbidity 1 0 
 
Table 4.6 – Unscheduled care attendances and reasons for attending accident and 
emergency.  Data was obtained (723 records, n=231 participants) from the NIECR. All 
incidences ± 12months of sample date were recorded. Record type (Day care (DC), In patient 
(IP), Out of hours (OOH), Accident and Emergency (A&E)) was determined and coded by the 
Western Health and Social Care Trust. Reasons for A&E attendance were noted by clinical 
professionals using the ICD-10 system. Data is presented at total number and % of all 
records.   
 
GLP-1Ra positive participants more frequently attended day care clinics (P=0.031) 
and out of hours services (P=0.025). Those not prescribed GLP-1Ra were more 
frequently admitted as inpatients, 34% GLP-1Ra (-) and at out of hours 























Table 4.7 – Unscheduled care attendances in GLP-1R agonist treated and GLP-1R agonist 
naïve participants.  Groups were determined by the presence or absence of a GLP-1Ra. GLP-
1Ra (+) n=88, GLP-1Ra (-) n=412. Data is presented as total ECR recorded attendances as a 
percentage of total group number. Data was obtained (723 records, n=231 participants) 
from NIECR and all unscheduled care ± 12 months of sample date were recorded and 
analysed using a Z-test for 2 proportions. *P<0.05 vs. GLP-1Ra *(-) group. 
 
 
4.3.5 Noted pharmacological adverse reactions in the DiaStrat cohort 
 
As illustrated in Fig. 4.24, within the DiaStrat cohort of 500 participants there were 420 
records of adverse reactions noted in 185 participants. Hypertensive medications (37.1%) 
had the highest recorded incidence of adverse events, followed by anti-bacterial adverse 
events (17.6%). Interestingly there were only 12 participants (6.2%) with a recorded adverse 
event to anti-diabetes medications (Fig. 4.24A). 
Angiotensin Receptor Blockers (ARBs) and Angiotensin-converting enzyme (ACE) 
inhibitors (35.9%) were the most commonly noted adverse reactions followed by statins 















GLP-1Ra(+) (n=88) GLP-1Ra(-) (n=412) 
Total % Total % 
Day care (DC) 48 55* 173 42 
In patient (IP) 25 28 142 34 
Out Of Hours (OOH) 2 2* 5 1 
Accident and Emergency (A&E) 56 64 274 67 
144 
 
A d v e rs e  re a c tio n s
 (4 2 0  re c o rd s )
3 7 .1 4 %   A n it-  h y p e r te n s iv e
1 7 .6 2 %   A n ti B a c te r ia l
6 .6 7 %   A n ti-d ia b e te s
6 .1 9 %   P a in
5 .2 4 %   A n ti-v ira l
5 .2 4 %   N S A ID
4 .5 2 %   A n ti-d e p re s s a n t
3 .5 7 %   D ig e s tiv e  d is o rd e r  d ru g s
3 .1 0 %   V a c c in e
1 .6 7 %   P ro c e d u re
0 .9 5 %   A n ti-h is ta m in e
0 .9 5 %   V a s c u la r  d ru g s
0 .9 5 %   V ita m in
0 .7 1 %   A n ti-e m e tic
0 .7 1 %   S te ro id a l
4 .7 7 %   O th e r
T o ta l= 1 0 0
M o s t c o m m o n ly  o b s e rv e d  a d v e rs e  re a c tio n s
to  a n ti-h y p e rte n s iv e  m e d ic a tio n  (1 5 6  re c o rd s )
3 5 .9 0 %   A R B s  &  A C E i
2 8 .2 1 %   S ta tin
1 6 .0 3 %   A n ti c o a g u la n t
1 1 .5 4 %   B e ta  b lo c k e r
3 .2 1 %   D iu re t ic
3 .2 1 %   P D E 5  In h ib ito r
1 .9 2 %   C a lc iu m  c h a n n e l b lo c k e r



























Figure 4.24 – Pharmacological adverse reactions in the DiaStrat cohort. (A) Percentage of 
clinically noted adverse reactions (420 records, n=185 participants). (B) Percentage of 
recorded adverse reactions to ICD-10 level 2 sub grouped anti-hypertensive medications 
(n=156 records). All adverse reaction data was obtained from Northern Ireland Electronic 
















This descriptive study assessed trends in anti-diabetes and non-diabetes drug 
prescriptions and comorbidities in a T2D population in Northern Ireland. The 
relationship between currently available diabetes measures were evaluated against 
drug and morbidity progression, using electronic health records and primary data.  
All parameters were evaluated in GLP-1 analogue treated individuals vs. all other 
anti-diabetes drug classes.      
Although the DiaStrat cohort was significantly male dominated, no sex 
differences were determined in key demographic characteristics including age, 
duration of diabetes, HbA1c, blood pressure or blood lipid levels. Females were more 
obese and introduced to insulin at a younger age than males; well-documented sex 
differences (Kautzky-Willer et al., 2016). As key markers of diabetes management 
were comparable irrespective of gender, subsequent analysis was conducted on the 
cohort as a whole.   
The mean age was 63 ± 11yrs and average diabetes duration was 12 ± 8 yrs, 
indicative of significant disease progression (Bansal et al., 2015). Seventy percent of 
participants were obese and ~93% were overweight, indicating body weight was 
poorly managed. HbA1c levels in 86% of the cohort were significantly greater than 
the NICE recommended target of 48mmol/mol. This cohorts average HbA1c was 
65.08 ±17 mmol/mol, which is substantially greater than the NICE revised target of 
53mmol/mol for individuals on multiple anti-diabetes drugs (NICE, 2015). In the UK, 
approximately 50% of patients achieve glycaemic targets (Mauricio et al., 2017), 
therefore this cohort may represent advanced or poorly managed disease. 
Historically, T2D patients managed with diet and oral anti-diabetes agents are 
treated in primary care, and patients requiring insulin therapy in secondary care 
(Branger et al., 1998). The participants in this study were predominantly recruited 
from secondary care and likely represent a severe T2D population. Average blood 
pressure and blood lipid levels in the DiaStrat cohort were within NICE 
recommended thresholds (NICE, 2016a). We observed significant therapeutic 
treatment of hyperlipidaemia and hypertension that may account for observed 
blood pressure and lipid profiles observed.  
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Anti-diabetes drug prescription patterns     
    
Most participants in the DiaStrat cohort were prescribed 3 or more anti-diabetes 
medications. A meta-analysis using Electronic Health Records across Europe and the 
USA found the average number of anti-diabetes prescriptions per participant to be 2 
in 2015 (Higgins et al., 2016), indicating DiaStrat may represent a more severe 
phenotype. The most frequently prescribed diabetes medications were Biguanides, 
Sulphonylureas, and DDP-IV inhibitors, while GLP-1R agonists (4th line) made up 7% 
of prescriptions. Prescription patterns revealed approximately 40% of patients 
receive insulin therapy and few receive metformin only (20%). The global T2D 
monotherapy average is 35% (Higgins et al., 2016). In this cohort metformin is 
frequently prescribed with insulin as a dual therapy. GLP-1Ras are also commonly 
prescribed as a dual medication, despite being a fourth line therapy. Such 
prescription trends evidence a change in clinical attitudes (ADA, 2016). Clinicians are 
moving away from NICE stepwise intensification, towards individual approaches, as 
advised by the ADA (Chamberlain et al., 2017a). The national average for insulin 
inclusive regimes is ~30% (Higgins et al., 2016) while ~40% of the DiaStrat cohort 
were on a insulin therapy. There was an average lag of ~10 years until insulin 
introduction. Large clinical studies, DCCT and UKPDS have indicated this level of 
delay can blunt response and evidence suggests that insulin therapy should be 
initiated much sooner (American Association of Diabetes, 2002).   
LDL was negatively correlated with number of diabetes medications. This 
effect is not likely to be due to diabetes specific medications, as only 
thiazolidinediones directly affect lipid metabolism (Griffis et al., 2004), and account 
for 2% of prescriptions.  It is thought metformin can directly affect the therapeutic 
potential of atorvastatin (Kashi et al., 2016); 82% of this cohort were on a metformin 
positive regime and 55% on atorvastatin. It is possible that metformin exposure is 
implicated in the improved blood lipid profiles observed. 
C-peptide is not currently measured during regular clinical visits but is useful 
as a measure of β-cell function and offers a surrogate marker of de novo insulin 
production for residual β-cells in diabetes (Leighton et al., 2017). Normal 
postprandial levels are 3-9 ng/ml in healthy individuals (Diabetes UK, 2017a). The 
average DiaStrat C-peptide was 6.6 ± 6.6 ng/ml. This suggests a wide range of insulin 
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production. Many participants were found to be secreting either low levels indicative 
of reduced β-cell function or high levels indicative of insulin resistance (Jones and 
Hattersley, 2013). BMI was not correlated with C-peptide. This is surprising as other 
studies have shown weight loss to improve insulin secretion and sensitivity and 
reduce HbA1c (Holter et al., 2017). The significant duration of diabetes, is 
undoubtedly a factor in compromised β-cell function and insulin resistance observed 
(Khodabandehloo et al., 2016). C-peptide was inversely correlated with the number 
of diabetes medications, indicative of a reduced insulin secretory capacity with 
disease progression.  Exogenous insulin therapy within the later treatment 
intensification groups may be responsible for the observed blunting of endogenous 
secretion from the β-cell (Jones and Hattersley, 2013). If C-peptide was routinely 
measured it would allow for a stronger prediction of response to non-insulin 
therapies, estimation of residual β-cell function and earlier indication of the need for 
exogenous insulin.      
GLP-1Ra are recommended as a 4th line medication (NICE, 2015), however,  
within the DiaStrat cohort, are observed as part of dual and triple therapies. Despite 
this, most patients prescribed GLP-1Ra will have advanced diabetes, and will 
generally have failed all non-insulin oral medications (NICE, 2017). In this work, 
HbA1c was no different in patients prescribed a GLP-1Ra compared to those on other 
diabetes medications. Despite reports of prominent effects of GLP-1 agonists on 
weight loss (Davies et al., 2015), the present study indicates participants on GLP-1Ra 
are significantly heavier. Prospective studies in a general T2D population will assess 
the impact of GLP-1Ra on glycaemic control and weight loss. 
 
Comorbidity in the DiaStrat cohort 
 
Elderly T2D patients are thought to suffer from at least 2 chronic conditions 
alongside their diabetes (Hermans and Dath, 2017).  Age, duration and HbA1c are 
thought to be positively correlated with comorbidity (Pratley and Gilbert, 2012). 
Such observations translate directly to this cohort. Most patients were over 60 yrs 
old, have had diabetes for 12.5 yrs and 62% had at least 4 comorbidities. The most 
commonly recorded comorbidities were conditions associated with the circulatory 
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system, nutritional or metabolic disorders and diseases linked to the digestive 
system. This pattern corresponds with comorbidity trends in Asia, Europe and the US 
(Franch Nadal et al., 2016). Musculoskeletal disorders were the 4th most frequent 
comorbidity, and have been implicated as being directly linked to obesity and 
diabetes (Uhl et al., 2014). High BMI and poor glycaemic control, which are 
characteristic of the DiaStrat cohort, are known to increase joint load, articular 
cartilage breakdown, and inflammation, ultimately increasing osteopathies 
(Anandacoomarasamy et al., 2009). Musculoskeletal complications were more 
prevalent than all microvascular complications that are more widely considered to 
be secondary complications of diabetes. 
Hypertension accounted for 50% of all cardiovascular comorbidity followed 
by heart disease. Hypertension rates were below the national average (Cicero and 
Ertek, 2011), presumably due to the aggressive pharmacological management 
observed. Within this cohort, CVD comorbidity was associated with increased 
duration of diabetes, advanced age and elevated HbA1c, BMI and C-peptide, which 
are common CVD risk factors around the globe (Simmons et al., 2017). Participants 
with recorded CVD had reduced LDL and total cholesterol compared to those 
without a diagnosis of CVD. Aggressive pharmacological management of CVD risk 
follows current clinical guidance (NICE, 2016a). Statins have been shown to reduce 
atherosclerosis and cardiac events with fewer adverse events compared to anti-
hypertensive medications (Mitchell and Simpson, 2012). The present data suggests 
that blood lipid levels are much more effectively managed than obesity and 
glycaemic control in this cohort.  
Endocrine comorbidities encompass a wide range of conditions (Michels and 
Eisenbarth, 2010), but in this study predominantly reflect recorded incidence of 
hyperlipidaemia and obesity. DiaStrat patients with endocrine disorders had an 
increased duration of diabetes, were older and had higher HbA1c and lower C-
peptide than those without. BMI is not a distinguishing risk factor for endocrine 
abnormality, however, notably those with and without recorded endocrine disorders 
were obese. Other studies have indicated obesity is a major driving force in 
endocrine disorders (Kautzky-Willer et al., 2016). The disconnect between ECR 
recorded and observed obesity may explain the absence of impact of BMI on 
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endocrine comorbidity. Participants with recorded endocrine disorders had a lower 
LDL and cholesterol than participants with no recorded incidence, likely reflecting a 
large cross over in CVD and endocrine disorders.  
Participants were exposed to significant polypharmacy, which tended to 
include multiple anti-hypertensives and statins. It is notable that obesity is not 
directly treated in the UK, and guidance is centred around education, exercise and 
regulation of secondary effects which include CVD and hyperlipidaemia (NICE, 
2014b).  
There is an indisputable link between obesity, diabetes and digestive system 
disorders (Fisher et al., 1999). Neuropathy causes the relaxation of the stomach 
allowing contents into the oesophagus (Koch, 1999) and obesity can cause 
compression of the stomach causing the same effect (Sugerman, 1998). There were 
a high degree of recorded digestive abnormalities throughout the upper and lower 
gastrointestinal (GI) tract, predominantly acid reflux. Western and eastern 
gastroesophageal reflux disease (GERD) prevalence differs due to diet and lifestyle 
but is thought to be 41% and 23% respectively (Mahadeva et al., 2005). Current 
clinical measures (Diabetes duration, age, HbA1c, BMI and blood lipids) were not 
different between patients with and without digestive disorders, however C-peptide 
was reduced.  
Low C-peptide is a shared characteristic between the most common 
comorbidities and is indicative of β-cell failure (Jones et al., 2016). Controversially 
other studies have shown high C-peptide levels to be linked to CVD mortality 
(Leighton et al., 2017) and significant insulin resistance (Patel and Abate, 2013). This 
complicates the clinical utility of C-peptide in relation to comorbidity.  
Microvascular complications were prevalent in the DiaStrat cohort; 
retinopathy made up 39% of ocular comorbidity and nephropathy made up 34% of 
genitourinary disorders. Recorded microvascular prevalence was low compared to 
macrovascular disease, only 9% of the cohort had retinopathy and 10% Chronic 
Kidney Disease. Such values are low when compared to the rest of Europe, where 
retinopathy accounts for ~25% (Lee et al., 2015a) and CKD ~30% (Gheith et al., 2016) 
of total comorbidity. Diseases of the eye and genitourinary system were linked to a 
longer duration of diabetes with retinopathy occurring at a later stage than CKD. 
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Patients with genitourinary disorders were further distinguished by a low HDL level. 
HDL has long been associated with reduced risk of CVD due to its role in reverse 
cholesterol transport (Lee-Rueckert et al., 2016), but it is also known that increasing 
HDL does not further reduce risk (Voight et al., 2012). HDL quality is now recognised 
as the key factor (Galvani and Hla, 2017). Patients with CKD have a lower quantity 
and quality of HDL due to impacted lipoprotein lipase activity, and increased 
endothelial dysfunction (Strauss et al., 2002).  
Osteoarthritis was the most common musculoskeletal complication, followed 
by spinal disc disorders and inflammatory rheumatoid arthritis. There is growing 
evidence that arthritis and spinal disc disorders are closely linked to metabolic 
syndrome (Wearing et al., 2006). There is increased cartilage degeneration due to 
abnormal joint load (Anandacoomarasamy et al., 2008), and increased white adipose 
tissue due to obesity (Hui et al., 2012). This produces inflammatory cytokines (TNFα, 
IL-6, MMPs), contributing to systematic inflammation and chondrocyte dysregulation 
(Castillo-Hernandez et al., 2016). Global prevalence rates of arthritis in T2D were 
~35% in 2012, and it is thought T2D patients are at 50% increased risk of developing 
a musculoskeletal condition (Vos et al., 2012b). In the present study there were no 
differences in duration of diabetes, age, HbA1c, BMI or lipids. 
According to NICE, people with chronic conditions such as obesity and 
diabetes are 3 times more likely to develop depression (NICE, 2016b). There were 55 
ECR recorded incidences of depression in DiaStrat but 295 prescriptions for anti-
depressants, to 224 patients. This raised questions regarding under reporting of 
conditions and off label prescribing. Amitriptyline constituted the majority of anti-
depressant prescriptions and was the 4th most common prescribed non-diabetes 
drug. Amitriptyline is widely prescribed to treat neuropathic pain associated with 
nerve disorders (Thompson and Brooks, 2015). This type of prescription could 
account for a portion of the recorded incidence, although only 2.2% of the Diastrat 
cohort had recorded nervous system disorders. Similar to musculoskeletal 
comorbidity, patients that are clinically diagnosed or treated for depression could 
not be distinguished by current diabetes measures. This again, is likely due to 
severity of disease in the DiaStrat cohort. Depression is common in diabetes 
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patients, due to comorbidity, pill burden and hospital requirements (Mut-Vitcu et al., 
2016).  
An assessment of patterns of multimorbidity revealed that there were not 
any significant comorbidity patterns within the cohort. A total of 342 participants 
had a unique comorbidity combination. The most common combination was a 
circulatory and endocrine complication, although this consisted of 21 individuals and 
both conditions are prevalent in many other combinations. It should be noted that 
for a comprehensive analysis of multimorbidity, a larger dataset is required. When 
considering 14 comorbid subgroups there are a possible 16,000 combinations (214). 
This data highlights the complexity facing clinicians for effective, personal 
management. The ADA have acknowledged this, and stressed how current patient 
management strategies can lead to gaps in patient care, due to a high expectation 
and difficulty in managing all aspects of comorbidity (American Diabetes Association, 
2016). In recent years this resulted in primary and secondary care providers being 
utilised and prioritising different aspect of disease (Khunti et al., 2001). It is 
interesting to note that less than 15% of participants in this study are on HbA1C 
target. The National Health and Nutrition Examination Surveys (NHANES) have 
reported that patients with multiple chronic conditions rarely meet glycaemic 
targets (Stark Casagrande et al., 2013). Many studies have correlated the ‘pill 
burden’ effect and increased unscheduled care as being significant factors (Bluher et 
al., 2015).  
Cardiovascular and endocrine system disorders were both more prevalent in 
GLP-1Ra treated patients and associated with a longer duration of diabetes, older 
age, high HbA1c and low C-peptide. GLP-1Ra positive patients were significantly 
younger and heavier than those not prescribed GLP-1Ra, perhaps evidencing moving 
away from NICE stepwise intensification, and towards a personalised medicine 
approach. This is likely due to the success this class of drugs has had in clinical trials 




Treating multimorbidity adds another layer of complexity to patient treatment 
regimes and has a profound effect on a patient’s ability to manage their diabetes. 
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Cardiovascular and musculoskeletal disorders have been associated with declining 
quality of life (UK Prospective Diabetes study group, 1998). Diabetes guidelines 
recognise quality of life as being linked with adverse outcomes in diabetes, such as 
response to therapy, disease progression and mortality (ADA, 2016).  
In the DiaStrat cohort 68% of participants are prescribed more than 5 non-
diabetes drugs, from ~3-5 individual drug classes, in line with recorded comorbidity. 
A recent European study assessed aggressive targeting of key diabetes measures 
(HbA1c and BP) on specific patient populations, based on their comorbidity profile 
(Schmieder et al., 2015). High risk CVD patients benefited from loosening of 
glycaemic medications and intensifying hypertensive medications, and low risk CVD 
patients benefited from sole aggressive diabetes therapy and loosening of 
hypertensive medications. This alternative treatment strategy resulted in improved 
diabetes management, quality of life and CVD risk (Schmieder et al., 2015). This 
study was the first to assess different therapeutic approaches and treatment targets 
in line with ADA recommendations (Ott et al., 2009). It shows that treating patients 
with comprehensive polypharmacy may not be the most effective method.  
Polypharmacy is routine in this cohort; there were a total of 3074 non-
diabetes medications prescribed. The most common drugs were antihypertensives; 
78% participants were prescribed at least one. Perhaps aligned with the frequency of 
prescription, antihypertensives, ARBs and ACEi, were also the most common adverse 
reaction noted in the DiaStrat population. Antihypertensive treatment exceeded 
noted hypertension, evidencing tight regulation of CVD risk. Studies have indicated 
that hypertensives are used as a long term management option to control CVD 
(Mukete et al., 2015), but there are significant adverse events associated with these 
drugs (McDowell et al., 2013). Unnecessary ‘pill burden’, and complicated regimes 
have been shown to obstruct effective diabetes management (Hauber et al., 2013). 
Lipid regulating medications were the second most frequently prescribed 
medication. Similar to the antihypertensives, the high prevalence resulted in a high 
number of recorded adverse events. Lipid medications were also over prescribed, 
209 participants had a clinically diagnosed lipid abnormality, but recent biochemical 
tests revealed 198 would be advised lipid treatment by NICE (NICE, 2016a). There 
were 428 patients on these medications, again posing a unnecessary ‘pill burden’ 
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(Bluher et al., 2015). This cohort is an extremely high risk group, and recent studies 
have demonstrated a positive cost – risk benefit to over prescribing statin 
medications (Heller et al., 2017). Statin therapy is an inexpensive pre-emptive 
measure (Aarnio et al., 2015) but uniform global prescription may have other 
inherent risks, linked to adverse events such as, high creatine kinase, sleep 
abnormalities, glycaemia increases and haemorrhagic stroke (Chaipichit et al., 2015).  
Medications to treat gastrointestinal problems were commonly prescribed in 
the DiaStrat cohort. Such conditions are recognised to have a significant impact 
quality of life (Lee et al., 2015b). Proton pump inhibitors, used to treat acid reflux 
(Tosetti and Nanni, 2017) represent 70% of digestive system prescriptions. Similar to 
CVD and endocrine medications, these drugs appear to be over prescribed. There are 
162 patients with a clinically recorded digestion disorder but 240 are prescribed a 
medication.  
In the present study duration of diabetes was associated with increased 
polypharmacy but this did not correlate with any improvement to HbA1c or C-
peptide. There was a weak negative correlation between BMI and the number of 
non-diabetes medications. The average BMI was over 35 in all groups. While 72 
patients had obesity noted within the ECR as a comorbidity but anthropological 
measures suggest 251 (50%) of the cohort would be classified as obese by NICE 
(NICE, 2017). Obesity is the most underreported comorbidity in this cohort, as is the 
case in many studies in the US and Europe (Chiu et al., 2017).  
LDL and total cholesterol were strongly correlated with the number of 
medications. NICE stipulate that for lipid regulating and hypertensive medications, 
after review if a patient is not responding the non-responsive medication should be 
removed and a different medication added (NICE, 2016a). This does not seem to be 
occurring, despite evidence that well informed simplification of prescriptions has a 
positive effect on patient outcome (Schmieder et al., 2015).  
In line with comorbidity prevalence, anti-hypertensive and lipid regulating 
drugs were more frequently prescribed to those on GLP-1Ra therapy. Interestingly, 
GLP-1Ra prescribed patients also had increased anti-depressant prescription. There 
is a well-established link between diabetes severity, number of comorbidities and 
depression (Berge and Riise, 2015). Depression can cause unhealthy behaviour, low 
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exercise, motivation and energy, leading to progressive worsening of diabetes 
(Chowdhury, 2004). Our results indicate that participants exposed to four or more 
anti-diabetes medications do not respond well to therapy, which may be due to 
increased levels of depression (Iglay et al., 2017).  
 
Unscheduled care attendances  
 
Due to the complexity of diabetes, research has shown patients are more likely to 
use hospital services (Steiner et al., 2006) and this has a significant impact on the 
NHS (Hex et al., 2012). A large proportion of hospital visits have been shown to be 
readmissions (Yam et al., 2010) but population studies on readmission rates and risk 
factors are poorly described. There were 231 participants and 723 records of 
participants admitted to hospital for unscheduled care ± 1yr of their sample date. 
That translates to 46% of the cohort and ~3 visits per patient. Research in the US 
indicated that the average number of hospital visits per year for a healthy individual 
is 1.5, indicating a high rate of unscheduled care for diabetes patients (Steiner et al., 
2006). Accident and Emergency (A&E) visits were the most common unscheduled 
care accounting for 328 records. This cohort is elderly and it is well known that 
elderly diabetes patients are prone to falls (Vinik et al., 2015). Injury is the most 
frequent reason for A&E attendance, followed by abnormal clinical readings, both of 
which are heavily influenced by age (Mayne et al., 2010) and most likely not directly 
linked to diabetes. The remainder of recorded A&E visits most likely result from 
diabetes related conditions including circulatory, digestive and respiratory problems 
(American Association of Diabetes, 2002). There were 221 admissions to day care 
(DC) and 167 inpatient (IP) admissions. Studies have shown that repeat admission 
whether it A&E, DC or IP is correlated with deficiencies in overall healthcare delivery 








Limitations   
 
This analysis has several limitations, the most significant being the modest sample 
size and absence of age and sex-matched controls to allow for comparisons of 
prescribing practice and comorbidity in the absence of diabetes. Vulnerabilities in 
accurate reporting of comorbidity due to collation of data from a number of 
healthcare providers by various professionals within the ECR cannot be ignored. 
DiaStrat participants were recruited from secondary care and likely represent a 
severe diabetes phenotype. Few participants had a low or normal BMI or HbA1c 
therefore changes associated with treatment and comorbidity were minimal. 
Analysis of a primary care sample would allow assessment of prescribing practice 
and comorbidity earlier in the disease timecourse, which may allow appropriate 
interventions to be identified and tested in prospective studies. The NIECR has a 
wealth of data but does not contain any financial information related to the 
treatment of disease. Future studies should integrate this information to identify the 
most expensive comorbidities and co-comorbidity clusters, enabling rational 
targeting of disease management.   
 
Conclusion      
     
This study identified diabetes prescription trends in Northern Ireland which differed 
from proposed stepwise NICE guidance (NICE, 2017). Significant polypharmacy was 
present and reflective of the diverse clinical profiles recorded. Majority of patients 
had a unique comorbidity cluster highlighting the complexities associated with 
effective disease management. Blood pressure and lipids were well managed, with 
evidence of aggressive treatment of CVD risk, however most patients were poorly 
managed with respect to glycaemia and bodyweight. The prescription and 
comorbidity trends identified in this study did not correlate strongly with any of the 
current biochemical measures assessed in the clinic (HbA1c, lipid profile). The data is 
suggestive that insulin and C-peptide would be a beneficial addition in the 
assessment of diabetes management. We hope to further this work using 
proteomics to better stratify and risk assess specific groups of patients to better 










Proteomic markers of T2D, glycaemic 
control, comorbidity and response to 








Abnormal glucose levels and poor control is a significant clinical problem that affects 
millions of type 2 diabetes (T2D) patients in the United Kingdom (UK). This study 
aimed to identify proteins associated with T2D, glycaemic control, comorbidity and 
response to therapy to develop better understanding of T2D pathogenesis. OLink 
proteomics, high throughput protein assays (4x 92 panels), were utilised to screen 
374 T2D patients and 20 non-diabetes controls. Quality control measures were met 
by 96-99% of all samples across panels.  
T2D and non-diabetes control patient demographics were significantly 
different with respect to age, BMI, HbA1c, lipid profile and number of chronic 
conditions (P<0.0001). A total of 55 proteins were indicative of T2D, and most 
strongly associated with syndecan-1-mediated signalling, according to Enrichr. The 
top 8 proteins could distinguish T2D well (~AUC 0.75). Unique protein panels were 
identified for obesity (n=10), poor glycaemic control (n= 30), and abnormal lipid 
levels (n=143). SORT, CASP3 and CD84 correlated negatively with diabetes regime 
intensification (R= -0.15, P=0.01), and CTRC was the only protein to correlate with 
recorded comorbidity number (R= -0.62, P<0.0001), although 10 proteins uniquely 
changed in patients with 1-3 comorbidities, and 21 in patients with more than 13 
comorbidities.  
Poor glycaemic control in response to GLP-1Ra was linked with 17 proteins in 
participants with HbA1c >53 mmol/mol, and 13 proteins were associated with obesity 
in GLP-1Ra treated individuals. Only changes to ITGA11 (P<0.01-P<0.001), and Ep-
CAM, (P<0.05-P<0.01) were specific for GLP-1Ra prescribed patients for glycaemic 
and weight related changes respectively. Using online enrichment software (Enrichr), 
pathways involved in vascular endothelial damage were identified as being a 
common feature between the most significant proteomic markers for all measured 
variables. The proposed markers need to be validated in secondary cohorts to 





5.1 Introduction  
 
Type 2 diabetes (T2D) is a multifaceted disease with many treatment options and 
numerous long-term complications and comorbidities (NICE, 2017). All of these 
aspects severely impact a patients quality of life (World Health Organisation, 2017). 
The development of micro and macrovascular complications are positively correlated 
with hyperglycaemia (Choby, 2017) and thought to be due to endothelial 
dysfunction. Endothelial dysfunction has long been associated with type 2 diabetes 
(Sena et al., 2013) and is thought to be caused by hyperglycemia and insulin 
resistance (Steinberg et al., 1996). It is classically characterised by reduced 
angiogenesis (Kolluru et al., 2012) which affects vascular endothelial cell 
recruitment, remodelling and sprouting (Tonnesen et al., 2000). If these processes 
fail there is increased vasodilation, oedema and inflammation (Avogaro et al., 2011), 
which has been shown to damage tissues such as the retina, kidney and brain 
(Sutton et al., 2002).  
Integrin signalling also plays an important role in vascular endothelial 
integrity (Finney et al., 2017). Integrins are transmembrane receptors that can 
activate a number of signal transduction pathways mediating various cell signals 
involved in the cell cycle (Borghesan and O'Loghlen, 2017), cellular organelle 
organisation, and receptor localisation (Giancotti, 1997). Integrins enable rapid, 
flexible responses to events at the cell surface (Hynes, 2002). Studies have 
demonstrated that high glucose affects expression of integrins and has a negative 
effect on the reendothelialization process, contributing to microvascular occlusion 
(Roth et al., 1993). Subsequent work implicated integrin alpha-v beta-3 (αvβ3) as a 
key protein associated with IGF-1 mediated atherosclerotic lesions and 
macrovascular disease (Cascella et al., 2010). Interestingly, GLP-1Ras have been 
shown to directly reduce this effect (Song et al., 2015) but whether this class of 
drugs interacts with integrins directly is unknown. Overall, proteins involved in the 
vascular endothelium have a significant impact on various aspects of macro and 
microvascular conditions (Finney et al., 2017) and are likely implicated in 
comorbidity in T2D.  
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Biomarkers indicative of endothelial change exist, and include plasminogen 
activator inhibitor-1 (PAI-1) for peripheral artery disease (Aso, 2007), vascular 
endothelial growth factor (VEGF) for heart disease  (Taimeh et al., 2013) and various 
cell adhesion molecules for diabetic nephropathy (Sabbisetti et al., 2014). These are 
generally not adopted in the clinic because they are also indicative of other 
conditions (Carmeliet, 2005), and therefore not specific. Novel and specific 
biomarkers associated with comorbidity may have significant value.  
Currently, in clinical practice glycosylated haemoglobin (HbA1c) is the most 
frequently used measure of glycaemic control (Metcalf et al., 2017). Most T2D 
patients have a target of 53 mmol/mol (7%) but very few achieve this (NICE, 2015). 
HbA1c is a useful biomarker for monitoring long term glycaemia in established type 2 
diabetes patients, but is limited in terms of its prognostic and predictive capabilities 
(Reynolds et al., 2006). Prevention, and management of early symptoms of 
comorbidity are the most effective ways of treating diabetes (Jelinek et al., 2017). 
Many current tests such as a lipid, glucose and creatinine blood examinations, as 
well as electrocardiograms (ECG) and foot and eye screenings are used in stereo by 
different clinicians and medical staff to diagnose and manage each aspect of 
comorbidity (Piette and Kerr, 2006). This involves significant patient and clinical time 
commitments (Baxter et al., 2016).  
The development of sensitive and specific markers that can accurately and 
specifically (Thambisetty and Lovestone., 2010) diagnose pre-diabetes, inform 
effective prescription and improve clinicopathological prediction, are highly sought 
after (Dorcely et al., 2017). Clinical utility is of great importance (Cramer et al., 2011). 
Discoveries must be detectable from non-invasive samples, such as blood, urine or 
saliva (Yao et al., 2017). In recent years blood is more routinely collected and 
regarded as being most effective for biomarker identification (Figueras-Roca et al., 
2017), irrespective of its complex proteome (Jambunathan and Galande, 2014). 
Thousands of proteins are present in plasma and serum and many are secreted into 
the blood under various disease conditions (Tu et al., 2010).  
New peripheral biomarkers have been developed in recent years. This has 
highlighted the scope for new discoveries (Yao et al., 2017). Low plasma adiponectin 
has been found to be a strong predictor of T2D advancement (Jiang et al., 2016). It is 
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thought that if used in conjunction with current anthropometric measurements, 
insulin sensitivity indexes and other insulin or non-glucose related biomarkers it may 
increase the accuracy of patient risk stratification and reduce clinical appointment 
times (Steiner et al., 2017). The glycoprotein, GlycA, has been reported to have 
utility as a predictor of incident T2D (Connelly et al., 2016a). Metabolites such as 
dimethylglycine (DMG) (Magnusson et al., 2015), 2-amino adipic acid (Wang et al., 
2013) and glycine (Yan-Do and MacDonald, 2017), have also been recognised as 
reliable markers of onset of diabetes and have shed light on mechanisms outside of 
glucose metabolism (Molnos et al., 2017).  
Biomarker development consists of four stages; discovery, verification, 
validation and product development (Pepe et al., 2001). Most biomarkers fail at 
clinical verification or validation (Diamandis, 2012), but recent multiplex 
technologies allow for large scale, non-targeted, proteomics (Olink, 2017). This 
approach facilitates high throughput, accurate measurement of hundreds of 
candidate proteins in large clinical cohorts.  
In this study we integrated 368 proteomic targets associated with the 
immune and inflammatory response, cell adhesion and differentiation, catabolic and 
apoptotic processes and gene regulation, with real world data obtained from ECRs. 
All quantified proteins were chosen based on previously published work (Ebtehaj et 
al., 2017). The protein panel was assessed to identify proteins associated with T2D 
onset, glycaemic control (HbA1c), BMI, blood lipids, diabetes therapy, C-peptide, 















5.2.1 Participant recruitment  
 
T2D participants were recruited from the Altnagelvin Hospital diabetes clinic, NI. 
Healthy non-diabetes controls were identified and sampled at the University of the 
Third Age (U3a). All recruitment was in accordance with ORECNI ethical 
recommendations, described in Chapter 2, Section 2.7.   
 
5.2.2 Sample collection 
 
5.2.2.1 Blood sampling 
 
Blood samples were obtained using 21 G Vacuette® safety needle (Greiner Bio-One, 
Stonehouse, UK; Cat no. 450091), as described in Chapter 2, Section 2.8.1.2. 
Approximately 26 ml of blood were extracted into 2 x 9 ml EDTA (K3E K3EDTA) 
coated Vacuette® tubes (Greiner Bio-One, Stonehouse, UK; Cat no. 455036) and 1 x 
8ml Serum (Z Serum Sep Clot Activator) tube (Greiner Bio-One, Stonehouse, UK; Cat 
no. 455071). All blood samples were processed immediately.  
 
5.2.3 Blood processing 
 
Polypropylene tubes were pre-labelled using Item Tracker© software (ItemTracker 
Software Ltd, Suffolk, UK), prior to processing for serum, plasma, protein, RNA and 
whole blood. Full protocol described in Chapter 2, section 2.8.1.3. All samples were 
then frozen at -80o C.  
 
5.2.4 Clinical database construction  
 
Relevant clinical information for all participants (n= 500) was obtained from Western 
Health and Social Care Trusts, Hicom Diamond.NET diabetes management system 
(Hitcom, Surrey, UK) and Orion Health technologies, Northern Ireland Electronic Care 
Record (NIECR) (Orion health, Hammersmith, UK). All data was used in compliance 
with research ethics and the Data Protection Act, 1998. Fields of data are described 
in Chapter 2, Section 2.11.1.  
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5.2.5 Multiplex proteomics  
 
Proteomic quantification was out conducted at OLink proteomics (OLink, SW). EDTA 
plasma from 374 T2D patients and 20 non-diabetes controls was analysed. A total of 
5 plates were shipped on dry ice (CO2, - 76o C). All data is presented as Normalised 
Protein Expression (NPX), OLink Proteomics’ arbitrary unit on a log2 scale. Full 
description in Chapter 2, Section 2.12.   
 
5.2.6 Statistical analysis   
 
All statistical analysis was conducted using Graphpad Prism software (Graphpad 
Software Inc., La Jolla, CA, USA; v6.0h). Student’s t tests and one way ANOVA with 
Tukey’s post-hoc test, and Receiver Operator Characteristic (ROC) curves were used 

























Samples were examined on four Proseek multiplex immunoassays (CVD II, CVD III, 
Inflammation, immune response; 92 analytes each). Quality control (QC) criteria 
were implemented and 96-99% of all samples met QC across all panels. 
Cardiovascular panels II & III exhibited a 99% overall protein detection rate, immune 
response and inflammation panels were 88% and 80%, respectively. Due to the fact 
that there were 14 duplicate proteins between panels and some analytes failed to 
meet QC, a total of 337 unique proteins were reportable. A list of all 368 proteins is 
included in Supplementary Table 1, and a list of proteins that failed QC is included in 




Cohort characteristics are described in Table 5.1. Control participants were 
significantly older than the T2D cohort, had a significantly lower BMI and HbA1c and 
significantly higher HDL, LDL and total cholesterol levels, as well as a significantly 
reduced number of recorded chronic conditions. 
DiaStrat   
Diabetes Cohort Non-Diabetes Cohort 
Total Mean (SD) % Total Mean (SD) % 
Number of Participants  374   100 20   100 
Males 225   60 9   45 
Age (yrs) 368 61.70 (10.6) 98 20 68.37 (9.1) **** 100 
Age at diagnosis (yrs) 280 50.63 (10.5) 75 ~ ~ ~ 
Duration (yrs) 297 11.03 (7.9) 79 ~ ~ ~ 
C-peptide (ng/ml) 365 6.33 (6.6) 98 ~ ~ ~ 
BMI (Kg/m2) 242 34.00 (8.3) 65 18 25.40 (3.2) **** 90 
HbA1c (mmol/mol) 363 63.00 (16.7) 97 18 36.22 (2.2) **** 90 
HDL (mmol/l) 356 1.15 (0.3) 95 16 1.70 (0.5) **** 80 
LDL (mmol/l) 356 1.87 (0.9) 95 16 2.58 (0.8) *** 80 
Total Cholesterol (mmol/l) 356 3.85 (0.9) 95 16 4.80 (1.1) *** 80 
Number of Diabetes Medications 321 2.10 (1.3) 86 ~ ~ ~ 
Number of Chronic Conditions 298 4.84 (4.2) 80 13 0.95 (0.9) **** 65 
 
Table 5.1 - Cohort characteristics. Significance determined using Student’s T-test. 




5.3.1 Proteins distinguishing between T2D and non-diabetes controls 
 
As illustrated in Table 5.2, a total of 55 proteins were significantly different in the 
T2D cohort compared to controls, and are listed from highest to lowest level of 
significance, with PRSS8 and MMP7 most significantly different (P= 0.00001) and 
LAMP3 and TREM1 just below the P<0.05 threshold. Pathway analysis revealed that 
this protein signature was associated with Syndecan-1-mediated signalling. Related 
pathways of the eight most significantly altered proteins are listed in Table 5.3 and 

























Table 5.2 - Proteins distinguishing type 2 diabetes patients and controls. N=374 T2D, N=20 
non-diabetes controls. 
DiaStrat v Control 
Number Protein  P-value Number  Protein  P-value 
1 PRSS8 0.00001 28 LIF-R 0.02266 
2 MMP7 0.00001 29 LPL 0.02394 
3 CDCP1 0.00016 30 PSGL-1 0.02401 
4 HSP 27 0.00141 31 ITGB1BP2 0.02534 
5 PAI 0.00143 32 PAR-1 0.02605 
6 HGF 0.00252 33 Ep-CAM 0.03011 
7 Gal-4 0.00303 34 FAM3B 0.03094 
8 VSIG2 0.00370 35 CXCL5 0.03102 
9 IDUA 0.00397 36 HO-1 0.03394 
10 IL-1RT1 0.00518 37 MMP12 0.03470 
11 HAOX1 0.00540 38 TNFRSF11A 0.03588 
12 ANG-1 0.00692 39 KIM1 0.03609 
13 TFF3 0.00727 40 FGF-21 0.03729 
14 CCL17 0.00790 41 PDGF subunit B 0.03788 
15 IL-27 0.00800 42 TRAIL-R2 0.03863 
16 PDGF subunit A 0.00876 43 U-PAR 0.03923 
17 PD-L1 0.00914 44 REN 0.03931 
18 IL-18R1 0.00931 45 CXCL6 0.03935 
19 PON3 0.01080 46 CLEC4D 0.04095 
20 SRC 0.01324 47 CASP-3 0.04209 
21 ITGA11 0.01429 48 DCBLD2 0.04219 
22 GALNT3 0.01472 49 JAM-A 0.04298 
23 KLRD1 0.01737 50 SLAMF1 0.04325 
24 CCL4 0.01740 51 NTF4 0.04380 
25 AREG 0.01741 52 SOD2 0.04622 
26 CXCL1 0.01766 53 MPO 0.04830 
27 CXCL1 0.01766 54 LAMP3 0.04914 
   


















Table 5.3 – Top 8 T2D associated proteins and related pathways 
 
  
Protein  Abbreviation  P-value Function Ref  Pathway 
Prostasin PRSS8 0.0000078 
Epithelial sodium 
channel regulation 
(Koda et al., 2009) 
CASP/PAK2-
p34/actin 
Matrix metalloproteinase-7 MMP7 0.0000105 
Breakdown of 
extracellular matrix / 
wound healing 
(Puthenedam et al., 
2011) 




Cell adhesion / 
glycoprotein action 
(Spassov et al., 2011) EGF/EGFR 
Heat shock protein 27 HSP 27 0.0014145 
Supports cell survival 
under stress 
conditions 
(Sharp et al., 2013) TNF / NfKb 
Plasminogen activator 
inhibitor-1  
PAI 0.0014335 Increases fibrinolysis (Aso, 2007) 
tPA / uPA / 
Plasmin 




(Gallagher, 2006)  HGF-cMET  
Regulatory protein GAL4 Gal-4 0.0030250 
Positive regulator of 
galactose-induced 
genes 
(Klar and Halvorson, 
1974) 
GAL4 - UAS 
system 
V-set and immunoglobulin 
domain containing 2 
VSIG2 0.0037027 
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5.3.2 Most significantly altered proteins in diabetes 
 
The protein concentration in the plasma of 374 diabetes patients was compared to 
20 non-diabetes controls using a Student T-Test. Fifty five proteins (Table 5.2) 
appeared to be associated with diabetes (P<0.05). The 8 most significant (A) PRSS8; 
P<0.0001, (B) MMP7; P<0.0001, (C) CDCP1; P<0.001, (D) PAI; P<0.01, (E) HSP 27; 
p<0.001, (F) GAL-4; P<0.001, (G) VSIG; P<0.01, (H) HGF; P<0.01 are illustrated in 
Figure 5.1. 
















Figure 5.1 - Proteomic Profile of 8 top proteins altered in T2D vs. non-diabetes controls. (A) 
PRSS8, (B) MMP7 (C) CDCP1, (D) HSP 27, (E) PAI, (F) HGF, (G) Gal-4, (H) VSIG2, (I) Enrichment 
analysis. N= 374 diabetes, N=20 non-diabetes. All data presented as box and whisker plots 
(min, mean, max) and showed all proteins of interest were increased in diabetes. Data 
enrichment was conducted on integrative web based software application Enrichr (Chen et 
al., 2013). All data was inputted and ranked for level of membership according to Enrichr 
protocol (N=55 proteins). All significantly associated pathways are shown (P<0.05).  
Significance was determined using Student’s T-test. **P<0.01, P<0.001, ****P<0.0001 vs. 
non-diabetes controls.    
Pathway  Source P-Value 
Syndecan-1-mediated signalling NCI-Nature 2016 0.007 
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Receiver Operator Characteristic (ROC) curve for discrimination between non-
diabetes controls and T2D demonstrated that PRSS8 (AUC 0.75), MMP7 (AUC 0.74), 
CDCP1 (0.74), PAI (AUC 0.72), GAL-4 (AUC 0.71), VSIG2 (AUC 0.70), HGF (AUC 0.73) 
were average (fair) at distinguishing disease. HSP 27 (AUC 0.64) was poor (Fig. 5.2), 









Figure 5.2 - ROC curves for most significantly altered proteins between non-diabetes 
controls and T2D. (A) ROC curves for PRSS8, MMP7, CDCP1, PAI. (B) ROC curves for HSP27, 
GAL-4, VSIG2, HGF. All proteins quantified from plasma and identified by in graph by colour 
key.  Non-diabetes control protein concentrations represented by black line.    
 
5.3.3 Proteins associated with increasing diabetes duration  
 
When looking at proteins altered with increasing duration of diabetes, there were 0 
proteins significantly changed in all groups (5-10, 10-15, 15-20, 20+ years) when 
comparing to patients with newly diagnosed (0-5 yrs) diabetes. Serpin Family A 
Member 12 (SERPINA12, Fig. 5.3A) declined from 0-15 years (P<0.05, R= - 0.15) and 
Thioredoxin reductase (TR, Fig. 5.3B) increased from 0-15 years (P<0.05, R= -0.15). 
These were the only common significantly changed proteins associated with 
diabetes progression between 0-15years. Renin (REN) expression was significantly 
increased from 15 yrs (Fig. 5.3C, D), although linear regression analysis could not 
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Figure 5.3 - Protein markers linked to diabetes duration. (A) SERPINA12, linear regression. 
(B) TR, linear regression. (C) REN, linear regression.  (D) Table illustrating significant changes 
as diabetes duration increases vs. newly diagnosed diabetes (0-5yrs). N=374 T2D patients. 
All trends expressed as OLink NPX values, and R values reported on graphs.   
 
There were 22 proteins associated with over 20 year’s diabetes duration (Table 5.4). 
Fibroblast growth factor 5 (FGF-5, Fig. 5.4A) and Decorin (DCN, Fig. 5.4B) were both 
solely increased (P<0.001, P<0.01 respectively) in patients that had been suffering 









Figure 5.4 - Proteins indicative of 20 + years diabetes.  (A) FGF5. (B) DCN. Protein expression 
was determined using OLink proteomics and normalised to in house OLink control. N= 374 
T2D patents. All data presented as box and whisker plots (min, mean, max). Data showed 
unique time dependent upregulation of proteins of interest.  Significance was determined 
using One-Way ANOVA and Tukey’s post hoc test. *P<0.05 vs. 0-5 yrs diabetes duration.  
vs. 0-5 years duration 
Protein 5-10yrs 10-15yrs 15-20yrs 20+yrs 
SERPINA12 0.024 0.007     
TR 0.028 0.008     

















Table 5.4 – Proteins associated with increasing diabetes duration. Proteins significantly 
altered in patients with diabetes duration of 5-10, 10-15, 15-20 and 20+ years compared to 
those within 0-5 years of diagnosis. Significance determined with Student’s T-Test of each 
grouping compared to a group with 0-5 year’s diabetes duration. 
 
 
5.3.4 Proteins associated with poor weight control in diabetes  
 
Participants were clustered according to BMI and disease state. There were ten common 
proteins between overweight and obese patients, compared to healthy weight diabetes 
patients. Leptin (LEP, Fig. 5.5A) was most significantly affected by BMI in diabetes and data 
indicated a progressive increase in leptin as BMI increased (overweight P=0.000005745, 
obese P= 0.00000000000001). It should be noted that leptin was also significantly increased 
in non-diabetes controls compared to diabetes patients with a healthy BMI (P<0.01). The 
non-diabetes controls had an average BMI of 25.4 Kg/m2, therefore leptin may be 
considered to be sensitive to BMI rather than disease state. Insulin-like growth factor 
binding protein 2 (IGFBP-2, Fig. 5.5B) was reduced in diabetes patients with a BMI above 
24.9 Kg/m2 and not in non-diabetes controls. Interleukin-18 (IL-18, Fig. 5.5C), the interleukin-
1 receptor antagonist (IL-1 ra, Fig. 5.5E), C-Type Lectin Domain Family 4 Member C (CLEC4C, 
Fig. 5.5G) and Proprotein convertase subtilisin/kexin type 9 (PCSK9, Fig. 5.5J) were all 
increased in overweight and obese diabetes patients compared to diabetes patients with a 
healthy BMI. IGFBP-2 (Fig. 5.5B), Contactin 1 (CNTN1, Fig. 5.5D), Matrix metalloproteinase-3 
(MMP3, Fig. 5F) and Epithelial cell adhesion molecule (EpCAM, Fig. 5.5I) were all significantly 
0-5 Y 
5-10y 10-15y 15-20y 20+y 
Protein P-value Protein P-value Protein P-value Protein P-value 
LAG3 0.021 SERPINA12 0.008 IL2 0.000 FGF-5 0.003 
SERPINA12 0.024 TR 0.008 FCRL3 0.002 DCN 0.005 
CXCL10 0.024 GLO1 0.019 ACE2 0.014 SCF 0.005 
MCP-2 0.025 uPA 0.024 TRANCE 0.021 SCF 0.007 
TR 0.029 HO-1 0.032 TGM2 0.028 NFATC3 0.009 
LPL 0.029 ITGB2 0.033 GLO1 0.036 PRELP 0.009 
hOSCAR 0.036 GH 0.033 IL18 0.040 EGFR 0.013 
PD-L1 0.037 GIF 0.038 PAPPA 0.041 TFF3 0.015 
NFATC3 0.040 GDF-15 0.038 ITGB6 0.042 TIMP4 0.019 
CXCL9 0.043 ALCAM 0.042 FAS 0.050 IL-17A 0.020 
  t-PA 0.043 REN 0.050 ST2 0.022 
  
 
CCL4 0.047 CXCL10 0.050 AREG 0.024 
  
 
NFATC3 0.047 ACE2 0.014 REN 0.024 
  
 
IL-6RA 0.047 TRANCE 0.021 CDSN 0.026 
  
 
MERTK 0.048 TGM2 0.028 IGFBP-2 0.026 
  
 







     
IGFBP-1 0.031 
  
     
TNFRSF11A 0.033 
  








     
GDF-15 0.037 
  
     
AMBP 0.039 
  
     
TNFRSF9 0.040 
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reduced in overweight and obese diabetes patients compared to diabetes patients with a 
healthy BMI. Interleukin 17 Receptor A (IL-17RA, Fig. 5.5H) was significantly reduced in 
overweight diabetes patients and was also reduced in the non-diabetes controls compared 
to diabetes patients with a healthy BMI.  Weighted Enricher pathway analysis revealed that 
the 10 proteins were associated with PTP1B and Notch homolog 1 (NOTCH) signaling as well 



















Figure 5.5 - Proteomic markers indicative of overweight and obesity in T2D. (A) LEP, (B) 
IGFBP-2, (C) IL-18, (D) CNTN1, (E) IL-1ra, (F) MMP3, (G) CLEC4C, (H) IL-17RA, (I) Ep-CAM, (J) 
PCSK9 (K) Enricher pathway analysis. Protein expression was determined using OLink 
proteomics and normalised to in house OLink control. N=20 non-diabetes controls, N=18 
diabetes patients with a healthy BMI (BMI 20-24.9 Kg/m2), N= 55 overweight diabetes 
patients (BMI 25-29.9 Kg/m2) and N=169 obese diabetes patients (BMI 30+ Kg/m2). Data 
shows mean protein levels for 10 proteins unique to overweight and obesity. Data 
enrichment was conducted on integrative web based software application Enrichr (Chen et 
al., 2013). All data was inputted and ranked for level of membership according to Enrichr 
protocol (N=10 proteins), and significantly associated pathways shown (P<0.05). Significance 
was determined using one- way ANOVA and Tukey’s post hoc test. *P<0.05, **P<0.01, *** 
P<0.001, ****P<0.0001, vs. diabetes patients with a healthy BMI (20-24.9 Kg/m2). ΔΔ P<0.01 
vs. non-diabetes controls.  
Pathway  Source P-Value 
PTP1B signalling NCI-Nature 2016 0.02 
Notch signalling NCI-Nature 2016 0.02 
HIF-1-alpha transcription factor network NCI-Nature 2016 0.03 
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5.3.5 Proteins associated with obesity 
 
There were a total of 14 proteins that were exclusively increased in patients with a 
BMI greater than 30 Kg/m2. Fatty acid binding protein 4 (FABP4) was significantly 
increased (Fig. 5.6A, P<0.001) and Paraoxonase 3 (PON3) was reduced (Fig. 5.6B, 











Figure 5.6 - Proteins indicative of BMI >30 Kg/m2. (A) FABP4, (B) PON3. All data presented 
as OLink NPX values. N=20 non-diabetes controls, N=18 diabetes patients with a healthy BMI 
(BMI 20-24.9 Kg/m2), N=55 overweight diabetes patients (BMI 25-29.9 Kg/m2) and N=169 
obese diabetes patients (BMI >30 Kg/m2). Significance was determined using one-way 
ANOVA and Tukey’s post hoc test. **P<0.01, *** P<0.001 vs. diabetes patients with a 
healthy BMI (20-24.9 Kg/m2).   
 
To further assess the specificity of markers associated with BMI in T2D, patients 
were grouped into non-diabetes controls and diabetes and then sub-grouped into 
healthy BMI (<24.9 Kg/m2) and overweight (>25 Kg/m2). Data showed that LEP 
(P<0.0001, Fig. 5.7A) IL-1ra (P<0.0001, Fig. 5.7C) and IL-18 (P<0.001, Fig. 5.7D) were 
increased and IGFBP-2 (P<0.0001, Fig. 5.7B) decreased, exclusively in overweight 
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Figure 5.7 – Specific proteomic markers of overweight in T2D. (A) LEP, (B) IGFBP-2, (C) IL1ra, 
(D) IL-18. All data presented as OLink NPX values. N=20 non-diabetes controls, N=18 
diabetes patients with a healthy BMI (20-24.9 Kg/m2), N= 224 diabetes patients with a 
BMI>25. Significance was determined using one way ANOVA and Tukey’s post hoc test. 
**P<0.01, *** P<0.001, ΔΔΔΔ v diabetes patients with a healthy BMI (20-24.9 Kg/m2).   
 
5.3.6 Proteins associated with poor glycemic control in T2D 
 
Participants were clustered according to NICE specified HbA1c guidelines non-
diabetes controls, on target (53 mmol/mol), poor (>53 mmol/mol) or extremely poor 
(>80 mmol/mol). A total of 30 proteins were significantly changed in diabetes 
patients with a HbA1c greater than 53 mmol/mol and 80 mmol/mol compared to on 
target patients <53 mmol/mol HbA1c (Table 5.5). Seven proteins were characteristic 
of poor and extremely poor glycaemic control in diabetes. Interleukin 6 (IL-6) was 
reduced (Fig. 5.8A, P<0.05) in patents with a HbA1c >53 mmol/mol (7%) <80 
mmol/mol (9.5%) and increased when HbA1c was above 80 mmol/mol. Integrin 
Subunit Beta 8 (ITGB8, Fig. 5.8B), Kidney Injury Molecule-1 (KIM1, Fig. 5.8C), 
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Protease, Serine 27 (PRSS27, Fig. 5.8D), Transferrin receptor protein 1 (TfR1, Fig. 
5.8E), Interleukin 17C (IL-17C, Fig. 5.8F) and Interleukin-1 receptor type 1 (IL-1RT1, 
Fig. 5.8G) were increased in diabetes and at both stages of HbA1c severity (P<0.05- 
P<0.001). There were no changes in these proteins when comparing non-diabetes 
controls to on target diabetes patients.   
Pathway enrichment analysis (Enrichr) (Chen et al., 2013) did not identify any 
common signaling pathways between the 7 dysregulated proteins common between 
poor and extremely poor glycaemic control. The protein signature associated with 
poorly controlled glycaemia (>53 mmol/mol, 7%) was associated with altered 
Integrin family cell surface interactions, while that associated with extremely poor 
glycaemic control  was linked to uPA and uPAR- signalling (Fig. 5.8H).   















Table 5.5 – Proteins associated with poor and extremely poor glycaemic control (HbA1c) in 
T2D. N= 121 on target <53, n=206 >54<85, n=37 >86. Significance determined using Student 
T test vs. on target (<53 mmol/mol HbA1c). 
On target  vs. Poor 
glycaemic  control 
>53 mmol/mol 
 
On target vs. extremely 
poor glycaemic control  
>80 mmol/mol 
Protein  P-Value 
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Figure 5.8 - Proteomic markers indicative of poor glycemic control. (A) IL6, (B) ITGB6, (C) 
KIM1, (D) PRSS27, (E) TR, (F) IL-17C, (G) IL-1RT1 (H) Enricher pathway analysis. Protein 
expression was determined using OLink assays and normalised to in house OLink control. 
N=20 non-diabetes controls (HbA1c 36 mmol/mol av), N=121 on target diabetes (HbA1c <53 
mmol/mol), N= 206 poor control (HbA1c >53 <80 mmol/mol) and N=37 extremely poor 
control (HbA1c >80 mmol/mol). Data shows levels of 7 proteins specific to poor glycemic 
control in diabetes. Data enrichment was conducted on the integrative web based software 
application Enrichr (Chen et al., 2013). All data was inputted and ranked for level of 
membership according to the Enrichr protocol (30 proteins were identified for poor and 
extremely poor glycaemic control groups). All significantly associated pathways are shown 
(P<0.05). Full list of proteins illustrated in Table 5. Significance was determined using one-
way ANOVA and Tukey’s post hoc test. *P<0.05, **P<0.01 and *** P<0.001 vs. on target 






Pathway  Source P-Value 
Poor 
















There were 21 proteins exclusively associated with extremely poor glycaemic control 
>80 mmol/mol HbA1c (Diagram 5.1) only 2 were significant to P<0.01 and unique to 
diabetes. Cathepsin D (CTSD, Fig. 5.9A) and IL-1RA (Fig. 5.9B) were both increased in 
the extremely poorly managed group compared to the on target group. There were 
22 proteins unique to patients with a poor glycaemic control (HbA1c >53 <80 
mmol/mol), many of which were subject to significant outliers that impacted upon 
trends. The proteins with the highest P-values were chosen for further analysis. C-C 
motif chemokine 11 (CCL11, Fig. 5.10A, P<0.05) and Fatty Acid-Binding Protein 2 

















Diagram 5.1 – Venn diagram illustrating proteins significantly altered in patients with poor 
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Figure 5.9 – Most significant proteins indicative of HbA1c >80 mmol/mol. (A) CTSD, (B) IL-
1ra. N=121 on target diabetes (HbA1c <53 mmol/mol), N= 206 poor glycaemic control (HbA1c 
>53 <80 mmol/mol) and N=37 extremely poor glycaemic control (HbA1c >80mmol/mol). 
Significance was determined using one-way ANOVA and Tukey’s post hoc test. **P<0.01 and 










Figure 5.10 – Most significant proteins indicative of poor glycaemic control (HbA1c >53 <80 
mmol/mol). (A) CCL11, (B) FABP2. N=121 on target diabetes (HbA1c <53mmol/mol), N= 206 
poor control (HbA1c >53<80 mmol/mol) and N=37 extremely poor control (HbA1c >80 
mmol/mol). Significance was determined using one-way ANOVA and Tukey’s post hoc test. 
**P<0.01 and *** P<0.001 on target diabetes (HbA1c <53 mmol/mol).  
 
5.3.7 Proteins associated with poorly controlled blood lipids in diabetes  
 
Two proteins, stem cell factor (SCF, Fig. 5.11A) and Galactose 4 (GAL-4, Fig. 5.11B) 
were universally implicated in changes in HDL, LDL and cholesterol. In patients with a 
healthy HDL level (>1 mmol/l) SCF was increased (P< 0.0001), while in patients with 
high LDL (>2 mmol/l) and total cholesterol (>4 mmol/l) this protein was significantly 
reduced, P<0.05 and P<0.05 respectively. GAL-4 levels were reduced in high HDL 
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Figure 5.11 - Common proteomic changes in patients with poorly controlled blood lipids. 
(A) SCF (B) GAL-4 was measured in plasma of diabetes participants and controls. Protein 
expression was determined using OLink assays and normalised to in house OLink control. N= 
108 HDL <1 mmol/l, N=248 HDL > 1mmol/l. N=233 LDL <2 mmol/l, N= 132 LDL >2 mmol/l, N= 
233 total cholesterol <4 mmol/l, N= 122 total cholesterol >4 mmol/l. All data presented as 
box and whisker plots (min, mean, max) Significance was determined using one-way ANOVA 
and Tukey’s post hoc test. **P<0.01 and ***P<0.001, ****P<0.0001 vs. <1 mmol/l HDL. 









Table 5.6 – Pathway enrichment analysis for blood lipid proteins. Data enrichment was 
conducted on integrative web based software application Enrichr (Chen et al., 2013). All data 
was inputted and ranked for level of membership according to Enrichr protocol. N=81 
proteins HDL, N=32 proteins LDL, N=30 proteins total cholesterol. Pathways identified via 
Nature Pathway Interaction Database. All significantly associated pathways are shown 
(P<0.05). 
 
Pathway enrichment analysis revealed plasma proteome profiles for HDL, LDL and total 
Cholesterol all had different primary pathway activation (Table 5.6), but interestingly were 








Direct p53 effectors  NCI-Nature 2016 0.01 










L CXCR3-mediated signalling events NCI-Nature 2016 0.001 





































Diagram 5.2 – Venn diagram of proteins significantly associated with alterations in blood 
lipids; clusters are dependent NICE guidance for hyperlipidaemia. Significance was 
determined from on target diabetes patients.  
 
5.3.7.1 Proteomic signature of reduced HDL  
 
There were a total of 81 significantly altered proteins in patients with reduced HDL.  
The top four were selected for regression analysis. SCF (Fig. 5.12A) displayed a non-
linear, positive regression (R= 0.48, P< 0.0001). PON3 (Fig. 5.12B) had a positive 
linear relationship (R= 0.36, P< 0.0001). Interestingly LPL expression and LDL 
receptor expression were inversely related. Lipoprotein lipase (LPL, Fig. 5.12C) had a 
positive non-linear relationship (R= 0.36, P< 0.0001) to plasma HDL concentration, 
while LDL receptor expression had a negative non-linear (R= -0.29, P< 0.0001, Fig. 
5.12D) relationship.  
 







































Reduced HDL <1 mmol/l Elevated LDL >2 mmol/l 
























































































R = 0 .4 6
P < 0 .0 0 0 1
P O N 3










R = 0 .3 6
P < 0 .0 0 0 1
L P L











R = 0 .3 6
P < 0 .0 0 0 1
L D L  re c e p to r










R =  - 0 .2 9


















Figure 5.12 - Plasma protein correlated with HDL concentration. (A) SCF (B) PON3 (C) LPL 
(D) LDL receptor. N=356 diabetes patients for all HDL correlations. Data presented as scatter 
plots with non-linear, Gaussian regression, fitted with least squares (ordinary) fit. R value 
representative of relationship.  
 
 
5.3.7.2 Proteomic signature of elevated LDL  
 
A total of 32 proteins were changed in patients with elevated LDL (>2 mmol/l). The 
top four were selected for regression analysis. Growth Differentiation Factor 15 
(GDF15, R=-0.23, P<0.0001, Fig. 5.13A), CCL11 (R= -0.22, P<0.0001, Fig. 5.13B) and C-
C motif chemokine 25 (CCL25, R= -0.24, P<0.0001, Fig. 5.13C) displayed a linear 
negative regression. TNF-related apoptosis-inducing ligand (TRAIL, Fig. 5.13D) 
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Figure 5.13 - Plasma protein correlated with LDL concentration. (A) GDF15 (B) CCL11 (C) 
CCL25 (D) TRAIL. N= 354 diabetes patients for all LDL correlations. Data presented as scatter 
plots with linear regression best line fitted. R value representative of relationship.    
 
5.3.7.3 Proteomic signature of elevated total cholesterol  
 
Elevated total cholesterol (>4 mmol/l) was correlated with 2 proteins, Tissue factor 
pathway inhibitor (TFP1, Fig. 5.14A) and LDL receptor (Fig. 5.14B). A total of 30 
proteins (Diagram 5.2) were increased in patients with elevated cholesterol although 
most changes were small and did not correlate with total cholesterol concentration. 
TFP1 and LDL receptor protein levels were positively correlated with total 









Figure 5.14 - Plasma proteins correlated with total cholesterol concentration. (A) TFP1 (B) 
LDL receptor. N= 354 diabetes patients for all total cholesterol correlations. All data 




5.3.8 Proteins associated with diabetes regime intensification and drug 
class 
 
There were 6 overlapping proteins (Diagram 5.3) in patients on 2, 3, and 4 + diabetes 
medications compared to medication naïve patients, however only Sortilin (SORT, R= 
- 0.15, P<0.01, Fig. 5.15A, B), Caspase 3 (CASP-3, R= -0.11, P<0.05, Fig. 5.15C, D) and 




















Diagram 5.3 – Illustration of significantly changed proteins associated with diabetes regime 
intensification. Clusters are dependent on the number of diabetes drugs a participant is 
prescribed. Significantly changed proteins are compared against average level of protein in 
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Figure 5.15 – Proteins associated with diabetes regime intensification. (A) SORT box and 
whisker plot (B) SORT linear regression (C) CASP-3 box and whisker plot (D) CASP-3 linear 
regression (E) CD84 box and whisker plots (F) CD84 linear regression. N= 52; 0 medications.  
N= 85; 1 medication. N= 83 2 medications. N= 104; 3 medications. N= 50; 4 + medications. 
Data presented as box and whisker plots (min, mean, max) showing significance level 
compared to 0 medications. Linear regression analysis shows all proteins have a negative 
relationship with regime intensification. Significance was determined using one-way ANOVA 
and Tukey’s post hoc test. *P<0.05, **P<0.01 vs. 0 medications  
  
5.3.8.1 Proteins associated with metformin therapy  
 
Metformin monotherapy is associated with initial treatment of T2D followed by 
addition of other oral medications and injectables, GLP-1Ras and insulin (NICE, 
2017). Thirty two proteins were significantly altered in metformin monotherapy 
patients. Twenty six proteins were specific to patients on injectables, and 77 proteins 
linked with any other oral type of diabetes medication (Diagram 5.4). The six most 



























Diagram 5.4 – Illustration of significantly changed proteins associated with metformin, all 
other oral medications and injectable diabetes medications. 55 further proteins were 













Table 5.7 – Most significantly changed proteins in metformin only prescribed patients. N= 
66 metformin (only), N= 163 all other prescription combinations, Significance determined 
using Student’s t test vs. metformin negative patients. 
 
Metformin Monotherapy 
Protein  P-value Trend  
MEPE 0.0000 ↑ 
MMP-1 0.0001 ↓ 
TIMP4 0.0002 ↓ 
CCL23 0.0004 ↑ 
COL1A1 0.0007 ↓ 
OPN 0.0008 ↑ 


































































































































5.3.9 Proteins associated with other oral diabetes medications 
 
There were 27 significant proteins (P<0.05, Table 5.8), unique to DDP-IVi prescribed 
patients. Lymphocyte-activation protein 3 (LAG3, P<0.01), Interleukin-18-binding 
protein (IL-18BP, P<0.01) and C-X-C motif chemokine 10 (CXCL10, P<0.01) were the 
most significant, and all were increased. SGLT2i prescribed patients had 11 
significant proteins specific to the class (Table 8). Hydroxyacid oxidase 1 (HAOX1, 
increased, P<0.01), IL-1RA (increased, P<0.05,) and Fms-related tyrosine kinase 3 
ligand (Flt3L, decreased, P<0.05) were most significant.   
 
DDP-IVi SGLT2i 
Protein  P value Trend Protein  P value Trend 
LAG3 0.0017 ↑ HAOX1 0.0041 ↑ 
IL-18BP 0.0028 ↑ IL-1ra 0.0137 ↑ 
CDCP1 0.0033 ↑ Flt3L 0.0145 ↓ 
CXCL10 0.0062 ↓ MMP7 0.0150 ↓ 
TRANCE 0.0064 ↓ THBS2 0.0168 ↑ 
CST5 0.0077 ↑ BTN3A2 0.0193 ↓ 
CCL28 0.0079 ↑ SCF 0.0197 ↓ 
TNFRSF13B 0.0155 ↑ hOSCAR 0.0206 ↓ 
NCR1 0.0228 ↑ AMBP 0.0238 ↓ 
NT-3 0.0250 ↑ IL18 0.0240 ↑ 
CXCL16 0.0254 ↑ OSM 0.0351 ↑ 
TNF-R2 0.0281 ↑ 
   
CD83 0.0323 ↑ 
   
FAM3B 0.0328 ↑ 
   
IL-17C 0.0330 ↑ 
   
CCL22 0.0336 ↓ 
   
CLEC7A 0.0373 ↑ 
   
PAI 0.0373 ↓ 
   
CXCL9 0.0407 ↑ 
   
SLAMF1 0.0423 ↑ 
   
CCL15 0.0439 ↑ 
   
CD163 0.0447 ↑ 
   
LY75 0.0450 ↑ 
   
CD5 0.0455 ↑ 
   
ITGB6 0.0457 ↑ 
   
IGFBP-7 0.0465 ↑ 
   
Gal-4 0.0483 ↑       
 
 
Table 5.8 - Proteins associated with DDP-IVi and SGLT2i therapy. N= 307 DDP-IVi (-), N= 67 
DDP-IVi (+). N= 303 SGLT2i (-), N= 70 SGLT2i (+). Significance determined using Student’s t 























Table 5.9 - Significantly changed proteins associated with SU and TZD therapy. N= 251 SU (-
), N= 123 SU (+). N= 362 TZD (-), N= 12 TZD (+). Significance determined using Student-T test 
vs. drug negative patients. 
 
Sulphonylurea treatment was associated with six unique protein changes (Table 5.9). 
CD84 (P<0.01,) CLEC4A (P<0.01,) and Tumor Necrosis Factor Superfamily Member 14 
(TNFSF14, P<0.05) were the most significant and all were decreased. Interestingly, 
TZDs were associated with 20 significantly altered proteins all of which were reduced 
(Table 5.9). The most significant were TNF receptor-associated factor 2 (TRAF2), 
Carbonic anhydrase 5A (CA5A) and Peroxiredoxin-1 (PRDX1) (P<0.01).   
 
5.3.10 Proteins associated with injectable diabetes medications 
 
There were 14 significantly (P<0.05) proteins specifically changed in GLP-1Ra treated 
patients, and 11 proteins altered specifically in insulin treated patients. There were 
two proteins altered in both GLP-1Ra and insulin treated patients (Diagram 5.5). The 
top two proteins unique to GLP-1Ra prescribed patients were Programmed cell 
death ligand 2 (PD-L2) and Hydroxysteroid 11-Beta Dehydrogenase 1 (HSD11B1), 
both were decreased (P<0.01). Growth Hormone (GH, P<0.01) and Integrin alpha-11 
(ITGA11, P<0.05) were exclusively increased in insulin prescribed patients. CPA1 and 
SU TZD 




CLEC4A 0.0062 ↓ TRAF2 0.0025 ↓ 
CD84 0.0062 ↓ CA5A 0.0031 ↓ 
TNFSF14 0.0199 ↓ PRDX1 0.0034 ↓ 
GRN 0.0364 ↑ PRSS8 0.0074 ↓ 
IL6 0.0397 ↑ MCP-4 0.0119 ↓ 
CTSZ 0.0424 ↑ CXCL1 0.0119 ↓ 
   
IDUA 0.0168 ↓ 
   
TNFRSF10A 0.0174 ↓ 
   
CASP-8 0.0177 ↓ 
   
GLO1 0.0186 ↓ 
   
DFFA 0.0234 ↓ 
   
SOD2 0.0273 ↓ 
   
KRT19 0.0311 ↓ 
   
PSIP1 0.0386 ↓ 
   
IL8 0.0393 ↓ 
   
ACE2 0.0414 ↓ 
   
PRDX5 0.0428 ↓ 
   
IFNLR1 0.0436 ↓ 
   
IL7 0.0445 ↓ 
   
ST2 0.0466 ↓ 
186 
 
CPB1 were increased in GLP-1Ra prescribed patients and decreased in insulin 










Table 5.10 – Top significantly changed proteins associated with injectable medications 
only. N= 310 GLP1-Ra (-), N= 64 GLP1-Ra (+). N= 261 Insulin (-), N= 113 Insulin (+). 





















Diagram 5.5 - Venn diagram of significantly changed proteins associated injectable 




GLP-1Ra Insulin GLP-1Ra & Insulin 
Protein P-value Trend Protein P-value Trend Protein P-value Trend 
PD-L2 0.002 ↓ GH 0.004 ↑ CPA1 0.000 Opposite (GLP-1Ra >) 
HSD11B1 0.008 ↓ ITGA11 0.014 ↑ CPB1 0.000 Opposite (GLP-1Ra >) 
BOC 0.013 ↓ FABP2 0.036 ↑    
DECR1 0.014 ↑ CCL17 0.045 ↓    
IL2 0.014 ↑ PRSS27 0.046 ↑    
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5.3.11 Proteins associated β-cell function (C-peptide) 
 
There were 4 proteins associated with all concentrations (0-5, 5-10, 10-15, 20+ 
ng/ml) of plasma C-peptide. Angiotensin converting enzyme 2 (ACE2, R=0.26, 
P<0.0001, Fig. 5.16A), IL-18 (R= 0.25, p< 0.0001, Fig. 16B) and LEP (R=0.24, p<0.0001, 
Fig. 16C) were positively correlated with plasma C-peptide levels and in all cases 
patients with 20 + ng/ml C-peptide had significantly more of the target protein than 
those with 0-5 ng/ml (P<0.05). ITGA11 (R= -0.24, P<0.0001, Fig. 16D) was negatively 















Figure 5.16 – Proteomic markers indicative of alterations in plasma C-peptide 
concentrations. (A) ACE correlation analysis. (B) IL-18 correlation analysis (C) LEP correlation 
analysis (D) ITGA11 correlation analysis. N= 219; 0-5 ng/ml C-peptide, N= 93; 5-10ng/ml C-
peptide, N= 21; 10-15ng/ml C-peptide, N= 31; 20+ng/ml C-peptide. Data identified 4 
proteins correlated with plasma C-peptide concentration. Significance was determined using 




Elevated C-peptide (>9 ng/ml) is characteristic of severe insulin resistance. There 
were a total of 32 proteins capable of distinguishing patients with a plasma C-
peptide of >9 ng/ml. Reduced C-peptide (<3 ng/ml) is indicative of severe β-cell 
188 
 
dysfunction and 68 proteins were characteristic of such individuals (Diagram 5.6). 
There were only 2 proteins highly significantly associated with a C-Peptide greater 
than 9 ng/ml (P< 0.01); MGMT (P< 0.001) and Zinc Finger and BTB Domain 
Containing protein 16 (ZBTB16, P<0.01). There were many highly significant proteins 
changed in patients with C-Peptide lower than 3 ng/ml; GH (P<0.0001) and IGFBP-2 












Diagram 5.6 – Venn diagram of significantly changed proteins associated low and high 
plasma C-peptide levels. Top two are in red. 
 
 
C-Peptide <3 ng/ml C-Peptide >9 ng/ml 
Protein P-value Trend Protein P-value Trend 
GH 0.0001 ↑ MGMT 0.001 ↑ 
IGFBP-1 0.0001 ↑ ZBTB16 0.01 ↑ 
 
Table 5.11 – Top significantly changed proteins associated with high and low C-Peptide 
levels. N= 101 C-peptide <3ng/ml, N= 204 C-Peptide >3<9ng/ml. N= 59 C-Peptide >9ng/ml. 
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5.3.12 Proteins associated comorbidity and comorbidity type  
 
Chymotrypsin C (CTRC) was the only assayed protein significantly associated with the 
presence of any comorbidity (Fig. 5.17A, P<0.05-P<0.001). Linear regression analysis 
showed CTRC negatively correlated (R=-0.62, P0.001, Fig. 5.17B) with comorbidity 
















Figure 5.17 – CTRC protein reduced in the presence of comorbidity. (A) CTRC box and 
whisker plots (B) CTRC linear regression.  N= 75; 0 comorbidities. N= 88; 1-3 comorbidities. 
N= 98; 3-6 comorbidities. N=56; 7-9 comorbidities. N=35; 10-12 comorbidities. N=22 13+ 
comorbidities. Significance was determined using one-way ANOVA with Tukey’s post hoc 
test. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 v 0 comorbidities.  
  
There were nine proteins (Table 5.12) associated uniquely with 1-3 comorbidities in T2D 
patients. CDSN (P<0.05) and TGF-alpha (P<0.05) were most significant. There were 17 
proteins significantly changed in patients with 13 + comorbidities (Table 5.12), TNF Receptor 
Superfamily Member 10a (TNFRSF10A, P<0.01) and HGF (P<0.01) were the most significant. 
Both were increased, although HGF was much more abundant in plasma (average NPX 8.5).   




1-3 Comorbidity  13+ Comorbidity  
Protein P-value Trend Protein P-value Trend 
CDSN 0.011 ↑ TNFRSF10A 0.004 ↓ 
TGF-alpha 0.015 ↑ HGF 0.005 ↓ 
MMP-10 0.016 ↓ IL12RB1 0.008 ↓ 
REN 0.021 ↓ KIM1 0.012 ↓ 
ADAM-TS13 0.024 ↓ LPL 0.021 ↓ 
CLEC4C 0.024 ↑ IL-17A 0.023 ↓ 
SCF 0.035 ↑ CLEC4D 0.028 ↓ 
PRSS8 0.040 ↓ IL-18R1 0.028 ↓ 
CXCL12 0.042 ↓ CD28 0.031 ↓ 
   CTSZ 0.033 ↑ 
  
  
AMBP 0.037 ↓ 
      VSIG2 0.038 ↓ 
  
  
THBS2 0.040 ↓ 
      TRAF2 0.041 ↑ 
  
  
AGRP 0.042 ↑ 
      OPG 0.046 ↓ 
  
  
PGF 0.048 ↓ 
 
Table 5.12 – Proteins associated with 1-3 (few) and 13+ (many) Comorbidities. N=75 0 
comorbidities. N=88 1-3 comorbidities. N= 22 13+ comorbidities. Significance determined 
using Student-T test vs. 0 comorbidities.  
 
5.3.12.1 Clustering of comorbidity in diabetes 
 
Patients were clustered by 3 comorbidity groups. The first was classic secondary diabetes 
complications, which included cardiovascular disease, Endocrine and nutritional disorders, 
disorders of the eye, genitourinary disorders. The second was other diabetes related 
conditions which included digestive and musculoskeletal disorders. The final group was 
patients that have clinically diagnosed depression. There were 118 proteins unique to micro 
and macrovascular disease patients. The top 20 are shown in Diagram 5.7. There were 20 
proteins specific to ‘other diabetes’ related conditions and 5 proteins indicative of 
depression (Diagram 5.7). 
The six most significant proteins for each group are shown in table 5.13. pro-Brain 
Natriuretic Peptide (NT-proBNP) and NCR1 were most strongly and uniquely associated with 
classic diabetes complications (P<0.0001), both were increased in the presence of disease. 
Glyoxalase I (GLO1) and Osteoclast-associated immunoglobulin-like receptor (hOSCAR) were 
specially increased in ‘other diabetes related conditions’ (digestive & musculoskeletal) 




























Diagram 5.7 – Venn diagram of proteins associated with classic diabetes complications 
(Micro & Macrovascular comorbidity, other diabetes comorbidities (digestive and 
musculoskeletal disorders) and clinically diagnosed depression; top 20 proteins associated 
with classic secondary diabetes complications included, remaining 98 included in 
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Micro & Macrovascular  Other diabetes related 
Clinically diagnosed 
depression 
Protein P-value Trend Protein P-value Trend Protein P-value Trend 
NT-proBNP 0.000 ↑ GLO1 0.050 ↑ TNFSF14 0.050 ↑ 
NCR1 0.000 ↑ hOSCAR 0.050 ↑ HGF 0.050 ↑ 
BTN3A2 0.000 ↑ LY75 0.050 ↑ CD244 0.050 ↑ 
FABP4 0.000 ↓ BOC 0.050 ↓ TRAIL 0.050 ↓ 
IL-15RA 0.000 ↑ IL10 0.050 ↓    
TNF-R1 0.000 ↑ 
ADAM-
TS13 0.050 ↑       
 
Table 5.13 – Top six proteins associated with micro & macrovascular disease, other 
diabetes related comorbidity and clinically diagnosed depression. N=154 micro & 
macrovascular disease (-), N=220 micro & macrovascular disease (+). N=259 other diabetes 
related comorbidity (-), N=115 other diabetes related comorbidity. (+). N= 331 depression (-




5.3.13 Proteins associated GLP-1 analogue treatment response with 
respect to glycemic control and body weight 
 
There were 17 proteins unique to GLP-1Ra prescribed patients with poor response 
defined in this case as those with elevated HbA1c (>54 mmol/mol). ITGA11 was the 
most significant and was the only protein uniquely changed (reduced) when 
compared to GLP-1Ra (-) patients (Fig. 5.18, P<0.01-P<0.001)   
There were 13 proteins associated obesity (>30 Kg/m2) in GLP-1Ra prescribed 
patients, again taken as an indicator of poor response. Ep-CAM was the most 
significant and the only protein specifically changed (increased) in GLP-1Ra (+) 
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Figure 5.18 – ITGA11 is associated with good glycaemic control in GLP-1Ra positive 
patients.  Protein expression was determined using OLink assays and normalised to in house 
OLink control. N= 112 GLP-1RA (-) HbA1c < 53.9. N= 191 GLP-1Ra (-) HbA1c >54. N= 9 GLP-
1RA (+) HbA1c < 53.9. N= 50 GLP-1Ra (+) HbA1c >54. Data presented as box and whisker 
plots (min, mean, max). Significance was determined using one-way ANOVA with Tukey’s 













Figure 5.19 – EP-CAM is associated with lower BMI in GLP-1Ra positive patients. Protein 
expression was determined using OLink assays and normalised to in house OLink control. N= 
63 GLP-1RA (-) BMI < 29.9. N= 131 GLP-1Ra (-) BMI >30. N= 9 GLP-1RA (+) BMI < 29.9. N= 50 
GLP-1Ra (+) BMI >30. All data presented as box and whisker plots (min, mean, max). 
Significance was determined using one-way ANOVA with Tukey’s post hoc test. *P<0.05, 









Table 5.14 – Pathway enrichment analysis for proteins associated with poor HbA1c and 
obesity control in GLP-1Ra prescribed patients. Data enrichment was conducted on 
integrative web based software application Enrichr (Chen et al., 2013). All data was inputted 
and ranked for level of membership according to Enrichr protocol (N= 17 proteins). 
Pathways identified via Nature Pathway Interaction Database. All significantly associated 
pathways are shown (P<0.05).  
 
Pathway enrichment analysis (Enrichr) (Chen et al., 2013) identified GLP-1Ra 
prescribed patients with poor glycemic control had altered Integrin family cell 
surface interactions (Table 5.14) and obese GLP-1Ra prescribed patients had 






























5.4 Discussion  
 
In this study we used a non-targeted proteomic approach to discover new risk 
markers associated with T2D, HbA1c, BMI, blood lipids, anti-diabetes drug 
prescription, C-peptide and 6 comorbid conditions previously identified in the 
DiaStrat cohort (Chapter 4). Pathway enrichment analysis was also conducted.  
Previous research using this group of patients (Chapter 4) and other meta-analysis 
have emphasised the importance of our chosen variables in T2D management and 
stratification (Wilding, 2014). This analysis has been designed to efficiently identify 
proteomic targets in areas that could inform best treatment and management 
practices.  
There were 55 proteins that differentiated T2D patients compared to non-
diabetes controls; the top 8 proteins were each capable of distinguishing between 
disease with a reasonable accuracy (AUC ~71%). PRSS8, Hsp27 and MMP7 are 
involved in the inflammatory response (Uchimura et al., 2014, Nahomi et al., 2014, 
Ayuk et al., 2016) and CDCP1 is involved in cell adhesion and endothelial dysfunction 
(Law et al., 2016). These processes can be impaired by PAI and HGF, both of which 
are catabolic proteins involved in angiopathy and cardiovascular disease (Lyon and 
Hsueh, 2003, Konya et al., 2014), and were altered in T2D in the present study.  
Enrichment analysis using all 55 proteins revealed Syndecan-1-mediated 
signalling as a common factor. Previous research has found syndecan-1 to be a 
reliable marker for endothelial glycocalyx degradation (Johansson et al., 2011). 
Protein levels have been found to correlate directly with endothelial damage, 
hyperfibrinolysis and inflammation (IL-6 and IL-10) (Stensballe et al., 2009). Other 
studies have proposed degradation of endothelial glycocalyx advances clot 
formation and protein C depletion (Rahbar et al., 2015), resulting in increased 
hyperfibrinolysis (Davenport et al., 2017) and ultimately endothelial cell death 
(Zouaoui Boudjeltia et al., 2012). This process would have a significant impact on a 
diabetes patient, resulting in loss of vascular integrity and ultimately organ damage 
(Lin et al., 2007). Syndecan-1 signalling has not been explored in the context of 
diabetes but could be a good marker for vascular damage (Clua-Espuny et al., 2017). 
Interestingly, Fibroblast growth factor 5 (FGF5) was the most significantly altered 
protein in long suffering diabetes patients with disease duration in excess of 20 
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years. This growth factor is involved in angiogenesis and would healing (Seo et al., 
2016). A number of studies have implicated FGF5 pathogenic variants in diabetes, 
hypertension (Xi et al., 2014) and dyslipidaemia (Li et al., 2015b). This study supports 
findings from other studies that have identified FGFs as being directly linked to 
diabetes duration (Pena et al., 2016). Decorin was the only other protein associated 
with an long duration diabetes, and interestingly is also involved in endothelial 
integrity (Davies et al., 2001). Decorin is a proteoglycan that interacts with VEGFR2 
to increase Paternally expressed 3 (Peg3) (Buraschi et al., 2013). This increases 
endothelial cell autophagy and inhibits angiogenesis (Neill et al., 2017). Other 
research has linked increased levels of Decorin to obesity and CVD onset (Bolton et 
al., 2008). Measuring this protein, together with other with syndecan-1 signalling 
components, could provide novel vascular endothelial cell markers indicative of 
vascular integrity and diabetes progression. 
Increased BMI (>24.9Kg/m2) in diabetes was found to be associated with 10 
proteins. As expected plasma leptin levels and PTPB1 signalling are most significantly 
affected (Feng et al., 2013a). There were also highly significant differences in IL-18, 
IGFBP-2, contactin 1 and MMP3 levels. IL-18 is a proinflammatory cytokine (Osborn 
et al., 2008), and well researched with respect to cardiovascular death and plaque 
formation (Libby, 2006). It is mainly produced by macrophages (Pirhonen et al., 
1999), but recent work has implicated adipose tissue as a contributing factor (Wood 
et al., 2005). Hyperglycaemia has also been positively correlated with circulating 
levels of IL-18, in normal and diabetes patients with impaired glucose tolerance 
(Esposito et al., 2002). It is currently a validated measure of endothelial integrity and 
atherosclerosis (Straface et al., 2010), but has potential to be used as a characteristic 
marker of obesity. Insulin growth factor (IGF) proteins regulate migration and tube 
formation of vascular endothelial cells (Nakao-Hayashi et al., 1992). IGF-1 has been 
shown to affect atherosclerosis (Thum et al., 2007) and insulin sensitivity (Nam et al., 
1997). IGFs are regulated by IGF binding proteins (IGFBP) (Monzavi and Cohen, 
2002). IGFBP-2 was reduced in overweight patients in the present study, this 
supports other work that has shown the sensitivity of this molecule to insulin (Nam 




Enrichment analysis implicated hypoxia-inducible factor (HIF) 1α signalling 
with the proteins in the obese patient cluster. HIF is regulated by cellular 02 (Wang et 
al., 2005b), however it is now known that insulin and IGF can induce expression 
(Feldser et al., 1999). HIF-1α increases IGFBP-2 expression (Tazuke et al., 1998), but 
in diabetes and obesity, insulin signalling is severely impaired (Spolcova et al., 2014); 
this would impact IGFBP-2 (Shin et al., 2017) and downstream IGF mediated 
angiogenesis (Nakao-Hayashi et al., 1992). The fact that MMP3 is also reduced 
further characterises the cohort as high vascular risk. MMP3 has been shown to have 
a negative regulatory role in adipocyte differentiation and low levels increase fat 
mass (Wu et al., 2017b). This would exacerbate cardiovascular risk (Burke et al., 
2008).  Any direct relationship or interaction between IL-18, IGFBP2 and MMP3 has 
yet to be defined.  
There were 30 dysregulated proteins in patients with a HbA1c >53<80 
mmol/mol and in patients with a HbA1c >80 mmol/mol (9.5%), but only 7 proteins 
were common between the two groups. Kidney injury molecule-1 (KIM1) was the 
most significant. It is thought to move into circulation as elevated glucose damages 
the kidney (Vos et al., 2012a). KIM1 is a sensitive and specific biomarker for chronic 
kidney injury (Sabbisetti et al., 2014), and levels are thought to be representative of 
altered actin cytoskeletons in renal microvascular endothelial cells. This cellular 
pathology  ultimately reduces cell adhesion (Sutton et al., 2002). To date there is no 
research correlating KIM1 with HbA1c. Enrichment analysis highlighted a pathway 
associated with endothelial integrity and cellular adhesion. Alterations in integrin 
family cell surface interactions were identified as being a major characteristic of poor 
glycaemia. Pre-clinical studies have shown that integrins function as adhesion 
receptors for extracellular ligands, transmitting biochemical signals into the cell 
(Michie et al., 1998). More than 150 proteins interact with integrin binding sites (Liu 
et al., 2000). Key insulin signalling proteins PI3K, AKT and MAPK are controlled by 
integrins (Delcommenne et al., 1998). These proteins are essential for maintaining 
insulin sensitivity and glucose homeostasis (Elghazi et al., 2006). Interestingly 
extremely poor glycaemic control (HbA1c- 80 mmol/mol, 9.5%) was characteristic of 
an alternate pathway, the uPA and uPAR signalling cascade. This cascade is activated 
in times of high glucose (Flores-López et al., 2016) and one of the main components 
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of the uPA/uPAR system is MMP9 (Kong et al., 2007). This enzyme increases 
endothelial cell damage and vascular permeability, and is a leading cause of vascular 
pathology (Kowluru and Mishra, 2017). It is notable that MMP9 was non- 
significantly increased in patients with a HbA1c >53 mmol/mol. Studies have indicated 
that in those without diabetes this protein is at very low levels and a high level is 
indicative of pathogenesis (Ayuk et al., 2016).  
There were only 3 common proteomic targets; SCF, GAL-4 and TNFRSF13, 
universally changed in patients with alterations in HDL, LDL and total cholesterol. 
Alterations in HDL (>1mmol/l) had the greatest effect on plasma proteins; a total of 
81 were significantly changed, compared to 32 in LDL (>2 mmol/l) and 30 in elevated 
total cholesterol (>4 mmol/l) patients. This is interesting as elevated HDL is thought 
to be protective, opposite in nature to LDL and cholesterol (Lim, 2017). Generally 
plasma HDL concentration correlated best with SCF, PON3, LPL and LDL receptor 
protein levels, when compared to proteins detected in elevated LDL and total 
cholesterol patients. Molecular pathway activity was different dependent on what 
aspects of a patients blood lipids were elevated. This is not surprising as HDL, LDL 
and total cholesterol have different pathophysiological effects (Batiste and Schaefer, 
2002). Interestingly, β1 integrin cell surface interactions, and HIF-1α transcription 
factor alterations were distinctive of altered HDL and these pathways were also 
characteristic of poor glycaemia (>53 mmol/mol). There is a close link between blood 
lipoprotein abnormalities and diabetes (Shishino et al., 2007), and is probably why 
there is a degree of overlap. HDL concentration can differentially control integrin 
function and cell motility (Pan et al., 2012). Research has shown HDL regulates β1 
integrin recycling, cell adhesion and migration, having a significant impact on 
vascular integrity (Camont et al., 2011).  
Diabetes regime intensification is characteristic of poor pharmacological 
response, high HbA1c and long diabetes duration according to NICE (NICE, 2015). 
Data from our previous work showed this is not always the case and intensification 
and drug prescription occurs on an individual basis. Peripheral proteomic changes 
are poorly described during diabetes regime intensification. This work identified 3 
proteins that were negativity correlated with the number of prescribed diabetes 
medications; Sortilin (SORT), Caspase-3 (CASP3), and CD84. SORT has recently been 
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identified as a novel molecular link between insulin resistance (Li et al., 2015a), 
Apolipoprotein B production and atherosclerosis (Strong et al., 2012). SORT inhibits 
Apolipoprotein B, lowering plasma cholesterol (Dubé et al., 2011), but during states 
of insulin resistance is degraded (Li et al., 2015a). It is thought SORT activity is 
dependent on PI3K activity (Li et al., 2017), and due to its sensitivity to insulin 
resistance (Li et al., 2015a) could be a good marker to inform diabetes prescription. 
CASP3 has been shown to be a marker of β-cell apoptosis (Liadis et al., 2005), high 
levels are indicative of a low β-cell population. It is thought this marker could inform 
on whether medications that target the β-cell would be effective (Holz et al., 1993). 
CD84 is part of the signalling lymphocyte activation molecule (SLAM) family (Romero 
et al., 2004) and is involved in the adaptive immune response (Cannons et al., 2010). 
There have been indications that SLAM proteins could be involved in the 
autoimmune destruction of βcells (Dufour et al., 2008), and that this could be 
occurring in T2D as well as T1D (Velloso et al., 2013). This area of research is poorly 
described and only recently being explored but could provide an explanation as to 
why CD84 is predictive of diabetes medication intensification.  
Proteomic profiles were generated for all classifications of anti-diabetes 
drugs (Biguanides, Dipeptidyl peptidase-4 inhibitors (DDP-IVi), Sodium-glucose 
Cotransporter-2 inhibitors (SGLT2i), Sulphonylureas (SU), Thiazolidinediones (TZDs), 
Glucagon-like peptide-1 receptor agonists (GLP-1Ra) and insulin. This type of 
profiling could aid in screening for patients that are responsive or tolerant to a 
particular medication. An interesting finding was that there were not any proteins 
(368 total) common to all classes. Although, from a mechanistic perspective this may 
not be surprising, all have different physiological effects. Metformin decreases 
hepatic glucose production (Liang and Giacomini, 2017), DDP-IVi increases the half-
life of GLP-1 (Bourdel-Marchasson et al., 2011), SGLT2i reduce glucose reabsorption 
in the kidney (Steen and Goldenberg, 2017), SU (Kuhn, 1988) and GLP-1 increase 
insulin secretion from the β-cell (Bourdel-Marchasson et al., 2011) and TZDs increase 
insulin sensitivity by impacting lipid metabolism (Sengupta et al., 2012). Insulin 
signaling signals tissues to take glucose from the blood (Wilcox, 2005). GLP-1Ra and 
insulin prescribed patients both had dysregulated Carboxypeptidase A1 (CPA1) and 
Carboxypeptidase B1 (CPB1). It is known that CPA1 positive cells have the capacity to 
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generate numerous types of pancreatic cells, including β-cells (Pagliuca and Melton, 
2013), and reductions indicate compromised β-cell populations. Both medication 
groups can directly affect the β-cell but characteristically have opposite expression 
levels (Buteau, 2011, Linden and Brooker, 1978). CPA1 and CPB1 were increased in 
GLP-1Ra patients and decreased in insulin dependent patients. CPA1 and CPB1 could 
be promising targets to quantify β-cell function, and warrant further research in this 
regard.  
We reported in Chapter 4 that the DiaStrat cohort has poorly managed 
glycaemia, and ~40% were prescribed insulin. In this study we identified that insulin 
treated patients have elevated plasma GH and FABP2. Other work has shown that 
GH neutralises the effect of insulin on glucose and lipid metabolism (Clemmons, 
2004), decreasing oxidation and supressing glucose uptake into muscle (Møller et al., 
1991). FABP2 is widely associated with increased fat oxidation and severe insulin 
resistance (Xu et al., 2016). This proteomic profile would indicate that insulin 
prescribed patients may not benefit from insulin appropriately due to high levels of 
inhibitory proteins. Other pharmacological approaches may be more effective.  
Establishing measures of insulin resistance is of high clinical significance for 
effective prescribing (Church and Haines, 2016). To date, fasting blood glucose tests 
or homeostatic model assessment (HOMA) have been used (McAuley et al., 2001), 
but are time consuming and labour intensive.  In this study we measured plasma C-
peptide and classified patients according to other published work (Radaelli et al., 
2010). A diabetic patient with a plasma C-peptide level >9 ng/ml was said to be 
insulin resistant.  The levels of 4 proteins were found to directly correlate with C-
peptide; Angiotensin-converting enzyme (ACE) was most strongly associated. This 
enzyme is a potent vasodilator and causes increased vascular permeability, and 
oedema (Fang et al., 2014). IL-18 and LEP were also positively correlated with 
increasing C-peptide, as well as obesity, supporting the established links between 
obesity and insulin resistance (Patel and Abate, 2013).   
There were 32 proteins specifically linked to severe insulin resistance, 
indicated by elevated C-peptide levels (>9 ng/ml C-peptide). MGMT and ZBTB16 
were most significant. MGMT is essential for genome stability and dysregulation is a 
well-established risk in many cancers (Sharma et al., 2009). Clinical studies have 
201 
  
implicated MGMT dysregulation in leukocytes as a contributing factor to various 
immune related diseases (Akçay et al., 2003). It is known that if the immune system 
cannot respond to inflammation, tissues become unresponsive to insulin and fat 
cells release more fatty acids into the blood which can compromise the vasculature 
leading to CVD (Lumeng, 2013). ZBTB16 is involved in lipid metabolism and increased 
levels have been correlated with decreased body fat storage, reductions overall 
bodyweight and glucose oxidation (Plaisier et al., 2012). 
There is a link between insulin resistance, hyperglycaemia and comorbidity 
(Castro et al., 2014). Current diabetes measures such as HbA1c are associated with a 
number of micro and macrovascular complications as well as increased mortality 
(Kranenburg et al., 2015), but  HbA1c levels do not necessarily correlate with the 
number of comorbidities a patient may suffer from, rather stratifies them as high or 
low risk. A single plasma proteomic marker was identified that is strongly negatively 
correlated with the number of comorbidities in T2D patients. Chymotrypsin C (CTRC) 
decreased with increasing comorbidity; a protein directly linked to chronic 
pancreatitis and the destruction of insulin producing cells (Rosendahl et al., 2008). 
CTRC regulates trypsin, which when cleaved in the pancreas ultimately causes 
pancreatic self-digestion (Afghani et al., 2015). CTRC declines with increasing 
physiological stress. This potentiates the need for insulin therapy due to the onset of 
chronic pancreatitis  
N-terminal prohormone of brain natriuretic peptide (NT-proBMP) and NCR1 
were uniquely increased in macrovascular (CVD) and microvascular (nutritional 
diseases, disorders of the eye, genitourinary disorders) disorders.  Globacom-1 
(GLO1) and hOSCAR were specifically increased in other diabetes related 
comorbidities such as digestive and musculoskeletal disorders. Interestingly none of 
these proteins were increased in clinically diagnosed depression patients and there 
were no proteins common to all comorbid conditions. Depression and cognitive 
decline are twice as common in diabetes patients (Holt et al., 2014), and are now 
considered diabetes complications (Bădescu et al., 2016). Few studies have explored 
how plasma proteins are changed in depression and diabetes patients, but recent 
work has identified key lipid biomarkers; cholesterol, omega 3 and omega 6 fatty 
acids was being potential markers of major depressive disorder (Parekh et al., 2017). 
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There were 11 proteins alterations shared between depression and macrovascular/ 
microvascular conditions and only 2 proteins linking depression to other diabetes 
related conditions, indicating that macrovascular complications are more highly 
associated with depression. Kidney Injury Molecule-1 (KIM1) and PD-L1 were most 
strongly linked. KIM1 is associated with CKD and vascular endothelial dysfunction 
(Panduru et al., 2015) which is caused by increased blood glucose and LDL (Atkins, 
2005). Many studies have shown KIM1 to be a reliable marker for low eGFR reads, 
and highly predictive of nephropathy (Panduru et al., 2015). Microvascular 
complications are correlated with longer duration diabetes and old age which are 
risk factors for depression (Iglay et al., 2017). The low grade proinflammatory state 
associated with vascular disease could also perpetuate a depressive state (Bădescu 
et al., 2016). KIM1 may therefore be predictive of depression risk.   
Programmed-death ligand 1 (PD-L1) is an interesting novel marker for 
cardiometabolic health and depression. PD-L1 is primarily thought to be a regulatory 
protein involved in the adaptive immune response; activation reduces proliferation 
of cytotoxic and helper T-cells (Shi et al., 2013). Studies have shown that alterations 
in PD-L1 and T-cell activation can negatively affect β-cell populations, causing insulin 
deficiency and insulin dependence (Wang et al., 2008), leading to hyperglycemia and 
vascular endothelial damage (Wongpiyabovorn et al., 2008). PD-L1 is poorly 
described with respect to diabetes and depression and further work is required to 
determine how and why PD-L1 is increased in depression and CVD patients.  
The UK Prospective Diabetes Study (UKPDS) and Diabetes Control and 
Complications Trial (DCCT) stressed the importance of suitable and timely 
introduction of insulin (American Association of Diabetes, 2002). Introducing insulin 
too early can present the patient to unnecessary risk associated with treatment, but 
too late and the patient will be exposed to comorbidity (Gale, 2008). GLP-1Ras are 
the only other injectable anti-diabetes medication and they primarily signal via c-
AMP to mediate insulin secretion (Holz, 2004), but have also been shown to have 
significant effects on insulin sensitivity and weight loss (Vilsbøll et al., 2008). They are 
an attractive anti diabetes treatment option and may be more suitable than insulin 
in some instances. Unfortunately, they are expensive and are thought to have 
approximately a 50% response rate (Iepsen et al., 2015b). This study aimed to 
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characterise poorly managed blood glucose and bodyweight in GLP-1Ra prescribed 
patients, indicative of poor response. There was only one protein; ITGA11, 
specifically decreased in GLP-1Ra prescribed patients, with well managed blood 
glucose (<53 mmol/mol). Pathway enrichment analysis identified alterations in 
integrin cell surface interactions as being a key characteristic of all the altered 
proteins in GLP-1Ra prescribed patients. This corresponds with earlier data 
integrating the whole cohort which also identified integrin alterations as being of 
important during high glycaemia. Interestingly the proteomic markers involved are 
different in GLP-1Ra prescribed patients, ITGA11, VEGFD, ITGB2, PD-42 were the 
most significant. These proteins are involved in vascular integrity rather than 
mediating signals involved in insulin signalling. ITGA11 is involved in cardiac fibrosis 
progression and upregulation has been linked to heart failure (Talior-Volodarsky et 
al., 2012). VEGFD is associated with angiogenesis and endothelial cell growth (Girling 
and Rogers, 2009). This profile indicates GLP-1Ra treated patients with poor 
glycaemic control have a more compromised vascular system than those with good 
glycaemic control. Although GLP-1Ra treated patients represent are a more severe 
phenotype than the remainder of the cohort, global measurement of these markers 
could provide useful information on vascular endothelial cell function and may be 
indicative of likelihood to derive benefit from GLP-1 analogues  
Obese (>30 Kg/m2), GLP-1Ra treated patients could be distinguished from 
GLP-1Ra negative patients by Ep-CAM. Pathway enrichment analysis using the most 
significantly changed proteins in obese GLP-1Ra (+) patients indicated these patients 
characteristically had altered HIF-1α transcription factor signalling. This pathway was 
also significantly altered in obese diabetes patients in general (whole cohort). The 
most significantly affected protein in GLP-1Ra prescribed patients was Ep-CAM, 
which was reduced in the cohort as a whole, although to a lesser extent. This would 
indicate that BMI has a significant effect on Ep-CAM whose primary function is cell 
adherence and promoting cell-cell interactions (Schnell et al., 2013). In vitro Ep-CAM 
has been found to be a key mediator of cell proliferation, differentiation, and cell 
migration (Litvinov et al., 1996), these characteristics are key for vascular tissue 
development (Hedin et al., 2004). Ep-CAM has a close relationship with HIF-1α in 
cancer (Yamada et al., 2014), so it is possible they interact in diabetes, although 
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currently the molecular mechanisms are unclear. Pathway enrichment analysis 
indicates a relationship and it is known HIF-1α is involved in angiogenesis via IGFBP-2 
(Feldser et al., 1999).  
Limitations  
 
This analysis has several limitations, the most significant being the modest sample 
size and small number of healthy controls included in analyses. Another major 
limitation was that all proteomic measurements were obtained from one time point 
and therefore no conclusions can be drawn with respect to individual drug response 
and comorbidity onset and progression. Resampling the patients and reassessing the 
same protein panels would provide useful longitudinal information on how key 
proteins respond to specific weight changes, pharmacological interventions and 
disease progression. Vulnerabilities in accurate reporting of comorbidity due to 
collation of data from a number of healthcare providers by various professionals 
within the ECR cannot be ignored. DiaStrat participants were recruited from 
secondary care and likely represent a severe diabetes phenotype. Few participants 
had a low or normal BMI or HbA1c therefore changes associated with treatment and 
comorbidity were minimal.  
Conclusion  
 
In the present study we have identified numerous proteins characteristic of T2D, 
HbA1c and BMI GLP-1Ra ‘response’. We also identified proteins associated with 
alterations in blood lipids (HDL, LDL, total cholesterol), diabetes treatment regime, 
and comorbidity progression. Interestingly there was commonalty between 
proteomic markers and their associated pathways. Vascular endothelial damage and 
alterations were a common feature between variables. This type of pathology is well 
documented in diabetes (Avogaro et al., 2011) and ultimately results in endothelial 
cell swelling, necrosis and progressive tissue damage (Sena et al., 2013). Follow up 
validation studies will determine the utility of the proposed panels of markers to 
help characterise and better inform clinical practice on efficient and effective 












SNPs associated with T2D and 
response to GLP-1 analogue therapy in 







Single nucleotide polymorphisms (SNPs) have become the genetic markers of choice 
and many loci are associated with T2D onset and progression. Studies have shifted to 
identifying markers of drug response. The aim of this study was to define variants on 
20 genes (GLP-1R, GIPR, INSR, IRS-1, IGFBP2, AKT, MAPK1, MTOR, LEP-R, STAT3, 
SH2B1, POMC, IL-6, IL-10, IL-18, IL-1RN, HGF, HAVCR1, SORT1, CASP3) related to 
insulin and leptin signalling in patients with T2D vs. controls, and in T2D GLP-1Ra 
responders vs. non-responders.  
Genotyping was conducted using the Affymetrix UK Biobank array (CGS, UK). 
A total of 2489 SNPs were identified across all genes; 105 were indicative of T2D, and 
25 of response to GLP-1Ra therapy. Rs140868873 (IRS1) was specific to T2D; 100% of 
controls had the AB genotype while 99.6% of T2D patients had the BB genotype. 
Rs117029769 (IGFBP2) was also specific to T2D (control 89.5% AB; T2D 97.2% BB, 
P<0.0000). In Rs72881029 (LEP-R) the AB genotype was associated with 100% of 
controls, while 97.6% T2D patients had the BB genotype (P<0.0000). In Rs11085808 
(HGF) 100% of controls had the AB genotype while 100% of T2D patients had the BB 
genotype (P<0.0000).  
T2D GLP-1Ra responders had different SNP genotypes to non-responders in a 
number of genes. In Rs71480142 (GLP-1R), 95.5% of non-responders had the AB 
genotype, while 87.7% of responders had the BB genotype (P<0.0000). In 
Rs115516351 (mTOR) the AA genotype was present in 100% of responders while the 
BB genotype was more prevalent in non-responders (63.6%, P<0.0000). In 
Rs72881029 (LEP-R) the AB genotype was associated with 100% of responders and 
40.9% in non-responders (P<0.0000). SNPs were associated with inflammation and 
immunity in IL-6, IL-10, IL1RN and IL-18 were also identified but were less predictive 
than those associated with insulin and leptin signalling.  
Many SNPs identified in this work are supported on the T2D knowledge 
portal, and some are novel. The highly specificity of SNPs implicated in response to 
GLP-1 analogue therapy suggests that GLP-1Ra response may be predicted by SNP 




6.1 Introduction  
 
In clinical practice, guidance is provided by NICE to manage T2D in a stepwise 
protocol driven manner (NICE, 2015). Recent data and new advice from the 
American Diabetes Association has prompted a move away from this approach to 
more patient specific management plans (Chamberlain et al., 2017a). These are 
directly influenced by individual signs, symptoms, drug characteristics and possible 
adverse events (ADA, 2016).  
Ensuring phenotypic homogeneity is important for effective treatment plans 
(Inzucchi et al., 2015), but studies have shown drug response is highly variable 
irrespective of accurate phenotype classification. Research has highlighted genetics 
as being a major causal factor of response variation (Arar et al., 2008). Response to 
metformin with respect to glycaemia has recently been shown to have a heritability 
figure of ~34%; therefore drug response is, in part, predicated by genetics (Zhou et 
al., 2014a).  
The effectiveness of a drug is dependent on its ability to reach its site of 
action in a high enough concentration to produce an effect (Zhou et al., 2016). 
Pharmacogenomics has predominantly focused on genes implicated in drug 
transport and metabolism to this regard (Daniels et al., 2016). Single Nucleotide 
Polymorphisms (SNPs) in genes involved in transport and metabolism affect drug 
action and a patients propensity to experience side effects (Holstein and Beil, 2009). 
In T2D metformin and SUs have been widely studied. Metformin is a first line 
therapy in T2D, but it is often insufficient as a monotherapy at controlling the 
condition (Mahrooz et al., 2015). Recently genetic variation in Organic Cation 
Transporter 1 (OCT1) gene has been shown to have a significant effect on metformin 
tolerance and response (Shu et al., 2007). OCT1 is involved in metformin metabolism 
in the liver (Wu et al., 2017a). It is now known that ~8% of white Europeans carry 
variants that negatively impact OCT1 action, which ultimately results in patients 
being at twice the risk of developing a severe intolerance (Dujic et al., 2016). SU are 
often a second line therapy in T2D (NICE, 2015), and drug action is usually 
inactivated by the liver enzyme cytochrome P450 2C9 (Dujic et al., 2017). Six percent 
of the population have a polymorphic version of cytochrome P450 2C9 and cannot 
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inactivate the SU; such patients are ~4x more likely attain an HbA1C of <53 mmol/mol 
(7%) (Dujic et al., 2017), and are at a higher risk of hypoglycaemia (Ragia et al., 
2009).              
The development of low cost genome wide arrays has moved research away 
from individual candidate gene studies towards multiple gene variant analysis (Scott 
et al., 2017). This high throughput approach, has a higher utility when the exact 
mechanism of a drug is uncertain (Volkman et al., 2017). Genetic variants or SNPs 
are becoming the genetic markers of choice (Akpinar et al., 2017). SNPs are densely 
and relativity evenly distributed throughout the human genome, most are non-
functional present in non-coding regions of the genome (Zhang and Lupski, 2015). 
Characterisation of pathogenic SNPs is a high priority in precision medicine (Florez, 
2017).  
Genome-Wide Association Studies (GWAS) are commonly used to assess 
traits of disease (Chung et al., 2015) but have had limited success with respect to 
drug response (Pollastro et al., 2015). The most significant success of GWAS studies 
for drug outcome was the identification of genetic variants on the Solute Carrier 
Organic Anion Transporter Family Member 1B1 (SLCO1B1) gene (Postmus et al., 
2014). This gene encodes for a statin transporter protein, and alterations have been 
shown to result in a 16x increased risk of statin induced myopathy (Link et al., 2008). 
Metformin is the only diabetes drug implicated by GWAS data for having a locus that 
affects response (Zhou et al., 2011). The UK Prospective Diabetes Study (UKPDS) 
identified a locus on chromosome 11 that altered drug response which was later 
confirmed in two independent cohorts and replicated in a European and Chinese 
cohort (van Leeuwen et al., 2012).  The locus is identified by RS11212617, and 
multiple studies have implicated Ataxia Telangiectasia Mutated (ATM) as being the 
encoded candidate gene (Zhou et al., 2014b). ATM translates a DNA damage protein 
that is altered in multiple cancers but is also a cause of ataxia telangiectasia 
(Ambrose and Gatti, 2013). In clinical studies patients with this condition have 
increased blood glucose and insulin resistance, supporting the notion that ATM has a 
significant effect on insulin metabolism (Connelly et al., 2016b).               
Glucagon-Like Peptide 1 analogues (GLP-1Ra) are a 4th line anti-diabetes 
treatment (NICE, 2015), and are also licenced as a weight loss therapy in the USA 
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(Danne et al., 2017). Clinical trials have indicated that these drugs are particularly 
prone to response variability. It is thought ~50% of patients respond, achieving 
significant reductions in HbA1c (1%+); some individuals have no effect or display 
gastrointestinal side effects (Iepsen et al., 2015b). Some of this variability may be 
contributed to lifestyle and non-compliance, but it is likely that a genetic component 
is involved (Nuffer and Trujillo, 2015). There is no current pharmacogenomic data in 
European or any other populations for response to GLP-1Ras. A clinical study in Asia 
looked specifically at the GLP-1R and failed to correlate any polymorphisms to GLP-
1Ra response (Lin et al., 2015). RS10305492, within the GLP-1 receptor, has been 
shown to protect against high glucose and cardiovascular disease (Wessel et al., 
2015). We hypothesise that it is likely that genes related to GLP-1’s insulinotropic 
and appetite regulatory effect (associated with phenotypic alterations in response to 
therapy) may be important in T2D generally and in the likelihood of response to GLP-
1 analogue therapy. To this end variants identified on the Glucose-Dependent 
Insulinotropic Polypeptide Receptor (GIPR) (Qi et al., 2012), Pro-opiomelanocortin 
(POMC) (Ternouth et al., 2011) and Insulin Receptor Substrate 1 (IRS1) (Zheng et al., 
2013) have been associated with diabetes onset, appetite regulation and insulin 
resistance, but not yet in response to therapy.  
 
In this study we aimed to characterise variants across 20 insulin and appetite 
signalling genes including GLP-1R, GIPR, INSR, IRS-1, IGFBP2, AKT, MAPK1, MTOR, 
LEP-R, STAT3, SH2B1, POMC, IL-6, IL-10, IL-18, IL-1RN, HGF, HAVCR1, SORT1 and 
CASP3. SNPs across all genes in patients with T2D were compared to controls to 
assess their importance in T2D generally.  Additionally the same SNPs were assessed 
in patients that have responded to GLP-1R analogue treatment compared to those 
who have not achieved glycaemic control in response to GLP-1 analogue therapy. 
Identification of SNPs involved in response to GLP-1 analogue therapy may allow 
prediction of drug response at baseline and could have a significant impact on 








6.2.1 Participant recruitment  
 
Type 2 diabetes participants were recruited from the Altnagelvin Hospital diabetes 
clinic, NI. Controls were identified and sampled at the University of the Third Age 
(U3a), Derry NI, as described in Chapter 2, Section 2.7.  Participants were considered 
to be GLP-1Ra responders if they met NICE criteria for response (reduction of 1% 
HbA1c and/or 3% reduction in bodyweight) or had a HbA1c <54 mmol/mol. Non-
responders were individuals receiving GLP-1 analogue therapy who failed to meet 
NICE criteria or had a HbA1c >65 mmol/mol. 
  
6.2.2 Blood sampling 
 
Blood samples were obtained using 21 G Vacuette® safety needle (Greiner Bio-One, 
Stonehouse, UK; Cat no. 450091), as described in Chapter 2, Section 2.8.1.2. 
Approximately 26ml of blood was extracted into 2 x 9 ml EDTA (K3E K3EDTA) coated 
Vacuette® tubes (Greiner Bio-One, Stonehouse, UK; Cat no. 455036) and 1x 8 ml 
Serum (Z Serum Sep Clot Activator) tube (Greiner Bio-One, Stonehouse, UK; Cat no. 
455071). Blood samples were processed immediately.  
 
6.2.3 Blood processing 
 
Blood sample polypropylene tubes were pre-labelled using Item Tracker© software 
(ItemTracker Software Ltd, Suffolk, UK), prior to processing for serum, plasma, 
protein, RNA and whole blood. Full protocol described in Chapter 2, Section 2.8.1.3.  
Samples were maintained at -80o C until required.  
 
6.2.4 DNA extraction  
 
DNA was extracted from EDTA whole blood samples using the Gentra Puregene 




6.2.5 DNA quantification 
  
The Qubit®Fluorometer (ThermoFisher Scientific, UK; Cat no. Q33216) and QubitTM 
dsDNA HS Assay kit (ThermoFisher Scientific, UK; Cat no. Q32854) were used for DNA 
quantification, as described in Chapter 2, Section 2.9.3.  
 
6.2.6 SNP genotyping 
 
SNP genotyping was conducted using the Affymetrix UK Biobank array by Cambridge 
Genomic Services (CGS, UK). Samples were prepared to CGS instructions as described 
in Chapter 2, Section 2.13.1.    
 
6.2.7 Variant calling 
  
In bound SNPs were identified using Axiom’s Genotype Console software 
(Affymetrix, UK). Samples with a SNP call rate of less than 97.2% or a QC value of < 
0.82 were considered to have failed QC and were excluded from subsequent 
analyses. A full list of target genes and comparisons described in Chapter 2, Section 
2.13.3. 
 
6.2.8 Statistical analyses 
 
Differences in genotypes in SNPs between T2D and controls and GLP-1Ra 
‘responders and non-responders’ were calculated using a Z-test for proportions. 













6.3.1 Identifying prevalent variants within the DiaStrat cohort 
 
This study consisted of two analyses; (A1) characterised the prevalence of SNPs in 20 
genes (Chapter 2, Section 2.13.3) associated with insulin and leptin signalling, 
inflammation and immunity in 254 T2D patients compared to 19 controls. The 
second analysis (A2) characterised the same SNPs in patients that responded GLP-1R 
analogues (HbA1c <53 mmol/mol) compared to those who did not respond or failed 
to achieve acceptable glycaemic control (HbA1c >65 mmol/mol). Table 6.1 shows that 
105 of 2489 SNPs analysed were associated with significantly different prevalence 
between T2D and controls (A1) while 25 were significantly different between GLP-1 
analogue responders and non-responders (A2).  
Gene 
Total number of 
SNPs per gene 
Number of 
significant SNPs  
Control vs. T2D (A1) 
Number of 
significant SNPs  
responders vs. non-
responders (A2) 
GLP-1R 61 1 1 
GIPR 65 2 2 
INSR 49 1 0 
IRS-1 38 2 1 
IGFBP2 57 2 0 
AKT 952 33 10 
MAPK1 68 7 0 
MTOR 59 2 1 
LEP-R 93 3 1 
STAT3 39 4 2 
SH2B1 1 0 0 
POMC 91 0 0 
IL6 60 1 1 
IL10 47 1 0 
IL18 104 1 1 
IL1RN 73 4 0 
HGF 69 2 0 
HAVCR1 4 0 0 
SORT1 35 0 0 
CASP3 524 39 5 
TOTAL 2489 105 25 
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Table 6.1 – Summary of genes of interest and SNPs associated with T2D and 
response to GLP-1 analogue therapy. A1 = T2D (n=254) vs. controls (n=19). A2 = 
GLP-1 responders (n=21) vs. non-responders (n=22).   
 
6.3.2.1 SNPs significantly associated with T2D 
 
Overall, ~98% of the analysed SNPs (Table 6.1) did not differ in prevalence between 
those with T2D and controls, although there were 105 SNPs associated with insulin, 
leptin, inflammation and immunity, which were significantly associated with T2D. 
The characteristics of all significant SNPs are illustrated below in Tables 6.2 – 8. All 
tables detail gene name abbreviation, Reference SNP cluster ID (RS number), Allele A 
and B, SNP call rate, Minor Allele Frequency (MAF) score and Hardy-Weinberg P 
value.   
 
6.3.2.1.1 Insulin signalling related SNPs in T2D 
 
Tables 6.2-4 illustrate 50 insulin related SNPs with significantly different prevalence 
in T2D patients versus controls. SNPS associated with GLP-1R, GIPR, INSR, IRS-1, 
IGFBP-2, MAP-K and MTOR are listed in Table 6.2. Notable SNPs include: rs13374714 
in IRS1; controls exclusively had the AB genotype (100%), while in T2D the BB 
genotype was present in 99.6% of individuals (P<0.0000). Rs117029769 of IGFBP2 
(control 89.5% AB; T2D 97.2% BB. P<0.0000). Rs117029769 is illustrated graphically 
in Figure 6.1.  AKT was the most polymorphic gene screened, a total of 952 SNPs 
were identified (Table 6.1). Rs72726656 (AKT) was the most significant, 100% of 
controls had the AB genotype and 94.0% of the diabetes cohort had the BB genotype 
(p<0.0000). Interestingly the most notable SNPs in this study have not been 
previously linked to insulin signalling on the type 2 diabetes portal (T2D-GENES 
Consortium, 2017) (Table 6.9).   
 
6.3.2.1.2 Leptin signalling related SNPs in T2D 
 
Table 6.5 lists 7 SNPs related to leptin signalling genes. Of the 3 identified on the LEP-
R, rs72881029 was most significant (P<0.0000). The rs72881029 SNP AB genotype 
was associated with 100% of controls, while 97.6% of the diabetes group had the BB 
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genotype, this is graphically illustrated in Figure 6.2. Polymorphisms present on the 
POMC gene were not as distinctive as those on LEP-R, however, rs112365258 was 
the most significant, with AB genotype more common in the control population 
(15.8% vs. 2.4% in diabetes (P<0.001)) and the BB genotype more common in T2D 
(97.6% vs 84.2% (P<0.001)). The importance of this SNP is supported on the type 2 
diabetes portal (T2D-GENES Consortium, 2017) were GWAS studies have linked it to 
increased BMI (Table 6.9). No significant SNPs were identified In the STAT3 or SH2B1.   
 
6.3.2.1.3 Inflammatory gene related SNPs in T2D 
 
There were a total of 8 SNPs significantly associated with T2D across 4 inflammatory 
related genes (IL-6, IL-10, IL-1RN, IL-18). Rs79653684 (IL1RN) was the most 
significant, the AB genotype accounted for 15.8% of controls and only 1.2% of the 
diabetes cohort (P<0.0000, Table 6.6, Fig. 6.3). Conversely the BB genotype 
accounted for 98.8% of diabetes patients and 84.2% of controls (P<0.001). The 
Rs62363106 SNP present on the IL6 gene was the only polymorphism significantly 
associated with pathogenesis on the type 2 diabetes portal (T2D-GENES Consortium, 
2017) (insulin response, Table 6.9), the distribution of this SNP is illustrated in Figure 
6.3.    
 
6.3.2.1.4 Immunity gene related SNPs in T2D 
 
There were 41 SNPs on immune related genes (HGF, CASP3), with different 
prevalence rates in T2D patients compared to controls. In Rs11085808 of HGF (Fig. 
6.4) 100% of controls had the AB genotype while 100% of T2D patients had the BB 
genotype (P<0.0000, Table 6.7). CASP3 was highly polymorphic, 39 SNPs differed 
from control. The most notable were rs114350724 (control, AB 100%; diabetes, BB 
100%; P<0.0000), rs115209861 (control AB 100%; diabetes BB 98.8%; P<0.0000), 
rs117301440 (control AB 94.7%; diabetes AA 99.6; P<0.0000) and rs1718840 (control 
AB 100%; diabetes BB 95.6%; P<0.0000). Eighteen of the 39 SNPs identified in this 
study were linked to pathogenesis on the diabetes portal (T2D-GENES Consortium, 
2017) (Table 6.9), but only rs114350724 has been linked with diabetes onset (Table 










SNP call rate (%) MAF H.W. P value % AA % AB % BB 
Control Diabetes Control Diabetes Control Diabetes Control Diabetes p-value Control Diabetes p-value Control Diabetes p-value 
GLP-1R rs17415505 T C 100 99.6 0.16 0.06 0.41 0.07 0.00 1.30 0.6311 31.60 11.30 0.0099 68.40 87.40 0.0192 
GIPR 
rs10415769 T G 100 99.6 0.32 0.26 0.00 0.08 31.58 8.76 0.0016 0.00 33.86 0.0022 68.42 56.97 0.3298 
rs57462612 T C 100 100 0.24 0.20 0.01 0.30 68.42 63.75 0.4097 15.79 33.47 0.1118 15.79 2.79 0.0038 
INSR rs140868873 A G 100 100 0.03 0.00 
0.91 
1.00 0.00 0.00 \ 5.26 0.00 0.0002 94.74 100 0.0002 
IRS1 
rs13374714 A T 100 99.6 0.50 0.00 0.00 1.00 0.00 0.00 \ 100 0.00 <0.0000 0.00 99.60 <0.0000 
rs200483572 A G 100 99.6 0.03 0.00 0.91 1.00 0.00 0.00 \ 5.25 0.00 0.0003 94.74 99.60 0.1689 
IGFBP2 
rs12786837 T C 100 95.2 0.11 0.02 0.61 0.72 78.95 95.22 0.0037 21.05 4.38 0.0022 0.00 0.00 \ 
rs117029769 T C 100 99.6 0.45 0.01 0.00 0.85 10.53 0.00 <0.0000 89.47 2.39 <0.0000 0.00 97.21 <0.0000 
MAPK1 
rs115587686 T G 100 88.1 0.05 0.19 0.81 0.31 0.00 2.39 0.4955 10.53 29.48 0.0764 89.47 56.18 0.0044 
rs2170185 A G 100 100 0.47 0.34 0.11 0.68 31.58 43.43 0.3138 31.58 45.82 0.2287 36.84 10.76 0.0009 
rs28380311 T C 84.2 100 0.06 0.00 0.79 1.00 0.00 0.00 \ 10.53 0.00 \ 73.68 100 <0.0000 
rs72743421 T C 100 99.6 0.13 0.04 0.51 0.55 73.68 92.43 0.0055 26.32 7.17 0.0039 0.00 0.00 \ 
rs74809741 T C 100 88.1 0.13 0.03 0.18 0.00 5.26 2.39 0.4471 15.79 0.40 <0.0000 78.95 85.26 0.4596 
rs79193319 A G 100 98.8 0.26 0.06 0.71 0.04 5.26 1.20 0.1566 42.11 10.36 <0.0000 52.63 87.25 <0.0000 
rs9276825 A G 100 100 0.45 0.41 0.27 0.15 36.84 14.34 0.0097 36.84 52.59 0.1853 26.32 33.07 0.5448 
MTOR 
rs79267611 T C 100 100 0.08 0.01 0.71 0.82 0.00 0.00 \ 15.79 2.79 0.0038 84.21 97.21 0.0038 
rs35612501 A G 100 98.0 0.13 0.04 0.51 0.53 0.00 0.00 \ 26.32 7.57 0.0056 73.68 90.44 0.0228 
Table 6.2 – SNPs associated with insulin signalling genes in T2D vs. controls. Included is db SNP RS ID, A allele, B allele, SNP call rate, Minor 
Allele Frequency (MAF), Hardy Weinberg (H.W) P value, % AA, %AB, % BB in control and T2D participants in SNPS associated with GLP-1R, 
GIPR, INSR, IRS-1, IGFBP2, MAKP1, MTOR. Control n=19, Diabetes n=254. Significance was determined using a Z-test for proportions. 




Table 6.3 – SNPs associated with insulin signalling genes in T2D vs. controls (continued).  Included is db SNP RS ID, A allele, B allele, SNP call rate, 
Minor Allele Frequency (MAF), Hardy Weinberg (H.W) P value, % AA, %AB, % BB in control and T2D participants in SNPS associated with AKT. 
Control n=19, Diabetes n=254. Significance was determined using a Z-test for proportions. Significant differences in the prevalence of genotypes 
are highlighted in red. Significance was accepted at P<0.05. 
 
 
Gene dbSNP RS ID A allele B allele 
SNP call rate (%) MAF H.W. P value % AA % AB % BB 
Control Diabetes Control Diabetes Control Diabetes Control Diabetes p-value Control Diabetes p-value Control Diabetes p-value 
AKT 
rs6497630 C G 100 100 0.32 0.19 0.04 0.41 36.84 64.94 0.0144 63.16 32.27 0.0062 0.00 2.79 0.4607 
rs72726656 A G 100 100 0.50 0.03 0.00 0.63 0.00 0.00 \ 100 5.98 <0.0000 0.00 94.02 <0.0000 
rs73156841 T C 100 99.6 0.11 0.05 0.05 0.43 84.21 90.04 0.4214 10.53 9.56 0.1375 5.26 0.00 0.0003 
rs73304795 A G 100 100 0.42 0.37 0.01 0.20 31.58 41.04 0.4177 21.05 43.03 0.0607 47.37 15.94 0.0006 
rs74381725 A G 100 99.6 0.11 0.02 0.05 0.70 5.26 0.00 0.0002 10.53 4.78 0.2759 84.21 94.82 0.0587 
rs75709259 A T 94.7 100 0.11 0.01 0.60 0.82 73.68 97.21 <0.0000 21.05 2.79 0.0001 0.00 0.00 \ 
rs76028668 T C 100 99.6 0.11 0.02 0.61 0.77 0.00 0.00 \ 21.05 3.59 0.0006 78.95 96.02 0.0012 
rs76975836 A T 100 99.2 0.16 0.13 0.36 0.02 5.26 0.00 0.0003 21.05 25.10 0.6937 73.68 74.10 0.9679 
rs77182850 T C 94.7 99.6 0.17 0.04 0.40 0.55 0.00 0.00 \ 31.58 7.17 0.0003 63.16 92.43 <0.0000 
rs77369429 A G 100 100 0.05 0.00 0.81 0.97 89.47 99.60 <0.0000 10.53 0.40 <0.0000 0.00 0.00 \ 
rs77709798 A G 100 100 0.08 0.02 0.01 0.75 5.26 0.00 0.0003 5.26 3.98 0.7856 89.47 96.02 0.1818 
rs78307740 A G 100 100 0.16 0.04 0.36 0.27 5.26 0.40 0.0168 21.05 6.77 0.0249 73.68 92.83 0.0039 
rs7907973 A G 100 98.4 0.42 0.26 0.12 0.53 42.11 54.18 0.3087 31.58 36.65 0.6573 26.32 7.57 0.0056 
rs79327580 T C 100 98.0 0.08 0.05 0.71 0.00 0.00 3.98 0.3752 15.79 1.99 0.0006 84.21 92.03 0.2387 
rs7994925 A T 100 99.2 0.39 0.37 0.00 0.28 0.00 15.14 0.0672 78.95 43.03 0.0024 21.05 41.04 0.0859 
rs80124654 T C 100 98.4 0.08 0.01 0.71 0.82 84.21 95.62 0.0304 15.79 2.79 0.0037 0.00 0.00 \ 
rs8192849 A C 31.6 99.6 0.42 0.03 0.08 0.60 0.00 0.00 \ 26.32 6.37 0.0017 5.26 93.23 <0.0000 










SNP call rate (%) MAF H.W. P value % AA % AB % BB 
Control Diabetes Control Diabetes Control Diabetes Control Diabetes p-value Control Diabetes p-value Control Diabetes p-value 
AKT 
rs11038533 T C 100 99.6 0.08 0.05 0.01 0.37 5.26 0.00 0.0002 5.26 10.76 0.4488 89.47 88.84 0.9329 
rs114321579 A G 100 99.6 0.11 0.02 0.61 0.70 78.95 94.82 0.0059 21.05 4.78 0.0037 0.00 0.00 \ 
rs115891681 T C 73.7 96.4 0.46 0.04 0.00 0.29 5.26 0.40 0.0168 68.42 6.77 <0.0000 0.00 89.24 <0.0000 
rs116108356 T C 100 100 0.11 0.01 <0.00 0.85 10.53 0.00 <0.0000 0.00 2.39 0.4955 89.47 97.61 0.0435 
rs116146530 T C 100 100 0.13 0.03 0.51 0.09 0.00 0.40 0.7828 26.32 5.18 0.0003 73.68 94.42 0.0006 
rs116193743 T C 100 99.6 0.11 0.03 0.61 0.67 0.00 0.00 \ 21.05 5.18 0.0060 78.95 94.42 0.0090 
rs116771750 T C 100 99.2 0.05 0.05 0.00 0.42 94.74 89.64 0.7139 0.00 9.56 0.1579 5.26 0.00 0.0003 
rs117945130 A G 100 99.6 0.08 0.03 0.01 0.67 89.47 94.42 0.3781 5.26 5.18 0.9873 5.26 0.00 0.0003 
rs118098404 T C 100 99.6 0.13 0.03 0.18 0.62 78.95 93.63 0.0184 15.79 5.98 0.0980 5.26 0.00 0.0003 
rs118183140 T C 100 100 0.11 0.03 0.61 0.67 0.00 0.00 \ 21.05 5.18 0.0060 78.95 94.82 0.0060 
rs12073329 A G 100 98.4 0.05 0.10 0.81 0.00 0.00 9.56 0.1579 10.53 0.40 <0.0000 89.47 88.45 0.8922 
rs2468774 C G 100 100 0.47 0.26 0.50 0.78 26.32 54.58 0.0173 42.11 39.04 0.7921 31.58 6.37 0.0001 
rs34243925 A G 100 100 0.11 0.05 0.05 0.45 5.26 0.00 0.0003 10.53 9.16 0.8432 84.21 90.84 0.3449 
rs34644046 T G 100 100 0.13 0.05 0.18 0.45 5.26 0.00 0.0003 15.79 9.16 0.3449 78.95 90.84 0.0956 
rs358832 T C 100 97.2 0.18 0.14 0.59 0.01 68.42 70.92 0.8176 26.32 26.29 0.9984 5.26 0.00 0.0002 
Table 6.4 – SNPs associated with insulin signalling genes in T2D vs. controls (Final).  Included is db SNP RS ID, A allele, B allele, SNP call rate, 
Minor Allele Frequency (MAF), Hardy Weinberg (H.W) P value, % AA, %AB, % BB in control and T2D participants in SNPS associated with AKT. 
Control n=19, Diabetes n=254. Significance was determined using a Z-test for proportions. Significant differences in the prevalence of 




















































Figure 6.1 – Cluster analysis for most significant SNPs in insulin signalling related genes. 
GIPR, rs10415769; IRS1, rs13374714; IGFBP2 rs12786837; IGFBP2, rs10415769; MAKP1 
rs2170185; AKT; rs72726656. Control n=19, Diabetes n=254. All cluster diagrams are 






Table 6.5 – SNPs associated with Leptin signalling genes in T2D vs. controls. Included is db SNP RS ID, A allele, B allele, SNP call rate, Minor Allele 
Frequency (MAF), Hardy Weinberg (H.W) P value, % AA, %AB, % BB in control and T2D participants in SNPS associated with LEP-R, POMC, SH2B1, 
STAT3. Control n=19, Diabetes n=254. Significance was determined using a Z-test for proportions. Significant differences in the prevalence of 














SNP call rate 
(%) 



























rs14004 A C 100 100 0.39 0.33 0.00 0.66 0.00 11.55 0.1168 78.95 43.03 0.0024 21.05 45.42 0.0389 
rs9268556 T C 100 100 0.39 0.31 0.00 0.53 21.05 47.81 0.0240 78.95 41.43 0.0015 0.00 10.76 0.1318 
rs72881029 T C 100 100 0.50 0.01 0.00 0.00 0.00 0.40 0.7828 100 1.99 <0.0000 0.00 97.61 <0.0000 
POMC 
rs3934473 A G 100 100 0.05 0.02 0.00 0.70 5.26 0.00 0.0002 0.00 4.78 0.3296 94.74 95.22 0.9245 
rs112365258 A G 100 100 0.08 0.01 0.71 0.85 0.00 0.00 \ 15.79 2.39 0.0017 84.21 97.61 0.0017 
rs116605122 T C 100 100 0.08 0.02 0.71 0.00 0.00 0.40 0.7828 15.79 3.19 0.0073 84.21 96.41 0.0127 
rs10772721 A G 100 99.6 0.11 0.34 0.61 0.59 0.00 10.76 0.1318 21.05 46.22 0.0332 78.95 42.63 0.0021 
SH2B1 No significant SNPs identified 




Table 6.6 – SNPs associated with inflammatory genes in T2D vs. controls. Included is db SNP RS ID, A allele, B allele, SNP call rate, Minor Allele 
Frequency (MAF), Hardy Weinberg (H.W) P value, % AA, %AB, % BB in control and T2D participants in SNPS associated with IL-6, IL-10, IL-1RN, IL-
18. Control n=19, Diabetes n=254. Significance was determined using a Z-test for proportions. Significant differences in the prevalence of 
















SNP call rate 
(%) 
MAF H.W. P value % AA % AB % BB 
Control Diabetes Control Diabetes Control Diabetes Control Diabetes p-value Control Diabetes p-value Control Diabetes p-value 
IL-6 rs62363106 T C 100 100 0.05 0.01 0.81 0.92 89.47 98.80 0.0036 10.53 1.20 0.0036 0.00 0.00 \ 
IL-10 rs117999816 T C 100 100 0.05 0.01 0.81 0.92 0.00 0.00 \ 10.53 1.20 0.0036 89.47 98.80 0.0036 
IL-1RN 
rs61875109 A C 100 99.6 0.42 0.22 0.55 0.80 21.05 5.18 0.0059 42.11 33.86 0.4659 36.84 60.56 0.0427 
rs146196345 T G 100 99.6 0.08 0.02 0.01 0.70 5.26 0.00 0.0003 5.26 4.78 0.9245 89.47 94.82 0.3263 
rs79653684 A G 100 100 0.08 0.01 0.71 0.92 0.00 0.00 \ 15.79 1.20 <0.0000 84.21 98.80 <0.0000 
rs4823900 T C 89.47 99.6 0.03 0.01 0.90 0.92 0.00 0.00 \ 5.26 1.20 0.1566 84.21 98.41 0.0002 
IL-18 
 
rs71326432 T C 100 81.67 0.03 0.20 0.91 0.00 94.74 57.37 0.0013 5.26 15.94 0.2113 0.00 8.37 0.1892 





































Figure 6.2 – Cluster analysis for defined SNPs of leptin signalling related genes. LEPR 
rs72881029; POMC rs3934473. All cluster diagrams are plotted on an X axis log scale, Y 
axis strength scale.           
 
Figure 6.3 – Cluster analysis for defined SNPs of inflammatory signalling related genes. 
IL6 rs62363106; IL-1RN rs79653684. All cluster diagrams are plotted on an X axis log 





Table 6.7 – SNPs associated with immunity related genes in T2D vs. controls. Included is db SNP RS ID, A allele, B allele, SNP call rate, Minor 
Allele Frequency (MAF), Hardy Weinberg (H.W) P value, % AA, %AB, % BB in control and T2D participants in SNPS associated with HGF and CASP3. 
Control n=19, Diabetes n=254. Significance was determined using a Z-test for proportions, significant differences in the prevalence of genotypes 








SNP call rate 
(%) 
MAF H.W. P value % AA % AB % BB 
Control Diabetes Control Diabetes Control Diabetes Control Diabetes p-value Control Diabetes p-value Control Diabetes p-value 
HGF 
 
rs62149753 A C 100 100 0.11 0.06 0.05 0.30 5.26 0.00 0.0003 10.53 12.35 0.8148 84.21 87.65 0.6629 
rs11085808 T C 100 100 0.50 0.00 0.00 1.00 0.00 0.00 \ 100 0.00 <0.0000 0.00 100 0.0000 
CASP3 
rs114350724 T C 100 100 0.50 0.00 0.00 1.00 0.00 0.00 \ 100 0.00 <0.0000 0.00 100 <0.0000 
rs115209861 T C 100 99.6 0.50 0.00 0.00 0.95 0.00 0.00 \ 100 0.80 <0.0000 0.00 98.80 <0.0000 
rs116910946 A G 73.68 99.6 0.00 0.00 1.00 1.00 0.00 0.00 \ 0.00 0.00 \ 73.68 99.60 <0.0000 
rs117172277 A G 63.16 99.6 0.46 0.08 0.54 0.19 10.53 84.46 <0.0000 36.84 15.14 0.0143 15.79 0.00 <0.0000 
rs117264186 T C 100 100 0.18 0.05 0.04 0.45 10.53 0.00 <0.0000 15.79 9.16 0.3450 73.68 90.84 0.0180 
rs117301440 A G 100 99.6 0.47 0.00 0.00 1.00 5.26 99.60 <0.0000 94.74 0.00 <0.0000 0.00 0.00 \ 
rs117416733 T C 63.16 100 0.13 0.04 0.62 0.47 0.00 0.00 \ 15.79 8.76 0.3082 47.37 91.24 <0.0000 
rs117450330 T C 100 99.6 0.08 0.02 0.71 0.80 84.21 96.41 0.0127 15.79 3.19 0.0073 0.00 0.00 \ 
rs117651071 T C 100 100 0.11 0.02 0.00 0.72 10.53 0.00 <0.0000 0.00 4.38 0.3515 89.47 95.62 0.2275 
rs117733754 T C 94.74 97.61 0.47 0.03 0.00 0.67 5.26 0.00 0.0003 89.47 5.18 <0.0000 0.00 92.43 <0.0000 
rs117871273 A G 100 100 0.11 0.02 0.61 0.70 78.95 95.22 0.0037 21.05 4.78 0.0037 0.00 0.00 \ 
rs1227518 A G 100 99.6 0.32 0.18 0.00 0.09 31.58 4.78 <0.0000 0.00 26.29 0.0101 68.42 68.53 0.9924 
rs12938916 A G 100 100 0.16 0.08 0.00 0.67 15.79 0.80 <0.0000 0.00 13.94 0.0810 84.21 85.26 0.9013 
rs13121941 T C 89.47 100 0.29 0.30 0.00 0.23 26.32 10.76 0.0429 0.00 39.04 0.0006 63.16 50.20 0.2758 
rs140868873 A G 100 100 0.03 0.00 0.91 1.00 0.00 0.00 \ 5.26 0.00 0.0003 94.74 100 0.0003 
rs148687847 C G 100 100 0.45 0.12 0.00 0.34 0.00 76.89 <0.0000 89.47 22.31 <0.0000 10.53 0.80 0.0007 
rs1695 A G 100 99.6 0.42 0.37 0.00 0.83 52.63 39.84 0.2738 10.53 45.82 0.0028 36.84 13.94 0.0079 
rs17056659 A G 100 99.6 0.08 0.05 0.01 0.43 5.26 0.00 0.0003 5.26 9.56 0.5330 89.47 90.04 0.9368 
rs1718840 A G 100 100 0.50 0.03 0.00 0.00 0.00 0.80 0.6961 100 3.59 <0.0000 0.00 95.62 <0.0000 




Table 6.8 – SNPs associated with immunity related genes in T2D vs. controls (Final). Included is db SNP RS ID, A allele, B allele, SNP call rate, 
Minor Allele Frequency (MAF), Hardy Weinberg (H.W) P value, % AA, %AB, % BB in control and T2D participants in SNPS associated with CASP3, 
HAVCR1 and SORT1. Control n=19, Diabetes n=254. Significance was determined using a Z-test for proportions. Significant differences in the 








SNP call rate 
(%) 
MAF H.W. P value % AA % AB % BB 
Control Diabetes Control Diabetes Control Diabetes Control Diabetes p-value Control Diabetes p-value Control Diabetes p-value 
CASP3 
rs4382459 T C 100 100 0.21 0.13 0.11 0.50 10.53 1.20 0.0036 21.05 23.51 0.8074 68.42 75.30 0.5053 
rs55690953 T C 100 81.67 0.05 0.23 0.81 0.33 0.00 5.18 0.3093 10.53 26.69 0.1192 89.47 49.80 0.0008 
rs56059137 A G 100 99.6 0.00 0.00 1.00 1.00 0.00 0.00 \ 0.00 0.00 \ 1000 9.60 <0.0000 
rs56259105 T C 100 99.6 0.26 0.15 0.42 0.21 57.89 71.31 0.2166 31.58 27.09 0.6723 10.53 1.20 0.0036 
rs56324835 T C 100 99.6 0.11 0.07 0.05 0.25 5.26 0.00 0.0003 10.53 13.55 0.7089 84.21 86.06 0.8235 
rs5771096 T C 100 99.6 0.05 0.21 0.81 0.00 0.00 20.72 0.0272 10.53 0.40 <0.0000 89.47 78.49 0.2546 
rs62411887 T C 94.74 100 0.17 0.07 0.01 0.88 10.53 0.40 0.0000 10.53 12.75 0.7782 73.68 86.85 0.1113 
rs649628 T C 100 99.6 0.08 0.06 0.01 0.28 5.26 0.00 0.0003 5.26 12.75 0.3367 89.47 86.85 0.7429 
rs6831849 A C 100 100 0.05 0.01 0.81 0.92 89.47 98.80 0.0036 10.53 1.20 0.0036 0.00 0.00 \ 
rs72826199 T C 94.74 99.6 0.06 0.01 0.00 0.90 5.26 0.00 0.0003 0.00 1.59 0.5793 89.47 98.01 0.0239 
rs72829254 T C 47.37 99.6 0.44 0.03 0.76 0.17 10.53 0.40 <0.0000 21.05 5.98 0.0132 15.79 93.23 <0.0000 
rs75943855 A C 63.16 100 0.33 0.02 0.08 0.75 0.00 0.00 \ 42.11 3.98 0.0000 21.05 96.02 <0.0000 
rs76975836 A T 100 99.2 0.16 0.13 0.36 0.02 5.26 0.00 0.0003 21.05 25.10 0.6937 73.68 74.10 0.9679 
rs77037706 A G 84.21 99.6 0.03 0.01 0.90 0.00 0.00 0.40 0.7828 5.26 1.99 0.3507 78.95 97.21 0.0001 
rs77588920 T C 100 94.02 0.05 0.00 0.81 0.95 0.00 0.00 \ 10.53 0.80 0.0007 89.47 93.23 0.5372 
rs7818461 C G 100 99.2 0.11 0.03 0.61 0.67 78.95 94.02 0.0132 21.05 5.18 0.0060 0.00 0.00 \ 
rs7907973 A G 100 98.41 0.42 0.26 0.12 0.53 42.11 54.18 0.3088 31.58 36.65 0.6573 26.32 7.57 0.0056 
rs79139872 T C 100 100 0.11 0.01 0.05 0.85 5.26 0.00 0.0003 10.53 2.39 0.0435 84.21 97.61 0.0017 
rs79250505 A G 100 100 0.18 0.06 0.32 0.04 0.00 1.20 0.6318 36.84 10.36 0.0007 63.16 88.45 0.0018 
HAVCR1 No significant SNPs identified 







































Figure 6.4 – Cluster analysis for defined SNPs of immune related genes. HGF 
rs11085808; CASP3; rs114350742. All cluster diagrams are plotted on an X axis log scale, 




6.3.2.2 Previous association of identified SNPs in the Type 2 Diabetes 
Knowledge Portal  
 
Gene dbSNP RS ID P-Value Association 
Insulin signalling genes 
GIPR rs10415769 <0.0000 Lipid metabolism 
IGFBP2 rs12786837 <0.05 Diabetes onset 
MAPK1 
rs115587686 <0.05 Lipid / Diabetes onset 
rs2170185 <0.05 Creatine metabolism 
rs9276825 <0.05 Lipid metabolism 
AKT 
rs11038533 <0.05 weight gain 
rs12073329 <0.001 increases adiposity 
rs7994925 <0.001 Proinsulin, triglycerides 
rs2468774 <0.05 Diabetes onset 
rs116108356 <0.05 Diabetes onset 
rs72726656 <0.05 Diabetes onset 
rs80124654 <0.05 Diabetes onset 
rs74381725 <0.05 Insulin sensitivity 
rs8192849 <0.001 Hba1c, insulin sensitivity 
Leptin signalling genes 
LEP-R 
rs14004 <0.0000 Adiposity, T2D, BMI 
rs9268556 <0.0000 Adiposity, T2D, BMI 
POMC 
rs3934473 <0.05 BMI 
rs112365258 <0.05 BMI 
Inflammation related genes 
IL6 rs62363106 <0.05 Insulin response 
Immune related genes 
CASP3 
rs114350724 <0.05 Diabetes onset 
rs117416733 <0.001 Insulin sensitivity 
rs117733754 <0.001 Insulin sensitivity 
rs117871273 <0.05 Diabetes onset 
rs1227518 <0.001 Height, weight, Hba1c 
rs12938916 <0.01 Adiposity 
rs148687847 <0.001 T2D, BMI 
rs1695 <0.001 Lipid metabolism 
rs17056659 <0.05 Adiposity 
rs3733344 <0.0001 Insulin response 
rs4382459 <0.05 T2D Schizophrenia 
rs55690953 <0.05 Heart disease 
rs56059137 <0.01 BMI, lipids 
rs56259105 <0.05 Heart disease 
rs62411887 <0.05 Diabetes onset 
rs6831849 <0.01 BMI 
rs77037706 <0.001 Heart disease 
rs7818461 <0.001 Diabetes onset 
 
Table 6.9 – SNPs identified on type 2 diabetes portal and associations related to T2D. Table 
includes all SNPs from current analysis that are reported on the type 2 diabetes portal (T2D-
GENES Consortium, 2017). Association is highest ranking trait from GWAS studies. P-value 
represents probability that the observed frequency could occur by chance. Table includes 
SNPS from insulin, leptin, inflammation and immune related genes.   
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6.3.3.1 SNPs associated with response to GLP-1 analogue therapy 
 
There were 25 SNPs that had a significantly different prevalence in patients that 
responded to GLP-1 analogues and had a HbA1c of <54 mmol/mol compared to ‘non-
responders’ who had a HbA1c of >65 mmol/mol. The characteristics of all significant 
SNPs are displayed in Tables 6.10 – 14, with cluster diagrams of 8 most significantly 
altered SNPs visualised graphically in Figures 6.5-8. Tables detail gene name 
abbreviation, Reference SNP cluster ID (RS number), Allele A and B, SNP call rate, 
Minor Allele Frequency (MAF) score and Hardy-Weinberg P value.  
 
6.3.3.1.1 Insulin signalling related SNPs associated with response to GLP-1 
analogue therapy: a GLP-1 polymorphism is highly significantly associated 
with response to therapy 
 
Table 6.10 illustrates 15 insulin related SNPs with significantly different prevalence in 
GLP-1Ra responders and non-responders. SNPS associated with GLP-1R, GIPR, INSR, 
IRS-1, IGFBP-2, MAP-K, MTOR and AKT are listed in Table 6.10. The GLP-1R had one 
SNP associated with response. In Rs71480142 the AB genotype was prevalent in non-
responders (>65 mmol/mol, 95.5%, P<0.0000) while the BB allele was prevalent in 
responders (<53 mmol/mol, 87.7%, P<0.0000). This cluster diagram for this SNP is 
illustrated in Figure 6.5. Rs115516351 (MTOR) was also highly distinctive between 
responders and non-responders. The AA allele combination was 100% associated 
with responders (P<0.0000), while the BB allele was linked with non-responders 
(63.6%, P<0.0000, Fig. 6.5). It is worth noting that the call rate for Rs115516351 in 




AKT had two noteworthy SNPs. Rs7952176 showed differential prevalence levels 
dependent on GLP-1Ra response. Responders typically had an AB genotype (61.9%. 
vs. 27.3%, P<0.05), while non-responders usually had the BB genotype (72.7% vs, 
33.3% P<0.01, Table 6.10). In Rs8192849 low AA and AB genotype prevalence was 
documented, and 90.91% of non-responders had the BB genotype while only 19.05% 
of responders were BB (P<0.0000). Call rate in non-responders, however, was 33.3% 
which may account for the difference observed in this SNP. Rs8192849 has been 
strongly correlated with HbA1c and insulin sensitivity on the type 2 diabetes portal 
(T2D-GENES Consortium, 2017) (Table 6.14), and cluster diagram of genotypes in 
responders and non-responders is illustrated in Figure 6.5. INSR, IGFBP2 and MAPK1 
did not express any SNPs that differed between responders and non-responders.    
 
6.3.3.1.2 Leptin signalling related SNPs associated with response to GLP-1 
analogue therapy 
 
Table 6.11 shows 3 SNPs associated with leptin signalling genes. In Rs72881029 of 
the LEP-R the AB genotype was 100% prevalent in responders and 40.9% in non-
responders. In Rs12410054 of POMC prevalence levels are significantly different, no 
responders had the BB genotype while 31.8% of non-responders were BB (P<0.01). 
Rs12410054 is identified on the type 2 diabetes portal (T2D-GENES Consortium, 
2017) as having a significant effect on adiposity (Table 6.14). Rs72881029 and 
Rs12410054 genotype cluster diagrams are illustrated in Figure 6.6. SH2B1 and 
STAT3 did not express any SNPs that differed significantly between groups.    
 
6.3.3.1.3 Inflammatory gene related SNPs associated with response to 
GLP-1 analogue therapy 
 
There were 2 SNPs identified on inflammatory related genes that differed between 
responders and non-responders (Table 6.12). Rs184477 of IL-6 was more prevalent 
as the AA genotype in responders vs. non-responders (90.5% vs. 54.6%, P<0.01), and 
as a AB genotype in non-responders (45.5% v 9.5%, P<0.01). The prevalence of each 




6.3.3.1.4 Immunity gene related SNPs associated with response to GLP-1 
analogue therapy 
 
Rs2228591 on the CASP3 gene was the only SNP identified to be significantly 
associated with GLP-1 analogue response. The AB genotype was significantly 
associated with responders (27.6% v 0%, P<0.01), while the AA genotype was 
associated with 100% of non-responders compared to 71.4% of responders (P<0.01). 
These genotype clusters can be seen in Figure 6.8. Rs2228591 has been linked to 























Table 6.10 – SNPs associated with insulin signalling genes in GLP-1 analogue responders and non-responders. Included is db SNP RS ID, A allele, 
B allele, SNP call rate, Minor Allele Frequency (MAF), Hardy Weinberg (H.W) P value, % AA, %AB, % BB in GLP-1R, GIPR, INSR, IRS-1, IGFBP2, 
MAKP1, MTOR. Responders (HbA1c <53.9) n=21. Non-responders (HbA1c >65) n=22. Significance was determined using a Z-test for proportions. 













% AA % AB % BB 
<53.9 >65 <53.9 >65 <53.9 >65 <53.9 >65 p-value <53.9 >65 p-value <53.9 >65 p-value 
GLP-1R rs71480142 A G 100 95.5 0.07 0.50 0.72 0.00 0 0 \ 14.29 95.45 <0.0000 85.71 0 <0.0000 
GIPR 
rs4941804 A G 100 100 0.36 0.43 0.03 0.07 23.81 9.09 0.1913 23.81 68.18 0.0035 52.38 22.73 0.0443 
rs6864090 A G 100 100 0.50 0.20 0.83 0.92 23.81 63.64 0.0086 52.38 31.82 0.1719 23.81 4.55 0.0684 
IRS1 rs77857696 A G 71.4 100 0.07 0.00 0.78 1.00 61.90 100 0.0013 9.52 0.00 0.1382 0.00 0.00 \ 
MTOR rs115516351 T G 100 77.3 0.00 0.41 1.00 0.00 100 13.64 <0.0000 0.00 63.64 <0.0000 0.00 0.00 \ 
INSR No significant SNPs identified 
IGFBP2 No significant SNPs identified 
MAPK1 No significant SNPs identified 
AKT 
  - T 71.4 59.1 0.50 0.04 0.00 0.89 0.00 54.55 <0.0000 71.43 4.55 <0.0000 0.00 0.00 \ 
rs6552231 T C 81.0 100 0.12 0.00 0.58 1.00 61.90 100 0.0013 19.05 0.00 0.0316 0.00 0.00 \ 
rs11261052 C G 100 100 0.00 0.18 1.00 0.30 0.00 0.00 \ 0.00 36.36 0.0022 100 63.64 0.0022 
rs8192849 A C 33.3 100 0.29 0.05 0.43 0.82 4.76 0.00 0.3004 9.52 9.09 0.9610 19.05 90.91 <0.0000 
rs4789687 A G 100 95.5 0.29 0.48 0.45 0.00 4.76 4.55 0.9731 47.62 81.82 0.0187 47.62 9.09 0.0049 
rs250101 A G 100 95.5 0.21 0.48 0.96 0.51 4.76 18.18 0.1700 33.33 54.55 0.1615 61.90 22.73 0.0092 
rs7952176 A G 100 100 0.36 0.14 0.11 0.46 4.76 0.00 0.3004 61.90 27.27 0.0223 33.33 72.73 0.0096 
rs425774 A G 100 100 0.45 0.16 0.79 0.48 19.05 72.73 0.0004 52.38 22.73 0.0443 28.57 4.55 0.0329 
rs6864090 A G 100 100 0.50 0.20 0.83 0.92 23.81 63.64 0.0086 52.38 31.82 0.1719 23.81 4.55 0.0684 













Figure 6.5 – Cluster analysis for most significant insulin signalling related SNPs in 
GLP-1 analogue responders and non-responders. GLP1-R rs71480142; MTOR 
rs115516351; AKT rs8192849; AKT; rs795`2176. Responders (HbA1c <53.9) n=22. 
Non-responders (HbA1c >65) n=21. All cluster diagrams are plotted on an X axis log 
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Table 6.11 – SNPs associated with leptin signalling genes in GLP-1 analogue responders and non-responders. Included is db SNP RS ID, A allele, B 
allele, SNP call rate, Minor Allele Frequency (MAF), Hardy Weinberg (H.W) P value, % AA, %AB, % BB in LEP-R, POMC, SH2B1, STAT3. Responders 
(HbA1c <53.9) n=21. Non-responders (HbA1c >65) n=22. Significance was determined using a Z-test for proportions. Significant differences in the 











SNP call rate (%) MAF H.W. P value % AA % AB % BB 
<53.9 >65 <53.9 >65 <53.9 >65 <53.9 >65 p-value <53.9 >65 p-value <53.9 >65 p-value 
LEP-R rs72881029 T C 100 50 0.50 0.41 0.00 0.02 0.00 0.00 \ 100 40.91 <0.0000 0.00 9.09 0.1571 
POMC rs1281146 A G 85.71 100 0.08 0.00 0.70 1.00 0.00 0.00 \ 14.29 0.00 0.0660 71.43 1000 0.0069 
POMC rs12410054 A G 100 100 0.05 0.16 0.00 0.37 4.76 0.00 0.3004 0.00 31.82 0.0047 95.24 68.18 0.0227 
SH2B1 No significant SNPs identified 








SNP call rate (%) MAF 
H.W. P 
value 
% AA % AB % BB 
<53.9 >65 <53.9 >65 <53.9 >65 <53.9 >65 p-value <53.9 >65 p-value <53.9 >65 p-value 
IL6 rs184477 A G 100 100 0.05 0.23 0.82 0.17 90.48 54.55 0.0086 9.52 45.45 0.0086 0.00 0.00 \ 
IL18 rs74782463 A G 100 100 0.17 0.00 0.51 1.00 71.43 100 0.0069 23.81 0.00 0.0149 4.76 0.00 0.3004 
IL10 No significant SNPs identified 
IL-1RN No significant SNPs identified  
Table 6.12 – SNPs associated with inflammatory genes in GLP-1 analogue responders and non-responders. Included is db SNP RS ID, A allele, B 
allele, SNP call rate, Minor Allele Frequency (MAF), Hardy Weinberg (H.W) P value, % AA, %AB, % BB in IL6, IL18, IL10, IL-1RN. Responders (HbA1c 
<53.9) n=21. Non-responders (HbA1c >65) n=22. Significance was determined using a Z-test for proportions. Significant differences in the 



















Figure 6.7 – Clustering of genotypes of rs184477 of IL-6 between GLP-1 analogue 
responders and non-responders. Cluster diagrams are plotted on an X axis log scale, 
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Figure 6.6 – Cluster analysis for most significant leptin signalling related SNPS in GLP-1 
analogue responders and non-responders. LEPR rs72881029; POMC rs12410054. All cluster 








Table 6.13 – SNPs associated with immunity related genes in GLP-1 analogue responders and non-responders. Included is db SNP RS ID, A allele, 
B allele, SNP call rate, Minor Allele Frequency (MAF), Hardy Weinberg (H.W) P value, % AA, %AB, % BB in SNPs within CASP3, HGF, HAVCR1, 
SORT1. Responders (HbA1c <53.9) n=21. Non-responders (HbA1c >65) n=22. Significance was determined using a Z-test for proportions. Significant 
















% AA % AB % BB 
<53.9 >65 <53.9 >65 <53.9 >65 <53.9 >65 p-value <53.9 >65 p-value <53.9 >65 p-value 
CASP3 
 
rs2228591 C G 100 100 0.14 0.00 0.45 1.00 71.43 1000 0.0069 28.57 0.00 0.0069 0.00 0.00 \ 
rs250101 A G 100 95.45 0.21 0.48 0.96 0.51 4.76 18.18 0.1700 33.33 54.55 0.1615 61.90 22.73 0.0092 
rs7746807 A C 100 100 0.36 0.41 0.11 0.24 33.33 22.73 0.4383 61.90 36.36 0.0940 4.76 40.91 0.0050 
rs56259105 T C 100 100 0.10 0.27 0.04 0.08 85.71 45.45 0.0056 9.52 54.55 0.0016 4.76 0.00 0.3004 
rs1997035 T C 100 100 0.40 0.43 0.00 0.93 0.00 31.82 0.0047 80.95 50.00 0.0333 19.05 18.18 0.9419 
HGF No Significant SNPs identified 
HAVCR1 No Significant SNPs identified 






Figure 6.8 – Cluster analysis for CASP3 rs2228591 in GLP-1 analogue responders 
and non-responders. Cluster diagrams are plotted on an X axis log scale, Y axis 
strength scale.       
     
6.3.3.2 Previous association of identified SNPs in the Type 2 Diabetes 














Table 6.14 – Associations linked with insulin related SNPs in GLP-1Ra responders 
and non-responders. Table includes all SNPs from current analysis that have a 
defined function on the type 2 diabetes portal. Association is highest ranking trait 
from GWAS studies. P-value represents probability that the observed frequency 
could occur by chance. SNPS from insulin, leptin, and immune related genes were 
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Insulin Signalling genes 
AKT 
rs250101 <0.05 Diabetes onset 
rs8192849 <0.001 HbA1c, insulin sensitivity 
rs11261052 <0.05 Insulin sensitivity 
rs6552231 <0.01 Lipid metabolism 
Leptin Signalling genes 
POMC rs12410054 <0.001 Adiposity 
Immunity related genes 
CASP3 
rs2228591 <0.001 Weight, BMI 
rs250101 <0.001 Diabetes onset 
rs7746807 <0.0001 Height, lipids 
rs56259105 <0.001 Heart disease 
rs1997035 <0.001 Adiposity 
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6.4 Discussion  
 
In the present study, informed by previous work (Chapter 3, 5), and the literature 
(Valentinis and Baserga, 2001, Zhao et al., 2012) we analysed 20 genes associated 
with T2D and GLP-1R agonist action. A total of 2489 SNPs were screened across the 
20 genes. One hundred and five SNPs were significantly different in those with T2D 
compared to controls, while we identified 25 SNPs associated with response to GLP-
1 analogue therapy. This study demonstrated that genetic alterations in insulin and 
leptin genes are characteristic of T2D and response to GLP-1 analogue therapy and 
suggests that drug response may be predicted in this drug class.  
There were eight insulin signalling related genes analysed; results indicated 
IRS1, IGFBP2 and AKT were most polymorphic and exhibited the highest degree of 
differentiation between T2D and controls. IRS1 is known to play a key role in the 
insulin stimulated PI3K pathway (Dong et al., 2006), and alterations in this gene have 
been linked to major impairments in insulin action (Li et al., 2016). A north American 
study reported SNPs present on the IRS1 gene may cause inflammation and oxidative 
DNA damage, negatively affecting the ability of IRS1 to bind to the insulin receptor 
(Feng et al., 2013b). The SNPs identified in this study are not present in the literature 
and will be validated in secondary cohorts within the UK and Europe.  
There were two SNPs on IGFBP2 indicative of diabetes. IGFBP2 is known to 
interact with IRS1 (Lavin et al., 2016). Low protein levels can affect IGF and IRS1 
bioavailability (Grimberg et al., 2006), which is necessary to potentiate the PI3K 
pathway and its downstream target AKT (Guo, 2014). IGFBP2 also has a close 
relationship with appetite regulatory hormone, leptin (Hedbacker et al., 2010). 
Clinical studies have shown that IGFBP2 increases weight loss, ameliorating T2D 
(Holden et al., 2009). Recent preclinical studies have shown that leptin increases 
IGFBP2 to regulate plasma insulin and glucose concentrations (Hedbacker et al., 
2010). Two polymorphisms in IGFBP2, rs9341105 and rs7603372, have been linked 
to long term weight loss and reduced plasma glucose levels in Caucasians, and were 
validated in large cohorts (n= 991) in the UK (Narayanan, 2013).  
IRS and IGF protein signalling converges on AKT to mediate various 
insulinotrophic actions (Shpakov, 2014). AKT was the most polymorphic gene 
236 
 
screened in this study, with many SNPs that are indicative of T2D (n=33). Other 
studies have shown AKT to be highly polymorphic (Matsubara et al., 2001), but few 
SNPs have been linked to T2D pathogenesis (Sun et al., 2011). A recent, small study 
in Asia showed that the presence of two SNPs on AKT, rs2494746 and rs2494738, 
impacted the PI3K/AKT/mTOR pathway, likely contributing to the progression of T2D 
(Yin et al., 2017). These were not identified in the current work. The importance of 
AKT signalling for healthy glucose metabolism is well established (Elghazi et al., 
2006). It is likely that genetic variation on the AKT pathway, affects diabetes 
progression. Screening these genes may be useful in patient risk stratification.  
In recent years leptin has become a promising target for treating obesity (Cui 
et al., 2017), diabetes (Iepsen et al., 2015a), and brain insulin resistance (Greco et al., 
2009). The present study identified three SNPs on the LEP-R and four SNPs on its 
downstream target POMC (De Jonghe et al., 2012) that are characteristic of T2D in 
this cohort that have not previously been reported. Other studies have 
demonstrated that SNPs on the LEP-R can affect BMI and lipid metabolism (Park et 
al., 2006a), while SNPs on the POMC gene have been shown to alter obesity traits 
(rs1009388, rs1866146) (Sutton et al., 2005). The exact physiological effect of the 
SNPs identified in this study is unknown. It is likely that they are genetic contributors 
of obesity and diabetes, and are promising candidates for further validation 
experiments.  
Inflammation is a characteristic of both diabetes and obesity (Wellen and 
Hotamisligil, 2005) and is a main cause of insulin resistance (Cefalu, 2009). Pro-
inflammatory cytokines negatively influence leptin and insulin signalling. There were 
four pro-inflammatory mediators IL-6 (1 SNP), IL10 (1 SNP), IL-1RN (4 SNPs) and IL18, 
(2 SNPs) analysed and 8 SNPs identified as having a significantly different prevalence 
in T2D. IL-6 is an established marker of insulin resistance in diabetes (Allen and 
Febbraio, 2010), but large meta-analysis (n=5383) have failed to link reported IL-6 
polymorphisms (rs2069827, rs1800797, rs1800795) to diabetes risk or circulating IL-
6 levels (Qi et al., 2006). The SNP identified in this study is novel, and there have not 
been any mechanistic studies to elucidate its effect. Recent studies have focused on 
correlating SNP-SNP interactions across multiple genes to account for disease 
progression with respect to inflammation (Murk and DeWan, 2016) as many 
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cytokines have tissue specific expression profiles (Kim et al., 2017). In T2D results 
have indicated that interplay between IL-6, TNFα and IL-10 exists; a combination of 
SNPs across these genes greatly increases diabetes risk and associated pathogenesis 
(Saxena et al., 2013). It is possible that the cytokines and SNPs identified in this study 
interact to affect disease progression, but further analysis will be required to support 
this suggestion.  
Caspase 3 (CASP3) was the most polymorphic immune related gene screened 
in this study, 39 SNPs were found to be different in T2D vs. controls indicative of a 
significant role in T2D pathogenesis. CASP3 is known to be involved in apoptotic cell 
death and β-cell loss in T2D (Mathis et al., 2001), and increased IL-6 has been linked 
to elevated CASP3 (Jin et al., 2016). There are few studies linking CASP3 SNPs to 
diabetes, but a large body of work implicates this gene in cancer progression (Chen 
et al., 2008) and other autoimmune disease (Onouchi, 2017). This data suggests it 
should be considered in future SNP analyses in T2D. 
The 20 genes analysed in the present study are highly polymorphic and a 
number of SNPs were significantly associated with T2D. As GLP-1 analogues affect 
insulin and leptin signalling, inflammation and the immune response we 
hypothesised that polymorphisms in genes associated with these processes may be 
associated with response and non-response to GLP-1 analogue therapy. 
Polymorphisms were found on both the GIP and GLP-1 receptors. Studies have 
shown that activation of each receptor can have glucose and lipid regulating effects 
(Kazafeos, 2011), and recent work has indicated how dual functionality results in a 
greater incretin effect than any single activation (Skow et al., 2016). Whether the 
genetic variation in the GIPR interacts with the GLP-1R is unknown. The one SNP on 
the GLP-1R (rs71480142) was highly significantly associated with response to 
therapy. The BB genotype (GG) was prevalent exclusively in responders. This novel 
finding will be replicated in secondary cohorts, but is suggestive that it may be 
possible to predict response to therapy utilising SNP genotyping.  
Rs115516351 on the MTOR gene was different in responders and non-
responders. GLP-1 can activate the IRS/ AKT / MTOR pathway to increase β-cell 
growth and viability (Park et al., 2006b). It is thought SNPs on the MTOR gene 
negatively affect this process, impacting the long term effects of GLP-1 on islet 
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function (Van de Velde et al., 2011). Currently Rs115516351 is not linked with 
diabetes pathogenesis, in the literature or on the type 2 diabetes knowledge portal 
(T2D-GENES Consortium, 2017). The only evidence of polymorphisms on MTOR with 
clinical impact were reported in a recent small study (n=134), which specified two 
SNPs (rs7212142, and rs9674559) as being strongly correlated with nephropathy 
(Zhu et al., 2015). Although not conclusive, this study demonstrated that MTOR 
alterations may affect diabetes outcome. 
Rs72881029 (LEP-R) was the only SNP in this study that was noteworthy in 
both T2D versus controls, and GLP-1Ra responders versus non-responders. This 
highlights the importance of leptin signalling in both T2D and GLP-1 analogue drug 
response. All control patients had the AB genotype and 97.6% of T2D patients had 
the BB genotype. GLP-1Ra responders were also 100% positive for the AB genotype, 
whereas 40% of non-responders were AB. Chapter 3 and studies in the literature 
have reported that leptin signalling may have insulin sensitising effects (Duan et al., 
2004). It is possible that this SNP impacts T2D and GLP-1Ra response. More work is 
warranted in this area. 
CASP3 was highly polymorphic and rs2228591 was one of the most 
interesting SNPs on this gene. The AA genotype (CC) was 100% prevalent in non-
responders, while responders were split between the AA and the AB genotypes, 
71.4% and 28.6% respectively. Although this gene is usually associated with cell 
death and β-cell dysfunction (Liadis et al., 2005), rs2228591 has been linked with 
increased BMI and weight on the type 2 diabetes knowledge portal (T2D-GENES 
Consortium, 2017).  
This studies main limitation is sample size, particularly for controls. 
Recruitment is ongoing and validation will be completed in larger sample sets. Due 
to well documented differences in ethnicity and geographical genotypes (T2D-GENES 
Consortium, 2017), validation in other cohorts would be valuable. Further 
multivariate analysis would also provide key insights in terms to gene-gene and SNP-
SNP interactions.     
In conclusion we have analysed 2489 SNPs across 20 genes associated with 
insulin and leptin signalling, and defined that many SNPs were associated with T2D 
generally and with response to GLP-1 analogues in a Northern Irish type 2 diabetes 
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population. Many of the SNPs identified are supported by findings on the type 2 
diabetes portal (T2D-GENES Consortium, 2017) and within the literature. Some are 
also novel and suggestive that treatment response to GLP-1 analogues may be 
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Abstract   
 
Type II diabetes (T2D) is a significant socioeconomic burden, with many long term 
complications that are now known to include depression and cognitive dysfunction. 
Clinically GLP-1Ras are an effective glycaemic and weight reducing therapy, and 
preclinically have been shown to improve memory and learning. This study aimed to 
assess the effect of GLP-1Ras on cognition, depression and anxiety in T2D patients. 
SMMSE and qMCI assessments, and Beck depression and anxiety inventories were 
used, and common biochemical measures including BMI, HbA1c and FBC taken for 
correlation analysis. Non diabetes controls (n=19, 47% male), diabetes controls (GLP-
1Ra naïve; n=13, 62% male), T2D GLP-1Ra responders (n=22, 59% male) and non-
responders (n=15, 80% male) were included.  
GLP-1Ra non-responders had a higher HbA1c than responders (P<0.01). Non-
responders, specifically, were on more anti-diabetes medications (P<0.05), and had a 
lower neutrophil count (P<0.05) than diabetes controls. They also had the highest 
percentage of cardiovascular (23%, P<0.01) related comorbidity. Non-responders 
were the only group to score higher (P<0.05) than controls in depression and anxiety 
tests. Cognitive dysfunction was more prevalent in non-responders; memory and 
perception scores were lower in non-responders compared to responders in the 
SMMSE (P<0.0001). In the qMCI, non-responders scored lower in delayed recall 
(P<0.05) and logical memory (P<0.05) domains compared to non-diabetes controls. 
Significant correlation between BMI and depression scores was observed (R=0.22, 
P=0.02) and qMCI, but not SMMSE, was significantly correlated with HbA1c (R=-0.53, 
P<0.0001). Neutrophil number was highly significantly positively correlated with 
both depression (R=0.27, P<0.0001), and anxiety (R=0.36, P<0.0001) but not with 
cognitive function. These preliminary results indicate response to GLP-1Ra therapy in 








7.1 Introduction  
 
The advancement of medicine means T2D patients are living longer (Kirkman et al., 
2012b). This presents clinicians with difficult decisions with respect to diabetes 
management as multimorbidity becomes more prevalent (Ligthelm et al., 2012). 
Micro and macrovascular complications are well known (Forbes and Fotheringham, 
2017), but the effect T2D has on cognitive function is poorly described (Yang et al., 
2015). Cognitive function in diabetes is of high clinical relevance because of the 
impact it has on self-care, regime adherence and quality of life (Vinik et al., 2017). 
Cognitive decline is a general term that incorporates 5 domains; learning, memory, 
attention, mental flexibility and executive function (O'Caoimh et al., 2012).   
Patients with T2D have been shown to exhibit a 3 times increased risk of 
deficits in learning, memory and executive function (Ott et al., 1999), and onset is 
often accompanied by mood disorders such as depression (Deschenes et al., 2017). 
Pathologically, T2D post mortem brains show vascular lesions and atrophy indicative 
of AD (Manschot et al., 2007). Longitudinal studies following asymptomatic 
individuals have shown that brain volume decreases with increased age and HbA1c 
(Kocahan and Doğan, 2017). Cognitive dysfunction in diabetes is thought to be 
affected by glycaemia, inflammation, and vascular complications (Prickett et al., 
2015). Cumulatively these disorders likely reduce blood flow to the brain decreasing 
the threshold at which cognition is impacted by other neurological illnesses (Feinkohl 
et al., 2015).  
Clinically, cognitive dysfunction in diabetes manifests via alterations in 
behaviour (Venditti, 2016). Effective diabetes management requires good planning 
and coordination to effectively monitor blood glucose, regime frequency and diet 
(NICE, 2017). As cognition declines the risk of glycaemic dysregulation increases 
(Kirkman et al., 2012a). In patients with simple regimes these signs may go 
unnoticed, but in high risk patients on complex insulin dependent regimes 
unintentional non-compliance can have a significant effect on patient outcome 
(Weinstock et al., 2016). It has been proposed that regular screening for executive 
dysfunction in elderly, T2D patients before prescribing complex insulin regimes 
would be clinically beneficial (Sinclair et al., 2013).  
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Studies have assessed the link between chronic disease, mood and cognitive decline 
(Iglay et al., 2017), but few correlations have been made between antidepressants 
and cognition; vortioxetine has been shown to increase cognitive performance 
(McIntyre et al., 2016).  
There is a convergence of cognitive dysfunction in patients with mood 
disorders and T2D, suggestive of intersecting neurobiological pathways (Geijselaers 
et al., 2015). It is possible that currently available treatments targeting T2D may 
mitigate cognitive insufficiencies (McIntyre et al., 2013).  Currently it is not clear 
whether tighter glycaemic control can reduce the risk or prevent further cognitive 
decline in T2D patients. Glucagon-Like Peptide 1 Receptor analogues (GLP-1Ra) have 
been shown to be effective at treating metabolic syndrome, by acting not only on 
blood glucose but on appetite, and lipolysis (Iepsen et al., 2015b).  There are many 
preclinical studies in various models that have shown GLP-1Ras to have protective, 
proliferative (Kelly et al., 2015) and anti-inflammatory effects in brain (Hou et al., 
2012), all of which reduce classic AD pathologies (Luchsinger, 2010). Other 
behavioural studies have shown GLP-1Ras to improve learning and memory 
(McClean and Holscher, 2014). This significant body of evidence suggests GLP-1Ras 
restore learning and memory in animals, and has prompted clinical trials for this 
class of drugs in AD; a phase 2b trial, Evaluating Liraglutide in Alzheimer's disease 
(ELAD, NCT 01843075), is ongoing but excludes participants with T2D.  
Preclinical results with GLP-1 analogues are promising (Kelly et al., 2015), but 
a disconnect exists between preclinical and clinical findings (Ruggeri et al., 2014), 
and data in human cohorts on the effect of GLP-1Ras on depression, anxiety and 
cognition in those with T2D are lacking. A small, domain based, pilot study (n=19) 
found that the GLP-1Ra, liraglutide had beneficial effects on cognitive function in 
non-diabetic participants with major depressive disorder (MDD) (Mansur et al., 
2017). Such findings are the earliest clinical indications that GLP-1Ra may be 
beneficial in patients with mood disorders. Further studies are required to define the 
therapeutic potential of liraglutide in psychopathological domains. 
Here we report interim findings assessing the effect of the GLP-1Ra, 
liraglutide, on aspects of cognitive function, depression and anxiety in a Northern 
Irish T2D population in GLP-1 analogue responders and non-responders, diabetes 
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controls and controls without T2D. HbA1c, drug prescriptions, self-reported 
comorbidity, and full blood count were also assessed. This study will develop a 
better understanding of liraglutide’s cognitive effects in T2D, and will provide 
evidence for the utility of GLP-1 analogues for the prevention of mood disturbances 
































7.2.1 Participant Recruitment 
 
Participants with T2D were identified by clinicians at the Altnagelvin Hospital 
diabetes clinic. Controls were identified and sampled at the University of the Third 
Age (U3a), Derry, NI.  Patient groups, inclusion, exclusion and ethical considerations 
are described in Chapter 2, Section 2.7.2.    
 
7.2.2 Sample Collection 
 
7.2.2.1 Blood sampling   
All blood samples were obtained using 21G Vacuette® safety needles (Greiner Bio-
One, Stonehouse, UK; Cat no. 450091), as described in Chapter 2, Section 2.8.2.1  
Approximately 50 ml of blood was extracted into 2x 9 ml EDTA (K3E K3EDTA) coated 
Vacuette® tubes (Greiner Bio-One, Stonehouse, UK; Cat no. 455036), 2x 4 ml EDTA 
(K3E K3EDTA) coated Vacuette® tubes (Greiner Bio-One, Stonehouse, UK; Cat no. 
455021) and 1x 8 ml Serum (Z Serum Sep Clot Activator) tube (Greiner Bio-One, 
Stonehouse, UK; Cat no. 455071). Blood samples were processed immediately after 
collection.  
 
7.2.2.2 Blood processing 
 
Polypropylene tubes were labelled using Item Tracker© software (ItemTracker 
Software Ltd, Suffolk, UK), prior to processing for serum, plasma, protein, RNA and 
whole blood, as described in Chapter 2, Section 2.8.2.2. Samples were stored at -80° 
C in HTA compliant freezers. 
 
7.2.3 Anxiety, Depression and cognitive screening  
 
7.2.3.1 Beck Anxiety Inventory (BAI) 
 
Participants completed a self-score inventory with 21 symptoms, according to how 
much each one had affected them the previous week. Full description in Chapter 2, 
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Section 2.14.1, and the full inventory can be found in Appendices; supplementary 
screen 1.   
  
7.2.3.2 Beck Depression inventory (BDI) 
 
Participants self-scored 21 questions ranking severity from 0-3. Higher scores are 
indicative of greater symptom severity. Full description in Chapter 2, Section 2.14.2, 
and the full inventory can be found in Appendices; Supplementary Screen 2.   
  
7.2.3.3 Standardized Mini-Mental State Examination (SMMSE) 
 
The SMMSE examination was conducted with Dr Molloy’s proposed script (Molloy 
and Standish, 1997). The test consisted of 12 questions with a maximum score of 30. 
The full protocol is described in Chapter 2, Section 2.14.3, and full test can be found 
in Appendices; Supplementary Screen 3.   
    
7.2.3.4 Quick mild cognitive impairment screen (qMCI)  
 
The questionnaire consists of 6 sections designed to address 6 domains of cognition. 
Orientation, registration, clock drawing, verbal memory (VM), verbal fluency (VF) 
and logical memory (LM), and is described fully in Chapter 2, Section 2.14.4 and the 
full test can be found in Appendices; Supplementary Screen 4.   
  
7.2.4 Clinical database construction 
  
Relevant clinical information for all participants was obtained from Western Health 
and Social Care Trusts, Hicom Diamond.NET diabetes management system (Hitcom, 
Surrey, UK) and Orion Health technologies, Northern Ireland Electronic Care Record 
(NIECR) (Orion health, Hammersmith, UK) as described in Chapter 2, Section 2.11.2.   
 
7.2.5 Statistical analysis   
 
All statistical analysis was conducted using Graphpad Prism software (Graphpad 






Cohort characteristics for the ‘GLP-1 response study’ are shown in Table 7.1 for 
healthy controls, diabetes controls, GLP-1 analogue responders and GLP-1 analogue 
non-responders. All data presented represent interim analyses as patient 
recruitment and analysis is ongoing. All groups, with the exception of controls (47%), 
were predominantly male, diabetes 62%, diabetes GLP-1 analogue responders 59%, 
diabetes GLP-1 analogue non-responders 80%. GLP-1Ra non-responders were the 
only group that differed in age between groups, they were significantly younger than 
non-diabetes controls (59yrs, P<0.05). Patients prescribed a GLP-1Ra were 
significantly heavier compared to GLP-1 naïve diabetes controls (P<0.001-P<0.0001) 
and non-diabetes controls (P<0.05-P<0.01).  HbA1c was higher in GLP-1 analogue 
non-responders compared to diabetes control (73 vs. 57.5 mmol/mol, p<0.01). The 
age participants left school was no different between groups.       
 
  GLP-1 
Response Study 
Non-diabetes Controls Diabetes Controls 
GLP-1 analogue  
responders 
GLP-1 analogue   








mean (SD) % 
Total 
(n) 
mean (SD) % 
Total 
(n) 
mean (SD) % 
Number of participants 19     13     22     15     
Male 9   47.4 8   61.5 13   59.1 12   80.0 
Female 10   5   9   3   
Age (yrs) 19 68.4 (9) 100.0 13 66.1 (12) 100.0 22 62.8 (10) 100.0 15 59.1 (9)* 100.0 
BMI (Kg/m2) 18 26.8 (3) 94.7 13 28.0 (9) 100.0 21 
36.2 
(8)****/ΔΔ 
95.5 14 35.6 (7)***/Δ 93.3 
Overweight – >25 10 27.7 (2) 52.6 13 28.0 (9) 100.0 20 36.8 (7)**/ ΔΔ 90.9 14 35.6 (7)* /Δ 93.3 
HbA1c (mmol/mol) 18 36.2 (2) 94.7 11 
57.5 
(12)**** 




above target - >48.9 0 36.2 (2) 0.0 9 
61.4 
(9)**** 














Ex 10   52.6 7   53.8 8   38.1 6   40.0 
Current 0   0.0 1   7.7 3   14.3 4   26.7 
Age left school (yrs) 17 18.2 (3) 89.5 13 16.4 (2) 100.0 20 16.2 (2) 90.9 15 16.1 (1) 100.0 
 
Table 7.1 – Demographics and clinical features of non-diabetes controls, diabetes controls, 
and T2D GLP-1 responders and non-responders. Data is presented as control, diabetes 
control, GLP-1 analogue responders and GLP-1 analogue non-responders. Each column 
describes the total number of participants, mean ± SD and % of total for each measure. All 
participants were aged 18-100 years. Targets used for HbA1c, and BMI were obtained from 
NICE. Significance was determined by one-way ANOVA and Tukey’s post hoc test. *P<0.05, 
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7.3.1 Diabetes patients have significantly increased polypharmacy 
compared to controls 
 
Non-diabetes controls were prescribed on average 1.5 medications while all groups 
with T2D were prescribed significantly more non-diabetes medications (P<0.0001, 
Fig. 7.1A). GLP-1Ra non-responders were prescribed significantly more diabetes 










Figure 7.1 – Diabetes patients have significantly increased polypharmacy compared to 
controls (A) Average number of drugs prescribed per group. (B) Average number of anti-
diabetes drugs prescribed per group. Each graph shows non-diabetes controls (n=19), 
diabetes controls (n=13), GLP-1Ra responders (n=22) and GLP-1Ra non-responders (n=15). 
Significance was determined using one-way ANOVA and Tukey’s post hoc test. 
****P<0.0001 vs. non-diabetes controls. ΔP<0.05 vs. diabetes controls.  
 
7.3.2 Full blood count (FBC)  
 
There was a weak but significant positive (R=0.31, P=0.01) correlation between 








Figure 7.2 – Correlation analysis between HbA1c and white blood cell (WBC) count. Data 
presented from total cohort (N=69) Data presented as a scatter plot with linear regression 
best line fitted. R value representative of relationship.  
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Total red blood cell (average 4.7 x 1012/l, Fig. 7.3A, RBC) and platelet (average 241 x 
109/l, Fig. 7.3B, PLT) counts were no different between groups. The white blood cell 
(WBC) count differed significantly (Fig. 7.3A). Diabetes controls (GLP-1Ra naïve) had 
a significantly higher WBC count (9 x 109/l, P<0.0001) than non-diabetes controls 
(average 6 x 109/l), as did GLP-1Ra responders (8 x 109/l, P<0.01) and non-responders 
(7.5 x 109/l, P<0.05). WBC differentiation revealed lymphocytes and monocytes did 
not differ between groups and variance could be attributed to neutrophil number 
(Fig. 7.3C). Non-diabetes controls had the lowest neutrophil number (3.6 x 109/l), 
and diabetes control patients had most (5.7 x 109/l, P<0.0001). GLP-1Ra responders 
and non-responders also had increased neutrophils compared to controls, 5.0 x 109/l 
(P<0.001) and 4.6 x 109/l (P<0.05) respectively (Fig. 7.3C). GLP-1 analogue non-
responders had reduced neutrophil counts compared to diabetes controls (P<0.05, 













Figure 7.3 – White blood cell counts are significantly increased in diabetes (A) RBC and 
WBC count. (B) platelet count. (C) WBC differentiation count, including neutrophils, 
lymphocytes and monocytes. Each graph shows non-diabetes controls (n=19), diabetes 
controls (n=13), GLP-1Ra responders (n=22) and GLP-1Ra non-responders (n=15). 
Significance was determined using one-way ANOVA and Tukey’s post hoc test. *P<0.05, 


















































































7.3.3 Comorbidity  
 
The non-diabetes control group had on average 1.3 chronic conditions, and the 
diabetes GLP-1Ra responders (average 2.8) and non-responders (average 2.9) had 
significantly more (P<0.05, Fig. 7.4). It is interesting to note that GLP-1Ra naïve 
diabetes controls had on average of 4 chronic conditions, this was significantly more 
than controls  (P<0.0001), but at this interim stage in the study, no difference could 













Figure 7.4 – Number of chronic conditions reported by participants of the GLP-1 study 
cohort (including diabetes). Graph shows non-diabetes controls (n=19), diabetes controls 
(n=13), GLP-1Ra responders (n=22) and GLP-1Ra non-responders (n=15). Significance was 
determined using one-way ANOVA and Tukey’s post hoc test. *P<0.05, ****P<0.0001   vs 
non-diabetes.  
 
Circulatory disorders contributed 4% of reported comorbidity in non-diabetes 
controls compared to 12% (P<0.05) in diabetes controls, 20% (P<0.05) in GLP-1Ra 
responders and 23% (P<0.01) in non-responders. Musculoskeletal disorders were 
more common in non-diabetes (24%) and diabetes controls (GLP-1 naïve, 20%) 
compared to GLP-1Ra responders (12%, P<0.05), and non-responders (0%, P<0.01). 
In contrast endocrine and nutritional disorders were less common in non-diabetes 
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18%, non-responders 17%). Neoplasms made up a higher percentage of reported 
comorbidity in non-diabetes controls (12%), when related to diabetes controls (5%), 
















Figure 7.5 – Percentage of comorbidity type reported by participants of the GLP-1 study. 
All comorbidities were coded according ICD-10 classification system. Graph shows non-
diabetes controls (n=19), diabetes controls (n=13), GLP-1Ra responders (n=22), GLP-1Ra 
non-responders (n=15). Significance was determined using a 2 proportion Z-test. *P<0.05, 
**P<0.01 vs. non-diabetes controls. ΔP<0.05, ΔΔP<0.01 vs. Diabetes controls. λ P<0.05 vs 
GLP-1 Responders. 
 
7.3.4 Depression and anxiety in GLP-1 analogue therapy 
 
As illustrated in Figure 7.6 GLP-1 analogue non-responders displayed significantly 
increased scores (P<0.05) in the Beck depression Inventory (Fig. 7.6A) and Beck 
Anxiety Inventory (P<0.05, Fig. 7.6B) compared to non-diabetes controls. No 
































































































































































Figure 7.6 – Beck Depression and Anxiety scores in GLP-1 analogue responders and non-
responders. Beck depression inventory (A), and anxiety inventory (B) scores in non-diabetes 
controls (N=19), diabetes controls (n=13), GLP-1 analogue responders (n=22) and GLP-1 
analogue non-responders (n=15). Maximum score in both inventories was 63. Significance 
was determined using one-way ANOVA and Tukey’s post hoc test. *P<0.05 vs. non-diabetes 
control.  
 
7.3.5 Cognitive function  
 
7.3.5.1 The Standardized Mini-Mental State Examination (SMMSE) 
 
Total scores in SMMSE were high, non-diabetes control participants scored 29.3 ± 
1.2, diabetes control patients scored 29.2 ± 1.2, T2D GLP-1Ra responders 28.5 ± 2.5 
and non-responders 27.7 ± 1.9. There was no difference between the groups’ total 
scores. Aphasia (Q6) was affected in diabetes controls and GLP-1 analogue non-
responders (P< 0.05), both groups scored ~20% more on these questions compared 
to controls and GLP-1Ra responders. GLP-1 analogue non-responders exhibited a 
~30% reduction in scores obtained in questions associated with memory and 
perception compared to controls, diabetes controls, and GLP-1 analogue responders 
(Q11, P<0.01-P<0.0001). There were no differences in scores in questions associated 
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Figure 7.7 – Difference in SMMSE scores across different cognitive domains. Illustrated are 
scores associated with different cognitive domains within the SMMSE. Non-diabetes control 
(n=19), diabetes control (n=13), GLP-1 analogue responders (n=22), GLP-1 analogue non-
responders (n=15). The total score for the MMSE is 30, while each domain represents a 
different number of marks. Data presented as a percentage of the question answered 
correctly (Q1=5, Q2=5, Q3=3, Q4=5, Q5=3, Q6=1, Q7=1, Q8=1, Q9=1, Q10=1, Q11=1, Q12=3). 
Significance determined using two-way ANOVA and Holm-Šídák’s post hoc test. 
****P<0.0001 vs non-diabetes. ΔΔ P<0.01 vs Diabetes. λλλλ P<0.0001 vs Responders.       
 
7.3.5.2 The Quick Mild Cognitive Impairment screen (qMCI) 
 
Overall scores in qMCI were not significantly different between groups, however 
non-diabetes controls scored 73.2 ± 6.9, diabetes controls scored 69.0 ± 4.6, 
diabetes GLP-1Ra responders 69.7 ± 10.5 and non-responders 67.5 ± 11.3. GLP-1 
analogue non-responders displayed reduced delayed recall (Q4, ~17%, P<0.05) and 
logical memory (Q6, ~12%, P<0.05) compared to non-diabetes controls. Diabetes 
controls also displayed reduced logical memory compared to controls (Q6, P<0.05), 
while GLP-1 analogue responders performed similarly to controls. Orientation, 
registration visuospatial and verbal fluency were no different between groups (Q1, 2, 
3, 5, Fig. 7.8).  
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Figure 7.8 – Difference in qMCI scores separated by cognitive domains. Illustrated are 
scores associated with different cognitive domains within the qMCI. Non-diabetes controls 
(n=19), diabetes controls (n=13), GLP-1 analogue responders (n=22), GLP-1 analogue non-
responders (n=15). Test scored out of 100, each domain represents a different number of 
marks. Data presented as a percentage of the question answered correctly (Q1=10, Q2=5, 
Q3=15, Q4=20, Q5=20, Q6=30). Significance determined using two-way ANOVA and Holm-
Šídák’s post hoc test. *P<0.05 vs non-diabetes. 
 
7.3.6 Relationship between BMI and HbA1c and depression, anxiety 
SMMSE and qMCI scores 
 
Correlation analysis determined that BMI significantly correlated with Beck 
depression inventory score (R=0.22, P<0.02, Fig. 7.9A) but not anxiety (R=0.16, 
P=0.18, Fig. 7.9C), SMMSE (R=-0.23, P=0.054, Fig. 7.9E) or qMCI (R=0.06, P=0.62, Fig 
7.9G). HbA1c did not significantly correlate with Beck depression (R=0.21, P<0.08, Fig. 
7.9B) or anxiety (R=0.22, P<0.07, Fig. 7.9D) inventory scores, nor with SMMSE 
performance (R=-0.08, P=0.48, Fig. 7.9F). The qMCI, however, showed a highly 
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Figure 7.9 – Correlation analysis between Beck Depression and Anxiety inventories, 
SMMSE, qMCI and HbA1c and BMI.  (A) Beck depression scores vs. BMI. (B) Beck depression 
scores vs. HbA1c. (C) Beck anxiety scores vs. BMI. (D) Beck anxiety scores vs. HbA1c. (E) 
SMMSE scores vs. BMI. (F) SMMSE scores vs. HbA1c. (G) qMCI scores vs. BMI. (H) qMCI scores 
vs. HbA1c. All data from non-diabetes controls (n=19), diabetes controls (n=13), GLP 
analogue responders (n=22) and GLP-1 analogue non-responders (n=15) were plotted. Data 
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7.3.7 Mood and Neutrophil correlations 
 
Due to the high degree of neutrophil variation between groups, cell number was 
correlated with Beck depression and anxiety scores and SMMSE and qMCI total 
scores.  Both depression (R=0.27, Fig. 7.10A) and anxiety (R=0.36, Fig. 7.10B) scores 
were strongly positively correlated with neutrophil number (P<0.0001), however 




















Figure 7.10 – Neutrophil count is positively correlated with Beck Depression and Anxiety 
scores. (A) Depression score vs. Neutrophil count. (B) Anxiety score vs. neutrophil count. (C) 
SMMSE scores vs. Neutrophil count. (D) qMCI scores vs. Neutrophil count. All data from non-
diabetes controls (n=19), diabetes controls (n=13), GLP analogue responders (n=22) and 
GLP-1 analogue non-responders (n=15) were plotted. Data presented as scatter plots with 







7.4 Discussion  
 
This clinical study assessed depression, anxiety and cognitive function in T2D 
patients treated with GLP-1R analogues. Patients were grouped depending on 
whether they were responding or not responding with respect to their HbA1c (-1%) 
and/or weight (-3%), as stipulated by NICE (NICE, 2015). Prescribed medications, 
HbA1c, full blood count, comorbidity records, and cognition measures (SMMSE, 
qMCI), depression and anxiety inventory scores were compared in GLP-1Ra 
responders and non-responders, non-diabetes controls and diabetes controls who 
were GLP-1Ra naïve.  
All diabetes groups were predominantly, unintentionally male (diabetes 
controls 62%; GLP-1Ra responders 59%; GLP-1Ra non-responders 80%), and males 
made up ~50% of the non-diabetes control group. This is not unusual, studies have 
shown diabetes to be more prevalent in males (van Zon et al., 2017). The only group 
to differ in age was the diabetes GLP-1Ra non-responders who were younger than 
the rest of the cohort. Both groups of GLP-1Ra treated patients were also 
significantly heavier than non-diabetes controls and diabetes controls. This may also 
be expected as GLP-1Ra are commonly prescribed to severe or late stage T2D 
patients, and are recommended for obese individuals (NICE, 2015). GLP-1 analogues 
have been shown to be an effective weight loss therapy (Nuffer and Trujillo, 2015). 
GLP-1Ra non-responders had a higher HbA1c than the responder group, GLP-1 is 
known to affect glycaemia (Iepsen et al., 2015b). There were no differences between 
the groups in the average age participants left school. Interestingly, research has 
shown education does not affect   dementia risk, or either assessments ability to 
differentiate between MCI and Alzheimer’s (Sharrett, 2012, O'Caoimh et al., 2012).  
Diabetes patients were prescribed ~12 medications irrespective of their 
diabetes treatment regime, while non-diabetes controls were prescribed 2. Our 
previous work (Chapter 4) and a number of other studies have indicated that this 
difference is due to the high degree of comorbidity present in diabetes (Jelinek et al., 
2017). GLP-1Ra non-responders were on more anti-diabetes medications than the 
diabetes control GLP-1Ra naive group, while GLP-1Ra responders were not. Our 
previous results indicated GLP-1Ras are prescribed as part of dual or triple therapy, 
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likely due to early, aggressive weight and glucose management plans in line with 
American Diabetes Association advice (Chamberlain et al., 2017a).  
A full blood count was determined for all participants. It is well established 
that haemoglobin, platelet and WBC levels are associated with a number of 
conditions (George-Gay and Parker, 2003). WBCs are often used as markers of 
cancer (low levels) (Ong et al., 2017) or infection (high levels) (Rempel et al., 2013), 
but studies have shown strong correlations with diabetes progression (Vozarova et 
al., 2002). In this study we positively correlated WBC levels to HbA1c. This is not 
unusual as diabetes pathogenesis is associated with chronic low grade inflammation 
(Duncan et al., 2003), driven by insulin resistance (Saltiel and Olefsky, 2017). Other 
clinical studies have reported elevated WBCs in glucose metabolism disorders (Jiang 
et al., 2014). This study indicated WBCs were elevated in diabetes patients compared 
to non-diabetes controls, and to a greater extent in GLP-1Ra naïve diabetes patients. 
Although significance could not be determined between GLP-1Ra treated and naïve 
patients at this interim stage, data is suggestive that GLP-1Ras impact WBC number, 
possibly due to anti-inflammatory effects (Hou et al., 2012). WBC differentiation 
showed neutrophils were the only cell type that was altered in diabetes, following a 
similar trend to the total WBC number. Neutrophils are part of the innate immune 
system, and fight infection (Lumeng, 2013). High levels have been shown to be 
indicative of non-infectious inflammation (Soehnlein et al., 2017), stress, and various 
other chronic conditions (Scott et al., 2011a). In the data reported here the highest 
levels were seen in GLP-1Ra naïve diabetes patients who also have the highest 
number of comorbid chronic conditions.   
GLP-1Ra non-responders had the highest percentage of circulatory and 
endocrine disorders, both of which, greatly affect quality of life (Ruo et al., 2003) and 
are linked to the highest rate of mortality in T2D (Micha et al., 2017). This is reflected 
in the Beck depression and anxiety inventory scores; non-responders were the only 
group to score significantly higher than the non-diabetes controls. Many studies 
have linked comorbidity, and quality of life to mood (Naicker et al., 2017). The high 
degree of cardiovascular and endocrine related conditions in non-responders 
appears to affect both depression and anxiety scores. These results support findings 
highlighting the importance of depression in the management of diabetes (Verma et 
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al., 2010), and highlights the importance of effectively managing glycaemia (Schmitt 
et al., 2017).    
In cognitive assessments total scores were not different between groups, 
although individual cognitive domains varied. Non-responders scored lower in 
questions relating to memory and perception, when compared to all other groups. 
GLP-1Ra are well-established as having positive cognitive effects in preclinical studies 
(McClean and Holscher, 2014), but these effects are poorly reported in clinical 
cohorts. Similar findings were found when assessing cognitive domains using the 
qMCI. No difference could be determined between total scores; however diabetes 
controls (GLP-1Ra naïve) and GLP-1Ra non-responders, scored lower than non-
diabetes controls in delayed recall and logical memory. The qMCI has been shown by 
many studies as being highly sensitive at differentiating mild cognitive impairment, 
with delayed recall and logical memory being the most influential components 
(O'Caoimh et al., 2012). GLP-1Ra responders do not differ from controls in these 
domains, and therefore GLP-1 analogues may be protective in terms of cognitive 
decline in T2D in a clinical setting. This has not been previously reported; we await 
findings from ongoing studies to verify this result. 
The data infers GLP-1Ra response, comorbidity, mood and cognition are 
linked. We conducted correlation analysis of BMI and HbA1c to Beck depression and 
anxiety scores and observed that only depression scores positively correlated with 
BMI. This was surprising as weight and glycaemia have both been linked to quality of 
life, diabetes complications (Steele et al., 2016) and mood (Nigatu et al., 2016);  
these findings are likely a result of small sample numbers recruited to date (~n=20). 
Correlation analysis of BMI and HbA1c vs. SMMSE and qMCI demonstrated that qMCI 
was strongly negatively correlated with HbA1c. This supports previously reported 
links between poor glycaemic control and cognitive decline (van den Berg et al., 
2009). Neutrophil levels were also correlated with depression and anxiety 
inventories, SMMSE and qMCI. A highly significant positive correlation was recorded 
between neutrophil number depression and anxiety. Other studies have reported 
similar correlations in neutrophil to lymphocyte ratio in depression (Aydin Sunbul et 
al., 2016). Neutrophil levels, however, did not correlate with scores in SMMSE and 
qMCI, which is of interest. The present study indicates WBC counts and neutrophils 
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in particular are indicative of depression and anxiety in T2D, and warrants further 
investigation. 
The main limitation of this study is the small group sizes, as this represents an 
interim analysis. This limited sensitivity to distinguish alterations in cognitive 
domains and small differences in depression and anxiety scores. All comorbidities 
and BMI records were self-reported by participants, which allows for a degree of 
unintentional inaccuracy. A true definition of medication response was difficult to 
determine retrospectively; response was determined using electronic health record 
data. Prospective cohorts will definitively assess the efficacy of GLP-1 analogues on 
cognitive outcomes.  
This interim analysis provides an early indication that GLP-1Ra response has a 
positive effect on comorbidity, depression, anxiety and cognitive performance, 
specifically related to memory and perception. WBCs and neutrophil number may 
also be a useful measure of T2D, depression and anxiety severity.  










































In this thesis we hypothesised that current clinical diabetes measures insufficiently 
stratify patients, ultimately resulting in poor anti-diabetes pharmacological response, 
comorbidity and cognitive decline. The identification of novel peripheral genetic and 
proteomic biomarkers indicative of T2D and response to GLP-1 analogue therapy 
may be used to target GLP-1 therapy towards known responders, and provide 
rationale for the use of GLP-1 analogues earlier in the T2D disease course.  
 
8.1 Summary of findings and field advancements   
 
In the third chapter transgenic animal models were used to define molecular 
mechanisms downstream of the GLP-1R that may be indicative of drug response in 
brain and whole blood. Initial results supported other work that indicated GLP-1 acts 
on the melanocortin system (Goldstone et al., 1997a), and has insulin sensitising 
effects (Idris et al., 2002). Results confirmed relevance of all 13 genes for future 
analysis in clinical populations.  All genes of interest were affected by a 70% knock 
down of the GLP-1R in the GLP-1 RKO mouse model. Early Aβ deposits that have 
been shown in young APP/PS1 mice also affected the panel (Radde et al., 2006). 
Target gene expression in C57BL/6 mice was highly sensitive to treatment duration. 
After 7 days most genes were upregulated and after 21 days all genes were globally 
down regulated. A relationship was identified between blood and brain gene 
expression. Peripheral levels after 1-7 days GLP-1Ra treatment mirrored what was 
recorded centrally after 3 weeks.  
In the fourth chapter we assessed currently available biochemical and 
anthropometric measures, and the clinical profiles of 500 T2D patients (DiaStrat) in 
the Western Trust. Data from electronic health records and primary insulin and C-
peptide ELISA data was used. We observed that glycaemia and bodyweight were 
poorly managed. Average HbA1c was 65 mmol/mol (8.1%), and 93% of patients were 
overweight. CVD was the most common comorbidity (25%), but hyperlipidaemia was 
well managed. It was evident from prescribing data that there was major deviation 
from NICE guidance (NICE, 2015). Cardiovascular disease (CVD) management 
appears to be prioritised over glycaemic control and bodyweight. We also 
demonstrated that C-peptide is a useful measure of diabetes and comorbidity 
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severity, and routine measurement should be incorporated into the clinic in addition 
to the regular monitoring of HbA1c. 
In chapters five and six proteomic and genetic biomarkers were identified 
using Proximity Extension Assays (PEA, OLink proteomics), that included 368 
proteins, and analysis of SNPs within 20 insulin and leptin related genes. Multiple 
specific protein panels were identified for diabetes, obesity, hyperglycaemia, 
common comorbidities, and diabetes drug response. There were proteins linked to 
leptin and insulin signalling, however, data enrichment (Enrichr) identified pathways 
involved in vascular endothelial damage as being the common feature between the 
proteomic markers for all quantified measures. We identified 105 SNPs in insulin and 
leptin related genes, that could discriminate between T2D and healthy controls, 
most of which were novel, with some previously reported on the T2D portal (T2D-
GENES Consortium, 2017). There were 25 SNPs identified specific to GLP-1Ra 
responders, with one highly specific SNP present on the GLP-1R.  
In chapter seven we further assessed differences between GLP-1Ra 
responders and non-responders and the effect GLP-1Ras have on mood and 
cognitive decline. Corresponding with findings in the literature, our data indicated 
that GLP-1Ra non-responders were at a higher risk of comorbidities (Sleiman, 2012), 
and had significantly higher depression and anxiety scores. Total scores for both 
SMMSE and qMCI were no different between groups, but cognitive domains relating 
to memory and perception were negatively affected in GLP-1Ra non-responders.  
 
8.2 Strengths and limitations   
 
8.2.1 Preclinical   
 
All experiments in chapter 3 were designed in vivo, to gain as much translational 
reliability as possible (Burkhardt and Zlotnik, 2013). Animal models are known to be 
a reproducible method for investigating disease and response mechanisms (Justice 
and Dhillon, 2016) that are less expensive and invasive than human trials 
(Vandamme, 2014).  
We used three mouse models C57BL/6, GLP-1RKO and APP/PS1, which 
enabled us firstly to assess potential biomarkers in response to GLP-1Ra treatment in 
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WT, and secondly to define if these effects translated and could be used in a model 
of AD. These effects were not measured in a model of diabetes or obesity. A 
streptozotocin induced T2D model (Gilbert et al., 2011), or a HFD induced model of 
obesity (Wang and Liao, 2012) could provide valuable insights and help define links 
between obesity/T2D and AD and assess the possibility that biomarkers of GLP-1R 
agonist response may be common between conditions.  
Central gene expression was detected consistently and accurately, while 
peripheral gene expression was possible for all genes, excepting GHSR. Peripheral 
data was more variable; this was most likely due to the small sample volume (50 µl) 
and sample number (n=5). There was also a discrepancy between cDNA load (25 ng 
in brain, 5 ng in blood); despite being normalised to internal control this may have 
affected variability observed. This work determined a relationship exists between 
the blood and the brain for our genes of interest. It is worth noting the blood and 
brain from the same mice were used for comparative experiments to reduce any 
inter animal variability, which has been documented in other work (Han et al., 2004). 
        
8.2.2 Clinical   
 
8.2.2.1 ECR Research 
  
Diabetes participants were recruited from secondary care and all were registered to 
the Western Health and Social Care Trust. This experimental design allowed us to 
define the effect of severe diabetes on prescribing trends and comorbidity, allowing 
better stratification of this high-risk group. Future studies should focus on recruiting 
from primary care to enable comparisons between proteomic and genetic changes in 
pre-diabetes, newly diagnosed T2D and late T2D (Jiao et al., 2017). This may 
facilitate more efficient generation of preventative and early diabetes markers, and 
would permit prospective assessment of first line therapy response.  
A strength of the DiaStrat study was access to multiple ECR systems, which 
covered all appointments of the participants in primary and secondary care. 
Computerised prescription records, drug interaction data, and longitudinal medical 
history information (Menachemi and Collum, 2011) allowed for effective clustering 
dependent on various biochemical and phenotypic characteristics. We first mined 
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the Diamond diabetes management solution by Hicom (HiCom, 2017). This is a web 
based application hosted by the Health Trust. From a research perspective, Diamond 
and other ECRs provided opportunities for participant identification (Casey et al., 
2016), clinicians were able to effectively screen research exclusion and inclusion 
criteria, and contact potential participants. Access to recruited participants medical 
records allowed for novel epidemiological insights into disease history, drug 
application and the effects of comorbidity (De Moor et al., 2015).  
The main limitation of the Diamond system at Altnagelvin is that it is solely 
focused on diabetes and is region specific. A lack of information relating to primary 
care or other health systems being used in the hospital resulted in a simplified, 
disease specific picture of healthcare (HiCom, 2017). In the DiaStrat study only T2D 
patients could be identified and recruited through Diamond. This limited our findings 
as there was no non-diabetes control ECR data to compare our data to.  
Due to the limitations of the Diamond system we also utilised a second ECR, 
the Northern Ireland Electronic Care Record (NIECR) by Orion health (Orion Health, 
2017). NIECR encompassed all primary and secondary care visits, and links all 
regional patient records across Northern Ireland (Orion Health, 2017). Diamond was 
incorporated into this system in 2016, ensuring no data loss. All data input was 
manually transferred from ECR systems to a separate spreadsheet for analysis. 
Manual data input increases the risk of human error (Menachemi and Collum, 2011), 
therefore quality control checks were carried out between diamond an NIECR data 
records to ensure the highest level of accuracy. The nature of electronic systems 
means multiple sources have access to patient accounts and are required to fill in 
patient interactions accurately. Different departments with different data input 
process can lead to a degree of error, or missing data (Menachemi and Collum, 
2011). This factor was taken into account when analysing the data. Patients with 







8.2.2.2 Proteomic screening 
 
In Chapter 5 we outsourced proteomic analysis to OLink proteomics, allowing for 
rapid high throughput targeted discovery of protein markers. This company is a 
specialist in the field of protein analysis, with advanced equipment and technical 
expertise not available at Ulster University (OLink, 2017). Utilising OLink services 
allowed for quick and reliable analysis of 374 T2D samples, and 20 non-diabetes 
control samples. Proximity Extension Assay (PEA) technology ensures precise and 
sensitive detection with a broad dynamic range (Assarsson et al., 2014). The array 
only requires 1 µl of sample (OLink, 2017). 
Plasma proteome analysis was chosen, due to its minimal invasiveness 
(Dayon, 2013). Blood sampling is regularly conducted in the diabetes clinic, therefore 
provision of blood samples tends not to distress participants (NICE, 2017). Blood is a 
complex body fluid which contains a large diversity of proteins (Muthusamy et al., 
2005), many are emitted by cells under various pathological or physiological 
processes (Anderson and Anderson, 2002). It is thought plasma is a promising source 
of peripheral biomarkers due to its circulation and contact with various tissues. It is 
likely a good indicator of overall health (Etzioni et al., 2003). Our results indicated 
that 92% of 368 screened proteins met QC and were detected. This is particularly 
high, much research has indicated that plasma can be a challenging tissue to screen 
(Omenn, 2006). It is acknowledged that a high degree of variability in the 
concentration and activation state of plasma proteins exists between patients 
(Nedelkov et al., 2005). There is a complex dynamic range of proteins in plasma, 
large plasma proteins; albumins (55%), globulins (38%) and fibrinogen (7%) make up 
the majority of total protein concentration (Tu et al., 2010), while low abundance 
hormones, cytokines and lipoproteins are usually difficult to detect (Anderson and 
Anderson, 2002). Fractionation techniques are usually carried out on samples to 
remove these proteins (Burnouf, 2007), but were not required for OLink analyses 
(OLink, 2017). 
There are three main limitations associated with the data captured within 
this chapter. The first is that clustering of patients was dependent on ECR data 
available at the time of sampling. Some measures may have been within weeks of 
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sampling date which may have introduced a degree of error to a patients 
classification. Inaccurate grouping would confound observations reported. For 
validation studies ensuring accurate classification would be preferable; taking 
additional blood samples and carrying out relevant biochemical tests on the same 
day would address this issue. Secondly samples were taken at one time point, and 
protein-protein; protein-gene multivariate interaction analysis was not conducted. 
Sampling patients longitudinally would permit repeated measures analysis of how 
proteins change over time, and in response to interventions, improving diagnostic 
and prognostic accuracy. Assessing the relationship between proteins and genes 
would provide important and insightful information that could improve our 
understanding of disease (Jones and Thornton, 1996).   
 
8.2.2.3 SNP genotyping of insulin and leptin associated genes 
 
In chapter six 266 T2D whole blood DNA samples and 19 non-diabetes control 
samples were outsourced to Cambridge Genomic Services for genetic screening 
using the Affymetrix UK Biobank SNP array (UK BioBank, 2017). There are 820,967 
SNP and indel markers on the array, that include ~95,500 markers of particular 
interest in various diseases, linked to phenotypic variation and 112,000 coding 
variants, with remaining content (629,000) covering a variety of genome wide 
markers found in Caucasian populations (UK BioBank, 2017).  
 Comparisons of SNP genotypes in 20 genes of interest were made between 
individuals with T2D and non-diabetes controls, with 105 SNPs indicative of diabetes. 
Comparisons were also made between T2D GLP-1Ra responders and non-
responders, with 25 SNPs identified that significantly influenced response.  
The main limitation associated with this experiment was sample size. Many 
studies have shown that to detect the influence of biological and technical variation, 
and rare biological variants large sample sizes are required (Nielsen et al., 2011). The 
non-diabetes control group consisted of 19 participants and was compared to 266 
individuals with T2D, which enabled a satisfactory differentiation rate. The T2D GLP-
1 responder and non-responder groups had ~20 participants; despite identifying 
some impressive SNP genotype differences, such low numbers may have affected 
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the detection of SNPs with low minor allele frequencies (Nielsen et al., 2011). 
Findings observed here will be validated in larger populations to determine their 
reproducibility, and further analysis is required on other SNPs associated with T2D 
and response to GLP-1 analogue therapy.  
 
8.2.2.4 GLP-1 response study  
 
In chapter 7 the effect of GLP-1Ra drug response on cognition, depression and 
anxiety was determined using SMMSE and qMCI assessments and Beck depression 
and anxiety inventories. The SMMSE and qMCI examinations are well accepted 
measures of cognition (O'Caoimh et al., 2012). The SMMSE is widely used in clinical 
practice to determine cognitive function (Molloy et al., 2005), but is known not to 
assess decision making abilities, limiting its usefulness in depressed, psychotic or 
frontal lobe disease patients (Freedman et al., 1991). The qMCI is more sensitive 
than the SMMSE for determining MCI particularly in older adults (O'Caoimh et al., 
2012), attributed specifically  to questions relating to episodic memory (O'Caoimh et 
al., 2013). Education level does not alter the ability of either examination to 
discriminate between dementia and MCI (O'Caoimh et al., 2012). The Beck 
depression and anxiety inventories are well established measures (Lovibond and 
Lovibond, 1995), used across various health services and in a number of disease 
areas (Beck et al., 1997, Richter et al., 1998). The main strength of this study was the 
recruitment of multiple control groups to normalise findings to GLP-1Ra response. 
Non-diabetes controls, diabetes controls (GLP-1Ra naïve) and diabetes GLP-1Ra non-
responders were compared to diabetes GLP-1Ra responders. All cognitive, mood and 
blood samples were acquired at one appointment to ensure correlations were 
reflective of that time point. Official cognitive assessment scripts and protocols were 
followed for all participants to minimise appointment condition variability (Molloy 
and Standish, 1997, O'Caoimh et al., 2012).  
The main limitation of this study was the small sample number, most groups 
were <n=20. This likely affected sensitivity and the ability to differentiate between 
the groups for cognitive, depression and anxiety screening instruments. Secondly, 
defining responders and non-responders is difficult. NICE define response as either a 
1% reduction HbA1c or a 3% reduction in body weight after 6 months exposure to 
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GLP-1 analogues (NICE, 2015). Using the ECR we found patients were kept on GLP-
1Ra irrespective of response, if a single criteria was met, or if they had previously 
responded, and the drug is maintaining glycaemia or weight. Response was 
therefore subjective, and was defined on this study as ‘currently responding’ with 
respect to glycaemia, bodyweight or both.  
         
 8.3 Potential translational impact 
 
Elevated or poorly controlled blood glucose, poor pharmacological response and 
resultant comorbidity are the main causes of poor quality of life and mortality in T2D 
(Cavalot et al., 2011). Diabetes biomarkers such as HbA1c have not changed since 
1975 (Tattersall et al., 1975). HbA1c is still considered a good marker in terms of 
monitoring glycaemic control (NICE, 2015), but there is much room for improvement 
in diabetes management. Secondary complications and comorbidities are associated 
with significant personal and economic burdens. Strategies to predict or measure 
response to therapy more effectively, and better understand the development of 
comorbidity will improve outcomes for patients and reduce overall healthcare costs 
in the long term. 
 In chapter 4 we demonstrated that current biomarkers have limited 
predictive capability when correlated with disease progression, prescribing patterns 
and multimorbidity. Evidence was presented that suggests glycaemic control and 
bodyweight are ineffectively controlled compared to blood lipids and blood 
pressure. This type of epidemiological information may better inform clinical practice 
and policy; there is certainly an argument for the introduction of obesity clinics to 
manage the high levels of obesity in the same manner that CVD risk has been 
targeted. This work also highlighted the need for new and specific genetic and 
protein biomarker panels that are capable of predicting risk associated with poor 
glycaemic control and comorbidity and allowing for more accurate stratification of 
T2D patients  
In diabetes, complications develop slowly over time (Iglay et al., 2016); we 
found evidence of this in Chapter 4 with most comorbidities linked to longer 
diabetes duration and older age. The use of ECR data in conjunction with biomarker 
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discovery techniques in chapters 5 and 6 permitted clustering analysis across 
numerous T2D and associated comorbidity variables. In this study we identified 
specific SNPs and proteins for T2D and GLP-1Ra response and investigated 
alterations and correlations with various biochemical measures. These novel findings 
have the potential to identify individuals at risk of T2D and assess the management 
of glycaemic control and predict onset of comorbidity in individuals with a T2D 
diagnosis. We report here, for the first time, a number of SNPs that are highly 
significantly associated with response to GLP-1Ra. SNP biomarkers, once 
reproducibility is confirmed in secondary cohorts, could allow for prediction of 
response to therapy. This would permit more efficient prescribing and reduced NHS 
costs by reducing the onset of comorbidities and secondary complications associated 
with non-response in those who will derive no clinical benefit.  
Results from Chapter 7 indicate that response to GLP-1 analogues, from a 
diabetes perspective i.e. in those who achieve reductions in HbA1c and bodyweight, 
may also be associated with reduced depression, anxiety and cognitive decline. This 
study is ongoing and more power is required to support the preliminary trends 
observed. Such a finding has high clinical and translational relevance due to the 
impact cognition has on drug regime adherence and disease progression in T2D 
(Iglay et al., 2017). 
 
8.4 Future direction 
 
From a preclinical perspective (Chapter 3) further profiling of peripheral leptin and 
insulin gene expression in response to liraglutide is required. A larger sample 
number would reduce the variability observed in peripheral gene expression data 
and permit more accurate definition of drug response. Genes of interest were 
expressed at much higher levels in brain than in blood, but we did not definitively 
determine whether transcriptional changes in brain affects blood mRNA or vice 
versa; it would be interesting to assess gene expression at the cellular level in blood 
using flow cytometry (Letzkus et al., 2014). It is possible that central and peripheral 
gene expression, in response to pharmacological treatment, is related to BBB 
function (Huntley et al., 2014); it would be interesting to assess this in future work. 
The effect of liraglutide in the APP/PS1 genotype should be expanded to include an 
271 
  
untreated APP/PS1 control and also liraglutide-treated and untreated diabetes 
model groups; this could provide valuable insights in the shared pathophysiology 
between T2D, AD (Luchsinger, 2010) and GLP-1Ra response.  
Chapter 4 would be strengthened by comparing findings to an age and sex 
matched non-diabetes control population. This would allow for more informative 
baseline comparisons to be made on the effect of T2D on BP, BMI, blood lipids, 
comorbidity and prescribing. A large non-diabetes control population would also 
allow increased sensitivity when analysing the proteomic and genetic profiling data 
in chapters 5 and 6 respectively. This could enable identification of more proteomic 
changes and SNP alterations with low minor allele frequencies to be detected. 
(Steinthorsdottir et al., 2014). In chapter six there is a possibility of missing 
significant findings in our genes of interest by using a SNP array. In future validation 
experiments, with larger participant numbers, whole genome sequencing should be 
conducted to able exon and intron spanning analysis (Kalari et al., 2006). This will 
increase insights into variation in the genes of interest associated with T2D and GLP-
1Ra response. All proteomic and genetic findings will be validated in larger 
multiregional cohorts to further assess accuracy and reliability.      
The Chapter 7 GLP-1 response study is ongoing. Further recruitment should 
increase power significantly. Follow up work is also planned to prospectively follow 
individuals prescribed GLP-1 analogues to permit validation of biomarkers identified 
in Chapters 3, 5 and 6. RNA samples were collected for all participants of the study. 
The leptin and insulin markers screened in vivo (Chapter 3) will be assessed in human 
samples via qPCR to assess their clinical utility, and the models translational capacity.   
 
8.5 Conclusion         
  
Leptin and insulin related genes can be detected centrally and peripherally in vivo. 
Peripheral levels after 7 days were indicative of central changes after 3 weeks and 
may act as putative markers of GLP-1Ra response in diabetes and, potentially, 
Alzheimer’s disease. ECR analysis of 500 T2D patients demonstrated current diabetes 
measures, HbA1c, BMI and blood lipid profile, were ineffective at predicting and 
managing T2D and associated comorbidities. C-peptide may act as a valuable 
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addition in the clinic for determining disease progression, and potentially drug 
response. New proteomic and genetic biomarkers capable of differentiating T2D and 
non-diabetes controls were identified. We also identified specific and sensitive 
protein markers to comorbidity onset and proteomic and SNP markers associated 
with GLP-1Ra response. Preliminary findings on the effect of GLP-1 analogues on 
cognition, depression and anxiety supported the notion that identifying markers of 
GLP-1Ra response in diabetes is of high clinical significance. Non-responders to GLP-
1Ras showed an increased risk of comorbidity and mood disorders, which may affect 
cognitive domains relating to memory and perception. The biomarker panels 
identified within this thesis, after further validation, may help stratify T2D patients 
that are at risk of poor anti-diabetes medication response and comorbidity, and 
better inform clinical practices on the best course of treatment, ultimately improving 
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Supplementary Table 1 – All proteins measured by OLink analysis  
                                             (Passed QC)   
Number Proteins  Number Proteins  Number Proteins  
1 BMP 6 41 GLO1 81 CTSL1 
2 ANG1 42 CD84 82 hOSCAR 
3 ADM 43 PAPPA 83 TNFRSF13B 
4 CD40 L 44 SERPINA12 84 TGM2 
5 SLAMF7 45 REN 85 LEP 
6 PGF 46 DECR1 86 CA5A 
7 ADAM TS13 47 MERTK 87 HSP 27 
8 BOC 48 KIM1 88 CD4 
9 IL 4RA 49 THBS2 89 NEMO 
10 SRC 50 TM 90 VEGFD 
11 IL 1ra 51 VSIG2 91 PARP1 
12 IL6 52 AMBP 92 HAOX1 
13 TNFRSF10A 53 PRELP 93 TNFRSF14 
14 STK4 54 HO1 94 LDL receptor 
15 IDUA 55 XCL1 95 ITGB2 
16 TNFRSF11A 56 IL16 96 IL17RA 
17 PAR 1 57 SORT1 97 TNF R2 
18 TRAIL R2 58 CEACAM8 98 MMP 9 
19 PRSS27 59 PTX3 99 EPHB4 
20 TIE2 60 PSGL1 100 IL2 RA 
21 TF 61 CCL17 101 OPG 
22 IL1RL2 62 CCL3 102 ALCAM 
23 PDGF subunit B 63 MMP7 103 TFF3 
24 IL27 64 IgGFc R IIb 104 SELP 
25 IL17D 65 ITGB1BP2 105 CSTB 
26 CXCL1 66 DCN 106 MCP 1 
27 LOX 1 67 Dkk1 107 CD163 
28 Gal 9 68 LPL 108 Gal 3 
29 GIF 69 PRSS8 109 GRN 
30 SCF 70 AGRP 110 MEPE 
31 IL18 71 HB EGF 111 BLM hydrolase 
32 FGF 21 72 GDF2 112 PLC 
33 PIgR 73 FABP2 113 LTBR 
34 RAGE 74 THPO 114 Notch3 
35 SOD2 75 MARCO 115 TIMP4 
36 CTRC 76 GT 116 CNTN1 
37 FGF 23 77 BNP 117 CDH5 
38 SPON2 78 MMP12 118 TLT2 
39 GH 79 ACE2 119 FABP4 




Supplementary Table 1 – continued   
Number Proteins  Number Proteins  Number Proteins  
121 PAI 161 uPA 201 PRDX1 
122 CCL24 162 CPB1 202 PRDX3 
123 TR 163 CHI3L1 203 FGF2 
124 TNFRSF10C 164 ST2 204 PRDX5 
125 GDF15 165 tPA 205 DPP10 
126 SELE 166 SCGB3A2 206 TRIM5 
127 AZU1 167 EGFR 207 DCTN1 
128 DLK1 168 IGFBP 7 208 ITGA6 
129 SPON1 169 CD93 209 CDSN 
130 MPO 170 IL 18BP 210 GALNT3 
131 CXCL16 171 COL1A1 211 FXYD5 
132 IL6RA 172 PON3 212 TRAF2 
133 RETN 173 CTSZ 213 TRIM21 
134 IGFBP 1 174 MMP 3 214 LILRB4 
135 CHIT1 175 RARRES2 215 NTF4 
136 TRAP 176 ICAM 2 216 KRT19 
137 CCL22 177 KLK6 217 ITM2A 
138 PSP D 178 PDGF subunit A 218 HNMT 
139 PI3 179 TNF R1 219 CCL11 
140 Ep CAM 180 IGFBP 2 220 MILR1 
141 APN 181 vWF 221 EGLN1 
142 AXL 182 PECAM 1 222 NFATC3 
143 IL 1RT1 183 NTproBNP 223 LY75 
144 MMP 2 184 CCL16 224 EIF5A 
145 FAS 185 PPP1R9B 225 EIF4G1 
146 MB 186 GLB1 226 CD28 
147 TNFSF13B 187 PSIP1 227 PTH1R 
148 PRTN3 188 ZBTB16 228 BIRC2 
149 PCSK9 189 IRAK4 229 HSD11B1 
150 UPAR 190 TPSAB1 230 NF2 
151 OPN 191 HCLS1 231 PLXNA4 
152 CTSD 192 CNTNAP2 232 SH2B3 
153 PGLYRP1 193 CLEC4G 233 FCRL3 
154 CPA1 194 IRF9 234 CKAP4 
155 JAM A 195 EDAR 235 JUN 
156 Gal4 196 IL6 236 HEXIM1 
157 IL 1RT2 197 DGKZ 237 CLEC4D 
158 SHPS 1 198 CLEC4C 238 PRKCQ 
159 CCL15 199 IRAK1 239 MGMT 






Supplementary table 1 – final  
Number Proteins  Number Proteins  Number Proteins  Number Proteins  
241 CXADR 281 GDNF 321 IL 10RB 361 TWEAK 
242 IL10 282 CDCP1 322 IL 22 RA1 362 CCL20 
243 SRPK2 283 CD244 323 IL 18R1 363 ST1A1 
244 KLRD1 284 IL7 324 PD L1 364 STAMPB 
245 BACH1 285 OPG 325 Beta NGF 365 IL5 
246 PIK3AP1 286 LAPTGF beta 1 326 CXCL5 366 ADA 
247 SPRY2 287 uPA 327 TRANCE 367 TNFB 
248 STC1 288 IL6 328 HGF 368 CSF1 
249 ARNT 289 IL 17C 329 IL 12B     
250 FAM3B 290 MCP 1 330 IL 24     
251 SH2D1A 291 IL 17A 331 IL13     
252 ICA1 292 CXCL11 332 ARTN     
253 DFFA 293 AXIN1 333 MMP 10     
254 DCBLD2 294 TRAIL 334 IL10     
255 FCRL6 295 IL 20RA 335 TNF     
256 NCR1 296 CXCL9 336 CCL23     
257 CXCL12 297 CST5 337 CD5     
258 AREG 298 IL 2RB 338 CCL3     
259 IFNLR1 299 IL 1 alpha 339 Flt3L     
260 DAPP1 300 OSM 340 CXCL6     
261 PADI2 301 IL2 341 CXCL10     
262 SIT1 302 CXCL1x 342 4E BP1     
263 MASP1 303 TSLP 343 IL 20     
264 LAMP3 304 CCL4 344 SIRT2     
265 CLEC7A 305 CD6 345 CCL28     
266 CLEC6A 306 SCF 346 DNER     
267 DDX58 307 IL18 347 EN RAGE     
268 IL12RB1 308 SLAMF1 348 CD40     
269 TANK 309 TGF alpha 349 IL33     
270 ITGA11 310 MCP 4 350 IFN gamma     
271 KPNA1 311 CCL11x 351 FGF 19     
272 LAG3 312 TNFSF14 352 IL4     
273 IL5 313 FGF 23 353 LIF     
274 CD83 314 IL 10RA 354 NRTN     
275 ITGB6 315 FGF 5 355 MCP 2     
276 BTN3A2 316 MMP 1 356 CASP8     
277 IL8 317 LIF R 357 CCL25     
278 VEGFA 318 FGF 21 358 CX3CL1     
279 BDNF 319 CCL19 359 TNFRSF9     




































Number  Protein Number  Protein Number  Protein 
1 ARNT 12 IL-20 23 KPNA1 
2 ARNT 13 IL-20RA 24 LIF 
3 BDNF 14 IL-22RA1 25 NF2 
4 BIRC2 15 IL-24 26 NRTN 
5 BNP 16 IL2RB 27 PAD12 
6 DGK2 17 IL3 28 Pi3 
7 EIF5A 18 IL33 29 PRKCQ 
8 FXYDS 19 IL4 30 T5LP 
9 IFN-gamma 20 IL5 31 TNF 
10 IL-1 alpha 21 IL5     
11 IL13 22 JUN     
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Number Protein Number Protein 
1 CTSZ 28 LAG3 
2 TRAF2 29 IL-18BP 
3 CA5A 30 IL-15RA 
4 CD163 31 TFF3 
5 LY75 32 CDCP1 
6 CD5 33 IL13 
7 ITGB6 34 IL-1RT1 
8 IGFBP-7 35 CXCL10 
9 Gal-4 36 TRANCE 
10 HAOX1 37 CST5 
11 IL-1ra 38 CCL28 
12 Flt3L 39 SPON1 
13 MMP7 40 TNFRSF13B 
14 THBS2 41 NCR1 
15 BTN3A2 42 NT-3 
16 SCF 43 CXCL16 
17 hOSCAR 44 TNFRSF14 
18 AMBP 45 TNF-R2 
19 IL18 46 MARCO 
20 DDX58 47 CD83 
21 OSM 48 FAM3B 
22 LOX-1 49 IL-17C 
23 CLEC4A 50 CCL22 
24 CD84 51 CLEC7A 
25 ITGA6 52 PAI 
26 TNFSF14 53 CXCL9 
27 PARP-1 54 SLAMF1 
    55 CCL15 
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Number  Protein Number  Protein Number  Protein 
21 TNFRSF14 54 IL12RB1 87 ICAM-2 
22 IL-17C 55 Notch 3 88 SH2B3 
23 LILRB4 56 GALNT3 89 STAMPB 
24 CLEC4D 57 LAMP3 90 PECAM-1 
25 CCL19 58 IL16 91 OPN 
26 CDSN 59 DCBLD2 92 IGFBP-2 
27 IL-10RB 60 CXADR 93 TRIM5 
28 KLRD1 61 EGLN1 94 KLK6 
29 EPHB4 62 ANG-1 95 NFATC3 
30 PGF 63 HO-1 96 FAM3B 
31 LAG3 64 HB-EGF 97 CD84 
32 IL2-RA 65 AZU1 98 ST1A1 
33 TNFRSF13B 66 TIE2 99 IL7 
34 TIMP4 67 PARP-1 100 PLXNA4 
35 IGFBP-7 68 CCL17 101 TF 
36 MILR1 69 TR 102 HCLS1 
37 TGF-alpha 70 MMP-10 103 ICA1 
38 PRELP 71 CCL22 104 MEPE 
39 ITGA6 72 Gal-3 105 CST5 
40 PDGF subunit B 73 PSP-D 106 RARRES2 
41 PON3 74 AREG 107 CX3CL1 
42 TNFRSF10A 75 AXL 108 CXCL16 
43 MMP7 76 Gal-4 109 PRTN3 
44 MB 77 KRT19 110 MCP-1 
45 CD4 78 GDF-15 111 CLEC4G 
46 SHPS-1 79 FGF-21 112 COL1A1 
47 CCL25 80 IgG Fc receptor II-b 113 MMP-3 
48 SPON2 81 CXCL12   
49 SLAMF1 82 Ep-CAM   
50 MCP-3 83 DLK-1   
51 CD93 84 IL1RL2   
52 LPL 85 CD40-L  
 
53 AMBP 86 CXCL1    
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Supplementary Screen 1 – Beck Anxiety Inventory 
Beck Anxiety Inventory  
  
Below is a list of common symptoms of anxiety.   Please carefully read each item in the list.  Indicate how much 
you have been bothered by that symptom during the past month, including today, by circling the number in the 
corresponding space in the column next to each symptom.  
  
  Not At All  Mildly but it 
didn’t bother me 
much.   
Moderately - it 
wasn’t pleasant 
at times  
Severely – it 
bothered me a lot  
Numbness or tingling  0  1  2  3  
Feeling hot  0  1  2  3  
Wobbliness in legs  0  1  2  3  
Unable to relax  0  1  2  3  
Fear of worst happening  0  1  2  3  
Dizzy or lightheaded  0  1  2  3  
Heart pounding/racing  0  1  2  3  
Unsteady  0  1  2  3  
Terrified or afraid  0  1  2  3  
Nervous  0  1  2  3  
Feeling of choking  0  1  2  3  
Hands trembling  0  1  2  3  
Shaky / unsteady  0  1  2  3  
Fear of losing control  0  1  2  3  
Difficulty in breathing  0  1  2  3  
Fear of dying  0  1  2  3  
Scared  0  1  2  3  
Indigestion  0  1  2  3  
Faint / lightheaded  0  1  2  3  
Face flushed  0  1  2  3  
Hot/cold sweats  0  1  2  3  
Column Sum          
  
Scoring - Sum each column.   Then sum the column totals to achieve a grand score.  Write that score here 
____________ .  
Interpretation  
 A grand sum between 0 – 21 indicates very low anxiety.  That is usually a good thing.  However, it is possible that 
you might be unrealistic in either your assessment which would be denial or that you have learned to “mask” the 
symptoms commonly associated with anxiety.   Too little “anxiety” could indicate that you are detached from 
yourself, others, or your environment.    
  
A grand sum between 22 – 35 indicates moderate anxiety.  Your body is trying to tell you something.  Look for 
patterns as to when and why you experience the symptoms described above.  For example, if it occurs prior to 
public speaking and your job requires a lot of presentations you may want to find ways to calm yourself before 
speaking or let others do some of the presentations.  You may have some conflict issues that need to be 
resolved.  Clearly, it is not “panic” time but you want to find ways to manage the stress you feel.  
  
A grand sum that exceeds 36 is a potential cause for concern.  Again, look for patterns or times when you tend to 
feel the symptoms you have circled.  Persistent and high anxiety is not a sign of personal weakness or failure.  It 
is, however, something that needs to be proactively treated or there could be significant impacts to you mentally 
and physically.  You may want to consult a counselor if the feelings persist.  
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Supplementary Screen 2 – Beck Depression Inventory 
 
Beck's Depression Inventory 
 




0 I do not feel sad. 
1 I feel sad 
2 I am sad all the time and I can't snap out of it. 
3 I am so sad and unhappy that I can't stand it. 
 
2. 
0 I am not particularly discouraged about the future. 
1 I feel discouraged about the future. 
2 I feel I have nothing to look forward to. 
3 I feel the future is hopeless and that things cannot improve. 
 
3. 
0 I do not feel like a failure. 
1 I feel I have failed more than the average person. 
2 As I look back on my life, all I can see is a lot of failures. 
3 I feel I am a complete failure as a person. 
 
4. 
0 I get as much satisfaction out of things as I used to. 
1 I don't enjoy things the way I used to. 
2 I don't get real satisfaction out of anything anymore. 
3 I am dissatisfied or bored with everything. 
 
5. 
0 I don't feel particularly guilty 
1 I feel guilty a good part of the time. 
2 I feel quite guilty most of the time. 
3 I feel guilty all of the time. 
 
6. 
0 I don't feel I am being punished. 
1 I feel I may be punished. 
2 I expect to be punished. 
3 I feel I am being punished. 
 
7. 
0 I don't feel disappointed in myself. 
1 I am disappointed in myself. 
2 I am disgusted with myself. 







0 I don't feel I am any worse than anybody else. 
1 I am critical of myself for my weaknesses or mistakes. 
2 I blame myself all the time for my faults. 
3 I blame myself for everything bad that happens. 
 
9. 
0 I don't have any thoughts of killing myself. 
1 I have thoughts of killing myself, but I would not carry them out. 
2 I would like to kill myself. 
3 I would kill myself if I had the chance. 
 
10. 
0 I don't cry any more than usual. 
1 I cry more now than I used to. 
2 I cry all the time now. 
3 I used to be able to cry, but now I can't cry even though I want to. 
 
11. 
0 I am no more irritated by things than I ever was. 
1 I am slightly more irritated now than usual. 
2 I am quite annoyed or irritated a good deal of the time. 
3 I feel irritated all the time. 
 
12. 
0 I have not lost interest in other people. 
1 I am less interested in other people than I used to be. 
2 I have lost most of my interest in other people. 
3 I have lost all of my interest in other people. 
 
13. 
0 I make decisions about as well as I ever could. 
1 I put off making decisions more than I used to. 
2 I have greater difficulty in making decisions more than I used to. 
3 I can't make decisions at all anymore. 
 
14. 
0 I don't feel that I look any worse than I used to. 
1 I am worried that I am looking old or unattractive. 
2 I feel there are permanent changes in my appearance that make me look 
unattractive 
3 I believe that I look ugly. 
 
15. 
0 I can work about as well as before. 
1 It takes an extra effort to get started at doing something. 
2 I have to push myself very hard to do anything. 









0 I can sleep as well as usual. 
1 I don't sleep as well as I used to. 
2 I wake up 1-2 hours earlier than usual and find it hard to get back to sleep. 
3 I wake up several hours earlier than I used to and cannot get back to sleep. 
 
17. 
0 I don't get more tired than usual. 
1 I get tired more easily than I used to. 
2 I get tired from doing almost anything. 
3 I am too tired to do anything. 
 
18. 
0 My appetite is no worse than usual. 
1 My appetite is not as good as it used to be. 
2 My appetite is much worse now. 
3 I have no appetite at all anymore. 
 
19. 
0 I haven't lost much weight, if any, lately. 
1 I have lost more than five pounds. 
2 I have lost more than ten pounds. 
3 I have lost more than fifteen pounds. 
 
20. 
0 I am no more worried about my health than usual. 
1 I am worried about physical problems like aches, pains, upset stomach, or 
constipation. 
2 I am very worried about physical problems and it's hard to think of much else. 
3 I am so worried about my physical problems that I cannot think of anything else. 
 
21. 
0 I have not noticed any recent change in my interest in sex. 
1 I am less interested in sex than I used to be. 
2 I have almost no interest in sex. 
3 I have lost interest in sex completely. 
 
INTERPRETING THE BECK DEPRESSION INVENTORY 
 
Now that you have completed the questionnaire, add up the score for each of the twenty-
one questions by counting the number to the right of each question you marked. The 
highest possible total for the whole test would be sixty-three. This would mean you circled 
number three on all twenty-one questions. Since the lowest possible score for each question 
is zero, the lowest possible score for the test would be zero. This would mean you circles 










You can evaluate your depression according to the Table below. 
 
Total Score____________________Levels of Depression 
 
1-10____________________These ups and downs are considered normal 
11-16___________________ Mild mood disturbance 
17-20___________________Borderline clinical depression 
21-30___________________Moderate depression 
31-40___________________Severe depression 



























































Supplementary Screen 4 – Quick Mild Cognitive Impairment (Qmci) 
screen 
Administration and Scoring Guideline 
 1.1 Orientation  
   Scoring 2 points for the correct answer, 1 point for wrong answers, and 0 points 
for no answer or a conceptually unrelated answer (see details below). 
 Timing Maximum of 10 sec for each answer.  
Instructions and Scoring Guide 
Year If the person gives the correct year score 2 points, the incorrect 
year score 1 point, and 0 points if no year is given. 
Country Score 2 points for correct country, 1 point for incorrect country, 
and 0 if no country is named. 
Month Score 2 points for the correct month or for the previous or 
following month if within two days of the change of the month (for 
example, if the date is September 30th, score the full 2 points if 
person answers October. Similarly, if the date is October 2nd, score 
2 points if person says September). Score 1 point if the month is 
incorrect and 0 if no month is named. 
Date Score 2 points for exact date or ± one day, 1 point for any other 
date, 0 if no date is named. 
Day of week 2 points for correct day, 1 point for incorrect day, 0 if no day 
named. 
 
To begin say...  
“I’d like to ask you some questions and give you some problems to solve.  Would 
that be OK?”  
What country is this? __________ 
What year is this?  __________ 
What month is this? __________ 
What is today’s date?  __________ 
What day of the week is this? __________ 
 





1.2 Word Registration  
 
   Scoring Score 1 point for each word recalled after the first reading. If subject 
recalls all five, repeat the five items once and then go on to clock drawing.  If subject 
does not repeat all 5, repeat the 5 items and ask the subject to repeat them.  Do this 
until the subject correctly recalls all 5 items or for a maximum of 3 trials. Do not 
score for trials 2 and 3.  These trials are to help the person learn in preparation for 
the delayed recall task.   
 Timing Say the words very deliberately, one per second.  Allow 10 sec for the 
recall. 
 
To begin say… 
“I am going to say 5 words.  After I have said these 5 words, repeat them back to 
me.  Are you ready?”  
dog  rain butter love door 
 
Score __________ / 5  
When finished, say…  “Remember these words because I’ll ask you to recall them 
later.” 
Alternate word groups include… 
cat Dark Pepper fear bed 




1.3 Clock Drawing  
 
   Scoring. Place the circle of the transparent scoring template over the circle of 
the patient’s completed clock.  Rotate the template circle so that the “12” s align.  
Score 1 point each if the 1, 2, 4, 5, 7, 8, 10, and 11 are in the correct quadrants.  
Score 1 point each if the 12, 3, 6, and 9 touch their quadrant lines.  Subtract one 
point for each number repeated or for numbers above 12.  (Should the patient not 
have drawn a “12” align the template with the 3, 6, or 9.) 
Score the placement of hands according to the tips and pivot.  Give 1 point for each 
hand between the dashed lines.  Score 1 point for hands connecting at the pivot. 
 Timing One minute.  
 
To begin… 
Give the sheet of paper with the pre-drawn circle and a pencil to the patient. Say 
“Now put in the numbers like the face of a clock.”  Then say “Set the hands to show 
ten past eleven.”  Place the numbers and hands as carefully as you can.” 




Score:  Numbers  Correct + ______/ 12 
  Errors - ______ 
 Hands  + ______/ 2 
 Pivot  + ______/ 1 
 










1.4 Delayed Recall 
   Scoring. Score 4 points for each word recalled. Subjects may recall words in any 
order.   
 Timing 10 sec. 
 
To begin say…  
A few minutes ago I named five words.  Name as many of those words as you can 
remember.  
dog  rain butter love door 
Score __________ / 20  
Alternate word groups include… 
cat Dark pepper fear bed 
rat Heat bread round chair 
 
 
1.5 Verbal Fluency 
Instructions and Scoring Guide 
   Scoring. Give ½ point for each correct word recalled to a maximum of 40 words.  
Round up the final score.  Do not count words with different suffixes twice (e.g. fish / 
fishes, mouse / mice, etc.).  Accept alternate species (e.g. blue jay, robin, sparrow, 
duck, etc.). Alternate forms include fruits and vegetables, cities and towns.   
 Timing.60 sec. Write down each word the patient says.  (You may need to develop 
some kind of “shorthand” for the speedier patients, such as writing the first 3 letters 
of each word and then completing them later.) 
 
To begin say…  
“Name as many animals as you can in one minute.  Ready? Go.” 







1.6 Logical Memory 
   Scoring. Give 2 points for each correct word item recalled verbatim.   All bolded 
words within each section must be recalled for score 2 points.  Otherwise score 0.  
Recall may be in any order.   
 Timing. 30 sec. Check off each word unit recalled.   
 
To begin say…  
“I am going to read you a short story. After I have finished reading I want you to 
tell me as much of the story as you can.  OK?”  [patient signifies agreement, then 
begin reading the paragraph at about 1 second for each word unit]  “The red… fox… 
ran across........… the bushes.”  
6. Logical Memory       
The red The brown The white 2 / 0 
fox Dog hen 2 / 0 
ran across ran across walked across 2 / 0 
the ploughed the metal the concrete  2 / 0 
field. bridge. road. 2 / 0 
It was chased by It was hunting It was followed by 2 / 0 
a brown a white a black 2 / 0 
dog. rabbit. cat. 2 / 0 
It was a hot It was a cold It was a warm 2 / 0 
May October September 2 / 0 
morning. day. afternoon. 2 / 0 
Fragrant  Ripe Dry 2 / 0 
blossoms apples leaves 2 / 0 
were forming on were hanging on were blowing in  2 / 0 
the bushes. the trees. the wind. 2 / 0 
 
Score __________ / 30  
QMCI Total Score ____________ / 100 
 
